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Abstract 
This thesis describes and evaluates ordering of pathology tests by general 
practitioners (GPs) in Australia. Over the past decade the volume and cost of 
pathology services generated by GP orders have grown markedly, raising questions 
about reasons for, and appropriateness of, orders contributing to the increase. 
This study uses data collected between 2000 and 2010 in the Bettering the Evaluation 
and Care of Health (BEACH) program, from 9,842 randomly sampled GPs about 
984,200 encounters and 1,490,194 pathology tests/batteries of tests. 
Multiple factors contributed to the total increase in volume of GP pathology orders 
from 2000–02 to 2006–08: increased likelihood of GPs’ deciding to order test(s), 
increased number of tests ordered by GPs per episode, increased number of problems 
managed at GP–patient encounters, and increased population attendance rates. Just 
22 health problems accounted for 59% of the growth in testing. 
Significant independent predictors of the volume of pathology ordered by GPs, 
included some GP and practice characteristics, but the principal explanatory variable 
was the type of problem being managed. 
For six common problems with high pathology test ordering rates, appropriateness of 
ordering was assessed, by measuring alignment of GPs’ ordering with guidance 
documents. Alignment was good for: hypertension, Type 2 diabetes, lipid disorders 
and weakness/tiredness; and poor for ‘health checks’ and overweight/obesity. 
Of the six problems investigated, overall increases in pathology ordering were seen 
for both ‘appropriate’ and ‘inappropriate’ tests. However, only a small proportion of 
tests were deemed inappropriate. I found no evidence to support concerns raised in 
the literature about assumed widespread inappropriate ordering, or assertions that 
increases in ordering reflect disproportionate increases in inappropriate ordering 
For the ongoing management of chronic problems, pathology testing guidance was 
poor. Australia has an ageing population and therefore chronic problem management 
and the testing associated with it will inevitably increase. Improved guidance 
regarding pathology testing in chronic problem management could help support GPs’ 
appropriate ordering in this high growth area. 
iii 
Acknowledgements 
I wish to acknowledge and thank the many people who have helped, supported and 
encouraged me throughout my PhD.  
I would like to express my gratitude to my research supervisors, Professor Helena 
Britt and Professor Graeme Miller, for their dedication, guidance, encouragement 
and editorial assistance. Thank you for supporting and encouraging my professional 
development over the years, and for creating a nurturing and supportive workplace in 
which such development is possible. 
Special thanks are extended to my colleagues at the Family Medicine Research 
Centre for their continued support and patience. In particular, I thank Lisa Valenti for 
her contribution in undertaking the majority of the data analysis for this thesis and 
Christopher Harrison for his analysis work. I am grateful to Joan Henderson for 
editing this thesis, and for her day-to-day support in our work environment. 
I also thank Julie O’Halloran for providing endless encouragement (and empathy) 
and sharing her wisdom, as we undertook our PhD journeys simultaneously. 
The research in this thesis was partially funded by a grant from the Quality Use of 
Pathology Program, Australian Government Department of Health and Ageing. The 
Postgraduate Research Support Scheme, and Research Student Grant Scheme from 
the Sydney School of Public Health at the University of Sydney provided financial 
support for conference attendance.  
I would also like to thank the members of the pathology profession who have shared 
their time, knowledge and experience. In particular, I wish to acknowledge and thank 
Ed Wilson, Michael Harrison, and Bev Rowbotham. 
I thank the organisations that have supported the BEACH program. During the 
period covered in this thesis, the BEACH program was supported by: Australian 
Government Department of Health and Ageing; AstraZeneca Pty Ltd (Australia); 
Merck, Sharp and Dohme (Australia) Pty Ltd; Pfizer Australia Pty Ltd; Sanofi-
aventis Australia Pty Ltd; Novartis Pharmaceuticals Australia Pty Ltd; Janssen-Cilag 
Pty Ltd; Abbott Australasia Pty Ltd; Wyeth Australia Pty Ltd; Roche Products Pty 
Ltd; Aventis Pharma Pty Ltd; National Prescribing Service Ltd; Australian 
iv 
Government Department of Veterans’ Affairs; The Office of the Australian Safety 
and Compensation Council, Department of Employment and Workplace Relations. 
Sincere thanks to the GPs who have participated in BEACH, without whom this 
research would not have been possible. 
I am grateful to my family for providing quiet reassurance and cheering me on from 
the sidelines. I thank my sister, Laura, for proof reading sections of this thesis. To my 
mum (Sharyn Sutton) and dad (Graeme Sutton), I am deeply grateful for your love, 
faith and support. Mum, thank you for teaching me to always consider another’s 
perspective, to challenge what I am told, and to make up my own mind—these life 
skills have served me well in my research career. 
Finally, I would like to thank my husband, Abdul, for his love, encouragement and 
mischievous sense of humour which helped maintain my equilibrium. This thesis 
would not have been possible without you. 
v 
Contents 
Abstract....................................................................................................................... ii 
Acknowledgements.................................................................................................... iii 
List of tables............................................................................................................... ix 
List of figures ........................................................................................................... xiii 
List of boxes ............................................................................................................. xiv 
Abbreviations ........................................................................................................... xv 
Symbols .................................................................................................................. xviii 
Glossary.................................................................................................................... xix 
1  Aims and candidate’s contribution.................................................................... 1 
1.1  Aims................................................................................................................ 1 
1.2  Candidate’s contribution................................................................................. 1 
2  Introduction ......................................................................................................... 4 
3  Method................................................................................................................ 20 
3.1  An overview of the BEACH study ............................................................... 20 
3.2  The BEACH method..................................................................................... 21 
3.2.1  Sample size ........................................................................................ 22 
3.2.2  The sample......................................................................................... 22 
3.2.3  GP recruitment................................................................................... 22 
3.2.4  Data collection................................................................................... 23 
3.2.5  Data elements .................................................................................... 24 
3.2.6  SAND substudy data ......................................................................... 29 
3.2.7  Data entry and classification.............................................................. 30 
3.2.8  Quality assurance............................................................................... 34 
3.2.9  Validity and reliability....................................................................... 34 
3.2.10  Representativeness ............................................................................ 35 
3.2.11  Statistical methods............................................................................. 37 
3.2.12  Extrapolated national estimates ......................................................... 39 
4  Overview of pathology ordering....................................................................... 42 
4.1  Background................................................................................................... 42 
4.2  Objectives ..................................................................................................... 42 
4.3  Method .......................................................................................................... 43 
4.3.1  Extrapolation ..................................................................................... 44 
4.4  Results........................................................................................................... 45 
4.4.1  Overview of data set .......................................................................... 45 
4.4.2  Problems generating high volumes of pathology orders ................... 55 
4.5  Discussion..................................................................................................... 73 
 
 
vi 
5  GP pathology testing versus recommended testing........................................ 81 
5.1  Objectives ..................................................................................................... 81 
5.2  Background................................................................................................... 81 
5.3  Method .......................................................................................................... 84 
5.3.1  General practice data ......................................................................... 84 
5.3.2  Selecting the problems for investigation ........................................... 84 
5.3.3  Identifying the guidelines and other sources of guidance ................. 87 
5.3.4  Determining recommended pathology testing................................... 88 
5.4  Hypertension................................................................................................. 90 
5.4.1  Background........................................................................................ 90 
5.4.2  Management rate in Australian general practice ............................... 90 
5.4.3  Pathology ordered for hypertension .................................................. 91 
5.4.4  Guidance documents for hypertension .............................................. 95 
5.4.5  Extent of alignment between GP testing and guidance documents... 95 
5.4.6  Discussion........................................................................................ 103 
5.5  Type 2 diabetes ........................................................................................... 111 
5.5.1  Background...................................................................................... 111 
5.5.2  Management rate in Australian general practice ............................. 112 
5.5.3  Pathology ordered for T2D.............................................................. 112 
5.5.4  Guidance documents for T2D ......................................................... 117 
5.5.5  Extent of alignment between GP testing and guidance documents. 117 
5.5.6  Discussion........................................................................................ 124 
5.6  Lipid disorders ............................................................................................ 131 
5.6.1  Background...................................................................................... 131 
5.6.2  Management rate in Australian general practice ............................. 131 
5.6.3  Pathology ordered for lipid disorders .............................................. 132 
5.6.4  Guidance documents for lipid disorder ........................................... 136 
5.6.5  Extent of alignment between GP testing and guidance documents. 137 
5.6.6  Discussion........................................................................................ 143 
5.7  Health check ............................................................................................... 151 
5.7.1  Background...................................................................................... 151 
5.7.2  Management rate in Australian general practice ............................. 151 
5.7.3  Pathology ordered for health check................................................. 152 
5.7.4  Guidance documents for health check............................................. 156 
5.7.5  Extent of alignment between GP testing and guidance documents. 156 
5.7.6  Discussion........................................................................................ 163 
5.8  Weakness / tiredness ................................................................................... 169 
5.8.1  Background...................................................................................... 169 
5.8.2  Management rate in Australian general practice ............................. 169 
5.8.3  Pathology ordering for weakness/tiredness ..................................... 170 
5.8.4  Guidance for weakness/ tiredness ................................................... 175 
5.8.5  Extent of alignment between GP testing and guidance documents. 176 
5.8.6  Discussion........................................................................................ 183 
vii 
5.9  Overweight/obesity..................................................................................... 188 
5.9.1  Background...................................................................................... 188 
5.9.2  Management rate in Australian general practice ............................. 189 
5.9.3  Pathology ordering for overweight/obesity ..................................... 190 
5.9.4  Guidance documents for overweight/obesity .................................. 194 
5.9.5  Extent of alignment between GP testing and guidance documents. 195 
5.9.6  Discussion........................................................................................ 201 
5.10 Discussion.................................................................................................. 206 
6  Investigation of FBC and lipid testing ........................................................... 219 
6.1  Background................................................................................................. 219 
6.2  Objectives ................................................................................................... 222 
6.3  Method ........................................................................................................ 222 
6.4  Results......................................................................................................... 225 
6.4.1  The sample....................................................................................... 225 
6.4.2  FBC testing...................................................................................... 226 
6.4.3  Lipid testing..................................................................................... 234 
6.5  Discussion................................................................................................... 241 
7  Predictors of GPs’ pathology ordering.......................................................... 252 
7.1  Background................................................................................................. 252 
7.2  Objective..................................................................................................... 256 
7.3  Method ........................................................................................................ 256 
7.4  Results......................................................................................................... 259 
7.4.1  The sample....................................................................................... 259 
7.4.2  Univariate analysis .......................................................................... 260 
7.4.3  Multivariate analysis ....................................................................... 265 
7.5  Discussion................................................................................................... 268 
8  Pathology generated by GP orders in the future.......................................... 277 
8.1  Objective..................................................................................................... 277 
8.2  Background................................................................................................. 277 
8.3  Method ........................................................................................................ 279 
8.4  Results......................................................................................................... 286 
8.5  Discussion................................................................................................... 295 
9  Discussion ......................................................................................................... 302 
10  Conclusion ........................................................................................................ 320 
References in citation order .................................................................................. 322 
References in alphabetical order (citation order in parentheses)...................... 351 
Appendices .............................................................................................................. 380 
Appendix 1: Publications and presentations from this thesis............................ 380 
Appendix 2: Example of a 2007–08 BEACH recording form .......................... 382 
Appendix 3: GP characteristics questionnaire, 2007–08................................... 384 
Appendix 4: Instructions for participating GPs................................................. 385 
Appendix 5: Patient information card ............................................................... 393 
viii 
Appendix 6: ICPC-2 and ICPC-2 PLUS code groups used for analysis of 
problems managed ...................................................................................... 396 
Appendix 7: ICPC-2 PLUS code groups used for analysis of pathology tests . 400 
 
ix 
List of tables 
Table 3.1:  Number of general practice professional services claimed from  
Medicare Australia each financial year, 2000–01 to 2009–10............... 40 
Table 4.1:  Overview of data set and summary of pathology ordering, 2000–08,  
2000–02 and 2006–08 ............................................................................ 48 
Table 4.2:  Distribution of pathology orders across MBS pathology groups and  
most frequent individual test orders for all problems, 2000–08,  
2000–02 and 2006–08 ............................................................................ 53 
Table 4.3:  Overview of problems that accounted for at least 1% of total  
problem–pathology links, 2000–08, 2000–02 and 2006–08 .................. 67 
Table 4.4:  Changes in pathology ordering for problems that accounted for at least  
1% of problem–pathology links, 2000–02 compared with 2006–08 ..... 69 
Table 4.5:  Extrapolated national estimated number (thousands) of management  
and pathology ordered for problems that accounted for at least 1% of 
problem–pathology links, changes from 2000–02 to 2006–08 ........... 71 (a)
Table 5.1:  Summary of hypertension data set, 2000–08, 2000–02 and 2006–08 ... 91 
Table 5.2:  Summary of pathology ordering for hypertension, 2000–08, 2000–02  
and 2006–08 ........................................................................................... 92 
Table 5.3:  Rate of pathology test orders for hypertension by MBS pathology  
groups and most frequent individual test orders within each group,  
2000–08.................................................................................................. 93 
Table 5.4:  Rate of pathology test orders for hypertension by MBS pathology  
groups and most frequent individual test orders within each group,  
2000–02 compared with 2006–08 .......................................................... 94 
Table 5.5:  Summary of guidance recommendations by most frequent individual  
test orders for hypertension, 2000–08 .................................................. 100 
Table 5.6:  Summary of support for GP pathology ordering for the most frequent 
individual test orders for hypertension, 2000–08................................. 101 
Table 5.7:  Rate of pathology ordering for hypertension by level of support,  
2000–08, 2000–02 and 2006–08 .......................................................... 102 
Table 5.8:  Summary of T2D data set, 2000–08, 2000–02 and 2006–08............... 112 
Table 5.9:  Summary of pathology ordering for T2D, 2000–08, 2000–02 and  
2006–08................................................................................................ 113 
Table 5.10:  Rate of pathology test orders for T2D by MBS pathology groups and 
most frequent individual test orders within each group, 2000–08 ....... 114 
Table 5.11:  Rate of pathology test orders for T2D by MBS pathology groups and 
most frequent individual test orders within each group, 2000–02 
compared with 2006–08....................................................................... 115 
Table 5.12:  Prescribed medications for T2D by Anatomical Therapeutic  
Chemical classification levels 3 and 4, 2000–02 and 2006–08............ 116 
Table 5.13:  Summary of guidance recommendations by most frequent individual  
test orders for T2D, 2000–08 ............................................................... 121 
x 
Table 5.14:  Summary of support for GP pathology ordering for the most  
frequent individual test orders for T2D, 2000–08................................ 122 
Table 5.15:  Rate of pathology ordering for T2D by level of support, 2000–08,  
2000–02 and 2006–08 .......................................................................... 123 
Table 5.16:  Summary of lipid disorders data set, 2000–08, 2000–02 and  
2006–08................................................................................................ 132 
Table 5.17:  Summary of pathology ordering for lipid disorder, 2000–08,  
2000–02 and 2006–08 .......................................................................... 133 
Table 5.18:  Rate of pathology test orders for lipid disorder by MBS pathology  
groups and most frequent individual test orders within each group, 
2000–08................................................................................................ 134 
Table 5.19:  Rate of pathology test orders for lipid disorder by MBS pathology  
groups and most frequent individual test orders within each group, 
2000–02 compared with 2006–08 ........................................................ 135 
Table 5.20:  Summary of guidance recommendations by most frequent individual  
test orders for lipid disorder, 2000–08 ................................................. 140 
Table 5.21:  Summary of support for GP pathology ordering for the most frequent 
individual test orders for lipid disorder, 2000–08 ................................ 141 
Table 5.22:  Rate of pathology ordering for lipid disorder by level of support,  
2000–08, 2000–02 and 2006–08 .......................................................... 142 
Table 5.23:  Summary of health check data set in patients aged 15+ years,  
2000–08, 2000–02 and 2006–08 .......................................................... 152 
Table 5.24:  Summary of pathology ordering for health check (patients 15+ years), 
2000–08, 2000–02 and 2006–08 .......................................................... 153 
Table 5.25:  Rate of pathology test orders for health check (patients 15+ years) by 
MBS groups and most frequent individual tests within each group, 
2000–08................................................................................................ 154 
Table 5.26:  Rate of pathology test orders for health check (patients 15+ years) by 
MBS groups and most frequent individual tests within each group, 
2000–02 compared with 2006–08 ........................................................ 155 
Table 5.27:  Summary of guidance recommendations by most frequent individual  
test orders for health check, 2000–08................................................... 160 
Table 5.28:  Summary of support for GP pathology ordering for the most frequent 
individual test orders for health check (patients aged 15+ years),  
2000–08................................................................................................ 161 
Table 5.29:  Rate of pathology ordering for health check by level of support,  
2000–08, 2000–02 and 2006–08 .......................................................... 162 
Table 5.30:  Summary of weakness/tiredness data set, 2000–08, 2000–02 and  
2006–08................................................................................................ 170 
Table 5.31:  Summary of pathology ordering for weakness/tiredness, 2000–08,  
2000–02 and 2006–08 .......................................................................... 171 
Table 5.32:  Rate of pathology test orders for weakness/tiredness by MBS groups  
and most frequent individual tests within each group, 2000–08.......... 172 
xi 
Table 5.33:  Rate of pathology test orders for weakness/tiredness by MBS groups  
and most frequent individual tests within each group, 2000–02  
compared with 2006–08....................................................................... 174 
Table 5.34:  Summary of guideline/guidance recommendations by most frequent 
individual test orders for weakness/ tiredness, 2000–08...................... 180 
Table 5.35:  Summary of support for GP pathology ordering for the most f 
requent individual test orders for weakness/tiredness, 2000–08.......... 181 
Table 5.36:  Rate of pathology ordering for weakness/tiredness by level of  
support, 2000–08, 2000–02 and 2006–08 ............................................ 182 
Table 5.37:  Summary of overweight/obesity data set (adult patients), 2000–08, 
2000–02 and 2006–08 .......................................................................... 189 
Table 5.38:  Summary of pathology ordering for overweight/obesity (adult  
patients), 2000–08, 2000–02 and 2006–08 .......................................... 191 
Table 5.39:  Rate of pathology test orders for overweight/obesity by MBS  
pathology groups and most frequent individual test orders within  
each group, 2000–08 ............................................................................ 192 
Table 5.40:  Rate of pathology test orders for overweight/obesity by MBS pathology 
groups and most frequent individual test orders within each group, 
2000–02 compared with 2006–08 ........................................................ 193 
Table 5.41:  Summary of guidance recommendations by most frequent individual  
test orders for overweight/obesity, 2000–08 ........................................ 198 
Table 5.42:  Summary of support for GP pathology ordering for the most frequent 
individual test orders for overweight/obesity, 2000–08....................... 199 
Table 5.43:  Rate of pathology ordering for overweight/obesity by level of  
support, 2000–08, 2000–02 and 2006–08 ............................................ 200 
Table 6.1:  Characteristics of patients in the FBC and lipid study sample............. 225 
Table 6.2:  FBC testing in general practice patients............................................... 228 
Table 6.3:  Time since previous FBC test when ordered for monitoring versus  
other purposes ...................................................................................... 229 
Table 6.4:  Most common problems for which GPs ordered a FBC test................ 230 
Table 6.5:  Most common differential diagnoses for investigative FBC tests ....... 231 
Table 6.6:  Purpose of ordering FBC tests for selected problems .......................... 233 
Table 6.7:  Lipid testing in general practice patients.............................................. 237 
Table 6.8:  Time since previous lipid test when ordered for monitoring versus  
other purposes ...................................................................................... 238 
Table 6.9:  Most common problems managed with a lipid test.............................. 239 
Table 6.10: Purpose of ordering lipid tests for selected problems .......................... 240 
Table 7.1:  Description of pathology ordering per 100 encounters with GPs ........ 260 
Table 7.2:  Univariate analysis of GP pathology ordering ..................................... 262 
Table 7.3:  Final multivariate model of independent predictors of GP pathology 
ordering ................................................................................................ 267 
Table 8.1:  Overview of pathology ordering data from the BEACH study  
2005–06 and 2009–10 .......................................................................... 286 
xii 
Table 8.2:  Total number of pathology tests/batteries of tests ordered by GPs for  
the Australian population ..................................................................... 287 
Table 8.3:  Number of GP contacts involving the ordering of at least one  
pathology test/battery of tests in the Australian population................. 287 
 
 
 
 
xiii 
List of figures 
Figure 3.1:  The BEACH relational database ............................................................ 25 
Figure 3.2:  The structure of the International Classification of Primary Care,  
Version 2 (ICPC-2) ................................................................................ 31 
Figure 4.1:  Rate of pathology test/battery orders per 100 encounters and per 100 
problems managed, 2000–01 to 2007–08 (95% confidence intervals) .. 47 
Figure 4.2:  Distribution of volume of pathology ordered across patient age groups, 
2000–08, 2000–02 and 2006–08 (95% confidence intervals)................ 49 
Figure 4.3:  Patient age-specific rate of pathology test orders per 100 encounters, 
2000–08, 2000–02 and 2006–08 (95% confidence intervals)................ 50 
Figure 4.4:  Distribution of the number of pathology tests/batteries ordered per 
encounter when at least one test was ordered, 2000–08, 2000–02 and 
2006–08 (95% confidence intervals)...................................................... 51 
Figure 5.1:  Age-specific rate of management of overweight/obesity (2000–08) and 
age-specific prevalence of overweight/obesity (2007–08) in adult 
patients ................................................................................................. 190 
Figure 6.1:  Patient age-specific rate of FBC orders (95% confidence intervals) ... 226 
Figure 6.2:  Patient age-specific rate of lipid orders (95% confidence intervals) ... 234 
Figure 8.1:  Age-sex–specific average number of pathology tests/batteries of tests 
ordered by GPs per person in the Australian population in 2005–06 
(95% confidence intervals)................................................................... 289 
Figure 8.2:  Age-sex–specific average number of pathology tests/batteries of tests 
ordered by GPs per person in the Australian population in 2009–10 
(95% confidence intervals)................................................................... 289 
Figure 8.3:  Age-sex–specific average number of GP contacts involving at least  
one pathology test/battery of tests per person in the Australian 
population in 2005–06 (95% confidence intervals) ............................. 290 
Figure 8.4:  Age-sex–specific average number of GP contacts involving at least  
one pathology test/battery of tests per person in the Australian 
population in 2009–10 (95% confidence intervals) ............................. 290 
Figure 8.5:  Estimated number (millions) of pathology tests/batteries of tests ordered 
by GPs for the projected Australian population 2015 to 2050 based on 
per head GP service use and GPs’ pathology ordering in 2005–06  
and 2009–10 (95% confidence intervals)............................................. 293 
Figure 8.6:  Estimated number (millions) of GP contacts involving at least one 
pathology test/battery of tests for the projected Australian population 
2015 to 2050 based on per head GP service use and GPs’ pathology 
ordering in 2005–06 and 2009–10 (95% confidence intervals) ........... 294 
 
xiv 
List of boxes 
Box 3.1:  Encounter data elements......................................................................... 26 
Box 3.2:  Patient data elements.............................................................................. 26 
Box 3.3:  Data elements about the problems managed .......................................... 27 
Box 3.4:  Data elements about pathology tests and other management of  
problems at the encounter ...................................................................... 28 
Box 3.5:  Data elements about the participating GPs and their practice................ 29 
Box 5.1:  Guidance documents reviewed for hypertension ................................... 95 
Box 5.2:  Guidance documents reviewed for T2D............................................... 117 
Box 5.3:  Guidance documents reviewed for lipid disorders............................... 136 
Box 5.4:  Guidance documents reviewed for health checks ................................ 156 
Box 5.5:  Guidelines and guidance documents reviewed for weakness/ 
tiredness................................................................................................ 175 
Box 5.6:  Guidance documents reviewed for overweight/obesity ....................... 194 
Box 6.1:  Example of SAND form completed by participating GPs (with  
instructions).......................................................................................... 224 
Box 7.1:  Variables included in univariate and multivariate analysis.................. 258 
Box 8.1:  Summary of source data....................................................................... 279 
Box 8.2:  Australian projected population 2015 to 2050 (millions) .................... 280 
Box 8.3:  Calculation example of GP ordered pathology (number of tests/batteries  
and GP contacts involving testing) for females aged 40–44 years ...... 285 
 
 
 
xv 
Abbreviations 
AACE American Association of Clinical Endocrinologists 
ABS Australian Bureau of Statistics 
ACE angiotensin converting enzymes  
ACRRM Australian College of Rural and Remote Medicine 
ADA American Diabetes Association 
AMTS Australian Morbidity and Treatment Survey 
ASGC Australian Standard Geographical Classification  
ATC Anatomical Therapeutic Chemical [classification]  
BEACH Bettering the Evaluation And Care of Health 
BMI body mass index 
bpac Best practice advocacy centre 
CDA Canadian Diabetes Association 
CHEP Canadian Hypertension Education Program 
CI confidence interval [in this thesis 95% CI is used] 
CK creatine kinase 
CRP C reactive protein 
CSANZ Cardiac Society of Australia and New Zealand  
CTFPHC Canadian Task Force on Preventive Health Care 
DA Diabetes Australia 
DAGDC Diabetes Australia Guideline Development Consortium 
DCGP Dutch College of General Practitioners 
DoHA [Australian Government] Department of Health and Ageing 
DVA [Australian Government] Department of Veterans’ Affairs 
ESC European Society of Cardiology  
ESH European Society of Hypertension  
ESR erythrocyte sedimentation rate 
eTG electronic Therapeutic Guidelines 
EUC electrolytes, urea and creatinine 
xvi 
FBC full blood count 
FMRC Family Medicine Research Centre 
FOBT faecal occult blood test 
FRACGP Fellowship of the Royal Australian College of General Practitioners 
FTE full-time equivalent 
GP general practitioner 
HbA1c haemoglobin, type A1c 
HDL high density lipoprotein 
HIV human immunodeficiency virus 
ICPC-2 International Classification of Primary Care (Version 2) 
ICPC-2 PLUS a clinical terminology classified according to ICPC-2 
ICSI Institute for Clinical Systems Improvement 
IDF International Diabetes Federation 
IHD ischaemic heart disease 
ISH International Society of Hypertension  
JNC 7 Joint National Committee [seventh report of the committee] 
LCL lower confidence limit [in this thesis, this refers to the 95% LCL] 
LDL low density lipoprotein 
LFT liver function test 
M,C&S microscopy, culture and sensitivity 
MBA multibiochemical analysis 
MBS Medicare Benefits Schedule 
MoH [Singapore] Ministry of Health 
MoU Memorandum of Understanding 
N/A not applicable 
NCEP National Cholesterol Education Program 
NEC not elsewhere classified  
NHF National Heart Foundation 
NHLBI National Heart, Lung, and Blood Institute 
NHMRC National Health and Medical Research Council 
NICE National Institute for Health and Clinical Excellence 
xvii 
NICE NHS NICE guideline designed for the National Health Service 
NLASSA National Lipid Association Statin Safety Assessment 
NOF National Obesity Forum  
NOS not otherwise specified 
OCCPG Obesity Canada Clinical Practice Guidelines 
OECD Organization for Economic Co-operation and Development 
Pap smear Papanicolaou smear 
PBS Pharmaceutical Benefits Scheme 
PSA prostate specific antigen 
PST Pathology Services Table [Category 6 of the MBS] 
RACGP Royal Australian College of General Practitioners 
RCPA Royal College of Pathologists of Australasia 
SAND Supplementary Analysis of Nominated Data 
SAS Statistical Analysis System 
SIGN Scottish Intercollegiate Guidelines Network  
STI sexually transmitted infection 
T2D Type 2 diabetes  
TFT thyroid function test 
UCL upper confidence limit [in this thesis, this refers to the 95% UCL] 
UK United Kingdom 
US United States [of America] 
USPSTF United States Preventive Services Task Force 
USyd University of Sydney 
WHO World Health Organization 
  
  
  
  
xviii 
Symbols 
‡ indicates that the term is defined in the Glossary 
/ indicates a statistically significant linear change  
/ indicates a marginally significant linear change 
— indicates no change 
< less than 
> more than 
 greater than or equal to 
 less than or equal to 
n number 
. . indicates that the table category/data item does not apply 
 
xix 
Glossary 
Throughout this thesis terms that are defined in the glossary are marked with the 
symbol ‘‡’. Terms are only marked the first time they are used in the text. 
 
Accreditation: Indicates that the practice is accredited against the Royal Australian 
College for General Practitioner’s ‘Standards for general practices’. 
Activity level: The number of MBS GP consultation service items claimed during 
the previous 3 months by a participating GP. 
Analyte: A chemical substance (in a fluid or other specimen from the body) that a 
laboratory test aims to detect. A single pathology test or battery of tests may 
include multiple analytes. 
Battery of tests: A standard group of related tests (sometimes called a ‘test profile’) 
that are ordered together and referred to as a group. For example, a ‘full blood 
count’ is a battery of tests that examine different parts of the blood, and often 
includes: white blood cell count, red blood cell count, haemoglobin, and 
platelets.  
Diagnosis/problem: A statement of the provider’s understanding of a health 
problem presented by a patient, family or community. GPs are instructed to 
record at the most specific level possible from the information available at the 
time. It may be limited to the level of symptoms. 
• New problem: The first presentation of a problem, including the first 
presentation of a recurrence of a previously resolved problem, but 
excluding the presentation of a problem first assessed by another provider. 
• Old problem: A previously assessed problem that requires ongoing care, 
including follow-up for a problem or an initial presentation of a problem 
previously assessed by another provider. 
Encounter: Any professional interchange between a patient and a GP. 
• Indirect: Encounter where there is no face-to-face meeting between the 
patient and the GP but a service is provided (for example, prescription, 
referral). 
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• Direct: Encounter where there is a face-to-face meeting of the patient and 
the GP. 
Episode coning rule: The MBS payment rule that restricts (to a maximum of three 
per ordering episode) the number of MBS pathology items that can be claimed 
by the pathologist for pathology tests ordered by GPs for non-hospitalised 
patients. Payment is made for the three items with the highest rebate amount.  
General practitioner (GP): A medical practitioner who provides primary, 
comprehensive and continuing care to patients and their families within the 
community. 
Health concession card: Patients holding a Health care/benefit card and/or a 
Repatriation health card. 
Health care/benefit card: A card entitling the holder to a higher level of 
Government subsidy for health services (for example, reduced-cost medicines 
under the Pharmaceutical Benefits Scheme). Examples of patients who may be 
eligible include pensioners, unemployed, low-income earners. 
ICPC-2 chapters: The main divisions within ICPC-2. There are 17 chapters 
primarily representing the body systems. 
Iso-resource group: A group of pathology tests that each use a similar amount of 
resources. The reimbursement and structure of some MBS pathology items are 
based on iso-resource groups of tests.  
Medicare Benefits Schedule (MBS) item: Each item number identifies a service 
funded through Medicare. The MBS lists all the Medicare services subsidised 
by the Australian Government, their schedule fees and conditions for use.  
• MBS GP consultation service items: Includes GP services provided 
under the MBS professional services category including MBS items 
classed as A1, A2, A5, A6, A7, A14, A17, A18, A19, A20, A22 and 
selected items provided by GPs classified in A11, A15 and A27. 
– Level A items: MBS item numbers 3, 4, 13, 19, 20. A ‘Level A’ item 
will be used for obvious and straightforward cases and this should be 
reflected in the practitioner’s records. In this context, the practitioner 
should undertake the necessary examination of the affected part if 
required, and note the action taken. 
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– Level B items: MBS item numbers 23, 24, 25, 33, 35. A ‘Level B’ 
item will be used for a consultation lasting less than 20 minutes for 
cases that are not obvious or straightforward in relation to one or more 
health related issues. The medical practitioner may undertake all or 
some of the following tasks (as clinically relevant): taking a detailed 
history, a clinical examination, arranging any necessary investigations, 
implementing a management plan, and providing appropriate care. 
– Level C items: MBS item numbers 36, 37, 38, 40, 43. A ‘Level C’ 
item will be used for a consultation lasting at least 20 minutes for 
cases in relation to one or more health related issues. The medical 
practitioner may undertake all or some of the following tasks (as 
clinically relevant): taking a detailed history, a clinical examination, 
arranging any necessary investigations, implementing a management 
plan, and providing appropriate care. 
– Level D items: MBS item numbers 44, 47, 48, 50, 51. A ‘Level D’ 
item will be used for a consultation lasting at least 40 minutes for 
cases in relation to one or more health related issues. The medical 
practitioner may undertake all or some of the following tasks (as 
clinically relevant): taking a detailed history, a clinical examination, 
arranging any necessary investigations, implementing a management 
plan and providing appropriate care. 
• MBS pathology item: Each pathology item number identifies a pathology 
service that is funded through Medicare. The MBS pathology items are 
listed in the Pathology Services Table of the MBS. 
Pathology ordering: The ordering of pathology tests or batteries of tests by GPs or 
other clinicians. Primarily in this thesis it refers to GPs’ ordering of pathology 
tests or batteries of tests. 
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Patient status: The status of the patient to the practice. 
• New patient: The patient has not been seen before in the practice. 
• Old patient: The patient has attended the practice before. 
Problem managed: See Diagnosis/problem. 
Problem–pathology link: The link between the pathology test (or battery) and the 
problem under management at the encounter. Each test must be linked to at 
least one problem, and up to four problems per encounter. There are more 
problem–pathology links than numbers of tests recorded at encounters. 
Provider: A person to whom a patient has access when contacting the health care 
system. 
Recognised GP: A medical practitioner who is: 
• vocationally recognised under Section 3F of the Health Insurance Act, or 
• a holder of the Fellowship of the Royal Australian College of General 
Practitioners who participates in, and meets the requirements for, quality 
improvement and continuing medical education as defined in the Royal 
Australian College of General Practitioner’s Quality Improvement & 
Continuing Professional Development Program, or 
• undertaking an approved placement in general practice as part of a training 
program for general practice leading to the award of the Fellowship of the 
Royal Australian College of General Practitioners, or undertaking an 
approved placement in general practice as part of some other training 
program recognised by the Royal Australian College of General 
Practitioners as being of equivalent standard.  
Repatriation health card: An entitlement card provided by the Department of 
Veterans’ Affairs that entitles the holder to access a range of Repatriation 
health care benefits, including access to prescription and other medications 
under the Pharmaceutical Benefits Scheme. 
Rubric: The title of an individual code in ICPC-2. 
Significant: This term is used to refer to a statistically significant result. Statistical 
significance is measured at the 95% confidence level in this report.  
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1 Aims and candidate’s contribution 
1.1 Aims 
This thesis aims to assess general practitioners’ (GPs) pathology test ordering and the 
changes in their ordering patterns; evaluate the quality of this ordering in terms of the 
variance among GPs, and its alignment with guidelines; and predict future ordering 
for an increasing and ageing population. More specifically, the aims are: 
• to describe GPs’ pathology test ordering, and growth over time in this ordering, 
in terms of the types of tests ordered, and the types of problems for which tests 
were ordered. 
• to identify the tests and problems that accounted for high growth in the volume 
of GPs’ pathology ordering over time, and the factors that contributed to this 
growth. 
• to determine the appropriateness of GPs’ pathology test ordering for selected 
problems in terms of its alignment with recommendations for pathology testing 
made in guidelines and other sources of guidance. 
• to determine the variance among GPs in their pathology test ordering rates and 
identify factors that may explain this variance. 
• to estimate the growth in volume of GPs’ pathology ordering to 2050, as a result 
of the projected growth and ageing of Australia’s population. 
1.2 Candidate’s contribution 
The candidate was fully involved in all aspects of the research reported in this thesis, 
including the conceptualisation, design, planning and conduct of the research. The 
candidate undertook an extensive literature review involving selection of databases, 
libraries and other sources of information including published guidelines and 
guidance documents. 
In this thesis I present a series of studies, all of which utilise data collected in the 
BEACH (Bettering the Evaluation and Care of Health) program. The candidate’s 
involvement in the BEACH program, at the Family Medicine Research Centre 
(FMRC), University of Sydney, is described below. 
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The study measuring the appropriateness of GPs’ pathology test ordering (reported in 
Chapter 5) was funded through a competitive grant from the Quality Use of 
Pathology Program, Australian Government Department of Health and Ageing. The 
candidate assumed full responsibility for conduct of the study, research design 
(including selection of problems for investigation, identification and review of 
guidance documents) and preparation of reports. Professors Helena Britt and Graeme 
Miller prepared the initial funding application, nominating the candidate as the 
responsible researcher. 
The candidate conceptualised, designed and initiated the SAND (Supplementary 
Analysis of Nominated Data) study (reported in Chapter 6). This included 
conceptualising and designing the questionnaire form and instructions, and obtaining 
ethics approval for the study from the Ethics Committee of the Australian Institute of 
Health and Welfare, and the Human Research Ethics Committee of the University of 
Sydney. The candidate prepared the specifications for the electronic data entry form 
which was implemented by the Centre’s IT manager, Mr Tim Chambers. The 
candidate also oversaw the data entry undertaken by trained casual staff. 
Data cleaning and checking were performed by the candidate and assisted by 
Ms Lisa Valenti, under instruction from the candidate. Statistical analyses for the 
results reported in Chapters 4 to 8 were specified by the candidate with the assistance 
of her supervisors Professors Helena Britt and Graeme Miller. The candidate 
independently performed the analyses for the extrapolations presented in Chapter 4. 
Under the candidate’s close instruction, senior analysts in the research team at the 
FMRC undertook the remaining analyses: Ms Lisa Valenti conducted the analyses 
for Chapters 4 to 7; and Mr Christopher Harrison conducted the analysis for 
Chapter 8. 
The preparation and creation of this manuscript, the literature review, reporting and 
interpretation of results, the discussion and conclusions made, are solely the work of 
the candidate.  
A list of publications and presentations arising from this thesis is provided in 
Appendix 1. Two publications of which the candidate is lead author have emanated 
from this work. The research presented in Chapter 4 was published as a peer-
reviewed chapter in the report General practice in Australia, health priorities and 
policies 1998–2008.1 The final report of the work conducted for the Quality Use of 
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Pathology Program grant (reported in Chapter 5) was published by the Australian 
Government Department of Health and Ageing online: Evidence-practice gap in GP 
pathology test ordering: a comparison of BEACH pathology data and recommended 
testing.2 As a result of this work, the Australian Government Department of Health 
and Ageing invited the candidate to become a member of the (pathology) Demand 
Management Advisory Committee (established in late 2011). Her involvement with 
this committee is ongoing. 
Candidate’s involvement in the BEACH study 
The research reported in this thesis uses data collected in the BEACH program, a 
continuous national study of general practice activity. BEACH commenced in April 
1998 and in April 2012 started its fifteenth year of data collection. 
The BEACH study was established two years prior to the candidate joining the 
research team at the FMRC. The candidate was initially employed at the FMRC in 
2000 while an undergraduate student as a casual data entry staff member. She 
completed her Honours thesis using BEACH data (Male consultations in general 
practice3) in 2001, and has been employed on a full-time basis since this time. Over 
the years the candidate has been involved in every aspect of the BEACH study 
including recruitment, data entry, training data entry staff, data checking, form 
design, planning and overseeing analysis for specific topics, producing and editing 
reports, preparing papers and presenting results at conferences. 
The candidate’s current primary work role is to update and design the BEACH 
recording forms. This includes annual updates of the standard BEACH data 
collection forms as required, co-ordination and design of the SAND substudies  
(in collaboration with external stakeholders), submission of forms for ethics 
approval, and preparing the forms for printing. The candidate is also responsible for 
co-ordinating the publication of the General Practice Series BEACH books, 
involving timeline management, editing and liaising with the publisher. 
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2 Introduction 
Pathology is defined as “the branch of medicine that studies the essential nature of 
disease, especially the structural, biochemical, and functional changes in the cells, 
tissues and organs of the body that cause or are caused by disease”.4 Pathology tests 
are critical in modern medical practice, and are essential for disease prevention, 
diagnosis and monitoring. 
In Australia, the use and cost of pathology testing has increased over past decades 
across multiple health sectors.5,6 A similar pattern has occurred in most developed 
countries, despite differences in how the various health systems are managed and 
pathology services funded.7-12 
This growth has raised concerns, in Australia and internationally, about what is 
driving the increased use of pathology testing, the viability of the increased costs, 
and whether this expenditure represents appropriate health care spending.6-9 Despite 
these concerns being expressed and investigated over decades, the use and cost of 
pathology tests have continued to increase.  
In Australia, over the decade 2000 to 2010, the cost of pathology services funded by 
the Australian Government through the national insurance scheme, Medicare, 
increased by 78.0%: from $1.2 billion in the 2000–01 financial year to $2.0 billion in 
2009–10.5 Similarly the volume of pathology services increased, from 62.1 million 
claimed (3.2 per capita) in 2000–01 to 103.7 million (4.7 per capita) in 2009–10, a 
67.0% increase in the number of claimed services and a 46.9% increase in the 
number of services per capita.5,13 
These pathology services represent those ordered by general practitioners‡ (GPs) and 
other medical specialists for non-hospitalised patients, and 68–70% of Medicare 
pathology outlays over the decade (E Wilson, personal communication, March 2011) 
were generated by GPs’ pathology ordering‡. The focus of this thesis is pathology 
ordering by GPs, as it accounts for the majority of the Government-funded pathology 
services in Australia.  
The structure of the Australian health care system is complex, as are the 
arrangements for Government funding of pathology services within the system. An 
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understanding of both is required to understand the context of the research presented 
in this thesis.  
A brief overview of the Australian health care system 
Governance of the Australian health care system is shared between the Federal, and 
the State and Territory Governments. The health care system is funded through a 
mixture of public and private sources including governments, health insurers and 
individual Australians. 
The Federal Government is responsible for national health policy, and controlling 
and managing the national health insurance scheme, Medicare. Through Medicare, 
the Australian population have access to free or subsidised treatment provided by a 
variety of health professionals. The Medicare Benefits Schedule (MBS) lists the 
health services for which Medicare benefits are available, the rebates for these 
services and the conditions for use. The health care system provides free treatment to 
Australian residents using public hospitals, and free or subsidised treatment by GPs 
and other medical specialists. Individual clinicians determine whether or not their 
services are charged directly to Government at the Medicare rebate level and are free 
to patients (referred to as bulk-billing). When not bulk-billed, the patient pays the fee 
set by the provider‡ and seeks reimbursement of the appropriate Medicare rebate, 
with the patient covering any difference between the fee and rebate. The Federal 
Government is also responsible for the Pharmaceutical Benefits Scheme (PBS), 
which subsidises the cost of prescribed medications. Private health insurance is 
optional in Australia, and its cost to an individual is subsidised through taxation 
rebates provided by the Federal Government. Private health insurance does not cover 
services provided by GPs or the pathology tests ordered by GPs, when such 
services/tests are covered by Medicare. 
As set out in the Australian Health Care Agreements, Federal and State/Territory 
Governments jointly fund public hospitals. The State and Territory Governments are 
responsible for the management of public hospitals and community care services. 
Australia’s health expenditure in 2009–10 was $121.4 billion, and accounted for 
9.4% of gross domestic product. Governments funded 70% of this expenditure and 
other non-government sources including patients, funded the remaining 30%.14  
In June 2010, the population of Australia was estimated to be 22.3 million people.15  
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General practitioners  
GPs are usually the first point of contact in the Australian health care system. In  
2009–10, about 83% of the Australian population had at least one GP visit funded by 
Medicare (Department of Health and Ageing [DoHA], personal communication, June 
2010). Payment for GP visits is largely on a fee-for-service basis, there being no 
compulsory patient lists or registration. People are free to see multiple GPs and visit 
multiple practices of their choice. 
GPs have a gatekeeper role in the health care system. GP ‘referral’ is needed in order 
for patients to access Medicare benefits for many health services including pathology 
tests, imaging tests and medical specialist care. GP referral is the most common way 
by which the population accesses Medicare-subsidised pathology services. Patients 
may also access these services through medical specialist referral. Similarly access to 
PBS-subsidised medications requires a prescription from a medical practitioner. 
In Australia, there were 24,029 practising primary care practitioners (vocationally 
recognised GPs‡ and other medical practitioners) in 2008, making up 23,188 full-
time equivalents (based on a 40 hour week), or 107.9 per 100,000 people.16 
The vast majority of GP services are funded through Medicare.17 In 2009–10 there 
were 116.6 million Medicare-funded GP encounters, an average of 5.2 per person in 
Australia, and the majority (79.5%) were bulk-billed.5,13 The Medicare cost for these 
GP encounters was about $4.9 billion.5 
The number of Medicare-funded GP services has increased over the decade 2000 to 
2010, from 100.6 million encounters in 2000–01 to 116.6 million in 2009–10.5 The 
number of services per person and the proportion of services that were bulk-billed 
were similar in 2000 and 2010. However there was a decline in both during the mid 
2000’s: the number of GP visits per person fell to a low of 4.8 per capita in 2003–04 
compared with 5.2 in 2000 and 2010;13 and the proportion of services bulk-billed fell 
to 68.2% in 2003–04 compared with 78–80% in 2000 and 2010.5 These falls 
prompted concerns about patient access to care and in response the Government 
introduced several ‘Strengthening Medicare’ initiatives in 200418 which were 
successful in increasing access to GP services. 
Pathology funding arrangements 
The pathology sector comprises private and public laboratories. Public laboratories 
are primarily based in public hospitals and private laboratories are based in the 
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community. The private sector is dominated by a few large private pathology 
companies. The way pathology services are funded and the type of laboratory 
conducting the testing varies based on the health setting in which pathology tests are 
ordered and the type of clinician ordering the test.  
Pathology ordered for patients of public hospitals is conducted in public laboratories 
and funded under the Australian Health Care Agreements. Pathology ordered by GPs 
and other medical specialists for non-hospitalised patients is funded through 
Medicare as set out in the MBS Pathology Services Table (PST), and mostly 
undertaken in laboratories owned by private pathology companies. The PST outlines 
the tests that are funded through MBS pathology items‡, their rebates and conditions 
of use.  
All MBS pathology services must be ordered (or ‘referred’) by GPs or other medical 
specialists. Pathologists claim for MBS pathology items for tests ordered on a fee-
for-service basis and can elect whether to bulk-bill patients for these services. A high 
proportion of pathology services are bulk-billed (i.e. free to the patient). Across the 
period 2000 to 2010, an average of 85.0% of MBS pathology services were bulk-
billed. 
While bulk-billing has remained high, the average rebate for MBS pathology items 
has decreased. In real terms the average rebate per MBS pathology item in 2008–09 
was below what it was when Medicare began in 1984.19 This has been achieved 
through amalgamation and centralisation of pathology laboratories in Australia and 
increased automation of testing. Therefore, while the total number and cost of 
Medicare-funded tests continues to increase, the proportion of total Medicare 
benefits accounted for by pathology services is decreasing. In 2000–01 pathology 
services accounted for 15.8% of Medicare benefits and in 2009–10 they accounted 
for 13.0%.5 
In funding MBS pathology services the Australian Government acts as the sole 
purchaser, setting the regulatory framework, and managing the PST.20 These 
structures and rules ensure high quality pathology services, and facilitate 
management of outlays. To some extent they have evolved in response to allegations 
during the 1980’s and 1990’s of fraud (such as inducements and ‘kickbacks’) and 
overservicing in Australia.21  
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The vast majority of pathology tests ordered by GPs are included in the MBS and 
funded through Medicare. However, there are some exclusions. For example, point 
of care tests, while available to GPs, are not currently funded by Medicare. In part 
this is due to poor cost-effectiveness.22  
This thesis is concerned with tests ordered by GPs that are funded through Medicare. 
Theoretically the data held by the Federal Government of the MBS pathology items 
claimed should provide a picture of the ordering behaviour of GPs. However, there 
are MBS structure and payment rules that mean the Medicare data cannot provide an 
exact reflection of pathology requested by GPs. The two main factors are the episode 
coning rule‡ and the structure of some MBS pathology items. 
The episode coning rule restricts the number of MBS pathology item numbers that 
can be claimed by the pathologist per episode of ordering for pathology tests 
requested by GPs for non-hospitalised patients. This rule means that a maximum of 
three MBS pathology items can be claimed per episode of ordering, payment being 
made for the three items with the highest rebate amount (i.e. highest cost). Some 
MBS pathology item numbers are exempt from the coning rule, such as Papanicolaou 
(Pap) smear items.23 
Each MBS pathology item number can either represent a single pathology test or 
multiple pathology tests. Item numbers that include multiple tests usually reflect iso-
resource‡ groupings, and for some of these items, the amount paid for such items is 
based on the number of tests ordered from within the group (referred to as ladder 
items). For example, one test from the group, two tests from the group, and so on, to 
a maximum of five tests from the group.23 
In addition to the MBS payment rules outlined in the PST, outlays for pathology 
services were capped through a series of Memoranda of Understanding (MoU) (up to 
2009) between the Australian Government and the pathology industry and 
profession. The first was introduced in 1996, and in 2008, at the commencement of 
the research for this thesis, the third MoU was in place. It covered 1 July 2004 to 
30 June 2009, and aimed to contain growth in outlays to an average of 5.3% per 
annum.24 
At the completion of the third MoU, the MBS pathology funding arrangements were 
reviewed.20 Following this review, the MBS funding arrangements remain largely 
unchanged, and a new 5-year funding agreement was introduced in July 2011.25 The 
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review was partially prompted by the 2008 audit of the MoU, undertaken to 
investigate why the financial objectives of the MoU were not being met. Over the 
2004–08 period, the annual growth in pathology outlays covered by the MoU was 
7%, rather than the projected 5%, following the Government’s introduction of 
national policy initiatives that produced an unanticipated increase in demand for 
pathology services. In addition to policy influences, the audit reported several factors 
that were thought to be associated with increased demand for pathology testing. The 
audit revealed that there was limited Government understanding of the drivers of 
demand and recommended that this be improved as it is essential for management of 
future pathology outlays.26  
Why is pathology testing increasing? 
Over the years, the increases in pathology testing have been attributed to numerous 
factors, including: the ageing population;9,26,27 defensive testing due to practitioner 
concerns about medicolegal implications of not testing;9,26,28 increasing patient 
demand for testing;26,28,29 increased disease awareness (e.g. due to educational 
campaigns) and disease prevalence, leading to increased diagnostic and/or 
management rates;27 changes in the management of established disease;9,27 increased 
availability of tests;9,26 improvements in testing technologies;29 increased use of 
computers for ordering tests;29,30 and policy initiatives.26,27,29 
In Australia, policy initiatives that have been associated with increases include those 
that aim to improve patient access to medical services (such as the Strengthening 
Medicare initiatives), improve provision of preventive care, and facilitate better 
management of diseases (such as MBS items‡ for health assessments and chronic 
disease management).26,27 Similar influence of policy initiatives on test ordering is 
seen internationally, for example the introduction of Quality and Outcomes 
Framework indicators that incorporated pathology test indicators in the United 
Kingdom (UK).29 
Another factor linked to increased use of pathology services is a lack of economic 
signal. In Australia, due to the structure of MBS pathology funding and the high rate 
of bulk-billing, the patient and the referring clinician do not pay for, and are unaware 
of, the costs of pathology tests. This funding situation is called the ‘third party payer 
problem’ and has been referred to as a “fundamental market flaw”.31 
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These factors are used to explain increases in pathology ordering by all clinicians, 
including that by GPs. The increased volume of pathology tests generated by GPs 
can be attributed to these factors working on the mechanisms of increasing GP 
workload, and/or changes in GPs’ pathology ordering behaviour. The latter can be 
characterised by changes in the GPs’ decision to initiate ordering, and the type and/or 
number of pathology tests ordered when the decision to order is made.  
The relationship between these factors and the increases in GPs’ ordering of 
pathology tests is not always proven. For example, while patient demand for testing 
is high (14–39% expect pathology or imaging tests when they visit the GP32-35) and 
GPs report this as a reason for ordering pathology,36,37 there is no evidence that 
patient demand has increased. Similarly the increased use of computers by GPs was 
thought to increase the ease with which pathology tests could be ordered and 
therefore contribute to increased GP demand.30 However, two studies found no 
independent effect of computer use on GPs’ pathology ordering.30,38 In contrast, the 
association of other factors is much stronger. For example the effect of Australia’s 
ageing population on increased demand for pathology tests can be established, as the 
use of pathology services increases with age.27 Similarly some national policy 
initiatives were determined to have increased the demand for pathology testing, and 
this resulted in adjustments to the third MoU.26 
With the numerous factors linked to increased demand for pathology testing, and the 
likely overlap between them,39 it is no wonder that understanding what is driving the 
increased demand for pathology testing has proved difficult. Further, it is reasonable 
to assume that the factors associated with increased demand would not equally affect 
all circumstances in which pathology tests were ordered.  
Notably absent in the literature that discusses increases in pathology testing, is 
information about the tests and clinical problems for which GPs’ pathology testing 
has increased.  
Why are pathology tests ordered? 
Two recent reviews investigated the reasons tests are ordered by clinicians.40,41 Both 
reviews took a very focussed approach: Whiting et al. concentrated on reasons tests 
were ordered for patients with undiagnosed symptoms,40 and Sood et al. only on 
variables that were related to the physician and were ‘non-evidence-based’.41 The 
focus taken by these reviews largely excluded the accepted clinical reasons for 
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pathology test ordering: to diagnose, monitor, assess prognosis, assess severity, or to 
screen for diseases.8,30,37,42 
Further, the extent to which results of the reviews can be generalised to describe the 
reasons that GPs’ order pathology tests is limited due to their narrow focus and the 
heterogeneity of the reviewed studies. Differences between the studies include: the 
types of tests investigated (i.e. a mixture of pathology, imaging and other diagnostic 
tests); the methodology used (including qualitative, quantitative and mixed methods); 
and the context of the study (i.e. the health settings, the types of clinicians ordering 
tests and the specific disease or test investigated).40,41 
Whiting et al. identified more than 30 reasons for ordering tests for undiagnosed 
symptoms and categorised these into five interrelated groups.40 Reasons classified as: 
diagnostic (e.g. to modify pretest probability of disease, rule disease ‘in’ or ‘out’); 
and therapeutic and prognostic (e.g. decide on appropriate treatment) could be 
considered evidence-based reasons for testing. However, the same could not be said 
for many of the: patient-related (e.g. patient preference); doctor-related (e.g. clinical 
experience and confidence in clinical judgement, speciality); and policy and 
organisational factors (e.g. practice size, test availability).40 
In their review, Sood et al. divided ‘non-evidence-based’ physician variables 
associated with ordering into those that could be modified and those that could not. 
Non-modifiable factors included geographic location, practice setting, age and sex, 
and clinical setting. Modifiable factors included experience and knowledge, belief 
systems, medicolegal concerns, financial incentives/awareness of cost of testing, and 
provision of feedback/education.41 It is somewhat inflammatory to label all of these 
factors as non-evidence-based. In particular, the provision of feedback and education, 
which is cited as being very successful in reducing test ordering and the “best-studied 
modifiable variable”, often involves the introduction of evidence through feedback 
and education. To label it as non-evidence-based is misleading.  
Despite the limited applicability of the reviews to general practice, Van der Weijden 
et al.36 found GPs in a small Dutch qualitative study reported similar reasons for 
ordering pathology testing in diagnostic uncertainty as those reported by Whiting et 
al.40 for undiagnosed symptoms. Variables most often linked by others to GPs’ 
pathology ordering are those related to the GP and the practice, and would be 
considered ‘non-evidence-based’ according to Sood’s review. GP variables linked to 
12 
testing include age,43-45 sex,43,46-48 geographic location and number of GPs working 
in the practice.43,45-47,49-51  
The bulk of the literature discussing reasons for pathology ordering focuses on the 
non-clinical reasons for testing, excluding the crucial fact that pathology is ordered in 
a clinical interaction between a patient and a clinician primarily for a clinical 
purpose. I believe the focus on non-evidence-based factors has occurred because they 
can be considered inappropriate and are potentially a modifiable area to target in the 
context of increasing testing. However, while they exist, a small study by Enno et al. 
demonstrated that they were not the primary reasons that GPs in Australia ordered 
pathology tests. The main reasons for ordering 3,419 pathology tests were: to 
establish a diagnosis (31.6% of 3,840 reasons for ordering), to monitor illness 
(29.1%), for screening (15.1%), or to monitor drug therapy (11.5%). GPs nominated 
non-evidence-based patient-related (3.7%) and doctor-related reasons (3.2%) far less 
frequently.37 
Inappropriate testing and outcomes 
The question of whether pathology tests are ordered appropriately has become an 
important issue due to the continuing increase in pathology ordering, and our 
inability to completely determine what is driving this increase.9,42,52-54  
Determining what testing is inappropriate and how much pathology testing is ordered 
inappropriately is difficult. In their review of 44 studies, Van Walraven and Naylor 
found that 5-95% of tests were reported as inappropriate, the majority of studies 
reporting that 10-50% of tests were inappropriate.52 They found that the level of 
evidence in studies evaluating the appropriateness was poor. The studies were 
heterogeneous in terms of the health setting investigated, the clinicians involved, the 
clinical problem investigated, and the tests investigated. In addition, the criteria used 
to judge appropriateness were found to be diverse and flawed. Part of the problem 
with assessing appropriate test use is the dearth of high-level evidence demonstrating 
the clinical value of pathology tests and the optimal way in which they should be 
used.39,52,55-57  
Despite the poor evidence, and Van Walraven and Naylor’s conclusion that 
“allusions to extensive inappropriate use should not be made without appropriate 
qualifiers”,52 these statements are common within the literature.8,9,28,29,58,59 It is 
reasonable on the basis of the available evidence to say that some pathology ordered 
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in selected circumstances is inappropriate and/or that some tests are ordered 
inappropriately. But to conclude that inappropriate test ordering is widespread, 
overstates the available evidence. 
Another statement repeated in the literature is that the increase in pathology ordering 
is due (either totally or partly) to increases in inappropriate pathology ordering.12,58 
However when you trace the origins of references used to support these statements 
the evidence is not there or is decades old. It appears that two true separate 
statements [(i) that pathology ordering is increasing, and (ii) that some of this testing 
is inappropriate] have merged to become a single unsubstantiated concept. 
Some have proposed that the appropriateness of pathology testing can be evaluated 
by whether it improves the patient’s or public’s health outcomes.60,61 This has given 
rise to the argument that the increased use of pathology testing has not corresponded 
with improved health outcomes or health status,9,31,61 the inference being that the 
increased use of testing is unjustified.  
This argument is extremely hard to prove or disprove as measuring outcomes 
associated with pathology ordering is notoriously difficult and studies that evaluate 
outcomes are rare.52,61,62 Partly this is because it is not the use of a pathology test in 
isolation that affects outcomes, it is the clinician’s actions (or lack thereof) in 
response to test results that affect outcomes. Further, numerous outcome measures 
can be used.61,63 There are examples in the literature where: use of pathology tests 
has resulted in improved outcomes;64,65 reduction in the use of tests has not adversely 
affected outcomes;66-68 and use of tests have contributed to adverse patient 
outcomes.69 Such studies are usually conducted in confined clinical settings (e.g. 
patients in hospital) where the association between testing and a specific outcome 
can be measured.  
There is no conclusive evidence to support the broad assertion that the increased use 
of pathology tests has not improved patient outcomes. The lack of quality evidence 
to measure outcomes has resulted in the call for an outcomes research agenda for 
pathology testing.42,57 The development of methods to assess such outcomes is a 
current area of research.70 
While these issues are important, the extrapolation of flawed evidence to make broad 
statements about the appropriateness (or lack thereof) of all pathology testing, paints 
the whole issue in an unnecessarily negative light. These general perceptions are 
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applied to all pathology ordered in all settings. As GPs in Australia order the 
majority of Medicare-funded pathology tests, the negative perception is often applied 
to their ordering behaviour, even though many of the studies of appropriateness and 
outcomes were not conducted in general practice.  
Criteria used to assess the quality of GPs’ pathology ordering behaviour often 
include the appropriateness of their ordering in selected clinical situations (e.g. for a 
specific disease) and the variance among GPs in their use of pathology tests. The 
presence of inter-GP variance is well established. Studies have found this variance is 
only partially explained by GP, practice and patient characteristics.43-51,71-73 
However, investigation of this variance often excludes consideration of the 
contribution of the clinical problem (or purpose) for ordering as these data are not 
routinely available. When included, the clinical problem being managed has been 
found to explain the largest proportion of variance.45,73 
Studies introducing interventions to improve appropriateness of GPs’ pathology 
ordering are used in the literature to demonstrate the presence of inappropriate 
ordering. Change, usually a reduction, achieved following interventions is used to 
‘prove’ that appropriateness of ordering can be improved. However, these studies 
rarely assess the appropriateness of these changes. Success is measured purely on test 
ordering rates without linked clinical data (such as the problem for which testing was 
ordered). Hence, while the intervention makes recommendations about appropriate 
pathology ordering in a given clinical situation using clinical data available to GPs at 
the time of ordering, such clinical data are not available in the assessment of the 
impact of the intervention. In the absence of such data, a measured change in the 
ordering rate of the related pathology tests is assumed to be due to improved 
appropriateness of ordering. 
I found two studies that directly assessed appropriateness of change following 
interventions targeting a limited number of pathology and diagnostic tests.74,75 The 
authors reported that this assessment was laborious and that appropriateness was only 
improved for selected tests. Both studies were randomised control trials. In one 
study, Verstappen et al. found that improvement in appropriateness aligned with 
reduction in use of tests.74 This was not the case for Winkens et al.75 who found that 
for one group of tests, GPs’ testing rates did not change but appropriateness of 
ordering improved, and for a second group of tests, GPs’ testing decreased 
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significantly but there was no change in the proportion of tests that were 
appropriate.75 It was hypothesised that this unusual finding was due to a high level of 
appropriate use of testing in the second group at baseline (prior to the intervention). 
Some authors acknowledge the limitation of being unable to assess appropriateness 
of change, but argue that such change can be assumed to be due to improved 
appropriateness because this is the basis of the intervention.76-79 I believe that this is a 
fair assumption in cases where testing is known (or likely) to be inappropriate at 
baseline. Most studies meet this requirement, interventions having been targeted to 
‘problem’ areas of pathology ordering. This approach is logical from the perspective 
that limited funds are available for interventions, and targeted interventions are likely 
to be cost-effective. However, in relation to the broader discussion of appropriateness 
of GP ordering, it is problematic.  
First, the need for cost effectiveness means that interventions are almost exclusively 
targeted to areas where a reduction in testing is anticipated. As summarised by 
Winkens and Dinant “ideal interventions would improve the rationality of ordering 
of investigations while at the same time leading to fewer requests being made.”9 
Consequently areas in which improved appropriateness of testing may lead to 
increases in testing are excluded. 
Second, targeting problem areas means that most interventional studies are 
conducted in very focussed clinical situations targeting a limited number of 
pathology tests58,80-84 or pathology testing for a limited number of clinical 
problems.11,75,77,85-87 While we know that a minority of problems and tests account 
for the majority of pathology ordered by GPs,45,79,82,88,89 this is not the basis for the 
selection of tests and problems. Therefore these studies do not provide an overall 
impression of the appropriateness of GPs pathology ordering behaviour. 
While these interventional studies can be used to demonstrate that there are areas of 
inappropriate ordering by GPs, they cannot be used to give an accurate evaluation of 
the extent of this inappropriate ordering. 
Interventions in pathology ordering 
Numerous interventions have been used in an attempt to modify clinicians’ 
pathology test ordering behaviour. In her 1991 review, Leese categorised 
interventions as involving: education; feedback; participation (i.e. involving 
clinicians in the need for, and development of an intervention); peer review; financial 
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incentives; and administrative changes (i.e. changes that control or direct choices 
regarding testing, such as policy change).90 Others have used similar categories to 
describe interventions.91-94  
Reviews of interventional studies found that success of the interventions was limited 
and the methodological quality of the studies was poor.91-94 For example, many 
studies lacked a control group or used a historical control group when evaluating 
interventions, and many lacked follow-up to determine whether the effect of 
interventions was sustained.93 The most recent review was conducted by Solomon et 
al. in 1998. Of the 49 studies reviewed that involved interventions to improve 
clinicians use of diagnostic tests, 76% reported favourable change in the clinicians 
use of tests. Despite the poor methodology and diversity of the studies, Solomon et 
al. found that those targeting multiple behavioural factors were more successful than 
those that targeted a single behavioural factor.91 
The extent to which results of these reviews can be applied to the general practice 
setting is limited due to the heterogeneity of the included studies. They included 
multiple types of tests (pathology and imaging), clinicians, health settings, and 
patient groups. Most of the reviewed studies were not conducted in general practice. 
For example of the 49 studies reviewed by Solomon et al. only 8 were conducted in 
general practice.91 
Several studies have reported interventions in general practice. Since 1990 results of 
19 intervention strategies have been published.11,58,74-77,79-87,95-100 Each ‘strategy’ 
often incorporated more than one intervention and some strategies were used in 
multiple studies. Types of interventions used include: changes to the laboratory order 
form (either paper-based11,80,83,97,99 or computer-based order form79,81,100), education 
(such as educational materials and meetings),11,58,74,75,77,82-85,95,100 
feedback,58,74,75,77,82,85,95,96 decision support,76,79,86,87 and changes to funding rules or 
arrangements.98,99 Guidelines were the basis for many of these interventions.74-77,83,85-
87,95 
Almost all of the published studies reported success in achieving all or some of the 
desired change (most often a decrease) in GPs’ pathology ordering rates, which may 
represent an element of publication bias. Only two reported no success in changing 
clinician behaviour.82,86  
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In Australia in the past 15 years, no studies were published that reported the effect of 
interventions targeting GPs’ pathology ordering behaviour. However, the Australian 
Government Quality Use of Pathology Program (established in 1999) supports 
quality ordering of pathology services and provision of quality services by funding 
projects that promote quality use of services.101 Other educational programs (such as 
the Common Sense Pathology series produced by the Royal College of Pathologists 
of Australasia [RCPA]102) and administrative interventions have also been 
introduced. To date, most national interventions have been administrative and reflect 
efforts to contain pathology outlays. These were primarily supply-based controls 
acting on the pathology industry through the MoUs and the MBS structures and 
rules.  
Few national initiatives have sought to modify demand for pathology services by 
referring GPs. Those that do have been largely incorporated into MBS rules, 
including indication and frequency restrictions for selected MBS pathology items.23 
For example, the MBS ‘HbA1c test’ item is only claimable for patients with 
established diabetes and can be claimed a maximum of four times within a 12 month 
period. Additionally, paper-based laboratory order forms are regulated to ensure that 
no ‘tick box’ lists of tests are provided, although the high level of GPs’ use of 
clinical software17 which allows ‘tick box’ pathology ordering may negate this 
measure. 
The Government’s ability to introduce interventions targeting GPs’ pathology 
ordering is hampered by the limitations of the Medicare data in describing the GPs’ 
pathology ‘referral’ behaviour. The Medicare data do not accurately reflect of the 
types of tests ordered by GPs due to the structure of the MBS items and the episode 
coning rule. In 2010, it was estimated that approximately 30% of MBS pathology 
items generated by GP orders were not eligible for funding due to coning.19 Further 
the Medicare data do not include any information about the clinical problems for 
which pathology tests were ordered. Such data are required to evaluate the 
appropriateness of GPs’ ordering and identify areas in which interventions may be 
needed. This evaluation step is missing in much of the international literature due to 
the lack of availability of clinical data (particularly the patient problem under 
management) related to GPs’ pathology ordering. This has led to judgements of 
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appropriateness based on limited evidence, and has hampered investigation of the 
clinical problems contributing to the increases in GPs’ pathology ordering. 
In Australia, data describing GPs’ pathology ordering behaviour are collected in the 
BEACH (Bettering the Evaluation and Care of Health) program. BEACH is a 
continuous cross-sectional national study of general practice activity, and is the only 
national source of data that allows analysis of the relationships between pathology 
ordered and problems managed‡ by GPs. Other factors such as the characteristics of 
the patient and the GP are also available for such analyses. For these reasons the 
BEACH data are used in this thesis. 
Two previous studies investigating GPs’ pathology ordering have been conducted 
using BEACH data.45,89 The first, conducted on 9 months of data collected in 1998, 
provided the first comprehensive national snapshot of GPs’ pathology ordering 
unaffected by the limitations of the Medicare data. It described GP characteristics 
associated with test ordering, the most common tests ordered, and the clinical 
problems for which pathology tests were ordered.89 The second was conducted using 
data from 1998 to 2001 and investigated increases in GPs’ pathology ordering with a 
focus on the GP characteristics associated with this increase.45 Since publication of 
these reports, upper level BEACH data summarising GPs’ pathology ordering 
(published annually) have demonstrated statistically significant increases in the 
likelihood and rate of GPs’ pathology ordering in Australia.103  
The ongoing increases in GPs’ pathology ordering evident in the BEACH and 
Medicare data are placing increasing pressure on Australia’s health budget. Many 
assumptions are made in the literature about why these increases are occurring and 
the appropriateness of GPs’ ordering. There is an underlying leaning that more 
testing represents poor quality, but with very little supporting evidence that measured 
increases in testing represent either ‘good’ or ‘bad’ change. This is partially due to a 
lack of clinical data describing the clinical context (e.g. clinical problems) of 
increases in pathology ordering. Such data are required to evaluate appropriateness 
of GPs’ pathology ordering. 
Framework for this thesis  
In this thesis I seek to address some of these issues. The overall aims are presented in 
Chapter 1, and topic-specific aims are included in the chapters in which they are 
investigated. In Chapter 3, I describe the methods used in this thesis. In Chapter 4, I 
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examine the changes in GPs’ pathology ordering patterns over time, and the 
pathology tests and the clinical problems contributing to the increase. For each of the 
identified clinical problems, I investigate the contribution of changes in GPs’ 
workload and GPs’ pathology ordering behaviour to the growth in pathology 
ordering. In Chapter 5, I evaluate the appropriateness of GPs’ pathology ordering for 
selected problems based on the extent to which GPs’ ordering aligns with pathology 
test recommendations made in clinical guidance for these problems. In Chapter 6, I 
investigate the use of the two most commonly ordered pathology test types by 
Australian GPs, the full blood count and lipid tests. Chapter 7 examines the extent to 
which the variance in GPs pathology ordering rates can be explained by GP, practice, 
and patient characteristics, the clinical problem under management, and the type of 
encounter. Chapter 8 considers the impact of the expected growth and ageing of the 
Australian population on GPs’ future pathology ordering. Discussion and 
conclusions are presented in Chapters 9 and 10. 
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3 Method 
In this thesis I use data collected in an ongoing research program called the BEACH 
(Bettering the Evaluation and Care of Health) study. The methods of the BEACH 
study are described in detail below.  
Throughout the thesis, additional methods have been designed and applied, and 
different data periods used for specific topics—these are described in detail in the 
method section of each chapter. Broadly the chapters rely on data that were collected 
at some point between April 2000 and March 2010. 
The description of BEACH and its methods provided in this chapter are drawn from 
previously published BEACH reports. The candidate has been a co-author of these 
reports since 2002. Each section is referenced to the report(s) from which it was 
sourced. 
3.1 An overview of the BEACH study 
The BEACH study is a continuous national study of general practice activity in 
Australia that commenced in April 1998 and began its fifteenth year of continuous 
operation in April 2012. The study was conducted by the Australian General Practice 
Statistics and Classification Centre, a collaboration between the Family Medicine 
Research Centre (FMRC) of the University of Sydney and the Australian Institute of 
Health and Welfare. This collaboration ceased in 2011 (after the data used in this 
thesis were collected), and the study has since been conducted by the FMRC alone.  
The BEACH study is supported by multiple stakeholders, including the Australian 
Government DoHA, pharmaceutical companies, not-for-profit organisations and 
other organisations that require general practice data (recognised in 
Acknowledgements). The program is overseen by an Advisory Board that is made up 
of representatives of each stakeholder organisation and representatives of the Royal 
Australian College of General Practitioners (RACGP), Australian College of Rural 
and Remote Medicine (ACRRM), Australian Medical Association, Australian 
General Practice Network and the Consumer Health Forum.104 
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Ethics approval 
For each year, ethics approval for the BEACH study was obtained from the Human 
Research Ethics Committee of the University of Sydney. From 1998 to 2011 ethics 
approval was also obtained from the Ethics Committee of the Australian Institute of 
Health and Welfare. 
Aims of the study 
The BEACH study has three primary aims: 
• to provide a reliable and valid data-collection process for general practice which 
is responsive to the ever-changing needs of information users, 
• to establish an ongoing database of GP–patient encounter information, 
• to assess patient risk factors and health states and the relationship these factors 
have with health service activity.104 
3.2 The BEACH method 
The core BEACH methodology, and data elements collected, did not change over the 
data years used in this thesis (2000 to 2010). While there have been minor changes 
over time (such as changes to questions on the GP profile), these do not affect the 
data elements used in this thesis. The example forms and instructions included as 
Appendices 2 to 5 reflect those used in the 2007–08 recording period.  
BEACH involves an ever-changing random sample of approximately 1,000 GPs per 
year. The study is paper-based. Each GP records details for 100 doctor–patient 
encounters‡ and each GP also completes a questionnaire about themselves and their 
practice.104  
The BEACH methods were developed from those used in the 1990–91 Australian 
Morbidity and Treatment Survey (AMTS) undertaken by the Department of General 
Practice at the University of Sydney.105 
While the BEACH study is ongoing, its methods are described throughout this 
chapter in past tense to describe how the BEACH data used in this study were 
collected. 
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3.2.1 Sample size 
Using data from the AMTS, Meza et al. developed sample size models for national 
general practice surveys.106 They found that a sample size of 1,000 GPs, each 
recording data about 100 patient encounters, provided reliable estimates of the most 
common problems managed and medications prescribed.106  
3.2.2 The sample  
In each year, the GP sample frame included all recognised GPs who had claimed at 
least 375 MBS general practice consultation service items‡ in the most recently 
available Medicare data quarter. The use of this cut-off meant that the vast majority 
of full-time and part-time GPs who were currently practising were included, but 
those who were very part-time or were not currently practising (e.g. on maternity 
leave) were excluded. 
Random samples for recruitment were drawn by DoHA. The samples included the 
GP’s: name, contact details at their major practice (address and telephone number), 
age, sex, and activity level‡ (that is, number of MBS general practice consultation 
service items‡ claimed in the previous quarter and in the previous 12 months).104  
3.2.3 GP recruitment 
The randomly sampled GPs were sent a letter describing the study, detailing what 
participation involved and inviting them to participate.104 An average of 60 GPs were 
sent letters each week.  
In order to retain their vocational registration, Australian GPs are required to 
participate in professional development programs conducted by the RACGP or the 
ACRRM. Registered GPs are required to participate in activities in the program to 
earn a specific number of points in each triennium (3 year period). BEACH is 
classified as a clinical audit, and participation earns GPs these points. 
Approximately ten days after the approach letter was sent, the GP was contacted via 
telephone by a trained recruiter to ask whether they would like to participate. When a 
GP agreed to participate, they were entered into the GP participant database, 
assigned an identification number and a starting date was arranged. A participating 
sample of 25 GPs per week (with a target completion rate of 20 GPs per week) was 
recruited for 50 weeks each year. This created a rolling ever-changing sample. 
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3.2.4 Data collection 
A research pack was posted to each GP 10 days before the start date. Each research 
pack contained: 
• a pad of 105 (to allow for error) paper encounter forms. An example of the 
encounter form is included as Appendix 2. 
• a one page questionnaire about the GP and their practice called the ‘GP Profile’. 
An example is included as Appendix 3. 
• a cover letter 
• a set of instructions about how to complete the encounter form and a sample of a 
completed form (Appendix 4) 
• two copies of the patient information card (Appendix 5). 
• height and weight conversion charts (imperial to metric) used to record details of 
the patients height and weight for conversion to body mass index 
• an alcoholic drinks chart providing information on ‘standard’ drinks. 
The patient information card was intended to inform patients that their GP was 
participating in the study. GPs were instructed to ensure that all patients were given 
the card to read. The card instructed the patients to advise their GP if they did (or did 
not) want unidentified details of their encounter recorded. Consent was obtained as 
per the ethics requirements: from 1998–99 to 2004–05 only verbal consent was 
required; from 2005–06 onward, GPs were required to include a note in the patient’s 
medical record that she/he had agreed to take part.  
A member of the research team telephoned each GP on their agreed starting date to 
remind the GP to commence recording, and to answer any questions the GP might 
have.  
GPs were instructed to record details for 102 patient encounters, in a consecutive 
manner (or as consecutive as possible where patient consent enabled this). The first 
100 encounter forms that were completed were used in the study. Each GP returned 
their completed pad and their GP profile using the reply paid envelope provided.  
24 
3.2.5 Data elements 
Three interrelated sets of data were collected in BEACH: encounter data; GP and 
practice data; and substudies of various topics. The substudies, referred to as SAND 
(Supplementary Analysis of Nominated Data), are described in Section 3.2.6.  
Figure 3.1 describes the relationships between the BEACH data elements 
diagrammatically. All variables can be directly related to GP and patient 
characteristics and to the encounter. All types of management (including pathology 
tests) are directly related to one or more problems being managed at the encounter. 
The data used in this thesis are highlighted in Figure 3.1, and defined below. 
Encounter data 
In BEACH, the encounter was defined as any professional interchange between a 
patient and a GP. Encounters can be ‘direct’‡ involving face-to-face meeting between 
the GP and patient or ‘indirect’‡ where there was no face-to-face contact but a 
service was provided (e.g. a prescription or referral arranged by telephone).  
Encounter data elements were collected on the encounter form (Appendix 2) and 
included details about the encounter itself, the patient, the problems that were 
managed and the management provided. The encounter data were cross-sectional. 
Therefore, the problems managed and the management provided reflect the 
encounter activity. 
  
 
 
Figure 3.1: The BEACH relational database 
Note: FTE—full-time equivalent; FRACGP—Fellow of the 
Royal Australian College of General practitioners; DVA—
Department of Veterans’ Affairs; NESB—non-English-
speaking background; SAND—Supplementary Analysis of 
Nominated Data. 
The encounter 
 date 
 direct (face to face) 
— Medicare Benefits Schedule 
item number(s) claimable 
— workers compensation 
— other paid 
— no charge 
 indirect (e.g. telephone) 
Patient substudies (SAND) 
 risk factors 
— body mass 
— smoking status 
— alcohol consumption  
 other topics 
Management of each problem 
Medications (up to four per 
problem) 
 prescribed 
 over-the-counter advised 
 provided by GP 
— drug class 
— drug group 
— generic 
— brand name 
— strength 
— regimen 
— number of repeats  
— drug status (new/continued) 
 
Other treatments (up to two per 
problem) 
 procedural treatments 
 clinical treatments (e.g. advice, 
counselling) 
 practice nurse involvement 
 
Pathology tests ordered (up to 
five per encounter) 
 individual tests (e.g. glucose test) or 
 batteries of tests (e.g. lipid profile) 
 
Other management 
 referrals (up to two per encounter) 
— to specialists 
— to allied health professionals 
— to emergency departments 
— hospital admissions 
 imaging ordered (up to three per  
 encounter) 
GP characteristics 
 age and sex 
 years in general practice 
 country of graduation 
 number of sessions per week 
 FRACGP status (yes/no) 
 currently a registrar (yes/no) 
 
Practice characteristics 
 practice size (FTE GPs) 
 postcode 
 accreditation status 
 after-hours arrangements 
 teaching practice (yes/no) 
The patient 
 age and sex 
 practice status (new/old) 
 Concession card status 
 DVA status 
 postcode of residence 
 NESB/Indigenous status 
 reasons for encounter 
Problems managed 
 diagnosis/problem label 
 problem status (new/old) 
 work-related problem status 
25 
26 
Encounter details  
The only data element describing the encounter that is used in this thesis, is the MBS 
item number (Box 3.1). It is used to classify the encounter as level A, B, C or D‡ 
(where applicable) based on the type of GP–patient consultation. These MBS levels 
are defined in the glossary.  
 
Box 3.1: Encounter data elements 
Element Definition and format 
 Medicare Benefits Schedule item 
 number‡ 
Item number recorded as claimable for the encounter. Up to 3 
item numbers per encounter (Free text number) 
‡ Definition of term is included in glossary. 
 
The patient  
Data elements about the patient used in this thesis are described in Box 3.2. The 
‘Health concession card’‡ variable used in Chapter 7 is a binary variable that was 
created using the health care/benefits card‡ and Repatriation health card‡ data 
elements. A patient with either of these cards was classed as having a health 
concession card. 
 
Box 3.2: Patient data elements 
Element Definition and format 
Age Day (2 digit number), month (2 digit number) and year (4 digit 
number) of the patient’s date of birth  
Sex Male, Female (Tick box) 
New patient status‡ Indicates whether this is the patient’s first visit to the practice 
(Yes/No tick box) 
Health care/benefits card‡ Patient holds a card entitling them to a higher level of 
Government subsidy for health services. Examples of 
patients who may be eligible include pensioners, 
unemployed, low income earners (Yes/No tick box) 
Repatriation health card‡ Patient holds a card from the Department of Veteran’s Affairs 
entitling them to a range of Repatriation health care benefits 
(Yes/No tick box) 
‡ Definition of term is included in glossary. 
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The problems managed  
Data elements collected about a problem under management at the encounter that are 
used in this thesis, are described in Box 3.3.  
 
Box 3.3: Data elements about the problems managed 
Element Definition and format 
Diagnosis/problem‡ A statement of the provider’s understanding of a health 
problem presented by a patient, family or community. GPs 
are instructed to record at the highest diagnostic level 
possible from the information available at the time. It can be 
recorded as a symptom, morbidity or process of care.  
At least one and up to four problems can be recorded per 
encounter. Free text 
Problem status, either ‘New’‡ or ‘Old’‡ New problem is defined as the first presentation of a 
problem, including the first presentation of a recurrence of a 
previously resolved problem, but excluding the presentation 
of a problem first assessed by another provider. 
Old problem is defined as a previously assessed problem 
that requires ongoing care, including follow-up for a problem 
or an initial presentation of a problem previously assessed by 
another provider. 
New/Old tick box for each problem.  
‡ Definition of term is included in glossary 
 
Pathology tests ordered and other management provided 
In BEACH, several types of management actions could be recorded, and all of these 
management activities were linked by the GP to the problem (or problems) for which 
they were given. 
In this thesis, pathology data are the main type of management data used. GPs 
recorded each pathology test in free text as either a single test (such as fasting 
glucose test) or a battery of tests‡ (such as a lipid profile) (Box 3.4). Up to five 
pathology tests or batteries of tests can be recorded per encounter. Each pathology 
test or battery must be linked to at least one problem but could be linked to up to four 
problems managed (the maximum recorded per encounter). This means that there can 
be a one-to-one, one-to-many or many-to-one relationship between pathology 
tests/batteries and problems managed. 
The medication ‘name’ data element was also used in Chapter 5 (Box 3.4). 
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Box 3.4: Data elements about pathology tests and other management of problems at 
the encounter 
Element Definition and format 
Pathology 
 Single test (e.g. fasting glucose test) 
 Battery of tests‡ (e.g. lipid profile) 
Pathology tests/batteries of tests ordered by the GP at the 
encounter.  
Up to five pathology tests or batteries of tests could be 
recorded per encounter. Each test or battery of tests was 
linked by the GP to the related problem or problems 
managed at the encounter for which the test was ordered. 
Free text, and circle the problem number(s) to which the 
test related.  
Medication  
Details collected include: name, form 
(where required), strength, regimen. 
Includes medications prescribed, supplied by the GP and 
advised for over-the-counter purchase. 
Up to 4 medications could be recorded per problem, and a 
maximum of 16 medications could be recorded per 
encounter.  
Tick boxes for GP-supply, and over-the-counter status. 
Free text for other medication data variables. 
‡ Definition of term is included in glossary 
 
GP and practice data 
In BEACH, a single page questionnaire was used to gather data about each 
participating GP and their practice (Appendix 3). As it is possible for a GP to work at 
multiple practices, GPs were instructed to provide details about their major practice.  
The GP and practice data elements used in this thesis are described in Box 3.5. In 
Chapter 7, the practice postcode was used to assign the relevant Australian State or 
Territory of the practice location, and to classify the rurality of the practice location 
using the Australian Standard Geographical Classification (ASGC) remoteness 
areas.107 
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Box 3.5: Data elements about the participating GPs and their practice 
Element Definition and format 
Age GP’s age. Free text (number). 
Sex GP’s sex. Circle ‘male’ or ‘female’. 
Years in general practice Number of years spent in general practice. Free text (number). 
Fellowship of the Royal Australian 
College of General Practitioners 
(FRACGP)  
Status of the GP as a fellow of the Royal Australian College of 
General Practitioner. Circle ‘yes’ or ‘no’.  
Country of graduation Country where the GP’s primary medical degree was obtained. 
Circle number to indicate one of the listed countries or record 
(in free text) an ‘other’ country.  
Year of graduation Year in which primary medical degree was obtained. Free text 
(number). 
Sessions per week/Workload Number of general practice sessions usually worked by the GP 
per week. A session is defined as approximately 4 hours e.g. a 
morning session. Free text (number). 
Practice postcode Postcode of the major practice address. Free text (number). 
Size of practice (number of full-time 
equivalent [FTE] GPs) 
Number of FTE GPs, including the participating GP, who work 
at the major practice. Free text (number). 
Accreditation‡ status  Whether the major practice is accredited according to the 
Royal Australian College of General Practitioner standards. 
Circle ‘yes’ or ‘no’. 
Status as a teaching practice Whether the major practice provides training for undergraduate 
medical students and/or GP registrars. Circle a number(s) to 
indicate training provided. 
‡ Definition of term is included in glossary. 
3.2.6 SAND substudy data 
Each recording form had a section at the bottom that was used to investigate 
additional topics not covered in the encounter-based data. These additional 
investigations are referred to as SAND substudies.108 
In each GP’s recording pad of 100 forms there were three ‘sets’ of SAND forms: one 
set of 40 forms and two sets of 30 forms. Each set represented a separate topic. 
The set of 40 forms were the same in every pad and covered selected patient risk 
factors: alcohol intake, smoking status and self-reported height and weight (for 
calculation of body mass index [BMI] using the World Health Organization’s BMI 
classification109). Start and finish times were also recorded for calculation of the 
length of the encounter. The encounter form attached as Appendix 2 includes this set 
of SAND questions. 
The questions on the two sets of 30 forms varied throughout each year. Each 
BEACH data year was divided into 10 five-week periods. In each five-week period 
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information was collected from about 100 GPs (20 recording per week), with a 
potential sample size of about 3,000 patient encounters on each topic. New studies 
were introduced at the beginning of each five-week period. It was possible to repeat 
topics over two or more different periods to increase the sample size. 
The order of SAND sections in the GP recording pack was rotated, so that the set of 
40 forms may have appeared first, second or third in the pad. Rotation of the forms 
minimised order effect on the data collected. 
SAND data are used in two places in this thesis.  
• The patient BMI data are used in Chapter 5, Section 5.9 to describe prevalence 
of overweight and obesity.  
• A SAND study was designed for this thesis to investigate GP ordering of full 
blood counts and lipid tests (see Chapter 6).  
3.2.7 Data entry and classification 
Data from the BEACH study were entered into a Microsoft Access database 
designed for the study. The Access database was designed to enable efficient 
accurate data entry (for example picklists that automatically classified the selected 
term). Data were entered by trained secondary coders. 
Most data elements collected in BEACH were classified according to the 
International Classification of Primary Care—Version 2 (ICPC-2), a product of the 
World Organization of Family Doctors (Wonca).110 ICPC-2 is accepted by the World 
Health Organization (WHO) in the WHO Family of International Classifications,111 
and is the recommended Australian standard for classification of data from general 
practice.112 
In this thesis, the data elements classified to ICPC-2 are problems managed, and 
pathology tests ordered. These elements were coded using ICPC-2 PLUS (see below) 
and classified to ICPC-2. 
International Classification of Primary Care 
The ICPC-2 has a biaxial structure, with 17 chapters on one axis (each with an 
alphabetic code) and seven components on the other (numeric codes) (Figure 3.2). 
Chapters are based on body systems, with additional chapters for psychological and 
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social problems. Component 1 includes symptoms and complaints and component 7 
covers diagnoses.  
Component 2 (diagnostic, screening and prevention) is often applied in describing 
the problem managed (for example, check-up, immunisation). Components 3 to 6 
cover other processes of care, including referrals, other treatments and orders for 
pathology and imaging. The components are standard and independent throughout all 
chapters.110  
                    
 Components A B D F H K L N P R S T U W X Y Z  
 1. Symptoms, complaints                    
 2. Diagnostic, screening,  
 prevention 
                  
 3. Treatment, procedures,  
 medication 
                  
 4. Test results                   
 5. Administrative                   
 6. Other                   
 7. Diagnoses, disease                   
 A General and unspecified L Musculoskeletal U Urological 
 B Blood and blood-forming 
organs 
N Neurological W Pregnancy and family 
planning 
 D Digestive P Psychological X Female genital 
 F Eye R Respiratory Y Male genital 
 H Ear S Skin Z Social 
 K Circulatory T Endocrine, metabolic and nutritional 
 
Figure 3.2: The structure of the International Classification of Primary Care, 
Version 2 (ICPC-2) 
ICPC-2 PLUS 
In 1995, recognising a need for a coding and classification system for general 
practice electronic health records, the Family Medicine Research Centre (then Unit) 
developed a clinical terminology classified according to the ICPC-2, called ICPC-2 
PLUS.113 It was based on the free text terms recorded by GPs in studies such as the 
AMTS.105 Approximately 800,000 encounter records were used in the development 
of the terminology,104 and it is regularly updated using the terms recorded in BEACH 
(approximately 1.2 million encounters from 1998 to 2010)17 and input from GPs 
using ICPC-2 PLUS in their electronic health records. 
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All free text data elements were coded using ICPC-2 PLUS. This ensured high coder 
reliability, and automatic classification of the concept. It also enabled analysis of the 
data at the classification level or (where required) at the more specific terminology 
level. 
Presentation of data classified in ICPC-2 
In this thesis, data coded in ICPC-2 PLUS are reported at the ICPC-2 classification 
level. However, there are some circumstances where this was not meaningful, and it 
was necessary to group concepts. 
Problems managed 
Where problems managed are grouped in this thesis they are marked with an asterisk 
in the tables and listed in Appendix 6 with the associated codes. 
Concepts may need to be grouped ‘above’ the classification level. This involves 
grouping multiple ICPC-2 codes. For example, two ICPC-2 codes K86 
(hypertension, uncomplicated) and K87 (hypertension, complicated) were grouped 
together and reported as ‘Hypertension (non-gestational)*’. 
Concepts are also grouped across the classification by grouping multiple ICPC-2 
PLUS terms. For example, multiple PLUS terms that describe checks-ups were 
grouped together and reported as ‘health check*’. 
Grouping of pathology data 
Pathology tests are classified in ICPC-2 in component 2, ‘Diagnostic, screening and 
prevention’. There are seven rubrics‡ within this component that relate to pathology 
tests. These rubrics can be applied in 16 of the 17 ICPC-2 chapters‡. They cannot be 
applied in the Social chapter of ICPC-2. The rubrics are: 
• –32 Sensitivity 
• –33 Microbiological/immunological test 
• –34 Blood test 
• –35 Urine test 
• –36 Faeces test 
• –37 Histological/exfoliative cytology 
• –38 Other laboratory test not elsewhere classified. 
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This means there are 112 rubrics available to classify pathology tests in ICPC-2. 
While it is possible to analyse and report the pathology data using ICPC-2, it is too 
broad for meaningful interpretation. For example, a fasting glucose test is classified 
in T34—Blood test associated with the Metabolic, endocrine, nutritional system.  
In Australia, pathology data are often reported using the groupings from the MBS 
PST in which pathology tests are grouped by pathology discipline. These groupings 
are more meaningful in the Australian setting so all pathology ICPC-2 PLUS codes 
are grouped to align with the MBS standard pathology groups. Some of the terms I 
have used to refer to these groups differ slightly from those used by the MBS, as I 
have used terminology that is common in general practice. The pathology groups 
analysed and reported in this thesis are: 
• Haematology 
• Chemistry (referred to as ‘Chemical’ in the MBS) 
• Microbiology 
• Immunology 
• Histopathology (referred to as ‘Tissue pathology’ in the MBS) 
• Cytopathology (referred to as ‘Cytology’ in the MBS) 
• Infertility and pregnancy tests 
• Simple basic tests 
• Other tests not elsewhere classified (NEC). This group includes pathology tests 
not included in any of the above groups (such as, the ‘Genetics’ MBS group). 
Each of these pathology groups with its associated ICPC-2 PLUS pathology codes is 
listed in Appendix 7. 
Individual pathology tests and batteries of tests are also grouped together to form 
logical reporting entities (for example, the ‘Glucose/glucose tolerance’ test group 
includes all types of serum glucose tests). All pathology tests/batteries of tests that 
include multiple ICPC-2 PLUS codes are marked with an asterisk in the tables and 
listed in Appendix 7 with the associated PLUS codes. 
Classification of pharmaceuticals 
Pharmaceuticals that are prescribed, provided by the GP or advised for over-the-
counter purchase are coded and classified according to the Anatomical Therapeutic 
Chemical (ATC)114 classification, which is the international standard for classifying 
34 
medications for drug utilisation studies.115 The ATC has a hierarchical structure with 
five levels. For example: 
• Level 1: C—Cardiovascular system 
• Level 2: C10—Serum lipid reducing agents 
• Level 3: C10A—Cholesterol and triglyceride reducers 
• Level 4: C10AA—HMG CoA reductase inhibitors 
• Level 5: C10AA01—Simvastatin (the generic drug). 
3.2.8 Quality assurance 
A quality assurance program was applied to ensure reliability of data entry. This 
included ongoing development and application of computer-aided error checks and 
‘locks’ at the data entry stage (such as preventing female-specific problems being 
coded for male patients), and a series of logical data checks (e.g. medication dose 
outliers) to identify encounters where the coded data should be checked against the 
original recording form. All forms entered by new data entry staff were checked 
against the original form, and as staff became more experienced a sample of forms 
(e.g. one-in-ten) were checked by senior research staff. This ongoing process 
identified areas where further training was required.108 
3.2.9 Validity and reliability 
In the development of a database such as BEACH, data gathering moves through 
specific stages: GP sample selection, cluster sampling around each GP, GP data 
recording, secondary coding and data entry. At each stage the data can be invalidated 
by the application of inappropriate methods. The methods adopted to ensure 
maximum reliability of coding and data entry have been described above. The 
statistical techniques adopted to ensure valid analysis and reporting of recorded data 
are described in Section 3.2.11. Previous work has demonstrated the extent to which 
a random sample of GPs recording information about a cluster of patients, represents 
all GPs and all patients attending GPs.116 Other studies have reported the degree to 
which GP-reported patient reasons for encounter and problems managed accurately 
reflect those recalled by the patient,117 and the reliability of secondary coding of 
reasons for encounter118 and problems managed.105 The validity of ICPC as a tool 
with which to classify the data has also been investigated in earlier work.119 
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3.2.10 Representativeness  
The extent to which data drawn from a sample can be generalised is a function of the 
ability of the sample to represent the population from which it is drawn. Random 
sampling of GPs improves the likelihood that a study will be representative, as each 
GP has equal probability of being selected. Even with random sampling, it is possible 
to end up with under-representation and/or over-representation of some groups 
within the final sample.108 
Sample weights can be calculated to improve the representativeness of the sample 
and adjust for any identified under-representation or over-representation within the 
sample. Weights were assigned by comparing the distribution of the sample against 
the distribution in the benchmark population for those characteristics that may 
influence the final results (e.g. GP age group and sex). Weights are calculated as the 
proportion of each subgroup in the population divided by the proportion in the 
sample. Over-representation results in a weight less than one, under-representation in 
a weight greater than one.108 
The BEACH study aims to gain a representative sample of GP–patient encounters. 
Representativeness of the GP sample is used to weight the encounters, based on the 
assumption that the characteristics of the patient encounter are related to the 
characteristics of the GP. Therefore to weight the encounters the representativeness 
of the GP sample needs to be determined. This is done by comparing the sample of 
participating GPs with GPs in the national sample frame (using MBS data supplied 
by DoHA). GP weights were calculated for the participants to match the age-sex 
distribution of all GPs in the total sample frame, correcting for any measured under-
representation or over-representation. Weightings for GP age were stratified by GP 
sex.  
The BEACH process requires that each GP provides details of 100 consecutive 
encounters. The assumption (based on earlier research) is that 100 encounters 
provide a reliable sample of the GP’s patients and practice style.106 However, there is 
considerable variation in the number of services provided by different GPs in a given 
year. This may have an impact on the reliability of any estimate due to the 
differences in the sampling fraction for each GP—a GP who provides 6,000 services 
in a given year should make a greater contribution to any national estimate of a 
selected activity than a GP who provides 3,000 services. Encounters were therefore 
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assigned an additional weight that was directly proportional to the activity level of 
the GP who recorded the encounter, based on the number of MBS general practice 
consultation service items claimed in the previous 12 months.  
The final annual weighted encounter data set was created by multiplying raw rates by 
the GP age-sex weight and the GP activity weight. However, weights can only be 
applied to each single annual sample of BEACH data because the MBS data supplied 
by DoHA (on which weighting is based) are only provided for the specific BEACH 
12 month data period (April to March). 
In this thesis, weighted annual data are used in Chapter 8. In all other results chapters 
(Chapters 4–7), it is not methodologically sound to apply weighting for various 
reasons. 
• In Chapters 4 and 5, multiple years of data are combined in the analysis, and it is 
not possible to apply weighting. However, combining multiple years of data 
increases the statistical power of the analysis. 
• In Chapter 6, a SAND substudy is analysed, and as this uses a subsample of the 
total BEACH sample, weighting cannot be applied. 
• In Chapter 7, it was not appropriate to weight the data because the variables used 
for weighting (GP age and GP sex) were adjusted for in the analysis.  
The representativeness of the each of the annual GP samples and samples of 
encounter data (both unweighted and weighted) used in this thesis, 2000–01 to  
2009–10, have been investigated and published elsewhere.17,120-128 This thesis centres 
on pathology testing ordered at encounters, therefore, the representativeness of the 
sampled encounters needs to be considered to determine whether the results can be 
generalised.  
Briefly, the representativeness of each annual encounter sample was assessed by 
comparing the age-sex distribution of patients at BEACH encounters where MBS 
general practice consultation service items were recorded as claimable with the 
age-sex distribution of patients at all encounters claimed in Australia as MBS general 
practice consultation service items (data provided by DoHA). To aid this 
comparison, precision ratios were created by dividing the proportion of BEACH 
encounters by the proportion of Australian MBS encounters in each age-sex 
group.121,125 In determining whether any estimate is reliable, power calculations use a 
precision of 0.2 or 20% of the true proportion (or value). Therefore the BEACH 
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encounters are considered a reliable representation of MBS encounters when the 
range of precision is 0.8–1.2.  
In each of the years of data used in this thesis (2000–01 to 2009–10), there was an 
excellent fit of the MBS and BEACH age and sex distribution both with and without 
weighting, with no age–sex category varying by more than 20% from the population 
distribution, with one exception. In 2008–09 one unweighted age–sex category 
(males aged 1–4 years) varied by 23% from the population distribution (based on raw 
data). After weighting, this ratio improved to within 20%.17,120-128 The fact that raw 
precision ratios (unweighted data) rarely varied by more than 20% indicates that each 
of the annual BEACH encounter samples is a good representation of Australian GP–
patient encounters. Therefore the unweighted data used in Chapters 4–7 can be 
considered a reliable representation of GP–patient encounters in Australia.  
3.2.11 Statistical methods 
The analysis of BEACH data was conducted with Statistical Analysis System (SAS) 
version 9.1.3.129 The primary unit of inference in the BEACH study is the encounter. 
Rates per 100 encounters are used when an event can occur more than once at the 
consultation (for example, problems managed or medications). Rates per 100 
problems are also used when a management event (such as pathology tests ordered) 
can occur more than once per problem managed.45,108  
Proportions (%) are used when describing the distribution of an event that can arise 
only once per encounter (for example, patient age, sex) or once per problem (for 
example, new problem), or to describe the distribution of events within a class of 
events (for example, problem A as a percentage of total problems).45,108 
In general, the results presented include: the number of observations (n), the rate per 
100 encounters or the rate per 100 problems managed, and the 95% confidence 
interval (CI).  
It is possible to report the rate of pathology test ordering as a rate per 100 encounters 
and as a rate per 100 problems managed. When presented as a rate per 100 
encounters, the number of pathology tests/batteries of tests at the encounter are 
analysed. When presented as a rate per 100 problems the analysis can be based on 
the number of pathology tests/batteries or the number of problem–pathology links.‡ 
The problem–pathology links must be used in analyses investigating GPs’ pathology 
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ordering behaviour for specific problems. In most cases, data presented as a rate per 
100 problems are based on the number of problem–pathology links. It is possible to 
link each test/battery to more than one problem; therefore there are more problem–
pathology links than numbers of tests recorded at encounters. This is discussed 
further in Chapter 4. 
BEACH is a single-stage cluster sample study design. The randomly sampled GPs 
each provide data about a cluster of 100 encounters. Studies with a cluster sample 
design violate the simple random sample (SRS) assumption because the probability 
of an encounter being included is a function of the probability of the GP being 
selected. There is also a secondary probability function of particular encounters 
being included in each GP’s cluster (e.g. associated with characteristics of the 
location or type of the practice) and this increases the likelihood of sampling bias. In 
cluster samples, variance needs to be adjusted to account for the correlation between 
observations within clusters.45,108 
When a study design other than SRS is used, analytical techniques that consider the 
study design should be used. In this thesis, survey procedures in SAS version 9.1.3 
were used to adjust the standard error used in calculating the 95% CIs, to 
accommodate the single-staged cluster sample study design.129 
Statistically significant differences 
In this thesis, a statistically significant difference between two results was assessed 
by comparing the 95% CI around each result. Non-overlapping 95% CIs indicate a 
statistically significant difference between the results. The magnitude of this 
difference can be described as at least p <0.05; however, non-overlapping CIs are 
known to be a conservative measure of significance.130-132 By using this measure I 
am increasing the specificity while reducing the sensitivity, thus decreasing the 
chance of false positive and increasing the chance of false negative results. Due to 
the number of comparisons made in this thesis, and the large sample size of the 
BEACH study, I believe it is more appropriate to reduce the chance of false positive 
results. 
Cumming and Finch stated that when comparing results from independent random 
samples, non-overlapping 95% CIs are more likely to represent a confidence level of 
approximately p <0.01 than p <0.05.131 Each annual sample of BEACH data is an 
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independent random sample. Therefore, in Chapters 4, 5 and 8, statistically 
significant changes over time measured using data from separate independent 
random samples, indicate a confidence level of p <0.01. 
The following gives an example of non-overlapping 95% CIs: 
Result A: 11.5 per 100 problems (95% CI: 11.3–11.7) is significantly less 
than Result B: 11.9 per 100 problems (95% CI: 11.8–12.0).  
When comparing results, if the two sets of CIs butt together the difference is 
regarded as marginal. For example: 
Result A: 11.5 per 100 problems (95% CI: 11.3–11.7) is marginally lower 
than Result B: 11.9 per 100 (95% CI: 11.7–12.1).  
If the CIs overlap, then no difference has been demonstrated. 
In measuring changes in pathology ordering over time in Chapters 4 and 5, results 
from April 2000 to March 2002 (referred to as 2000–02), are compared with those 
from April 2006 to March 2008 (2006–08). Grey shading in tables indicates changes 
between 2000–02 and 2006–08, darker shading indicates a statistically significant 
change and lighter shading indicates a marginal change. The direction and type of 
change is indicated for each result in the far right column of the tables:  
• / indicates a statistically significant linear change  
• / indicates a marginally significant linear change  
• — indicates there was no change. 
3.2.12 Extrapolated national estimates  
Extrapolations can be used to estimate the number of occurrences of a selected event 
at GP encounters in Australia at a single time point or to estimate the total national 
effect of measured change. In this thesis, extrapolations are made to estimate the 
number of encounters in Australia involving the management of selected problems 
and the number involving pathology ordering.  
The extrapolation method described in this section is the standard method used 
throughout this thesis. Extensions of this method are used in Chapters 4 and 8, and 
are described in the methods section of these chapters. 
Extrapolations are calculated using the total number of MBS general practice 
consultation service items claimed in Australia in each financial year, rounded to the 
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nearest 100,000.5 These are listed for each year (2000–01 to 2009–10) in Table 3.1. 
Throughout this thesis, the number of MBS general practice consultation service 
items claimed in Australia is referred to as the number of national MBS GP–patient 
encounters.  
Table 3.1: Number of general practice professional services claimed from Medicare 
Australia each financial year, 2000–01 to 2009–10 
Financial year Number of GP MBS items Rounded number of GP MBS items 
2000–01 100,645,000 100,600,000 
2001–02 99,921,000 99,900,000 
2002–03 96,919,000 96,900,000 
2003–04 96,330,000 96,300,000 
2004–05 98,180,000 98,200,000 
2005–06 101,095,000 101,100,000 
2006–07 103,433,000 103,400,000 
2007–08 109,518,000 109,500,000 
2008–09 113,045,000 113,000,000 
2009–10 116,646,000 116,600,000 
Note: MBS – Medicare Benefits Schedule. 
Source: Medicare statistics.5 
When an extrapolation is based on data from multiple years, the average number of 
national MBS GP–patient encounters (rounded to the nearest 100,000) is used for the 
extrapolation and the extrapolation is interpreted as the average ‘per annum’ estimate 
in those years. Chapters 4 and 5 include extrapolations that are based on data from 
multiple years. These chapters use data collected over the period April 2000 to 
March 2008 (referred to as 2000–08); and changes over time are measured by 
comparing results from the first two years of the study period (2000–02) with those 
from the last two years (2006–08). For 2000–08 data, the number of national MBS 
GP–patient encounters used for extrapolation is 100.8 million. For 2000–02 data, the 
number of national MBS GP–patient encounters used is 100.3 million, and for  
2006–08 data, it is 106.5 million. 
The method used to calculate extrapolations is described below. The national number 
of encounters from 2000–02 is used in the example to describe the method, but it can 
be applied for other periods. To calculate the number of encounters involving the 
management of a specific problem: 
• divide the BEACH management rate of each problem i.e. the ‘rate per 100 
encounters’ for 2000–02 by 100, and then multiply by the total number of MBS 
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general practice consultation service items in 2000–02, 100.3 million (rounded to 
the nearest 100,000) to give the estimated number of GP encounters at which the 
problem was managed nationally per year in 2000–02. 
As an example the management rate of hypertension is extrapolated. In BEACH, 
hypertension was managed at a rate of 9.1 per 100 encounters in 2000–02. To 
extrapolate: (9.1/100) x 100.3 million = an estimated 9.1 million encounters 
where hypertension was managed in general practice per year in 2000–02. 
The above extrapolation is used most commonly throughout this thesis. All 
extrapolation estimates made are average annual estimates. For example, the number 
of encounters at which hypertension is managed by GPs was estimated to be 
9.1 million encounters per annum in 2000–02. 
Analysis of some problem data (and the related pathology testing data) are restricted 
by patient age. For example, overweight/obesity problems are investigated in patients 
aged 18 years and over. When data pertaining to these problems are extrapolated the 
number of GP–patient encounters is adjusted based on the proportion of encounters 
in the selected age group. For example, in 2000–02, 84.1% of encounters were with 
patients aged 18 years and over, therefore the number of GP–patient encounters used 
in extrapolations related to overweight/obesity data was 84.4 million (84.4% of 
100.3 million). 
Extrapolation estimates are rounded to the nearest 100,000 if more than a million, to 
the nearest 10,000 if between 100,000 and a million, and to the nearest 5,000 if less 
than 100,000. 
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4 Overview of pathology ordering 
4.1 Background 
As in most developed countries, the volume and cost of pathology tests ordered by 
GPs in Australia has increased over the past decades.5,6 In the literature, this increase 
is usually described in terms of the overall increase in and/or cost of pathology tests. 
Rarely are the clinical problems or pathology tests that contribute to this increase 
described.  
It would be expected that data about tests contributing to the increase may be 
available in Australia from sources such as Medicare claims data or from laboratories 
that perform testing ordered by GPs. However, this is not the case because of 
limitations of these data sources. MBS payment structure and rules, in particular the 
episode coning rule and the structure of MBS pathology items (as described in 
Chapter 2), mean that Medicare data do not provide an accurate view of the tests 
ordered by GPs. 
The private pathology laboratories that conduct the bulk of GP-ordered pathology 
testing have data on the tests ordered by GPs. As private companies own these 
laboratories, the data are not readily accessible and the extent of data recorded is 
unclear. Further, accessing a representative sample of GP ordering from laboratories 
is logistically difficult. 
In order to describe the clinical problems contributing to the increase in GPs’ 
pathology ordering, data about the problem must be linked to the pathology tests 
ordered by GPs. This type of data is rarely available. The BEACH study collects this 
data for all pathology tests recorded by participating GPs.  
In the absence of knowledge about the causes of increases in pathology ordering 
many assumptions have been made in the literature. This chapter seeks to examine 
the influence of GP workload and pathology ordering behaviour on the national 
increase in pathology ordering. 
4.2 Objectives 
• To describe the extent to which general practice encounters involve pathology 
ordering, and the changes over time in GPs’ pathology ordering behaviour. 
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• To investigate the types of pathology tests and batteries of tests ordered by GPs 
and what changes have occurred. 
• To identify problems that generate the majority of GPs’ pathology ordering, and 
to determine whether the management rate of these problems has changed (i.e. 
change in GP’s clinical workload) and/or whether GPs’ ordering behaviour in the 
management of these problems has changed. 
• To identify problems for which GPs’ pathology ordering behaviour has changed, 
and specifically those where assessment of appropriateness of GPs’ pathology 
ordering may be indicated. 
4.3 Method 
Data used in this chapter were recorded in the BEACH study over eight years, from 
April 2000 to March 2008, inclusive (labelled as 2000–08). Changes in pathology 
ordering behaviour are measured using two 2-year data points: April 2000 – March 
2002 and April 2006 – March 2008 inclusive (labelled respectively as 2000–02 and 
2006–08).  
The majority of analysis in this chapter uses unweighted data from multiple years. 
When data years are combined the data cannot be weighted (see Section 3.2.10). 
Weighted data is only used in this chapter for Figure 4.1 where single year data are 
presented.  
Investigation of GP pathology ordering for all problems (Section 4.4.1) is based on 
the number of tests/batteries recorded at GP–patient encounters. As it is not based on 
problem–pathology links, each test/battery is counted only once per encounter. 
However, investigations of pathology ordering behaviour of GPs for specific 
problems and calculation of extrapolations (Section 4.4.2) are based on the number 
of problem–pathology links. It is possible for a test/battery to be linked by the GP to 
more than one problem; therefore there are more problem–pathology links than 
number of tests recorded (see Section 3.2.11). 
The most common individual pathology tests/batteries, each accounting for at least 
1% of pathology tests in either 2000–08, 2000–02 or 2006–08 are described and 
changes from 2000–02 to 2006–08 investigated.  
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Individual problems each generating at least 1% of total problem–pathology links in 
either 2000–08, 2000–02 or 2006–08 are described and changes from 2000–02 to 
2006–08 investigated to determine whether there were changes in: the management 
rate of the problem; the likelihood of pathology being ordered in the management of 
the problem; the number of pathology tests/batteries ordered for that problem. 
Investigation of pathology ordering for these selected problems is based on the 
pathology linked by the GP to the selected problem.  
4.3.1 Extrapolation  
Three types of extrapolations are made in this chapter, the first using the method 
described in Section 3.2.12, and the second and third using an extension of this 
method. These extrapolations are used to demonstrate the magnitude of national 
change from 2000–02 to 2006–08. Extrapolation estimates made in this chapter are 
rounded to the nearest 10,000. 
In this chapter extrapolations are based on data from multiple years; therefore, the 
average number of MBS GP–patient encounters over the period is used for each data 
point (2000–02 and 2006–08), and this is interpreted as the average ‘per annum’ 
estimate in those years. The number of national GP encounters used for extrapolation 
of 2000–02 data is 100.3 million and for 2006–08 data is 106.5 million. 
The first type of extrapolation is used to estimate the number of encounters involving 
the management of a specific problem per year nationally (see Section 3.2.12).  
The second and third types of extrapolations are based on the problem–pathology 
links for each problem. The second type of extrapolation estimates the number of 
contacts with the selected problem at which at least one pathology test/battery was 
ordered at GP encounters per year. The calculation was: 
• for each problem divide the number of problems involving at least one pathology 
test by the number of BEACH encounters in 2000–02, and multiply by the  
total number of MBS general practice consultation service items in 2000–02 
• repeat the process using data for 2006–08.  
The difference between the two estimates gives the estimated national change 
between 2000–02 and 2006–08 in the number of problem contacts where at least one 
pathology test/battery was ordered. 
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The third type of extrapolation estimates the number of pathology tests/batteries 
ordered for each specific problem per year. The calculation was: 
• for each problem divide the number of pathology tests/batteries of tests linked to 
the problem by the number of BEACH encounters in 2000–02, and multiply by 
the total number of MBS general practice consultation service items in 2000–02 
• repeat the process using data for 2006–08.  
The difference between the two estimates gives the estimated national change 
between 2000–02 and 2006–08 in the number of pathology tests/batteries ordered for 
each specific problem. 
4.4 Results 
4.4.1 Overview of data set 
From April 2000 to March 2008, 7,843 GPs participated in BEACH, and provided 
data about 784,300 encounters involving the management of 1,174,893 problems. At 
these encounters GPs ordered 307,013 pathology tests/batteries of tests. In 2000–02, 
there were 198,200 encounters recorded and 64,389 pathology tests/batteries ordered 
by 1,982 GPs, and in 2006–08 there were 188,300 encounters recorded and 87,444 
pathology tests/batteries ordered by 1,883 GPs (Table 4.1). 
In BEACH, each pathology test/battery was linked to at least one and up to four 
problems per encounter. There were more problem–pathology links than 
tests/batteries: in 2000–08, there were 3.1% more links than tests (n = 316,572 
problem–pathology links); in 2000–02, there were 3.2% more links than tests 
(n = 66,429 problem–pathology links); in 2006–08, there were 3.8% more links than 
tests (n = 90,753 problem–pathology links) (results not tabled).  
Pathology ordered  
In 2000–08, pathology tests/batteries were ordered at a rate of 39.1 tests/batteries per 
100 encounters, and 26.1 per 100 problems. At least one pathology test/battery was 
ordered at 16.8% of encounters and for 12.8% of problems managed (Table 4.1). 
Figure 4.1 presents the annual rate of pathology ordered by GPs at encounters and in 
the management of problems over the eight years of the study. From 2000 to 2008 
there was a significant‡ linear increase in the rate of pathology ordered by GPs per 
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100 encounters, and per 100 problems managed (Figure 4.1), supporting the validity 
of measuring changes over time by comparing data from 2000–02 with that from 
2006–08. 
The rate of pathology tests/batteries ordered per 100 encounters increased 
significantly from 32.6 per 100 encounters in 2000–02 to 46.4 per 100 in 2006–08. 
This was due to significant increases in: 
• the likelihood of at least one pathology test/battery being ordered at encounters 
(14.9% of encounters in 2000–02 and 18.7% in 2006–08)  
• the number of pathology tests ordered per encounter once the decision to order 
was made (217.8 per 100 tested encounters in 2000–02 and 247.8 in 2006–08) 
(Table 4.1). 
The number of problems managed per GP encounter also increased significantly 
from 147.3 per 100 encounters in 2000–02 to 153.3 per 100 in 2006–08. As this 
indicates an increase in the volume of clinical work undertaken per encounter, it is 
important to measure the rate of pathology per 100 problems managed. The rate of 
pathology tests/batteries ordered per 100 problems managed significantly increased 
from 22.2 per 100 in 2000–02 to 30.3 in 2006–08. This was due to significant 
increases in: 
• the likelihood of at least one pathology test/battery being ordered in the 
management of problems (11.4% of problems in 2000–02 and 14.2% in  
2006–08) 
• the number of pathology tests ordered per problem once the decision to order 
was made (200.1 per 100 tested problems in 2000–02 and 221.3 in 2006–08) 
(Table 4.1). 
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Note: encs – encounters; probs – problems.  
Figure 4.1: Rate of pathology test/battery orders per 100 encounters and per 100 
problems managed, 2000–01 to 2007–08 (95% confidence intervals) 
Rate 
BEACH year
 
Table 4.1: Overview of data set and summary of pathology ordering, 2000–08, 2000–02 and 2006–08 
 2000–08  2000–02 2006–08  
 Number
Rate/
Per cent
95% 
LCL
95% 
UCL Number
Rate/ 
Per cent 
95% 
LCL
95% 
UCL Number
Rate/
Per cent
95% 
LCL
95% 
UCL Change 
General practitioners 7,843 . . . . . . 1,982 . . . . . . 1,883 . . . . . . . . 
Number of encounters 784,300 . . . . . . 198,200 . . . . . . 188,300 . . . . . . . . 
Problem management rate per 100 
encounters 1,174,893 149.8 149.2 150.4 291,890 147.3 146.1 148.4 288,610 153.3 151.9 154.7
 
Pathology order rate per 100 encounters 307,013 39.1 38.6 39.7 64,389 32.6 31.7 33.5 87,444 46.4 45.2 47.7  
At least one pathology order per 
encounter (Per cent of all encounters) 131,586 16.8 16.6 17.0 29,559 14.9 14.6 15.3 35,284 18.7 18.3 19.2  
Pathology order rate per 100 tested 
encounters  . . 233.1 231.6 234.7 . . 217.8 214.9 220.6 . . 247.8 244.6 251.1  
Pathology order rate per 100 problems 
managed 307,013 26.1 25.8 26.5 64,389 22.2 21.6 22.7 87,444 30.3 29.6 31.0  
At least one pathology order per problem 
(Per cent of all problems managed) 150,187 12.8 12.6 12.9 33,196 11.4 11.1 11.6 41,019 14.2 13.9 14.5  
Pathology order rate per 100 tested 
problems  . . 210.8 209.5 212.1 . . 200.1 197.6 202.6 . . 221.3 218.5 224.0  
Note: Pathology data reported in this table are based on the number of pathology tests/batteries. The number of problem–pathology links is not used in the problem-based analyses reported in this table (see 
Section 3.2.11 and Section 4.4.1). Shading indicates a statistically significant change between 2000–02 and 2006–08. The direction and type of change is indicated for each measure: / indicates a 
statistically significant change. LCL – lower confidence limit; UCL – upper confidence limit. 
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Figure 4.2 shows the distribution of the volume of pathology tests/batteries by patient 
age groups in 2000–08, 2000–02 and 2006–08. The patient age groups accounting 
for the highest volume of pathology tests/batteries ordered in 2000–08 were the  
45–64 year age group (33.9% of tests/batteries) and the 25–44 year age group (27.4% 
of tests/batteries) (Figure 4.2). 
The pattern of distribution was similar in 2000–02 and 2006–08. However, there 
were statistically significant changes over time in the proportion of testing accounted 
for by some age groups. Between 2000–02 and 2006–08, there was a significant 
decrease in the proportion of tests/batteries ordered for patients aged less than 
45 years (41.0% in 2000–02 and 37.2% in 2006–08), and significant increases in the 
proportion ordered for patients aged 45–64 years (33.2% in 2000–02 and 34.9% in 
2006–08) and for those aged 75 years and over (12.1% in 2000–02 and 14.0% in 
2006–08) (Figure 4.2).  
The distribution of likelihood of testing at encounters (i.e. at least one pathology 
test/battery ordered) across patient age groups is not presented in this thesis because 
it showed the same pattern of overall age distribution and changes over time as that 
presented in Figure 4.2 for volume of pathology. 
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Figure 4.2: Distribution of volume of pathology ordered across patient age groups, 
2000–08, 2000–02 and 2006–08 (95% confidence intervals) 
Age group (years) 
Per cent 
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Figure 4.3 shows the age-specific rates of pathology ordering at encounters. In  
2000–08, the rate of testing was highest at encounters with patients aged 45–64 years 
(48.8 pathology tests/batteries per 100 encounters with patients in this age group), 
followed by those with patients aged 65–74 years (44.2 per 100) and 25–44 years 
(43.6 per 100) (Figure 4.3).  
Between 2000–02 and 2006–08, there were significant increases in the age-specific 
rates of pathology ordering at encounters with all patient age groups except at those 
with children aged less than 5 years. Patients aged 25 to 74 years had the highest age-
specific rates of pathology testing, and these age groups also had the largest age-
specific increases in pathology ordering rates from 2000–02 to 2006–08 (Figure 4.3). 
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Figure 4.3: Patient age-specific rate of pathology test orders per 100 encounters, 
2000–08, 2000–02 and 2006–08 (95% confidence intervals) 
Rate per 100 encounters 
Age group (years) 
 
 
The number of pathology tests ordered per encounter when at least one pathology 
test was ordered is presented in Figure 4.4. At encounters where pathology testing 
was ordered (tested encounters), GPs most commonly ordered one or two pathology 
tests/batteries (45.6% and 15.9% of tested encounters respectively in 2000–08). Over 
time there was a significant decrease in the proportion of tested encounters with one 
or two tests/batteries ordered: in 2000–02, 48.7% of tested encounters had one test 
and 17.0% had two, while in 2006–08, 43.1% had one test and 14.5% had two tests. 
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Simultaneously, there was a significant increase in the proportion with four or five 
tests/batteries ordered at tested encounters (Figure 4.4). 
The distribution of number of tests per tested problem is not presented in this thesis 
as it showed the same pattern of overall distribution and changes over time as that 
presented in Figure 4.4 for number of tests per tested encounter.  
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Figure 4.4: Distribution of the number of pathology tests/batteries ordered per encounter 
when at least one test was ordered, 2000–08, 2000–02 and 2006–08 (95% confidence 
intervals) 
Percentage of tested encounters 
Number of tests
 
Types of pathology tests ordered 
Table 4.2 describes the pathology orders made for all problems by MBS pathology 
groups and the most common individual pathology tests, in the total data period 
2000–08, and changes measured from 2000–02 to 2006–08. Pathology data are 
reported as rates per 100 problems as the number of problems managed per 
encounter increased over the study period. 
At the MBS pathology group level, chemistry tests were the tests most commonly 
ordered by GPs in 2000–08 (14.3 per 100 problems managed), followed by those 
classified as haematology (4.9 per 100), microbiology (3.9) and cytopathology (1.5). 
Between 2000–02 and 2006–08, there were statistically significantly increases in the 
order rates of chemistry, haematology, microbiology and cytopathology tests; and 
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marginal significant increases in histopathology and immunology test order rates 
(Table 4.2).  
The most common individual tests or batteries of tests ordered by GPs in 2000–08 
were full blood counts (FBC) (3.5 per 100 problems), lipid tests (2.5 per 100), 
electrolytes, urea and creatinine (EUC) tests (1.8), liver function tests (LFT) (1.7), 
and glucose tests (1.6). The 22 most common tests/batteries accounted for 85.7% of 
all pathology tests recorded by GP participants in 2000–08 (Table 4.2).  
Between 2000–02 and 2006–08, there were significant increases in the ordering rate 
(per 100 total problems) of almost all frequently ordered individual tests. There were 
statistically significant increases in the order rate of FBC, lipid tests, EUC tests, LFT, 
glucose tests, thyroid function tests (TFT), multibiochemical analysis (MBA), 
ferritin, ‘other chemistry’ tests, HbA1c, ‘other microbiology’ tests, prostate specific 
antigen (PSA), histology skin tests, C reactive protein (CRP) and vitamin B12 tests. 
There were also marginal increases in the rates of Pap smears, urine microscopy, 
culture and sensitivity (M,C&S), coagulation tests, and vaginal swab M,C&S 
(Table 4.2). 
 
 
Table 4.2: Distribution of pathology orders across MBS pathology groups and most frequent individual test orders for all problems, 2000–08, 
2000–02 and 2006–08  
 2000–08 2000–02 2006–08  
Pathology test ordered Number (%)
Rate per 100 
problems(a)
95% 
LCL
95%
UCL Number (%)
Rate per 100
 problems(a)
95% 
LCL
95% 
UCL Number (%)
Rate per 100 
problems(a)
95% 
LCL
95% 
UCL Change 
MBS pathology groups              
 Chemistry 167,676 (54.6) 14.3 14.0 14.5 33,843 (52.6) 11.6 11.2 12.0 49,681 (56.8) 17.2 16.7 17.7  
 Haematology 57,594 (18.8) 4.9 4.8 5.0 12,636 (19.6) 4.3 4.2 4.5 15,743 (18.0) 5.5 5.3 5.6  
 Microbiology 45,604 (14.9) 3.9 3.8 4.0 10,098 (15.7) 3.5 3.3 3.6 12,186 (13.9) 4.2 4.0 4.4  
 Cytopathology 17,152 (5.6) 1.5 1.5 1.5 3,931 (6.1) 1.4 1.3 1.4 4,534 (5.2) 1.6 1.5 1.7  
 Other tests NEC 6,285 (2.0) 0.5 0.5 0.6 1,492 (2.3) 0.5 0.5 0.6 1,741 (2.0) 0.6 0.5 0.7 — 
 Histopathology 5,218 (1.7) 0.4 0.4 0.5 978 (1.5) 0.3 0.3 0.4 1,456 (1.7) 0.5 0.4 0.6  
 Immunology  4,540 (1.5) 0.4 0.4 0.4 970 (1.5) 0.3 0.3 0.4 1,369 (1.6) 0.5 0.4 0.5  
 Infertility and pregnancy tests 1,841 (0.6) 0.7 0.2 0.2 502 (0.8) 0.2 0.1 0.2 374 (0.4) 0.1 0.1 0.1 — 
 Simple basic tests 1,103 (0.4) 0.1 0.1 0.1 193 (0.3) 0.1 0.1 0.1 360 (0.4) 0.1 0.1 0.1 — 
Individual pathology tests/batteries             
 Full blood count  40,882 (13.3) 3.5 3.4 3.5 8,629 (13.4) 3.0 2.8 3.1 11,696 (13.4) 4.1 3.9 4.2  
 Lipids*  29,578 (9.6) 2.5 2.5 2.6 6,627 (10.3) 2.3 2.2 2.4 8,410 (9.6) 2.9 2.8 3.0  
 Electrolytes, urea and creatinine* 21,037 (6.9) 1.8 1.7 1.8 4,234 (6.6) 1.5 1.4 1.5 6,175 (7.1) 2.1 2.0 2.3  
 Liver function*  20,183 (6.6) 1.7 1.7 1.8 4,201 (6.5) 1.4 1.4 1.5 6,067 (6.9) 2.1 2.0 2.2  
 Glucose/glucose tolerance* 18,615 (6.1) 1.6 1.5 1.6 4,215 (6.5) 1.4 1.4 1.5 5,170 (5.9) 1.8 1.7 1.9  
 Thyroid function*  17,225 (5.6) 1.5 1.4 1.5 3,335 (5.2) 1.1 1.1 1.2 5,034 (5.8) 1.7 1.7 1.8  
 Pap smear* 16,818 (5.5) 1.4 1.4 1.5 3,844 (6.0) 1.3 1.2 1.4 4,449 (5.1) 1.5 1.4 1.6  
 Urine M,C&S* 14,243 (4.6) 1.2 1.2 1.2 3,371 (5.2) 1.2 1.1 1.2 3,613 (4.1) 1.3 1.2 1.3  
(continued) 
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Table 4.2 (continued): Distribution of pathology orders across MBS pathology groups and most frequent individual test orders for all problems,  
2000–08, 2000–02 and 2006–08 
 2000–08 2000–02 2006–08  
Pathology test ordered Number (%)
Rate per 100 
problems(a)
95% 
LCL
95%
UCL Number (%)
Rate per 100
 problems(a)
95% 
LCL
95% 
UCL Number (%)
Rate per 100 
problems(a)
95% 
LCL
95% 
UCL Change 
Individual pathology tests/batteries (continued)            
 Multibiochemical analysis*  12,094 (3.9) 1.0 1.0 1.1 2,181 (3.4) 0.8 0.7 0.8 3,615 (4.1) 1.3 1.1 1.4  
 Erythrocyte sedimentation rate 8,018 (2.6) 0.7 0.7 0.7 1,974 (3.1) 0.7 0.7 0.7 1,908 (2.2) 0.7 0.6 0.7 — 
 Ferritin* 7,780 (2.5) 0.7 0.6 0.7 1,463 (2.3) 0.5 0.5 0.5 2,540 (2.9) 0.9 0.8 0.9  
 Other chemistry*  7,467 (2.4) 0.6 0.6 0.7 1,035 (1.6) 0.4 0.4 0.4 2,594 (3.0) 0.9 0.8 1.0  
 Hormone assay* 7,118 (2.3) 0.6 0.6 0.6 1,663 (2.6) 0.6 0.5 0.6 1,739 (2.0) 0.6 0.5 0.7 — 
 HbA1c* 6,901 (2.2) 0.6 0.6 0.6 1,330 (2.1) 0.5 0.5 0.5 1,959 (2.2) 0.7 0.6 0.7  
 Coagulation* 6,201 (2.0) 0.5 0.5 0.5 1,447 (2.2) 0.5 0.5 0.5 1,539 (1.8) 0.5 0.5 0.6  
 Other microbiology* 5,872 (1.9) 0.5 0.5 0.5 1,089 (1.7) 0.4 0.4 0.4 1,702 (1.9) 0.6 0.5 0.6  
 Hepatitis serology* 4,697 (1.5) 0.4 0.4 0.4 1,191 (1.8) 0.4 0.4 0.4 1,116 (1.3) 0.4 0.3 0.4 — 
 Prostate specific antigen* 4,656 (1.5) 0.4 0.4 0.4 893 (1.4) 0.3 0.3 0.3 1,514 (1.7) 0.5 0.5 0.6  
 Histology; skin 4,603 (1.5) 0.4 0.4 0.4 790 (1.2) 0.3 0.3 0.3 1,328 (1.5) 0.5 0.4 0.5  
 C reactive protein 3,522 (1.1) 0.3 0.3 0.3 472 (0.7) 0.2 0.1 0.2 1,288 (1.5) 0.5 0.4 0.5  
 Vaginal swab M,C&S 3,091 (1.0) 0.3 0.2 0.3 741 (1.2) 0.3 0.2 0.3 830 (0.9) 0.3 0.3 0.3  
 Vitamin B12* 2,482 (0.8) 0.2 0.2 0.2 400 (0.6) 0.1 0.1 0.2 847 (1.0) 0.3 0.3 0.3  
 Subtotal 263,083 (85.7) . . . . . . 55,125 (85.6) . . . . . . 75,133 (85.9) . . . . . . . . 
Total pathology tests 307,013 (100.0) 26.1 25.8 26.5 64,643 (100.0) 22.2 21.6 22.7 87,444 (100.0) 30.3 29.6 31.0  
(a) The rate at which the pathology test was ordered, expressed as a rate per 100 problems managed. Based on the number of pathology tests/batteries (not problem–pathology links) (see Section 3.2.11 and 
Section 4.4.1). For the number of problems in each data period see Table 4.1.  
* Includes multiple ICPC-2 PLUS codes (see Appendix 7).  
Note: Only the pathology tests/batteries accounting for more than 1% of all tests/batteries in any of the three data periods are included. Shading indicates a statistically significant change between 2000–02  
and 2006–08. The direction and type of change is indicated for each measure: / indicates a statistically significant change (darker shading), / indicates a marginal change (lighter shading), and  
— indicates no change. LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified; M,C & S – microscopy, culture and sensitivity. 
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4.4.2 Problems generating high volumes of pathology 
orders 
There were 22 problems that each accounted for 1% or more of problem–pathology 
links recorded by GPs in BEACH. These problems accounted for more than half of 
problem–pathology links in each period (53.4% in 2000–08, 52.5% in 2000–02 and 
54.8% in 2006–08) (Table 4.3).  
Table 4.3 presents for each data period and for each problem: (i) the number of times 
it was recorded as a problem managed in the data set; (ii) the GP clinical workload it 
accounted for (management rate per 100 encounters); and (iii) the volume of 
pathology orders it generated (per cent of problem–pathology links). 
Table 4.4 reports for 2000–02 and 2006–08 GP pathology ordering behaviour in the 
management of each problem, that is, the likelihood of testing (per cent of problem 
contacts involving at least one pathology test order) and the number of tests/batteries 
ordered (per 100 tested contacts with the problem).  
Problems in Tables 4.3 and 4.4 are listed in decreasing order according to the 
proportion of total problem–pathology links accounted for by each problem in  
2006–08 (Table 4.3). 
For each problem, Table 4.5 reports the extrapolated estimates for 2000–02 and 
2006–08 of: (i) the number of national encounters involving its management; (ii) the 
number of national encounters involving at least one pathology order; (iii) the 
number of pathology tests/batteries of tests ordered in its management in Australia. It 
also describes the amount of national change from 2000–02 to 2006–08 attributed to 
each problem. Problems in Table 4.5 are listed in decreasing order according to the 
proportion of national change accounted for by each problem. 
Tables 4.3, 4.4 and 4.5, that are referred to throughout this section, are located on 
pages 67–72. 
When the total rates of pathology ordering for 2000–02 and 2006–08 are 
extrapolated to the GP encounters claimed through Medicare (100.3 million per year 
in 2000–02 and 106.5 million per year in 2006–08), these data suggest that compared 
with 2000–02, in 2006–08 there were: 
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• 6.4 million additional problems per year for which the GP ordered at least one 
pathology test/battery of tests (23.2 million per year in 2006–08 compared with 
16.8 million per year in 2000–02) 
• 17.7 million additional tests/batteries of tests ordered per year by GPs (51.3 
million per year in 2006–08 compared with 33.6 million per year in 2000–02) 
(Table 4.5). 
GP pathology ordering behaviour did not change in the management of seven of the 
22 problems investigated. These problems were sexually transmitted infections, 
urinary tract infection, pregnancy, arthritis, anaemia, hypothyroidism, and atrial 
fibrillation (Table 4.4). Pathology tests/batteries ordered for these seven problems 
accounted for a considerable proportion of total pathology ordering (12.1% of total 
problem–pathology links in 2000–02 and 11.7% in 2006–08) (Table 4.3). However 
there was no change in GPs’ pathology ordering behaviour (i.e. decision of whether 
to test and number of tests per order) in the management of these problems. Any 
contribution to national change made by these problems was due to the increase in 
the total number of GP encounters claimed through Medicare with or without a 
simultaneous change in the management rate of the problem between 2000–02 and 
2006–08 (Table 4.5). Therefore, these problems are not described in further detail in 
this chapter. 
GP pathology ordering increased significantly in the management of 15 of the 22 
problems investigated, from 2000–02 to 2006–08. These were: hypertension, Type 2 
diabetes, lipid disorders, female genital check-ups, health checks (in patients aged 
15 years and over), weakness/tiredness, ‘blood test’, ‘abnormal test results’, 
depression, menstrual problems, ischaemic heart disease, abdominal pain, 
overweight/obesity (in patients aged 18 years and over), menopause and viral illness 
(Table 4.4). The changes in GPs’ pathology ordering in the management of these 15 
problems are described in greater detail below. 
Hypertension 
The management rate of hypertension in general practice in Australia did not differ 
significantly between 2000–02 and 2006–08 (9.1 per 100 encounters in 2000–02 and 
9.5 per 100 in 2006–08). Pathology ordered for hypertension problems accounted for 
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5.9% of all problem–pathology links recorded in 2000–02 and 6.3% in 2006–08 
(Table 4.3). 
The rate of pathology ordering per 100 hypertension contacts increased significantly, 
from 21.6 per 100 contracts in 2000–02 to 32.3 per 100 in 2006–08. This increase 
was due to significant increases in the likelihood of pathology being ordered in the 
management of hypertension (8.7% of hypertension contacts in 2000–02 compared 
with 11.9% in 2006–08), and increased number of pathology tests/batteries ordered 
per tested hypertension problem (248.2 per 100 tested contacts in 2000–02 compared 
with 270.4 per 100 in 2006–08) (Table 4.4). 
When these data were extrapolated to the number of GP encounters claimed through 
Medicare nationally, I estimated there were about: 
• 950,000 more encounters involving the management of hypertension problems in 
2006–08 (10.1 million per year) than in 2000–02 (9.1 million per year) 
• 410,000 additional hypertension contacts that involved the ordering of at least 
one pathology test/battery (tested contacts) in 2006–08 (1.2 million per year) 
compared with 2000–02 (790,000 per year) 
• 1.3 million additional pathology tests/batteries ordered for hypertension in  
2006–08 (3.2 million per year) than in 2000–02 (2.0 million per year). Pathology 
ordered in the management of hypertension accounted for 7.2% of the total 
national increase in pathology ordering that occurred between 2000–02 and 
2006–08 (Table 4.5). 
Type 2 diabetes 
The management rate of Type 2 diabetes (T2D) increased significantly from 2.6 per 
100 encounters in 2000–02 to 3.3 per 100 in 2006–08. Pathology ordered for T2D 
problems accounted for 5.0% of all problem–pathology links recorded in 2000–02 
and 6.0% in 2006–08 (Table 4.3). 
The rate of pathology ordering increased significantly from 63.6 tests/batteries 
ordered in 2000–02 per 100 contacts with T2D to 88.4 per 100 in 2006–08. This was 
due to significant increases in both the likelihood of pathology testing being ordered 
for T2D (27.3% in 2000–02 to 31.6% in 2006–08 of T2D problems), and the number 
of tests ordered once the decision to order tests was made (232.9 per 100 tested T2D 
contacts in 2000–02 and 280.2 in 2006–08) (Table 4.4).  
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When these data were extrapolated to the number of GP encounters claimed through 
Medicare nationally, I estimated there were about: 
• 850,000 more encounters involving the management of T2D in 2006–08 
(3.5 million per year) than in 2000–02 (2.6 million per year) 
• 380,000 additional T2D contacts that involved the ordering of at least one 
pathology test/battery (tested contacts) in 2006–08 (1.1 million per year) than in 
2000–02 (720,000 per year) 
• 1.4 million additional pathology tests/batteries ordered for T2D in 2006–08 
(3.1 million per year) than in 2000–02 (1.7 million per year). T2D accounted for 
8% of the national increase in pathology ordering that occurred between 2000–02 
and 2006–08 (Table 4.5). 
Lipid disorders 
From 2000–02 to 2006–08, there was a significant increase in the management rate 
of lipid disorders, from 2.9 per 100 encounters to 3.5 per 100. Pathology ordered for 
lipid problems accounted for 5.1% of all problem–pathology links recorded in  
2000–02 and 4.9% in 2006–08 (Table 4.3). 
The rate of pathology ordering increased from 58.2 per 100 contacts with lipid 
disorders in 2000–02 to 66.5 per 100 in 2006–08. This was due to a significant 
increase in the number of tests ordered per tested lipid problem (191.4 tests/ batteries 
per 100 tested contacts in 2000–02 compared with 219.4 per 100 in 2006–08). There 
was no change in the likelihood of pathology tests being ordered in the management 
of lipid disorders (30.4% of lipid disorder contacts in 2000–02 and 30.3% in  
2006–08) (Table 4.4). 
When these data were extrapolated to national GP Medicare encounters, I estimated 
that, compared with 2000–02, in 2006–08 there were about: 
• 820,000 more encounters involving the management of lipid disorders 
• 250,000 more lipid disorder problems for which pathology was ordered 
• 790,000 more tests/batteries ordered for lipid disorders (accounting for 4.5% of 
the national increase in pathology tests/batteries) (Table 4.5).  
Female genital check-ups/Pap smears 
The management rate of female genital check-ups/Pap smears increased significantly 
from 2.0 per 100 encounters in 2000–02 to 2.4 in 2006–08. Pathology ordered for 
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female genital check-ups/Pap smears accounted for 4.7% of all problem–pathology 
links recorded in 2000–02 and 4.6% in 2006–08 (Table 4.3). 
The rate of pathology ordering increased from 79.1 per 100 contacts with female 
genital check-ups/Pap smears in 2000–02 to 93.1 per 100 in 2006–08. This was due 
to an increased likelihood of pathology tests being ordered (70.1% of female genital 
check-up/Pap smear contacts in 2000–02 to 77.9% in 2006–08), and an increased 
number of tests being ordered once the decision to order had been made (112.9 per 
100 tested contacts in 2000–02 to 119.5 in 2006–08) (Table 4.4).  
When these data were extrapolated to national GP Medicare encounters, I estimated 
that, compared with 2000–02, in 2006–08 there were about: 
• 530,000 more encounters involving management of female genital check-
ups/Pap smears 
• 580,000 more female genital check-up/Pap smear problems for which pathology 
was ordered 
• 790,000 more tests/batteries ordered for female genital check-ups/Pap smears 
(accounting for 4.4% of the national increase in pathology tests/batteries) 
(Table 4.5).  
Health checks  
The management rate of health checks in patients aged 15 years and over increased 
significantly from 1.1 per 100 encounters in 2000–02 to 1.5 in 2006–08. Pathology 
ordered for health checks accounted for 3.4% of all problem–pathology links 
recorded in 2000–02 and 4.9% in 2006–08 (Table 4.3).  
The rate of pathology ordering increased significantly from 122.0 tests/batteries in 
2000–02 per 100 health check contacts to 178.9 per 100 in 2006–08. This was due to 
a significant increase in the number of tests for health checks ordered, once the 
decision to order tests was made (250.1 per 100 tested health check contacts in  
2000–02 to 334.1 in 2006–08). There was no significant change in the likelihood that 
GPs would order pathology in the management of health checks (48.8% of contacts 
in 2000–02 and 53.5% in 2006–08) (Table 4.4).  
When these data were extrapolated to the number of GP encounters claimed through 
Medicare nationally, I estimated there were about: 
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• 460,000 more encounters involving the management of health checks in 2006–08 
(1.4 million per year) than in 2000–02 (930,000 per year) 
• 290,000 additional health check contacts that involved the ordering of at least 
one pathology test/battery (tested contacts) in 2006–08 (750,000 per year) than in 
2000–02 (460,000 per year) 
• 1.4 million additional pathology tests/batteries ordered in the management of 
health checks in 2006–08 (2.5 million per year) than in 2000–02 (1.1 million per 
year). The proportion of the national increase in pathology tests/batteries ordered 
by GPs between 2000–02 and 2006–08 attributable to health checks was 7.6% 
(Table 4.5). 
Weakness and tiredness 
There was no change in the management rate of weakness/tiredness (0.8 per 100 
encounters in 2000–02 and 0.7 in 2006–08) over the study period. Pathology ordered 
for weakness/tiredness problems accounted for 4.0% of all problem–pathology links 
recorded in 2000–02 and 3.5% in 2006–08 (Table 4.3).  
The rate of pathology ordered for weakness/tiredness increased significantly (177.9 
per 100 contacts in 2000–02 to 233.0 in 2006–08), due to an increased likelihood of 
pathology tests being ordered (50.3% of contacts in 2000–02 to 62.2 in 2006–08). 
The data also suggests a trend toward increased numbers of tests ordered per tested 
weakness/tiredness problem, but this did not reach statistical significance (Table 4.4).  
When these data were extrapolated to national GP Medicare encounters, I estimated 
that, compared with 2000–02, in 2006–08 there were about: 
• 10,000 more encounters involving management of weakness/tiredness 
• 100,000 more weakness/tiredness problems for which pathology was ordered 
• 450,000 more tests/batteries ordered for weakness/tiredness (accounting for 
2.5% of the national increase in pathology tests/batteries) (Table 4.5).  
‘Blood test’ problems 
Problems labelled as ‘blood tests’ were managed at a significantly higher rate in 
2006–08 (0.8 per 100 encounters) than in 2000–02 (0.6 per 100). Pathology ordered 
for ‘blood test’ problems accounted for 2.5% of all problem–pathology links 
recorded in 2000–02 and 3.3% in 2006–08 (Table 4.3). 
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The rate of pathology tests/batteries for ‘blood test’ problems increased significantly 
(from 147.6 to 199.1 per 100 ‘blood test’ contacts), due to an increased likelihood of 
pathology tests being ordered (68.8% of blood test contacts in 2000–02 to 75.0% in 
2006–08), and increased numbers of tests ordered per tested problem (214.7 
tests/batteries per 100 tested contacts in 2000–02 to 265.4 in 2006–08) (Table 4.4).  
When these data were extrapolated to national GP Medicare encounters, I estimated 
that, compared with 2000–02, in 2006–08 there were about: 
• 290,000 more encounters involving management of ‘blood test’ problems 
• 250,000 more ‘blood test’ problems for which pathology was ordered 
• 870,000 more tests/batteries ordered for ‘blood test’ problems (accounting for 
4.9% of the national increase in pathology tests/batteries) (Table 4.5).  
‘Abnormal test result’ problems 
The management rate of problems labelled as ‘abnormal test results’ increased 
significantly from 0.7 per 100 encounters in 2000–02 to 1.1 per 100 in 2006–08. 
Pathology ordered for ‘abnormal test result’ problems accounted for 1.4% of all 
problem–pathology links recorded in 2000–02 and 2.0% in 2006–08 (Table 4.3). 
The rate of pathology tests/batteries ordered for ‘abnormal test result’ problems 
increased from 68.6 per 100 ‘abnormal test result’ contacts to 88.5 in 2006–08, due 
to an increased likelihood of pathology tests being ordered (42.3% of contacts in 
2000–02 to 52.5% in 2006–08). There was no change in the number of tests ordered 
per 100 tested contacts (162.9 per 100 tested contacts in 2000–02 and 168.6 in  
2006–08) (Table 4.4). 
When these data were extrapolated to national GP Medicare encounters, I estimated 
that, compared with 2000–02, in 2006–08 there were about: 
• 430,000 more encounters involving management of ‘abnormal test results’ 
• 300,000 more ‘abnormal test result’ problems for which pathology was ordered 
• 530,000 more tests/batteries ordered for ‘abnormal test result’ problems (3.0% of 
the national increase in pathology tests/batteries) (Table 4.5).  
Depression 
There was a marginally significant increase in the management rate of depression 
between 2000–02 (3.9 per 100 encounters) and 2006–08 (4.2 per 100). Pathology 
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ordered for depression problems accounted for 1.1% of all problem–pathology links 
recorded in 2000–02 and 1.3% in 2006–08 (Table 4.3). 
There was a significant increase in the ordering of pathology tests in the management 
of depression, from 9.8 per 100 contacts in 2000–02 to 14.7 per 100 in 2006–08. This 
was due to a significant increase in the likelihood of pathology tests/batteries being 
ordered for depression problems (from 3.3% of depression problems in 2000–02 to 
4.6% in 2006–08). There was no change in the number of tests/batteries ordered per 
tested problem (299.6 per 100 tested depression problems in 2000–02 and 322.4 per 
100 in 2006–08) (Table 4.4). 
When these data were extrapolated to national GP Medicare encounters, I estimated 
that, compared with 2000–02, in 2006–08 there were about: 
• 590,000 more encounters involving the management of depression problems 
• 80,000 more depression problems involving at least one pathology request 
• 280,000 more tests/batteries ordered for depression problems (1.6% of the 
national increase in pathology tests) (Table 4.5). 
Menstrual problems 
The management rate of menstrual problems did not change, remaining at 0.8 per 
100 encounters in 2000–02 and 2006–08. Pathology ordered for menstrual problems 
accounted for 1.4% of all problem–pathology links recorded in 2000–02 and 1.3% in 
2006–08 (Table 4.3). 
There was a significant increase in the rate of pathology ordered in the management 
of menstrual problems (60.6 per 100 contacts in 2000–02 to 80.2 in 2006–08), due to 
increased numbers of tests ordered per tested problem (209.3 per 100 tested 
menstrual problem contacts in 2000–02 compared with 252.3 in 2006–08). There 
was no change in the likelihood of pathology being ordered in the management of 
menstrual problems (28.9% in 2000–02 and 31.8% in 2006–08) (Table 4.4). 
When these data were extrapolated to national GP Medicare encounters, I estimated 
that, compared with 2000–02, in 2006–08 there were about: 
• 50,000 more encounters involving the management of menstrual problems 
• 40,000 more menstrual problems involving at least one pathology request 
• 190,000 more tests/batteries ordered for menstrual problems (1.1% of the 
national increase in pathology tests) (Table 4.5). 
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Ischaemic heart disease 
There was a marginal decrease in the management rate of ischaemic heart disease 
(IHD) from 1.4 per 100 encounters in 2000–02 to 1.2 per 100 in 2006–08. Pathology 
ordered for IHD problems accounted for 1.4% of all problem–pathology links 
recorded in 2000–02 and 1.2% in 2006–08 (Table 4.3). 
The pathology test order rate per 100 contacts with IHD increased significantly, from 
33.3 per 100 IHD contacts in 2000–02 to 46.7 in 2006–08. This was due to a 
significant increase in the number of tests/batteries ordered for IHD problems once 
the decision to order had been made (231.3 tests/batteries per 100 tested IHD 
problems in 2000–02 compared with 272.6 tests per 100 in 2006–08). However, 
there was no change in the likelihood of pathology ordering being involved in the 
management of IHD problems (Table 4.4). 
When these data were extrapolated to national GP Medicare encounters, I estimated 
that, compared with 2000–02, in 2006–08 there were about: 
• 90,000 fewer encounters involving the management of IHD problems 
• 20,000 more encounters with IHD problems for which pathology was requested 
• 140,000 more tests/batteries ordered for IHD problems (0.8% of the total 
national increase in pathology tests) (Table 4.5). 
Abdominal pain  
There was no change in the management rate of abdominal pain over the study 
period, staying at 0.6 per 100 encounters. Pathology ordering in the management of 
abdominal pain accounted for 1.1% of all problem–pathology links recorded in 
2000–02 and 1.0% in 2006–08 (Table 4.3).  
The rate of pathology tests/batteries ordered for abdominal pain increased from 57.5 
per 100 contacts in 2000–02 to 79.1 in 2006–08. This was due to a significant 
increase in the number of tests/batteries ordered for abdominal pain problems once 
the decision to order had been made (224.8 per 100 tested abdominal pain contacts in 
2000–02 compared with 283.1 in 2006–08). There was no change in the likelihood 
that pathology would be ordered in the management of abdominal pain (25.6% of 
contacts in 2000–02 and 27.9 in 2006–08) (Table 4.4). 
When these data were extrapolated to national GP Medicare encounters, I estimated 
that, compared with 2000–02, in 2006–08 there were about: 
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• 60,000 more encounters involving the management of abdominal pain problems 
• 30,000 more encounters with abdominal pain problems for which pathology was 
requested 
• 180,000 more tests/batteries ordered for abdominal pain problems (1.0% of the 
total national increase in pathology tests) (Table 4.5). 
Overweight/obesity  
The overweight/obesity analysis in this section includes problems managed that were 
labelled by the GP as obesity or overweight at encounters with patients aged 18 years 
and over. From 2000–02 to 2006–08, there was no significant change in the 
management rate of overweight/obesity, remaining at 1.2 per 100 adult encounters. 
Pathology ordered for overweight/obesity problems accounted for 0.9% of all 
problem–pathology links recorded in 2000–02 and 1.0% in 2006–08 (Table 4.3). 
The rate of pathology tests ordered in the management of overweight/obesity among 
adult patients increased between 2000–02 and 2006–08 by more than 50% (30.6 to 
47.1 per 100 overweight/obesity contacts). This increase was due to an increased 
likelihood that at least one test/battery was ordered (11.7% of contacts for 
overweight/obesity in 2000–02 and 16.5% in 2006–08). The number of tests ordered 
per tested problem did not change significantly (262.3 per 100 tested contacts in 
2000–02 and 285.9 per 100 in 2006–08) (Table 4.4).  
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When these data were extrapolated to national GP Medicare encounters, I estimated 
that, compared with 2000–02, in 2006–08 there were about: 
• 100,000 more encounters involving the management of overweight/obesity 
(1 million per year in 2000–02 and 1.1 million per year in 2006–08) 
• 60,000 additional tested overweight/obesity contacts (120,000 per year in  
2000–02 and 180,000 per year in 2006–08) 
• 210,000 additional tests/batteries requested for overweight/obesity (310,000 per 
year in 2000–02 and 520,000 per year in 2006–08). Of the total national increase 
in pathology tests/batteries, 1.2% was attributable to pathology ordered in the 
management of overweight/obesity (Table 4.5).  
Menopausal complaint  
The management rate of menopausal symptoms and complaints decreased 
significantly from 1.6 per 100 encounters in 2000–02 to 1.0 in 2006–08. Pathology 
ordered for menopausal complaint problems accounted for 1.5% of all problem–
pathology links recorded in 2000–02 and 0.9% in 2006–08 (Table 4.3). 
There was a significant increase in the order rate of pathology tests/batteries for 
menopausal complaints (33.0 per 100 contacts in 2000–02 and 44.5 in 2006–08), due 
to increased likelihood of pathology tests being ordered from 13.4% of menopausal 
complaint contacts in 2000–02 to 19.6 in 2006–08. The number of tests ordered per 
tested problem did not change significantly (247.0 per 100 tested contacts in  
2000–02 and 227.7 per 100 in 2006–08) (Table 4.4). 
When these data were extrapolated to national GP Medicare encounters, I estimated 
that, compared with 2000–02, in 2006–08 there: 
• were about 480,000 fewer encounters involving the management of menopausal 
complaint problems  
• was no change in the number of menopausal contacts involving at least one 
pathology test 
• were about 30,000 fewer tests/batteries requested for menopausal complaints. 
The proportion of the national change in pathology tests/batteries ordered by GPs 
in 2006–08, compared with 2000–02, attributable to menopausal complaints was 
–0.2% (Table 4.5). The decrease in the management rate outweighed the effect of 
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the increased pathology ordering of the GPs, creating a net decrease in pathology 
ordering attributable to menopausal complaints. 
Viral illness  
There was a significant decrease in the management rate of viral illness from 1.4 per 
100 encounters in 2000–02 to 1.1 in 2006–08. Pathology ordered for viral illness 
problems accounted for 1.1% of all problem–pathology links recorded in 2000–02 
and 0.9% in 2006–08 (Table 4.3). 
There was a significant increase in the order rate of pathology tests/batteries for viral 
illness, increasing from 26.7 per 100 contacts in 2000–02 to 37.4 in 2006–08. There 
was a trend toward increased likelihood of tests being ordered for viral illness, but 
this did not reach statistical significance. There was also no change in the number of 
tests ordered per tested contact over the study period for viral illness (Table 4.4). 
When these data were extrapolated to national GP Medicare encounters, I estimated 
that, compared with 2000–02, in 2006–08 there: 
• were about 260,000 fewer encounters involving the management of viral illness  
• was no change in the number of viral illness contacts involving at least one 
pathology test 
• were about 60,000 more tests/batteries requested for viral illness. The proportion 
of the national change in pathology tests/batteries ordered by GPs in 2006–08, 
compared with 2000–02, attributable to viral illness was 0.3% (Table 4.5).  
 
Table 4.3: Overview of problems that accounted for at least 1% of total problem–pathology links, 2000–08, 2000–02 and 2006–08  
 
Number of problems 
managed 
 Management rate per 100 encounters(a)  
(95% CI) 
 Number of pathology tests linked  
to the problem (% of total links)(c) 
Problem 2000–08 2000–02 2006–08 2000–08 2000–02 2006–08
(b)
 2000–08 2000–02 2006–08 
Hypertension 
(non-gestational)* 72,171 18,007 17,793 9.2 (9.0–9.4) 9.1 (8.8–9.4) 9.5 (9.1–9.8) — 18,889 (6.0) 3,884 (5.9) 5,744 (6.3) 
Type 2 diabetes 22,938 6,172 2.9 (2.9–3.0) 2.6 (2.5–2.8) 3.3 (3.1–3.4)  5,211 17,709 (5.6) 3,314 (5.0) 5,459 (6.0) 
Lipid disorders 25,248 5,782 6,629 3.2 (3.2–3.3) 2.9 (2.8–3.0) 3.5 (3.4–3.7)  15,777 (5.0) 3,363 (5.1) 4,410 (4.9) 
Female genital 
check-up/Pap smear* 17,416 3,920 4,471 2.2 (2.1–2.3) 2.0 (1.8–2.1) 2.4 (2.2–2.6)  14,778 (4.7) 3,100 (4.7) 4,163 (4.6) 
8,120 1,846 2,464 1.2 (1.1–1.2) 1.1 (1.0–1.2) 1.5 (1.4–1.6)Health check (15+ years)*   12,008 (3.8) 2,252 (3.4) 4,407 (4.9) 
Weakness/tiredness 5,627 1,509 1,373 0.7 (0.7–0.8) 0.8 (0.7–0.8) 0.7 (0.7–0.8) — 11,559 (3.7) 2,684 (4.0) 3,199 (3.5) 
Blood test – all* 5,222 1,121 1,516 0.7 (0.6–07) 0.6 (0.5–0.6) 0.8 (0.7–0.9)  9,444 (3.0) 1,655 (2.5) 3,018 (3.3) 
Sexually transmitted 
infection* 5,999 1,141 0.8 (0.7–0.8) 0.6 (0.5–0.6) 1.0 (0.8–1.1)  7,128 (2.3)1,830 1,198 (1.8) 2,292 (2.5) 
Urinary tract infection* 13,283 3,253 3,152 1.7 (1.7–1.7) 1.6 (1.6–1.7) 1.7 (1.6–1.7) — 8,201 (2.6) 2,003 (3.0) 2,026 (2.2) 
Pregnancy* 8,077 1,799 2,730 1.0 (1.0–1.1) 0.9 (0.8–1.0) 1.5 (1.3–1.6)  6,030 (1.9) 1,197 (1.8) 2,022 (2.2) 
Abnormal test result* 6,955 1,389 2,022 0.9 (0.9–0.9) 0.7 (0.7–0.8) 1.1 (1.0–1.1)  5,462 (1.7) 953 (1.4) 1,790 (2.0) 
Arthritis – all* 29,755 7,788 3.8 (3.7–3.9) 3.9 (3.8–4.1) 3.6 (3.4–3.7)6,703  5,577 (1.8) 1,277 (1.9) 1,345 (1.5) 
Depression* 31,309 7,658 7,898 4.0 (3.9–4.1) 3.9 (3.7–4.0) 4.2 (4.0–4.4)  3,943 (1.2) 749 (1.1) 1,164 (1.3) 
Menstrual problems* 5,961 1,489 1,419 0.8 (0.7–0.8) 0.8 (0.7–0.8) 0.8 (0.7–0.8) — 4,247 (1.3) 902 (1.4) 1,138 (1.3) 
(continued) 
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Table 4.3 (continued): Overview of problems that accounted for at least 1% of total problem–pathology links, 2000–08, 2000–02 and 2006–08  
 
Number of problems 
managed 
 Management rate per 100 encounters(a)  
(95% CI) 
 Number of pathology tests linked  
to the problem (% of total links)(c) 
Problem 2000–08 2000–02 2006–08 2000–08 2000–02 2006–08
(b)
 2000–08 2000–02 2006–08 
Anaemia* 5,129 1,271 1,188 0.7 (0.6–0.7) 0.6 (0.6–0.7) 0.6 (0.6–0.7) — 4,363 (1.4) 1,007 (1.5) 1,077 (1.2) 
Ischaemic heart 
disease* 10,048 2,707 2,261 1.3 (1.2–1.3) 1.4 (1.3–1.5) 1.2 (1.1–1.3)  3,959 (1.3) 902 (1.4) 1,055 (1.2) 
Hypothyroidism 4,990 1,057 1,397 0.6 (0.6–0.7) 0.5 (0.5–0.6) 0.7 (0.7–0.8)  3,541 (1.1) 728 (1.1) 1,036 (1.1) 
Abdominal pain* 4,803 1,215 1,185 0.6 (0.6–0.6) 0.6 (0.6–0.7) 0.6 (0.6–0.7) — 3,389 (1.1) 699 (1.1) 937 (1.0) 
Overweight/obesity 
(adults)* 7,797 1,975 1,935 1.2 (1.1–1.2) 1.2 (1.1–1.3) 1.2 (1.1–1.3) — 2,916 (0.9) 605 (0.9) 912 (1.0) 
Atrial fibrillation 6,334 1,323 1,813 0.8 (0.8–0.8) 0.7 (0.6–0.7) 1.0 (0.9–1.0)  3,251 (1.0) 642 (1.0) 900 (1.0) 
Menopausal complaint 10,044 3,093 1,923 1.3 (1.2–1.3) 1.6 (1.5–1.7) 1.0 (0.9–1.1)  3,687 (1.2) 1,020 (1.5) 856 (0.9) 
Viral illness 9,814 2,847 2,086 1.3 (1.2–1.3) 1.4 (1.3–1.5) 1.1 (1.0–1.2)  3,174 (1.0) 760 (1.1) 780 (0.9) 
Subtotal  317,040  77,401 79,960 . . . . . .  169,033 (53.4) 34,894 (52.5) 49,730 (54.8) 
Total  1,174,893 291,890 288,610 149.8 (149.2–150.4) 147.3 (146.1–148.4) 153.3 (151.9–154.7)  316,549 (100.0) 66,429 (100.0) 90,753 (100.0) 
(a) Management rate of the problem, expressed as a rate per 100 encounters. For the number of problems in each data period see Table 4.1. Shading indicates a change between 2000–02 and 2006–08, darker 
shading indicates a statistically significant change and lighter shading indicates a marginal change. 
(b) The direction and type of statistically significant change is indicated for each measure between 2000–02 and 2006–08: / indicates a statistically significant change, / indicates a marginal change, 
and — indicates no change.  
(c) The number and proportion of pathology tests/batteries of tests linked to each problem. It is possible for a single pathology test/battery to be linked to more than one problem (see Section 3.2.11 and 
Section 4.4.1). 
* Includes multiple ICPC-2 PLUS codes (see Appendix 6). 
Note: Problems that account for at least 1% of problem–pathology links in any of the three data periods are included in this table. CI – confidence interval.  
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Table 4.4: Changes in pathology ordering for problems that accounted for at least 1% of problem–pathology links, 2000–02 compared with 2006–08  
 
Pathology per 100 problem contacts(a)
(95% CI) 
Per cent of problem contacts with 
at least 1 test(c) (95% CI) 
Pathology per 100 tested problems(d)  
(95% CI) 
Problem  2000–02 2006–08
(b)
 2000–02 2006–08
(b)
 2000–02 2006–08 
(b)
 
Hypertension  
(non-gestational)* 21.6 (20.0–23.2) 32.3 (30.3–34.2)  8.7 (8.1–9.3) 11.9 (11.3–12.6)  248.2 (239.5–257.0) 270.4 (262.5–278.4)  
Type 2 diabetes 63.6 (59.6–67.6) 88.4 (83.7–93.2)  27.3 (25.8–28.8) 31.6 (30.1–33.0)  232.9 (224.8–241.0) 280.2 (272.4–288.1)  
Lipid disorders 58.2 (54.7–61.6) 66.5 (62.5–70.6)  30.4 (28.9–31.9) 30.3 (28.9–31.8) — 191.4 (184.6–198.2) 219.4 (211.6–227.3)  
Female genital  
check-up/Pap smear* 79.1 (76.4–81.8) 93.1 (90.2–96.0)  70.1 (62.2–72.0) 77.9 (76.2–79.7)  112.9 (110.7–115.1) 119.5 (116.7–122.2)  
Health check  
(15+ years)*  122.0 (110.7–133.3) 178.9 (167.3–190.4)  48.8 (45.1–52.5) 53.5 (50.7–56.3) — 250.1 (236.1–264.2) 334.1 (322.8–345.4)  
Weakness/tiredness 177.9 (164.0–191.8) 233.0 (217.3–248.7)  50.3 (46.7–53.9) 62.2 (58.5–65.9)  353.6 (343.2–364.0) 374.6 (363.5–385.7) — 
Blood test – all* 147.6 (136.3–159.0) 199.1 (186.4–211.8)  68.8 (65.7–71.8) 75.0 (72.2–77.8)  214.7 (201.6–227.8) 265.4 (253.1–277.8)  
Sexually transmitted 
infection* 105.0 (95.3–115.7) 125.2 (115.3–135.2) — 42.6 (39.3–45.9) 46.6 (43.9–49.3) — 246.5 (231.4–261.6) 268.7 (251.2–286.2) — 
Urinary tract infection* 61.6 (58.9–64.3) 64.3 (61.4–67.1) — 53.4 (51.4–55.4) 55.7 (53.7–57.7) — 115.3 (112.5–118.0) 115.4 (112.6–118.2) — 
Pregnancy* 66.5 (60.5–72.6) 74.1 (68.6–79.6) — 34.5 (31.9–37.1) 35.0 (33.0–37.0) — 192.8 (180.6–240.9) 211.7 (200.8–222.6) — 
Abnormal test result* 68.6 (62.7–74.5) 88.5 (83.2–93.9)  42.3 (39.4–45.1) 52.5 (50.2–54.9)  162.9 (154.1–171.7) 168.6 (161.6–175.6) — 
Arthritis – all* 16.4 (14.6–18.2) 20.1 (18.0–22.1) — 5.5 (5.0–6.1) 6.5 (5.9–7.1) — 296.3 (283.7–308.9) 308.5 (294.2–322.8) — 
Depression* 9.8 (8.4–11.2) 14.7 (12.8–16.7)  3.3 (2.8–3.7) 4.6 (3.9–5.2)  299.6 (280.2–319.0) 322.4 (300.6–344.3) — 
Menstrual problems* 60.6 (54.3–66.9) 80.2 (72.2–88.2)  28.9 (26.5–31.4) 31.8 (29.1–34.5) — 209.3 (196.1–222.4) 252.3 (238.4–266.2)  
(continued) 
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Table 4.4 (continued): Changes in pathology ordering for problems that accounted for at least 1% of problem–pathology links, 2000–02 compared 
with 2006–08  
 
Pathology per 100 problem contacts(a)
(95% CI) 
Per cent of problem contacts with 
at least 1 test(c) (95% CI) 
Pathology per 100 tested problems(d)  
(95% CI) 
Problem  2000–02 2006–08
(b)
 2000–02 2006–08
(b)
 2000–02 2006–08 
(b)
 
Anaemia* 79.2 (71.8–86.6) 90.7 (82.3–99.0) — 34.9 (32.2–37.7) 37.3 (34.4–40.2) — 226.8 (215.4–238.2) 243.1 (230.4–255.8) — 
Ischaemic heart disease* 33.3 (29.2–37.5) 46.7 (41.3–52.1)  14.4 (12.9–15.9) 17.1 (15.4–18.8) — 231.3 (216.3–246.3) 272.6 (257.5–287.8)  
Hypothyroidism 68.9 (62.3–75.5) 74.2 (68.2–80.1) — 43.0 (39.7–46.2) 44.4 (41.5–47.2) — 160.4 (150.7–170.1) 167.1 (158.2–176.0) — 
Abdominal pain* 57.5 (50.8–64.3) 79.1 (70.4–87.8)  25.6 (23.0–28.2) 27.9 (25.3–30.6) — 224.8 (210.0–239.6) 283.1 (265.7–300.5)  
Overweight/obesity (adults)* 30.6 (24.6–36.7) 47.1 (39.9–54.4)  11.7 (9.7–13.7) 16.5 (14.1–18.9)  262.3 (241.4–283.3) 285.9 (268.2–303.6) — 
Atrial fibrillation 48.5 (43.9–53.1) 49.6 (45.3–54.0) — 37.4 (34.4–40.5) 37.4 (34.6–40.2) — 129.7 (121.8–137.6) 132.7 (125.6–139.9) — 
Menopausal complaint 33.0 (28.9–37.0) 44.5 (37.9–51.1)  13.4 (12.0–14.7) 19.6 (15.2–23.9)  247.0 (231.4–262.5) 227.7 (191.1–264.2) — 
Viral illness 26.7 (22.8–30.6) 37.4 (32.0–42.7)  10.6 (9.3–12.0) 13.4 (11.7–15.1) — 250.8 (232.9–268.8) 279.6 (261.2–298.0) — 
Total problems 22.8 (22.2–23.4) 31.4 (30.7–32.2)  11.4 (11.1–11.6) 14.2 (13.9–14.5)  200.1 (197.6–202.6) 221.3 (218.5–224.0)  
(a) The rate at which pathology tests/batteries of tests were ordered for each problem (based on the number of problem–pathology links), expressed as a rate per 100 specified problems. For details on the number 
of cases and pathology tests for each problem see Table 4.3. 
(b) The direction and type of change is indicated for each measure between 2000–02 and 2006–08: / indicates a statistically significant change, / indicates a marginal change, and — indicates no 
change.  
(c) The proportion of contacts with each problem where at least one pathology test/battery was ordered. 
(d) The number of pathology tests/batteries per 100 tested contacts with each problem. 
* Includes multiple ICPC-2 PLUS codes (see Appendix 6). 
Note: Problems that account for at least 1% of problem–pathology links in either 2000–08, 2000–02 or 2006–08 are included in this table. Shading indicates a statistically significant change between 2000–02 and 
2006–08. CI – confidence interval. 
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Table 4.5: Extrapolated national estimated number (thousands) of management and pathology ordered for problems that accounted for at least 1% 
of problem–pathology links, changes from 2000–02 to 2006–08(a)  
 
Number of encounters with each 
problem 
 Number of problem contacts 
involving pathology(b)  
Number of pathology tests for each 
problem(b) 
Problem 2000–02 2006–08 Change(c) 2000–02 2006–08 Change(c) 2000–02 2006–08 Change(c)
Per cent of the 
change due to 
each problem(d) 
Type 2 diabetes 2,640 3,490 850 720 1,100 380 1,680 3,090 1,410 8.0 
Health check (15+ years)* 930 1,390 460 460 750 290 1,140 2,490 1,350 7.6 
Hypertension  
(non-gestational)* 9,110 10,060 950 790 1,200 410 1,970 3,250 1,280 7.2 
Blood test – all* 560 850 290 390 640 250 840 1,710 870 4.9 
Lipid disorders 2,920 3,750 820 890 1,140 250 1,700 2,490 790 4.5 
Female genital check-up/ 
Pap smear* 1,860 2,390 530 1,390 1,970 580 1,570 2,350 790 4.4 
Sexually transmitted 
infection* 570 1,000 430 250 480 240 610 1,300 690 3.9 
Pregnancy* 910 1,540 630 310 540 230 610 1,140 540 3.0 
Abnormal test result* 690 1,120 430 300 600 300 480 1,010 530 3.0 
Weakness/tiredness  760 780 10 380 480 100 1,360 1,810 450 2.5 
Depression* 3,870 4,470 590 130 200 80 380 660 280 1.6 
Hypothyroidism 530 790 260 230 350 120 370 590 220 1.2 
Overweight/obesity 
(adults)* 1,000 1,090 100 120 180 60 310 520 210 1.2 
Menstrual problems* 750 800 50 220 260 40 460 640 190 1.1 
Atrial fibrillation 670 1,030 360 250 380 130 320 510 180 1.0 
(continued) 
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Table 4.5 (continued): Extrapolated national estimated number (thousands) of management and pathology ordered for problems that accounted for 
at least 1% of problem–pathology links, changes from 2000–02 to 2006–08(a)  
 
Number of encounters with each 
problem 
 Number of problem contacts 
involving pathology(b)  
Number of pathology tests for each 
problem(b) 
Problem 2000–02 2006–08 Change(c) 2000–02 2006–08 Change(c) 2000–02 2006–08 Change(c)
Per cent of the 
change due to 
each problem(d) 
Abdominal pain* 610 670 60 160 190 30 350 530 180 1.0 
Ischaemic heart disease* 1,360 1,280 -90 200 220 20 460 600 140 0.8 
Urinary tract infection* 1,640 1,780 140 880 990 110 1,010 1,150 130 0.7 
Arthritis – all* 3,910 3,770 -140 220 250 30 650 760 110 0.6 
Anaemia* 640 670 30 220 250 30 510 610 100 0.6 
Viral illness 1,440 1,180 -260 150 160 0 380 440 60 0.3 
Menopausal complaint 1,560 1,080 -480 210 210 0 520 480 -30 -0.2 
Total 100,300 106,500 6,200 16,800 23,200 6,400 33,620 51,330 17,710 100.0 
(a) Extrapolations are presented in thousands and are rounded to the nearest 10,000.  
(b) Calculations are based on the number of problem–pathology linkages. There are more problem–pathology linkages than pathology tests recorded as each pathology test can be linked to more than one 
problem (see Section 3.2.11 and Section 4.4.1). 
(c) Calculations of change were made prior to rounding to the nearest 10,000. Due to the rounding, calculating change using the 2000–02 and 2006–08 data presented in the table above may produce a 
different result to that reported in the ‘Change’ column. 
(d) The proportion of the total extrapolated national increase in pathology tests/batteries (n = 17.7 million) that was attributable to each problem. 
* Includes multiple ICPC-2 PLUS codes (see Appendix 6). 
Note: Problems that account for at least 1% of problem–pathology links in either 2000–08, 2000–02 or 2006–08 are included in this table.  
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4.5 Discussion 
This chapter has provided a comprehensive overview of GPs’ pathology ordering in 
Australia in 2000–08. It described the total increase in GPs’ pathology ordering that 
occurred between 2000–02 and 2006–08, and identified the most common individual 
tests and clinical problems contributing to the measured increase in pathology 
ordering. 
Three factors (each of which can operate independently) contributed to the total 
increase in the volume of pathology tests/batteries of tests ordered by GPs between 
2000–02 and 2006–08: an increase in the number of national GP encounters in the 
country (reflecting an increase in total GP workload); a statistically significant 
increase in the number of problems managed per encounter (reflecting a change in 
GPs’ encounter workload); and a statistically significant increase in GPs’ pathology 
ordering in the management of these problems (reflecting change in GPs’ pathology 
ordering behaviour). The latter was measured as an increase in the rate of pathology 
ordering due to increases in the likelihood of GPs’ initiating pathology ordering in 
the management of problems, and the number of tests ordered per occasion of 
testing. 
These findings differ considerably from those of the earlier BEACH study that 
investigated change in GPs’ pathology ordering between 1998 and 2001, which 
found that GPs’ ordering increased due to an increase in the number of tests ordered 
per tested problem, without any change in likelihood of testing.45 The other two 
factors did not contribute to the national increase in total volume of pathology 
ordered in general practice from 1998 to 2001. This suggests that the behaviour of 
increased likelihood of ordering pathology tests has occurred since that time.  
From the perspective of managing financial outlays associated with pathology 
testing, the increase in occasions of testing has a greater impact than the number of 
tests ordered on each occasion of testing.133 This is because the majority of the costs 
associated with laboratory testing are labour costs. Each additional test ordered on a 
single occasion contributes a relatively small additional cost burden due to the high 
use of automated machinery in the pathology sector.134  
The extrapolations used in this chapter incorporate the increases in the three factors 
to estimate the national effect of change. When extrapolated, the BEACH data 
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suggest that in 2006–08, compared with 2000–02, there was a national increase of 
about 53% in the volume of tests/batteries ordered by GPs. In contrast, the volume of 
Medicare-funded pathology items increased by 54% from 2000–01 to 2007–08.5 
However, this does not accurately reflect changes in GP pathology ordering 
behaviour, as only 70% of the MBS pathology items are generated by GPs 
(E Wilson, personal communication, March 2011). Further, only three pathology 
item numbers can be claimed per episode of ordering (due to episode coning), and 
multiple tests may be included in each MBS item.23 While BEACH data reflect 
actual GP orders for pathology tests, it is likely that it under-estimates the true 
number of pathology tests/batteries ordered, as there is only space for up to five 
tests/batteries to be recorded per encounter (see ‘strengths and limitations’ below). 
Individual tests ordered by GPs  
The majority of pathology ordered by GPs’ was generated by a relatively small 
number of tests—the 22 most common tests accounted for 86% of all GP-ordered 
tests in 2000–08. This finding aligns with that reported in earlier studies: the 20 most 
common tests accounted for 80% of all pathology ordered by GPs in Australia in 
199889 and in the Netherlands in 1996–97;79 and, similarly, in the UK in 1997–98 the 
28 most common test types accounted for 95% of GPs’ pathology ordering activity.82 
In the current study, there were significant increases between 2000–02 and 2006–08 
in GPs’ ordering rates for the majority of the commonly ordered individual tests; 
only three individual tests showing no change. The size of the increase varied 
considerably between the individual tests, from a marginal increase of 8% in the 
ordering rate of urine M,C&S tests to an increase of 200% in the order rate of 
vitamin B12 tests. GPs’ ordering rate of the five most commonly ordered tests 
increased by between 26% and 55%. Despite these increases, the types of tests 
ordered by GPs stayed relatively constant between 2000–02 and 2006–08 and they 
accounted for a similar proportion of total pathology ordered over time, suggesting 
that the majority of the increase in GPs’ pathology ordering reflected an increase in 
the ordering of common tests rather than the emergence of new tests. 
The problems generating the highest volume of tests 
GPs’ management of a relatively small group of clinical problems accounted for the 
majority of pathology ordered by GPs. The 22 problems investigated in this study 
accounted for 53.4% of all problem–pathology links.  
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The most common problems for which GPs ordered pathology tests stayed relatively 
constant from 2000–02 to 2006–08. However, GPs’ pathology ordering for these 22 
problems increased. Extrapolation suggests they accounted for 59% of the national 
increase in pathology ordered in general practice. This national increase was due to: 
increases in GPs’ pathology ordering in the management of the problems; changes in 
the GP workload accounted for by these problems; and the increase in number of GP 
encounters nationally.  
It is important to consider the influence of GP workload in combination with GPs’ 
pathology ordering behaviour. The example of ‘menopausal complaint’ demonstrates 
why these aspects must be considered together. GPs’ pathology ordering in the 
management of menopausal problems increased significantly. Specifically GPs were 
more likely to initiate pathology testing for ‘menopausal complaint’ in 2006–08 than 
in 2000–02. In isolation this result would suggest that there would be an increase in 
the volume of pathology associated with the management of menopausal complaints. 
However, due to a significant decrease in the management rate of menopausal 
complaint problems, the opposite was true.  
The change in management rate was likely triggered by the 2002 publication of 
results from the Women’s Health Initiative study that indicated adverse effects were 
associated with use of hormone replacement therapy (HRT).135 Following this 
finding, use of HRT declined. As HRT was the principal method of managing 
menopausal complaints, this led to the decrease in management rate of menopausal 
complaints at GP–patient encounters. The total decrease in the management rate of 
menopausal complaints was a greater influence than the increase in likelihood of 
GPs’ ordering pathology. This is a good example of how a change in evidence 
influences volume of pathology ordered in general practice. 
Menopausal complaint was the only problem for which a decrease in pathology 
ordering was found. Generally speaking in the absence of a change in GPs’ ordering 
behaviour, there was an increase in volume of tests generated by each problem due to 
the national increase in GP workload (as demonstrated by the increased number of 
encounters over time) with or without a contributing increase in GPs management 
rate of the individual problem. Hence for each of the seven problems for which GPs’ 
pathology ordering behaviour did not change, there was still a national increase in 
total number of tests ordered.  
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I have described the increasing volume of pathology tests/batteries ordered by GPs as 
being related to changes within three factors (total GP workload, management rates 
of problems and GPs’ pathology ordering behaviour in the management of these 
problems). Many potential causes for these changes are discussed in the literature, 
and the influence of some of these causes may be seen in the results of this chapter. 
Some causes of change will be beyond the control of GPs, while others may 
contribute to changes in GPs’ pathology ordering behaviour. The quality or 
appropriateness of a change also varies, it may reflect ‘good’ clinical practice (for 
example, in response to new evidence) or ‘bad’ (for example, defensive testing). 
Examples of causes of change in GPs’ pathology ordering are given below.  
The publication of new guidelines or changes to existing guideline recommendations 
relating to pathology testing have the potential to change GPs’ pathology ordering. 
Such changes are often made in response to emergence of new evidence.  
The increase in the number of national GP encounters is largely beyond the control 
of GPs. Australia’s ageing population will have contributed to the past increase in 
number of GP encounters, as rates of attendance increase with age.136 Over the 
period of 2000 to 2008 the proportion of the population aged 65 years or more 
increased from 12.4% to 13.2%,15 and this is expected to continue. By 2050 it is 
projected to be 22-24%.137 The influence of population ageing on future growth in 
pathology ordering is investigated in Chapter 8.  
Health policy initiatives have been associated with an increased volume of pathology 
tests.26,27,29 Depending on their content and design, these initiatives have the potential 
to influence pathology ordering by changing GP workload and/or GPs’ pathology 
ordering behaviour. How such initiatives are targeted (e.g. to the GP, or to the 
patient) will also influence whether GPs have any control over the changes in 
pathology that may be generated by the initiatives. For example, the ‘Strengthening 
Medicare’ package introduced in 2004–05 is a population-based initiative that aimed 
(among other things) to improve access to GP services.18 It was regarded as 
successful in achieving this aim and contributed to the increase in GP workload over 
the period investigated in this study. The content of the initiative was unlikely to 
have caused any change in GPs’ pathology ordering behaviour, but the growth in 
workload it generated was accepted by the Government as contributing to growth in 
Medicare pathology outlays between 2004 and 2009.26  
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The Practice Incentives Program (PIP) is a national initiative that provides a series of 
financial incentives for specific activity in general practice. PIP incentives were 
introduced for diabetes (in late 2001) and cervical screening (in late 2000). These 
incentive payments were made for specific outcomes which required pathology 
testing and recall systems within general practice to meet these targets.138 These may 
have contributed to both the increased management rate and the increased pathology 
ordering for these problems that were reported in this study. 
The broad range of problems for which GPs ordered pathology tests, illustrates the 
different clinical purposes for which GPs order pathology tests. For example, the 
majority of pathology ordered in the management of chronic problems such as 
hypertension and T2D is likely to be for monitoring purposes, whereas testing in the 
management of weakness/tiredness problems is likely to be for diagnostic purposes, 
and that ordered in the management of health checks and female genital check-ups 
for screening purposes.  
Most of the problems I have investigated in this chapter reflect diseases or 
symptoms. Two notable exceptions are problems labelled as ‘blood test’ and 
‘abnormal test results’. Increases in workload and pathology ordering related to 
management of these problems may represent a change in GPs’ process of care when 
ordering tests and giving results at GP–patient encounters. This study spans a period 
of workforce crisis and financial stress in general practice.139 Discontent with level of 
Medicare rebates led to falls in bulk-billing rates in the early 2000’s.5 It is possible 
that GPs changed their process of managing blood tests and results to increase 
income from this management by always seeing the patient to prepare the blood test 
order and provide results. 
Also occurring at around the same time was the December 2001 introduction of 
privacy legislation that covered, for the first time, patient information collected, used 
and communicated by GPs.140 The legislation stated the need to ensure the identity of 
the patient prior to communicating any sensitive information. Telephone 
communication may make this difficult. It is now not uncommon for general 
practices to have policies precluding communication of test results over the 
telephone. Almost half of Australians surveyed in the 2008–09 Patient Experience 
Survey who had had a pathology test, received the test results at a follow-up 
appointment.141 
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The increase in the management rate of abnormal test results may reflect an increase 
in the number of false positive test results. False positive results are a function of the 
reference range used to determine whether a result is ‘normal’. When a 95% 
reference range is used to test a normal sample, there is a 95% chance that the result 
will be normal and a 5% chance that the result will be inappropriately reported as 
abnormal.142-144 The current study demonstrates that the number of tests ordered on 
each occasion of testing is increasing. As the number of tests ordered increases, so 
too does the probability that at least one false positive result will be reported. Most 
GPs are aware of the likelihood of false positive results and manage these intuitively. 
However, it is possible that medicolegal concerns may be contributing to the change 
in GPs’ pathology ordering behaviour in the management of abnormal test results.  
GPs’ awareness of medicolegal issues was high throughout the period of this study 
due to the political and media coverage of the ‘medical indemnity crisis’ which 
followed the collapse of the general insurer HIH in 2001 and the 2002 voluntary 
liquidation of Australia’s largest medical defence organisation. The causes of the 
crisis were complex, and involved poor regulation of defence organisations, 
insufficiencies in their financial arrangements, and an increased number of 
medicolegal claims.145,146 National data on medicolegal claims involving GPs are 
only readily available from 2007–08 onward. Of the new claims initiated in 2007–08, 
general practice was the speciality that generated the highest proportion (21%). This 
is due to the high number of services provided by GPs. The most common type of 
claim made regarding GPs was related to ‘diagnosis’ (26.4% of all claims against 
GPs) which includes missed, delayed or incorrect diagnosis. As pathology testing is 
frequently involved in the diagnostic process, it is conceivable that some of the 
change observed in GPs management of abnormal test results may be due to 
defensive behaviour. Further, medicolegal concerns have been frequently described 
as a reason for ordering pathology tests.9,26,28,36,147 
The management rate and GPs’ pathology ordering increased for both ‘blood test’ 
and ‘abnormal test results’ problems over the study period. Some of the many 
external factors that may have contributed to these changes have been discussed 
above. 
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Strengths and limitations 
The strength of the investigation of pathology ordering associated with individual 
problems, is that the analytical approach used enabled separation of the influence of 
(a) the GP workload associated with the management of each problem and (b) the 
GPs’ pathology ordering behaviour in the management of each problem. These data, 
together with national Medicare claims data for GP encounters have been used in the 
extrapolations to estimate the national increase in pathology ordering attributed to 
each problem.  
There are limitations that should be considered when interpreting the extrapolations. 
Extrapolations are only estimates and are likely to provide an underestimate of the 
true ‘GP workload’ because they are made to Medicare-claimed GP services, not to 
the total number of GP encounters per year (which include those not charged for, and 
those paid by sources other than Medicare, for example, state governments, 
WorkCover, employers). Approximately 5% of GP encounters are funded by sources 
other than Medicare.121  
Further the extrapolated estimates of pathology ordering are based on the problem–
pathology links. Each test may be linked (by the GP) to more than one problem being 
managed at the encounter. Therefore, it is possible for a single pathology test/battery 
to be linked to more than one problem. In each of the data periods used in this 
chapter there were 3–4% more links than tests. Therefore the extrapolations may 
overestimate the number of tests attributed to the problem.  
In BEACH there was also an increase over time in the number of encounters where 
the maximum number of pathology tests/batteries (five) were recorded, suggesting 
that the number of tests/batteries missed may be increasing due to lack of space on 
the recording form. Therefore, extrapolations may under-represent the number of 
tests ordered by GPs and the amount of change that has occurred.  
Despite these limitations, the extrapolations provide an estimate of the contribution 
of each problem to the increase in the national volume of pathology generated from 
GP orders. This is the first time that such analyses have been attempted. 
Conclusion 
This chapter highlights the influence of increases in GP workload and change in 
GPs’ pathology ordering behaviour on the total volume of pathology ordering. This 
study provides, for the first time, information on the problems under management 
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that contribute to the growth in GPs’ pathology ordering. It also demonstrates that 
change in GPs’ pathology ordering behaviour is not always a contributing factor to 
the total volume of pathology associated with an individual problem. Further, even 
when present, changes in GPs’ pathology ordering behaviour are not the sole factor 
contributing to national increases.  
GPs’ ordering rates of 22 pathology tests, and testing in the management of 22 
problems, generated the majority of the volume and growth in GPs’ pathology 
ordering between 2000–02 and 2006–08. 
The findings of this chapter are used as the basis for selection of problems for the 
evaluation of the appropriateness of GPs’ pathology ordering in the next chapter. The 
criteria used to select problems consuming increasing amounts of pathology 
resources were: (a) contribution to a high volume of total pathology ordering; (b) 
GPs’ management has been characterised by changes in their pathology ordering 
behaviour. Hence, of the 22 problems investigated in this chapter, 10 were identified 
priorities for investigation of appropriateness. These were: hypertension, T2D, lipid 
disorders, health checks, weakness/tiredness, overweight/obesity, depression, 
menstrual problems, IHD, and abdominal pain (see Chapter 5).  
The increases in GPs’ pathology ordering described in this chapter do not provide 
any indication of the appropriateness of this ordering, and are likely to reflect both 
‘good’ and ‘bad’ behaviours. The investigation of appropriateness of GPs’ pathology 
ordering is the focus of Chapter 5. 
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5 GP pathology testing versus 
recommended testing 
The results of the previous chapter confirmed that GPs’ pathology ordering in the 
management of all problems increased significantly over time. However, 
investigation of the problems generating the highest volume of pathology ordering, 
demonstrated that GPs pathology ordering behaviour did not change for all problems. 
Further, for the problems where GPs’ ordering increased, the type of ordering 
behaviour that changed differed across problems. While discerning whether GPs’ 
pathology ordering behaviour changed, the research described in Chapter 4 did not 
investigate the types of tests nor the appropriateness of tests ordered in the 
management of each of these problems. 
5.1 Objectives 
In this chapter I will investigate the types of tests ordered by GPs for selected 
problems and evaluate the extent to which GPs’ pathology ordering for these selected 
problems aligns with recommendations for pathology testing made in national and 
international guidelines and other sources of guidance for the management of 
selected problems. Secondary objectives are: 
• to identify whether any changes over time that occurred in pathology ordered for 
selected problems reflect a change to be ‘more’ or ‘less’ in line with 
recommendations. 
• to evaluate the quality of guidance for pathology testing available and identify 
areas in which guidance needs to be improved (such as areas where guidance is 
lacking or inconsistent).  
5.2 Background  
The increased rate of pathology testing and associated cost increases has stimulated 
much research and debate into the reasons for the increased demand. Numerous 
factors have been described in the literature as contributing to the increase.9,26-30 One 
of the aspects of the debate is whether these factors are contributing to increases in 
appropriate or inappropriate pathology ordering. 
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Several authors have implied that inappropriate pathology testing is widespread, and 
that the continued increase in pathology testing reflects inappropriate 
ordering.8,9,12,28,29,58,59 The Carter report (investigating pathology ordering in the UK) 
noted that several ‘witnesses’ reported widespread unnecessary testing but found 
there were “no robust studies which verify this statement.”8 However, it is relatively 
safe to conclude from the published literature that there is a degree of inappropriate 
or unnecessary pathology ordering by GPs and other clinicians.11,52,76,85,96  
Concern about appropriate ordering is not new, having been discussed for several 
decades.28,42,148-150 What is unclear is the proportion of pathology testing that is 
inappropriate, and whether inappropriate testing is increasing. 
Defining and measuring appropriateness of pathology ordering is difficult. In their 
review, van Walraven and Naylor52 found huge variability in the volume (5–95%) of 
tests ordered that were deemed ‘inappropriate’ in studies. This variation was due to 
the different clinical scenarios in the studies reviewed, and the diverse and often 
flawed methods used to evaluate appropriateness. Although most of the reviewed 
studies were not conducted in general practice, the review highlights the difficulty of 
defining appropriateness. This is echoed by Smellie, who noted that the 
appropriateness of pathology tests “depends on the clinical context of the patient, the 
severity of the disorder, administrative necessities and many other factors.”54  
To date there have been no large studies attempting to define the amount of 
inappropriate pathology testing in general practice. Much of the evidence used to 
support the presence of inappropriate pathology ordering by GPs is drawn from 
studies reporting results of interventions that aim to improve appropriateness of their 
pathology ordering.11,58,74-77,79-87,95-97 Guidelines are usually the basis of these 
interventions. However, as discussed in Chapter 2, these studies are often targeted to 
‘problem’ areas of pathology ordering where the intervention is most likely to be 
cost-effective by achieving a reduction in use of pathology testing. As such they are 
conducted in very focussed clinical situations targeting a limited number of 
pathology tests58,80-84 or pathology testing for a limited number of clinical 
problems.11,75,77,85-87 Only a handful of interventions target groups of tests and/or 
problems that reflect the breadth of clinical situations in which GPs’ order pathology 
tests.76,79,82,88,95 
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Success of these intervention studies is usually judged on the basis of a reduction in 
pathology testing following the intervention. The assumption is made that the 
reduction is a reduction in inappropriate tests. However most studies do not assess 
the appropriateness of the reduction in testing. A reduction (even when only 
inappropriate tests are reduced) does not enumerate the proportion of tests that are 
inappropriate as there may be situations where the test was used inappropriately but 
the intervention was not successful. This is illustrated by van Wijk et al. who 
introduced a decision support tool to support appropriate pathology ordering by 
GPs,79 and then assessed the appropriateness of GPs’ ordering after the 
intervention.88 The intervention reduced ordering,79 but the subsequent assessment 
demonstrated that only 40% of pathology ordering sets for 12 indications were 
compliant with guidelines.88 Van Wijk et al. did not measure whether the reduction 
in ordering represented improved appropriateness, but the subsequent assessment 
demonstrates that there is potential for further improvement in GPs’ ordering for the 
12 indications investigated. Thus a ‘successful’ intervention is not a reflection of the 
underlying appropriateness of GPs’ ordering. 
The extent to which results of these studies can be generalised is limited by the 
diversity of the circumstances being investigated. Other authors have misinterpreted 
findings of such studies extrapolating them beyond the context of the clinical 
situation in which the study was designed, resulting in statements such as “between 
25 and 40% of all tests sent to the laboratory are unnecessary”.28 
There is currently insufficient evidence to determine the proportion of GP-ordered 
pathology tests that could be considered inappropriate in Australia. However, it is 
important to establish whether inappropriate pathology ordering is an issue, and if it 
is, the extent of this inappropriate ordering, before investing resources in 
interventions to improve pathology ordering. Whether such interventions should be 
targeted to specific clinical problems, types of tests or other areas of testing (such as, 
purpose of testing e.g. diagnostic versus monitoring) also needs to be determined. 
This chapter aims to evaluate the proportion of the tests ordered by GPs that are 
appropriate, for each of a subset of clinical problems that are generating a high 
volume of pathology ordering in general practice. 
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5.3 Method 
5.3.1 General practice data 
The data used in this chapter were collected in the BEACH study over 8 years from 
April 2000 to March 2008 (referred to as 2000–08). Changes over time were 
measured by comparing results from the first two years of the study period (April 
2000 to March 2002) with those from the last two years (April 2006 to March 2008) 
(referred to as 2000–02 and 2006–08 respectively).  
In BEACH, all pathology tests recorded are linked (by the GP) to the specific 
problem(s) for which they were ordered. The analysis of pathology ordering in this 
chapter is based on these problem–pathology links (see Section 3.2.11). I used 
unweighted data in the analysis because multiple data years were combined (see 
Section 3.2.10). 
5.3.2 Selecting the problems for investigation 
A problem was considered for investigation if GPs’ pathology ordering had increased 
for that problem between 2000–02 and 2006–08, and if:  
• it was considered a National Health Priority Area, and/or  
• the problem generated a high volume of total pathology ordering, and/or  
• pathology ordering was commonly used by GPs in the management of the 
problem.  
The eight National Health Priority Areas in Australia (in 2008) were: arthritis and 
musculoskeletal conditions, asthma, cancer control, cardiovascular health, diabetes 
mellitus, injury prevention and control, mental health, and obesity.151  
A total of 22 problems generating high volumes of pathology ordering by GPs were 
identified in Chapter 4. Of these, I identified 10 as priorities for investigation based 
on the criteria above. These were: hypertension, Type 2 diabetes, lipid disorders, 
health checks, weakness/tiredness, overweight/obesity, depression, menstrual 
problems, ischaemic heart disease, and abdominal pain. The first six problems from 
this list were investigated because they generated the highest volume of pathology 
tests ordered by GPs and/or were areas of current policy interest.  
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Defining the problems  
The six problems investigated are defined below. The list of ICPC-2 or ICPC-2 
PLUS codes included for each problem is provided in Appendix 6. 
Hypertension 
Hypertension includes problems recorded by GPs that were classified as 
uncomplicated or complicated hypertension in ICPC-2 (codes K86 and K87). It 
excludes hypertension in pregnancy (pre-eclampsia) because this condition is not 
managed in the same way. 
Type 2 diabetes 
Type 2 diabetes includes problems recorded by GPs that were classified as ‘non-
insulin dependent diabetes’ (ICPC-2 code T90). In line with ICPC-2 inclusion 
criteria, this includes diabetes mellitus not specified by the GP as Type 1 or Type 2. 
Lipid disorder 
Lipid disorder includes problems recorded by GPs that were classified as ‘lipid 
disorder’ in ICPC-2 code T93.  
Health check 
‘Health check’ was investigated when recorded as a clinical problem at encounters 
with patients aged 15 years or more. ‘Health check’ problems are a group of ICPC-2 
PLUS (terminology) codes classified as check-ups in the general and unspecified 
chapter of ICPC-2 (codes A30 and A31). The ‘health check’ problems can be 
considered preventive in nature but whether each is for primary, secondary or tertiary 
prevention is not recorded in the BEACH data set. The age limit (of 15 years and 
over) was selected because check-ups for children rarely involve pathology testing.  
Check-ups that were likely to be privately funded (such as employment check-ups) 
were excluded because any pathology generated in the management of these checks 
would also be privately funded. This is one of the few areas in general practice that 
generates a substantial amount of privately funded pathology. The majority of 
pathology ordered by GPs is publicly funded through the MBS and this is the focus 
of this thesis.  
Check-ups related to a specific health condition were also excluded because presence 
of this condition would affect pathology test selection and the resources GPs use to 
guide their test selection. In addition, the specific condition usually indicated that the 
check-up was not preventive.  
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Weakness/tiredness  
Weakness/tiredness was investigated when recorded by the GP as the clinical 
problem under management. It includes problems classified as ‘weakness/tiredness’ 
in ICPC-2 (code A04). This does not include all patient presentations of 
weakness/tiredness. In many cases GPs were able to assign a presentation of 
weakness/tiredness to a more specific diagnosis based on other information (e.g. 
patient history). The problem label of weakness/tiredness indicates that a more 
precise diagnostic label could not be assigned to the problem at the time of the 
encounter.  
Overweight/obesity  
Overweight/obesity includes problems labelled by the GP as ‘obesity’ or 
‘overweight’ (ICPC-2 codes T82 and T83) at encounters with adult patients (aged 
18 years and over). This does not represent all encounters with overweight/obese 
adult patients, only those at which overweight or obesity was managed as a specific 
problem at the encounter. It also does not include GP management of 
overweight/obesity as part of the management of other morbidity (e.g. weight/diet 
advice in the management of hypertension). 
The method(s) used by the GP to define the problem as obesity or overweight is not 
known. It may be clinical opinion, calculation of BMI, waist measurement, weight 
measurement, or a combination of the above indications.  
Overweight and obesity were combined to provide a larger sample with greater 
statistical power than obesity alone. In addition, many of the available guidance 
documents were for overweight/obesity. If a patient is overweight they are at 
considerable risk of progressing to obesity. Hence the WHO regards overweight as 
preobesity.109 
The analysis of pathology ordering for overweight and obesity was limited to adults 
because guidance provided for management of overweight/obesity in children and 
adolescents differed from that for adults. Further, most encounters (95.1%) involving 
the management of overweight/obesity were with adult patients.  
87 
5.3.3 Identifying the guidelines and other sources of 
guidance  
National and international guidelines, and other published guidance documents for 
the management of each selected problem were identified using literature searches in 
Medline and internet-based search engines and databases (e.g. Google, National 
Guideline Clearinghouse, TRIP Database). The most recently available international 
and national guidelines and other Australian sources of GP guidance for each 
selected problem published prior to May 2009 were reviewed.  
Search terms used included disease management and practice guidelines and terms 
related to the specific problem. For example, for overweight/obesity search terms 
included overweight, obesity, and body weight. Additional websites and databases 
were found by consulting ‘related links’ on websites and ‘related articles’ links 
within electronic databases.  
Peak bodies that develop and disseminate guidelines were identified, and their 
published guidelines examined for any relating to the selected problems. Reference 
lists in documents were also reviewed to find other relevant publications. 
Any guidelines or guidance documents that were largely based on another guidance 
document were excluded, and the source guidance document reviewed. Only 
guidance published in English or with an English translation available was included. 
The guidance documents reviewed in this study included guidelines and other types 
of published guidance documents (such as the pathology manual produced by the 
RCPA). All types of guidance documents were reviewed because GPs use multiple 
sources when looking for clinical information, including guidelines and other 
published guidance documents.152 The review also sought to evaluate the extent to 
which pathology test recommendations were consistent among guidance documents. 
Therefore it was considered appropriate to review all published sources of guidance 
available to GPs.  
Some guideline authors have also produced abbreviated GP guides and fact sheets in 
an effort to overcome identified barriers to guideline use by GPs (e.g. length of 
guidelines).153 These guides were compared with the matching guidelines to identify 
mismatches (e.g. differences in level of recommendations, and omissions). 
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Throughout the remainder of this chapter the term ‘guidance documents’ is used to 
refer to both guidelines and other sources of guidance. 
5.3.4 Determining recommended pathology testing 
Guidance documents were reviewed to identify pathology tests recommended in the 
management of the specific problems. Level of support was determined for each 
pathology test/battery of tests that accounted for at least 1% of pathology tests 
ordered for the selected problem.  
When there were differences among guidance document recommendations for an 
individual test, the level of support for the test was determined by agreement in the 
majority of guidance documents. 
Tests were classified as:  
• supported: those that the guidance documents indicated have a role in any phase 
of management of the problem. For example, tests only recommended for 
diagnosis were considered supported. In addition tests that were recommended 
for a large specific group of patients were considered supported (e.g. all female 
patients). 
• having conditional support: guidance documents indicated the test has a role in 
the management of the problem in certain circumstances (such as the presence of 
a risk factor).  
• unsupported: tests that the guidance documents specifically stated should not be 
performed or tests not mentioned by guidance documents as having a role in the 
management of the problem.  
• support unable to be determined: level of support in guidance documents was 
unclear for two groups of tests—multibiochemical analysis (MBA) and ‘other 
chemistry’ tests.  
The MBA group includes two tests: the MBA test and the electrolytes and liver 
function test (E&LFT) (see Appendix 7). The MBA group potentially includes a 
large number of biochemical analytes‡. The MBS chemical analysis pathology 
item 66500 gives an example of the range of biochemical tests that could be 
included in a MBA.23 The specific analytes measured in response to a GP’s order 
for a MBA or E&LFT test varied between laboratories, therefore it was not 
possible to determine the exact tests included in the MBA group. When a 
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guidance document recommended one or more biochemical tests that could be 
considered part of the MBA group (but did not mention the MBA or E&LFT 
tests) this is discussed in the relevant section.  
The ‘other chemistry’ group includes a large number of individual chemistry 
tests that are not frequently ordered in general practice. The included tests are 
listed in Appendix 7. Where an individual test within the group accounted for 
more than 1% of pathology tests for an investigated problem it was evaluated 
and discussed in the relevant section. 
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5.4 Hypertension 
5.4.1 Background 
Hypertension is the most common cardiovascular condition in the population.154 
Cardiovascular disease was made a National Health Priority Area in 1996 due its’ 
high burden of morbidity and mortality.155 High blood pressure accounted for 7.6% 
of the burden of disease in Australia (in 2003).156 In 1999–00, the prevalence of 
hypertension was 29% of Australians aged 25 years and over, and prevalence 
increased with age.157 
A 2005 SAND substudy of 9,156 patients estimated the prevalence of hypertension 
to be 23.3% of patients at encounters in general practice. After adjusting for 
frequency of attendance, the prevalence was 17.6% of the general practice patient 
population (i.e. patients who attend general practice at least once).158 
Hypertension is identified and managed because of the cardiovascular risk associated 
with high blood pressure.159-162 Pathology testing does not have a role in the 
diagnosis of hypertension, but does have a role in identifying causes of secondary 
hypertension and detecting cardiovascular risk factors and disease.  
5.4.2 Management rate in Australian general practice 
In BEACH, hypertension was managed at 72,169 encounters by 7,489 GPs in  
2000–08, at a rate of 9.2 per 100 encounters (Table 5.1). This equates to an estimated 
9.3 million GP encounters per year where hypertension was managed in Australia. 
The vast majority (99.9%) of hypertension managed was uncomplicated 
hypertension (results not tabled), and there was no change in the management rate of 
hypertension between 2000–02 and 2006–08 (Chapter 4). In contrast, the 
management rate of ‘new’ hypertension problems increased significantly (by 24%), 
from 0.48 per 100 encounters in 2000–02 to 0.60 in 2006–08 (Table 5.1), indicating 
an increase in its diagnosis or detection rate. 
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Table 5.1: Summary of hypertension data set, 2000–08, 2000–02 and 2006–08 
 2000–08 2000–02 2006–08  
Variable Number 
Rate per 100 
encounters 
(95% CI) 
(n = 784,300) Number
Rate per 100 
encounters 
(95% CI) 
(n = 198,200) Number 
Rate per 100 
encounters 
 (95% CI) 
(n = 188,300) Change
General 
practitioners 
7,489 
 
. . 1,900 . . 1,810 
 
. . . . 
 
Hypertension 
encounters  
72,169 
 
. . 18,007 . . 17,792 
 
. . . . 
 
Hypertension 
problems managed 
72,171 
 
9.2 
(9.0–9.4)
18,007 9.1 
(8.8–9.4)
17,793 
 
9.5 
(9.1–9.8) — 
New hypertension 
problems 
4,237 
 
0.54 
(0.52–0.56)
958 0.48 
(0.44–0.52)
1,131 
 
0.60 
(0.56–0.64)  
Note: Data about hypertension problems managed are drawn from Chapter 4, Table 4.3. CI – confidence interval. Shading 
indicates a statistically significant change between 2000–02 and 2006–08. The direction and type of change is 
indicated for each measure: / indicates a statistically significant change, and — indicates no change. 
5.4.3 Pathology ordered for hypertension 
Pathology was ordered at a rate of 26.2 tests/batteries of tests per 100 hypertension 
contacts in 2000–08. One in ten hypertension problem contacts (10.2%) resulted in at 
least one pathology order. Once the decision to order pathology was made GPs 
ordered on average 2.56 tests/batteries per tested problem (Table 5.2).  
As described in Chapter 4, the rate of pathology ordering per 100 hypertension 
contacts increased significantly between 2000–02 and 2006–08. This was due to 
significant increases in both the likelihood of pathology being ordered in the 
management of hypertension and the number of tests ordered per tested hypertension 
problem (Table 5.2). 
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Table 5.2: Summary of pathology ordering for hypertension, 2000–08, 2000–02 and 
2006–08 
 2000–08 2000–02 2006–08  
Variable Number 
Per cent / 
Rate of 
hypertension 
problems 
(95% CI) 
(n = 22,938) Number
Per cent / 
Rate of 
hypertension
problems 
(95% CI)
(n = 18,007) Number 
Per cent / 
Rate of 
hypertension
problems 
(95% CI)
(n = 17,793) Change
Pathology (Rate per 100 
hypertension problems) 
18,889 
 
26.2 
(25.3–27.1)
3,884 21.6 
(20.0–23.2)
5,744 
 
32.3 
(30.3–34.2)  
At least one pathology 
order (Per cent of 
hypertension problems)  
7,377 
 
10.2 
(9.9–10.6)
1,565 8.7 
(8.1–9.3)
2,124 
 
11.9 
(11.3–12.6)  
Number of tests/ 
batteries per 100 tested 
hypertension problems 
. . 
 
256.1 
(251.8–260.4)
. . 248.2 
(239.5–257.0)
. . 
 
270.4 
(262.5–278.4)  
Note: Pathology ordering data from 2000–02 and 2006–08 are drawn from Chapter 4, Table 4.4. CI – confidence interval. 
Shading indicates a statistically significant change between 2000–02 and 2006–08. The direction and type of change 
is indicated for each measure: / indicates a statistically significant change. 
Types of pathology tests/batteries ordered  
Table 5.3 shows the rate of pathology tests/batteries ordered for hypertension in 
2000–08 by MBS groups and the most common individual types of tests ordered. 
Chemistry tests were the group most often ordered (21.0 per 100 hypertension 
contacts) and the most common were:  
• lipid tests (5.8 per 100 hypertension contacts)  
• EUC tests (5.3 per 100 contacts) 
• glucose/glucose tolerance tests (2.9 per 100)  
• LFTs (2.3) (Table 5.3). 
Haematology tests (4.0 per 100 contacts), in particular FBC tests (3.6), were also 
commonly ordered in the management of hypertension (Table 5.3). 
One-eighth (16.4%) of pathology tests were ordered for ‘new’ cases of hypertension. 
While the rate of pathology ordering for new cases was significantly higher than the 
average rate, the majority of tests ordered by GPs were for the ongoing management 
or monitoring of hypertension (Table 5.3). 
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Table 5.3: Rate of pathology test orders for hypertension by MBS pathology groups 
and most frequent individual test orders within each group, 2000–08 
 All hypertension problems New hypertension problems 
Pathology test Number
Rate per 100 
hypertension 
problems 
(95% CI) 
(n = 22,938) Number
Per cent 
of test 
Rate per 100 new 
hypertension 
problems 
(95% CI) 
(n = 1,421)
Chemistry  15,148 21.0 (20.2–21.7) 2,387 15.8 56.3 (52.6–60.0)
 Lipids*  4,203 5.8 (5.6–6.1) 644 15.3 15.2 (13.9–16.5)
 EUC*  3,836 5.3 (5.1–5.6) 528 13.8 12.5 (11.4–13.6)
 Glucose/glucose 
 tolerance* 2,119 2.9 (2.8–3.1) 348 16.4 8.2 (7.3–9.1)
 LFT*  1,624 2.3 (2.1–2.4) 281 17.3 6.6 (5.8–7.4)
 MBA*  1,237 1.7 (1.6–1.9) 207 16.7 4.9 (4.2–5.6)
 TFT*  768 1.1 (1.0–1.1) 179 23.3 4.2 (3.6–4.8)
 Other chemistry*  456 0.6 (0.5–0.7) 78 17.1 1.8 (1.4–2.3)
 PSA* 270 0.4 (0.3–0.4) 45 16.7 1.1 (0.8–1.4)
 HbA1c* 182 0.3 (0.2–0.3) 14 7.7 0.3 (0.2–0.5)
Haematology  2,917 4.0 (3.8–4.2) 528 18.1 12.5 (11.3–13.6)
 FBC  2,564 3.6 (3.4–3.7) 480 18.7 11.3 (10.3–12.3)
 ESR 261 0.4 (0.3–0.4) 40 15.3 0.9 (0.7–1.2)
Other tests NEC  462 0.6 (0.6–0.7) 74 16.0 1.8 (1.3–2.2)
 Blood test 197 0.3 (0.2–0.3) 30 15.2 0.7 (0.4–1.0)
Microbiology 293 0.4 (0.4–0.5) 107 36.5 2.5 (2.0–3.0)
 Urine M,C&S* 274 0.4 (0.3–0.4) 100 36.5 2.4 (1.9–2.9)
Other pathology groups 69 . . 7 10.1 . .
Total pathology tests  18,889 26.2 (25.3–27.1) 3,103 16.4 73.2 (68.6–77.9)
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Only the groups of tests/individual tests accounting for  1% of all pathology tests for the selected problem are 
included. CI – confidence interval; EUC – Electrolytes, urea and creatinine; MBA – multibiochemical analysis;  
TFT – thyroid function tests; PSA – Prostate specific antigen; FBC – full blood count; ESR – erythrocyte 
sedimentation rate; M,C&S – microscopy, culture and sensitivity; NEC – not elsewhere classified. 
Changes in the types of pathology tests/batteries ordered 
Table 5.4 shows the most common pathology tests/batteries ordered for hypertension 
in 2000–02 and 2006–08. Listed below are the tests for which significant change in 
GPs’ order rate occurred between 2000–02 and 2006–08 (listed in decreasing test 
rate order). There were significant increases in the order rate of: 
• lipid tests—28% increase 
• EUC tests—36% increase  
• FBCs—64% increase 
• glucose/glucose tolerance tests—35% increase  
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• LFTs—71% increase 
• MBA tests—109% increase 
• TFTs—75% increase 
• PSA tests—200% increase 
• ‘other chemistry’ tests—400% increase (Table 5.4). This was mostly due to 
increases in the rate of urinary albumin and albumin:creatinine ratio tests that are 
grouped within the ‘other chemistry’ group. 
Table 5.4: Rate of pathology test orders for hypertension by MBS pathology groups 
and most frequent individual test orders within each group, 2000–02 compared with 
2006–08 
 2000–02 2006–08 
Pathology test Number
Rate per 100 
hypertension 
problems 
(95% CI) 
(n = 18,007) Number
Rate per 100 
hypertension 
problems 
(95% CI) 
(n = 17,793) Change
Chemistry  3,105 17.2 (15.9–18.6) 4,615 25.9 (24.3–27.6)  
 Lipids*  970 5.4 (4.8–6.0) 1,220 6.9 (6.4–7.3)  
 EUC*  816 4.5 (4.1–5.0) 1,084 6.1 (5.5–6.6)  
 Glucose/glucose tolerance* 462 2.6 (2.3–2.9) 616 3.5 (3.1–3.8)  
 LFT*  306 1.7 (1.5–1.9) 524 2.9 (2.6–3.3)  
 MBA*  199 1.1 (0.9–1.3) 407 2.3 (2.0–2.6)  
 TFT*  141 0.8 (0.6–0.9) 254 1.4 (1.2–1.6)  
 Other chemistry*  39 0.2 (0.1–0.3) 174 1.0 (0.8–1.2)  
 PSA* 39 0.2 (0.1–0.3) 110 0.6 (0.5–0.7)  
 HbA1c* 36 0.2 (0.1–0.3) 55 0.3 (0.2–0.4) — 
Haematology  588 3.3 (2.9–3.6) 900 5.1 (4.6–5.5)  
 FBC 501 2.8 (2.5–3.1) 811 4.6 (4.2–5.0)  
 ESR 65 0.4 (0.3–0.5) 71 0.4 (0.3–0.5) — 
Other tests NEC  97 0.5 (0.4–0.7) 135 0.8 (0.6–0.9) — 
 Blood test 39 0.2 (0.1–0.3) 64 0.4 (0.2–0.5) — 
Microbiology 74 0.4 (0.3–0.5) 78 0.4 (0.3–0.6) — 
 Urine M,C&S* 67 0.4 (0.3–0.5) 72 0.4 (0.3–0.5) — 
Other pathology groups 20 . . 16 . .  
Total pathology tests  3,884 21.6 (20.0–23.2) 5,744 32.3 (30.3–34.2)  
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note:  Only the groups of tests/individual tests accounting for  1% of all pathology tests for the selected problem are 
included. CI – confidence interval; NEC – not elsewhere classified; also see Abbreviations. Shading indicates a 
statistically significant change between 2000–02 and 2006–08. The direction and type of change is indicated for each 
measure: / indicates a statistically significant change, and— indicates no change 
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5.4.4 Guidance documents for hypertension 
Eleven guidance documents were reviewed for hypertension (Box 5.1).  
Box 5.1: Guidance documents reviewed for hypertension 
Title Year Author  Abbreviated 
to 
Guide to management of hypertension 
2008: assessing and managing raised 
blood pressure in adults163 
2008 National Heart Foundation (NHF) of 
Australia 
NHF 
Hypertension: management of 
hypertension in adults in primary care164
2006 National Collaborating Centre for Chronic 
Conditions and the British Hypertension 
Society. National Institute for Health and 
Clinical Excellence (NICE) guideline 
[United Kingdom] 
NICE 
Seventh report of the Joint National 
Committee on Prevention, Detection, 
Evaluation, and Treatment of High 
Blood pressure (JNC 7)165 
2004 United States Department of Health and 
Human Services, National Institutes of 
Health 
JNC 7 
Hypertension in older people166 2001 Scottish Intercollegiate Guidelines 
Network (SIGN) 
SIGN 
Statement on management of 
hypertension167 
2003 World Health Organization (WHO) and 
International Society of Hypertension 
(ISH) 
WHO & ISH 
Guidelines for the management of 
arterial hypertension168 
2007 European Society of Hypertension (ESH) 
and of the European Society of 
Cardiology (ESC) 
ESH & ESC 
Health care guideline: hypertension 
diagnosis and treatment169 
2006 Schwartz G, Canzanello V, Woolley A, 
Miller T, O'Connor P, Klein D et al. 
Institute for Clinical Systems Improvement 
(ICSI) guideline [United States of America] 
ICSI 
Canadian Hypertension Education 
Program recommendations for the 
management of hypertension: parts 1170 
and 2171 
2007 Canadian Hypertension Education 
Program (CHEP) 
CHEP 
RCPA manual, hypertension section172 2004 The Royal College of Pathologists of 
Australasia (RCPA) 
RCPA 
Murtagh’s general practice, 
hypertension chapter173 
2007 Murtagh J [Australia] Murtagh 
Patient presentations in general 
practice: blood pressure check up and 
hypertension review sections174 
1999 Steven I [Australia] Steven 
5.4.5 Extent of alignment between GP testing and guidance 
documents  
In Table 5.5, the frequently ordered pathology tests/batteries for hypertension are 
categorised by level of support in the guidance documents listed in Box 5.1. The key 
explaining the colours used in the table is provided before Table 5.5.  
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Supported tests 
The four types of tests that were recommended in the majority of guidance 
documents were lipids, EUC, FBC and glucose/glucose tolerance (Table 5.5). 
Together these four tests accounted for 67.4% of tests/batteries ordered by GPs for 
hypertension (Table 5.6). The order rate of these tests increased significantly 
between 2000–02 and 2006–08 (Table 5.4). 
Lipid and glucose testing were almost unanimously recommended (Table 5.5), most 
often as part of the initial assessment of newly diagnosed hypertension. The reason 
for testing lipids was to determine patient’s cardiovascular risk profile, and for 
glucose testing it was to detect undiagnosed diabetes. Ongoing testing was 
recommended in three guidance documents (JNC 7,165 Steven,174 CHEP170,171) and in 
one other it was referred to in a footnote of a flowchart (NHF163).  
There was unanimous agreement among guidance documents for EUC testing 
(predominately creatinine, potassium and sodium testing), primarily to assess kidney 
function both as end (or target) organ damage (in ongoing management) and kidney 
disease as a cause of secondary hypertension (in the initial assessment). EUC was 
also recommended in the monitoring of response to medications, specifically 
potassium monitoring in the management of diuretics, and sodium and creatinine in 
the monitoring of angiotensin converting enzyme (ACE) inhibitors and angiotensin 
receptor blockers/angiotensin II receptor antagonists (see medication monitoring 
discussion in Section 5.4.6).  
The FBC (also referred to as a ‘complete blood picture’ or ‘full blood evaluation’) is 
a battery of tests. GPs routinely order a FBC rather than the individual analytes or 
components within it. Most of the hypertension guidance documents reviewed 
recommended that one or more of the analytes in a FBC should be tested (Table 5.5). 
Haematocrit and/or haemoglobulin tests (two analytes within a FBC) were 
commonly recommended, but the rationale for ordering these tests was not 
given.163,165,168,169,173 In contrast, the CHEP guideline specifically recommended 
against the use of these tests as they did not aid in investigation or monitoring of 
hypertension.170  
The SIGN guideline recommended FBC testing because the mean cell volume (one 
part of a FBC) may indicate excess alcohol consumption, and such consumption is 
associated with resistance to antihypertensive therapy and to risk of stroke.166 
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Alcoholism/excess alcohol consumption was also mentioned as a potential cause of 
secondary hypertension in other guidance documents.164,165,169-172 However, with the 
exception of SIGN, no other guidance documents recommended pathology tests to 
identify excess alcohol consumption.  
In all guidance documents, when FBC testing was recommended it was only as part 
of the initial assessment. 
Tests with conditional support 
There were four types of tests that had conditional support or mixed levels of 
support: LFT, TFT, urine M,C&S, and albumin (urinary albumin or 
albumin:creatinine ratio) tests (Table 5.5) and together they accounted for 15.3% of 
tests ordered by GPs for hypertension (Table 5.6). Between 2000–02 and 2006–08 
there were significant increases in the order rate of LFT, TFT and ‘other chemistry' 
tests (which includes albumin tests) and no change in the rate of urine M,C&S 
(Table 5.4) 
LFT was recommended in two guidance documents (Table 5.5). The NHF guideline 
recommended LFT as part of the investigations of a newly diagnosed patient, but the 
reason for testing was not given.163 The SIGN guideline recommended testing of 
Gamma glutamyl transpeptidase (one part of LFT) as a possible indicator of 
alcoholism/excess alcohol intake.166 As discussed above, many guidelines discussed 
alcoholism/excess alcohol intake as a cause of secondary hypertension.164,165,169-172 
Thyroid disease was mentioned as a possible cause of secondary hypertension in six 
guidance documents (Table 5.5). Testing was only recommended if thyroid disease 
was suspected (e.g. clinical suspicion or abnormal physical examination) as part of 
the initial assessment. 
Two guidance documents recommended urine M,C&S in initial investigation of 
newly diagnosed hypertension to identify possible urinary tract infection.168,174 NHF 
recommended it as a follow-up test if urinalysis was abnormal.163 RCPA 
recommended it as part of ‘further investigation’ if necessary.172 
Testing for microalbuminuria (using urine albumin or albumin:creatinine ratio tests) 
was recommended in the majority of guidance documents but for different reasons. 
Some recommended testing as part of the routine initial assessment,164,166,167,174 while 
others recommended it if the patient had an abnormal urinalysis test163,168,169 or the 
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patient had diabetes.170,171,173 JNC 7 stated that urine albumin or albumin:creatinine 
ratio tests were optional unless diabetes or kidney disease is present, in which case it 
was recommended annually.165  
Support unable to be determined 
It was not possible to determine whether MBA and ‘other chemistry’ tests (excluding 
urine albumin tests) were recommended in the guidance documents (see 
Section 5.3.4). These two tests accounted for 7.8% of pathology ordered for 
hypertension (Table 5.6).  
With the exception of urinary albumin and albumin:creatinine (split from the ‘other 
chemistry’ group and discussed above), the remainder of the ‘other chemistry’ group 
was classified as having unclear guidance. 
The MBA test was not recommended in any guidance documents. However, some 
tests that may be considered part of the MBA, such as EUC and LFT, were partially 
or completely supported in the management of hypertension (as discussed above). 
Unsupported tests 
The guidance documents did not recommend testing of PSA, erythrocyte 
sedimentation rate (ESR), HbA1c and unspecified ‘blood tests’ (Table 5.5). These 
four tests together accounted for 4.8% of pathology ordered by GPs in the 
management of hypertension (Table 5.6). PSA was the only test within this group to 
increase significantly between 2000–02 and 2006–08 (Table 5.4).  
Other tests mentioned in the guidance documents  
Other tests mentioned in guidance documents were urinalysis, uric acid, calcium and 
CRP. These were ordered rarely, each accounting for less than 1% of pathology 
ordered for hypertension.  
Urinalysis was recommended in nine of the eleven guidance documents as part of the 
initial investigations for hypertension to assess kidney function.163,165,166,168-174 
Uric acid and calcium testing were rarely ordered as individual tests. However it is 
possible that they would be tested as part of a MBA. Testing urate/uric acid was 
recommended in four guidance sources. It was recommended as a measure of kidney 
function,168,173 as part of the initial assessment163 or as a baseline when initiating a 
diuretic.166 Calcium testing was recommended as part of the initial review in three 
guidance documents as an indicator for hyperparathyroidism.165,166,169 
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The CRP, a non-specific measure of inflammation175 was recommended in 
Murtagh.173 The rationale for ordering this test was not provided. While CRP was 
rarely ordered, GPs did order the ESR (an alternative test to the CRP). ESR was not 
recommended in guidance documents (see above) (Table 5.5). 
Key to Table 5.5 
Colour Description 
 The document specifically recommended this test. Any notes within the cell indicate 
further detail. For example, a specific disease to test for within subset of patients; a 
specific test within a group.  
 The document stated that this test should be considered. Any notes within the cell indicate 
further detail (e.g. a specific test to consider) 
 Unable to determine guidance (see Section 5.3.4).  
 The document specifically stated not to do this test. Additional information is supplied if 
certain conditions apply (e.g. specific clinical situations). 
 Guidance document does not mention this test 
 
Table 5.5: Summary of guidance recommendations by most frequent individual test orders for hypertension, 2000–08 
Pathology test  
Per cent of 
hypertension 
pathology 
(n = 18,889) NHF163 NICE164 JNC 7165 SIGN166 
WHO & 
ISH167 
ESH & 
ESC168 ICSI169 CHEP170,171 RCPA172 Murtagh173 Steven174 
Lipids*  22.3            
EUC*  20.3            
FBC  13.6 Hb  Haematocrit   Hb & haematocrit Haematocrit  
 Hb & 
haematocrit  
Glucose/glucose tolerance* 11.2            
LFT*  8.6    Gamma GT        
MBA*  6.6            
TFT*  4.1            
Urine M,C&S* 1.5 If abnormal urinalysis        
 
  
PSA* 1.4            
ESR 1.4            
Other chemistry (excluding 
urinary albumin/ 
albumin:creatinine ratio) 
1.3         
 
  
Urinary albumin/ 
albumin:creatinine ratio 1.1 
If abnormal 
urinalysis     
If abnormal 
urinalysis 
If abnormal 
urinalysis Diabetes 
 Diabetes  
HbA1c* 1.0            
Blood test 1.0            
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Hb – haemoglobulin; also see Abbreviations. Any notes within the coloured cells are described in detail in Section 5.4.5. 
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Evaluation of GP pathology ordering against guidance documents 
Table 5.6 provides a summary of the individual tests recorded in BEACH and the 
level of support provided in the guidance documents for each. Of the tests/batteries 
ordered by GPs for hypertension in 2000–08: 
• 67.4% were supported  
• 24.2% had conditional support or support could not be determined  
• 4.8% were not supported by the guidance documents.  
The individual tests/batteries listed in Table 5.6 accounted for 96.3% of pathology 
ordered for hypertension because only the most commonly ordered tests were 
evaluated. 
Table 5.6: Summary of support for GP pathology ordering for the most frequent 
individual test orders for hypertension, 2000–08 
Pathology test supported by guidance Number 
% of all pathology for 
hypertension 
Supported 12,722 67.4 
 Lipids*  4,203 22.3 
 EUC*  3,836 20.3 
 FBC 2,564 13.6 
 Glucose/glucose tolerance* 2,119 11.2 
Conditional/unclear support 4,567 24.2 
 LFT*  1,624 8.6 
 MBA*  1,237 6.5 
 TFT*  768 4.1 
 Other chemistry*  
 (excluding urine albumin/albumin:creatinine ratio) 248 1.3 
 Urinary albumin/Albumin:creatinine ratio 208 1.1 
 Urine M,C&S* 274 1.5 
Unsupported 910 4.8 
 PSA* 270 1.4 
 HbA1c* 182 1.0 
 ESR 261 1.4 
 Blood test 197 1.0 
Subtotal (n, % of total tests) 18,199 96.3 
Total pathology tests  18,889 100.0 
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Only the groups of tests/individual tests accounting for  1% of all pathology tests for the selected problem are 
included. See Abbreviations. 
In 2000–08, GPs ordered supported pathology tests at a rate of 17.6 tests/batteries per 
100 hypertension problems, followed by tests with conditional support (6.0 per 100), 
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and unsupported tests (1.3). Tests ordered for hypertension but not evaluated were 
ordered at a rate of 1.3 per 100 hypertension problems. The rate at which GPs 
ordered tests in all ‘level of support’ groups increased significantly over time 
(Table 5.7). 
Table 5.7: Rate of pathology ordering for hypertension by level of support, 2000–08, 
2000–02 and 2006–08 
 2000–08 2000–02 2006–08  
Level of support 
Rate per 100 
hypertension 
problems 
 (95% CI) (n = 72,171)
Rate per 100 
hypertension 
problems 
 (95% CI) (n = 18,007)
Rate per 100 
hypertension 
problems 
 (95% CI) (n = 17,793) Change
Supported  17.6 (17.0–18.3) 15.3 (14.0–16.5) 21.0 (19.6–22.3)  
Conditional/unclear 
support 6.0 (5.7–6.3) 4.2 (3.8–4.6) 8.0 (7.4–8.6)  
Unsupported  1.3 (1.2–1.4) 1.0 (0.8–1.2) 1.7 (1.4–1.9)  
Not evaluated 1.3 (1.2–1.4) 1.1 (0.9–1.3) 1.6 (1.4–1.9)  
Note: CI – confidence interval. Shading indicates a statistically significant change between 2000–02 and 2006–08. The 
direction and type of change is indicated for each measure: / indicates a statistically significant change. 
GPs ordered only pathology tests that were supported or conditionally supported at 
8.7% (95% CI: 8.4–9.0) of hypertension problems in 2000–08. A further 1.2%  
(95% CI: 1.1–1.3) of hypertension problems involved at least one unsupported test, 
and 90.1% (95% CI: 89.7–90.4) of problems involved either no pathology tests 
(89.8%) or tests that were not evaluated (0.3%) (results not tabled). 
Between 2000–02 and 2006–08 there were significant increases in the proportion of 
hypertension problems that involved GP orders for: 
• only completely or partially supported tests, 7.5% (95% CI: 6.9–8.0) in 2000–02 
and 10.1% (95% CI: 9.4–10.7) in 2006–08. 
• at least one unsupported test 1.0% (95% CI: 0.8–1.1) in 2000–02 and 1.6% (95% 
CI: 1.4–1.9) in 2006–08 (results not tabled).  
When GPs ordered unsupported tests, they were usually accompanied by one or more 
supported/partially-supported tests (75% of occasions). Unsupported tests were 
ordered alone at the remaining 25%. GPs ordered only unsupported pathology tests at 
0.3% of hypertension problems in 2000–08. This did not change significantly over 
time, 0.2% (95% CI: 0.1–0.3) in 2000–02 and 0.4% (95% CI: 0.2–0.5) in 2006–08 
(results not tabled). 
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5.4.6 Discussion 
Pathology testing was recommended in the management of hypertension in all 
guidance documents, and the majority (> 90%) of tests ordered by GPs were 
recommended (with either partial or complete support) in this guidance. 
The statistically significant increase in the rate of GPs’ total pathology ordering for 
hypertension between 2000–02 and 2006–08 was reflected in significant increases in 
the rate of tests that were supported, partially supported, and unsupported in 
guidance documents. The largest increase was in the rate of partially supported tests.  
Due to the increase in total rate of pathology ordering, the correlation between GPs’ 
ordering and level of support, as a proportion of total tests should be considered. 
Supported tests decreased as a proportion of total tests between 2000–02 and  
2006–08, counteracted by an increase in partially supported tests. The proportion of 
total pathology tests that were unsupported stayed stable. Overall this suggests that 
the increase in GPs ordering did not result in testing being ‘more’ or ‘less’ in line 
with recommendations. However this disguises a shift in GPs’ ordering, from 
supported to partially supported tests that warrants investigation. 
Pathology testing in the initial assessment 
The majority of pathology recommendations made in guidance documents were for 
the initial assessment of newly diagnosed hypertension. An initial assessment was 
recommended for all patients to detect cardiovascular risk and end organ damage 
(usually kidney damage).  
Guidance documents also recommended investigation of secondary causes of 
hypertension (as part of the assessment of hypertension) if initial testing was 
abnormal or other clinical indicators suggested that secondary hypertension was 
likely. The causes of secondary hypertension that involve pathology ordering in their 
diagnosis are listed with the relevant recommended test(s) (as defined by the 
guidance):  
• kidney disease—EUC, albumin, albumin:creatinine ratio 
• aldosteronism—aldosterone, renin 
• Cushing’s syndrome—cortisol 
• phaeochromocytoma—catecholamines, methylated amines 
• parathyroid disease—parathyroid hormone, calcium 
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• thyroid disease—thyroid-stimulating hormone, T4 (i.e. TFT) 
Only kidney disease and thyroid disease were tested for by GPs in the management 
of hypertension. The tests for the rare diseases that cause secondary hypertension 
(aldosteronism, Cushing’s syndrome, phaeochromocytoma) were ordered very 
infrequently, accounting for less than 1% of pathology tests for hypertension. This 
reflects appropriate pathology ordering by GPs based on the low probability of these 
diseases. 
It is possible that GPs ordered pathology tests/batteries for the initial assessment of 
hypertension at the time of its ‘diagnosis’ as a new clinical problem, explaining the 
higher pathology order rate at these new cases compared with the average for 
hypertension problems. There was a significant increase in the management rate of 
new cases of hypertension (between 2000–02 and 2006–08), suggesting an increase 
in the number of new cases, which contributed to the increase in the total rate of 
pathology ordered for hypertension. Despite this increase, new cases accounted for a 
small proportion of hypertension contacts and total pathology ordered for 
hypertension (6% and 16% respectively). 
There are limitations to linking pathology testing to new cases as a way of defining 
the initial assessment. A new case indicates that the patient was diagnosed at that 
consultation. But GPs may order pathology tests for the initial assessment after the 
diagnosis (e.g. at the second or third consultation). While this may occur, the chronic 
nature of the disease suggests that a large proportion of tests recommended as part of 
the initial investigation were ordered in ongoing management.  
As tests were considered ‘supported’ if recommended at any phase of management, it 
is important to establish whether tests recommended only for the initial assessment 
have a role in the ongoing management of hypertension.  
Pathology testing in long-term management 
Hypertension usually requires life long management. Guidance documents 
highlighted this fact and often included a section on long-term management, with 
recommendations for frequency of review and intensifying therapy. However, most 
did not provide guidance about the need for pathology testing in long-term 
management. This is alarming because the majority of contacts (94%) and pathology 
tests (84%) ordered by GPs were for the long-term management of hypertension. 
 105 
The guidance documents that did discuss pathology tests for monitoring did so in 
relation to: reassessing cardiovascular risk; monitoring (or detecting) end organ 
kidney damage; and monitoring medications. 
Reassessing cardiovascular risk (involving lipid and glucose testing) was 
recommended in four guidance documents. Steven174 recommended annual testing 
and was the only one to specify interval between monitoring. CHEP referred to a 
diabetes guideline for assessment of ‘incident’ diabetes (i.e. the development of 
diabetes) and recommended lipid testing ‘with a frequency reflecting the clinical 
situation’.170,171 JNC 7 recommended that cardiovascular risk should be monitored.165 
Similarly, NHF recommended reassessing cardiovascular risk ‘regularly’ but this 
was only mentioned in a footnote to a management flowchart.163  
Presence of end organ kidney damage is also considered a cardiovascular risk in 
patients with hypertension. JNC 7165 and CHEP170,171 specifically recommended 
monitoring of electrolytes and creatinine for all patients; only JNC 7165 specified an 
interval (1–2 times per year). The SIGN guideline recommended annual testing for 
proteinuria.  
When guidance was given, specific information about the interval between testing 
was often omitted. Information from other sources would need to be used by GPs if 
they wanted to know about interval between monitoring. For example, the 
cardiovascular risk guideline recommended reassessment based on risk level (every 
2 years in low risk, 6–12 monthly in medium, and based on clinical situation in high 
risk);176 and the RACGP recommended annual testing for diabetes in patients aged 
45 years and over with hypertension.177  
It should not be necessary for GPs to reference multiple sources to find this 
information. Producers of hypertension guidance should improve recommendations 
on reassessment of cardiovascular risk in long-term care, including the specific 
pathology testing required and interval between testing. 
Medication monitoring  
Pathology tests related to medication use were discussed in most guidance 
documents, but specific recommendations about testing and frequency of tests were 
often not provided. Some guidance documents listed the common side effects of 
medications (including hypo/hyperkalaemia, hyponatraemia, hyperglycaemia, 
worsening renal function) without recommending the testing needed to identify side 
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effects.165,167-171,173,178 Others did not specifically mention the side effects.164,172,174 It 
is possible that some of the guidance documents may have considered the monitoring 
of adverse medication effects outside the scope of the guidance. 
When guidance was provided for medication monitoring, potassium and/or creatinine 
testing was recommended (dependent on the medication used) but no 
recommendation for frequency of testing was given. Some examples are given 
below.  
• Testing potassium in use of thiazide diuretics. The SIGN guideline 
recommended testing within 4–6 weeks of initiation but monitoring was not 
discussed.166 Steven recommended annual testing of sodium and potassium for 
patients taking diuretics without discussing the side effects of its use.174 The 
NHF guideline recommended action if potassium levels were below the 
reference range in patients taking thiazide but the recommendation to test and the 
interval to monitor was not given.163 The NHF also listed hyperglycaemia, gout, 
and hyponatraemia as possible adverse effects of thiazide use ‘to be considered’ 
but whether these should be tested for was not clear.163 
• Monitoring serum creatinine and potassium in use of ACE inhibitor or 
angiotensin receptor blocker. SIGN recommended testing creatinine and 
potassium within 1–2 weeks of therapy initiation.166 NHF and NICE discussed 
the possibility of an initial rise in creatinine at initiation of these medications 
without specifically mentioning the need to test creatinine.163,164 NHF 
recommended ‘monitoring of kidney function’ when combination therapy of 
ACE inhibitor and angiotensin receptor blocker was used but no information on 
the monitoring interval or the specific test was given.163  
In monitoring medications, GPs may have used other sources such as the electronic 
Therapeutic Guidelines (eTG) (an Australian resource for medication guidance). It 
recommended testing electrolytes (i.e. potassium) and creatinine prior to initiation of 
ACE inhibitors or angiotensin receptor blockers and one to two weeks after initiation 
or dose adjustments. However clear guidance on adverse effect monitoring was not 
provided for thiazide diuretics or loop diuretics—the common adverse effects were 
listed but testing was not mentioned.179  
Information about the role of pathology testing in monitoring adverse effects of 
medication was poor. Guidance documents need to provide clearer recommendations 
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about whether testing for adverse effects of hypertension medications is required, the 
interval between tests and the duration that monitoring needs to persist. 
Alternatively, if not considered within the scope of the guidance, this should be 
clearly stated and appropriate resources referenced. Further, the completeness of 
recommendations for pathology testing in these alternative resources should be 
checked (as demonstrated by the example of diuretics in the eTG). 
The discussion in this section demonstrates that guidance documents either lacked 
guidance or provided incomplete guidance about pathology testing in the long-term 
management of hypertension. Despite this, the guidance available did suggest that 
lipid, glucose, electrolyte and kidney function tests had a role in its ongoing 
management. These tests accounted for about half of pathology ordered for 
hypertension, and their order rate increased significantly between 2000–02 and 
2006–08. This suggests that GPs are acting in accordance with the limited guidance 
available. 
GPs’ use of these tests is further supported by research that shows that hypertension 
rarely occurs in isolation. In 80% of people it is clustered with metabolic conditions 
(dyslipidaemia, insulin resistance, glucose intolerance and obesity).162 While test 
recommendations in guidance documents for the initial assessment of hypertension 
reflect these comorbidities, they are not necessarily present at the time of diagnosis. 
The underlying prevalence of these diseases and the fact that they may develop over 
the longer term in patients with hypertension further supports GPs’ continued 
ordering of these tests. 
The lack of guidance about the required interval between monitoring is concerning. 
However, even if guidance was provided, I would not have been able to assess this 
using the cross-sectional BEACH data. This assessment would require quality 
longitudinal data (which may be available from the pathology industry) but such 
investigation was outside the scope of this thesis. 
Tests for which guidance was lacking 
There was a significant discord between guidance documents’ recommendations and 
GPs’ ordering for hypertension for four tests: FBC, LFT, TFT and MBA. For three of 
these (FBC, LFT and TFT), guidance documents only recommended their use in the 
initial assessment of hypertension, but GPs usually ordered them in ongoing 
management (more than three-quarters of occasions), suggesting their level of 
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support may be over-estimated. The fourth test, the MBA, was not recommended in 
any guidance documents. Despite this lack of guidance, GPs’ ordering of these tests 
increased significantly between 2000–02 and 2006–08, and they accounted for one-
third of total tests ordered for hypertension in 2000–08. 
The rationale for recommending FBC and LFT in the initial assessment was provided 
by only one guideline (to identify excess alcohol consumption).166 However, no 
recommendations were made for ongoing management.  
The lack of rationale is more concerning for FBC (than for LFT) because it was 
frequently recommended (6 out of 11 documents) and commonly ordered by GPs. It 
raises questions about what clinical purpose the FBC fulfils for GPs in hypertension 
management, and on what guidance authors based their recommendations. For 
example, was evidence found that supported FBC use? Were recommendations 
consensus-based or based on the guidance authors’ clinical experience? GPs’ have 
reported in qualitative research that clinical experience influences their pathology 
ordering.36 However, the fact that one guideline specifically recommended against 
FBC use (because it did not aid either initial investigation or monitoring of 
hypertension) adds weight to the argument that guidance authors should revisit the 
FBC recommendation. Future guidance should include the rationale for the test (to 
aid in its clinical interpretation) and its role (if any) in monitoring, and if applicable, 
the frequency of testing required. 
GPs’ ordering of LFTs may be associated with the management of lipid levels, in 
particular, monitoring side effects of lipid-lowering medications such as statins (see 
Section 5.6.6). While guidance documents did not recommend monitoring of LFT for 
this purpose, they did recommend assessment and management of lipid levels.  
Thyroid disease was discussed as a cause of secondary hypertension, suggesting that 
most TFTs would be ordered in initial testing, but GPs usually ordered them in 
ongoing care. Information on whether there is a need to reassess TFT when initial 
results are clinically insignificant is needed in guidance documents. For example, are 
there certain patient groups for whom reassessing thyroid function is valid (such as, 
older patients, if incidence increases with age) and what is the interval at which 
patients should be reassessed if it is valid to do so? The RACGP’s guideline on 
preventive activities in general practice states that there is unproven benefit in 
screening for thyroid disease in adults.177 Although this guidance is not specific to 
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hypertension, GPs’ clinical experience may suggest that there is value in reassessing 
TFT when managing hypertension. However, the question about the validity of 
reassessing TFT should be investigated further and the findings incorporated into 
future hypertension guidance. 
The increase in the proportion of GP-ordered tests classified as ‘partially supported’ 
(mentioned earlier in this discussion) was mainly due to increases in the rate of LFT, 
TFT and MBA tests. These tests were classified as partially supported because either 
very few guidance documents recommended the test (in the case of MBA and LFT) 
or guidance suggested their use should be confined to a specific clinical situation (for 
TFT).  
The four tests for which guidance was unclear are likely to represent the greatest 
opportunity to decrease the volume of pathology ordered by GPs for hypertension. 
Reducing their use would require investigation of whether the tests are clinically 
useful in the management of hypertension at any stage (including for ongoing 
monitoring). The results of this investigation should be used to improve guidance 
documents, and this guidance promoted to GPs to improve test ordering (if 
necessary). 
Summary 
GPs’ selection of appropriate pathology tests in the management of hypertension was 
excellent, the vast majority being recommended in guidance documents. However, 
the lack of recommendations provided in guidance documents about pathology 
testing in long-term management of hypertension is alarming given the majority 
(84%) of pathology ordered by GPs was for ongoing care. Guidance needs to be 
improved in this area, specifying the tests required and the recommended interval 
between monitoring tests. Future research is needed to investigate whether 
deficiencies identified in guidance also represent areas in which GP pathology 
ordering could be improved. 
The lack of guidance about the testing interval required for monitoring tests may 
provide an opportunity to decrease the number of testing occasions (where at least 
one pathology test was ordered) for hypertension, which increased over the study 
period. If further investigation reveals that the recommended testing interval is less 
frequent than current GP practice there would be potential for decrease. However, 
the reverse may be found, that current practice is less frequent than recommended 
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testing, which would suggest an increase in the number of testing occasions is 
needed.  
Targeting a reduction in unsupported tests will achieve modest reductions in volume 
of pathology (as they accounted for only 5% of pathology ordered for hypertension), 
and would be unlikely to reduce the number of testing occasions, because GPs 
usually ordered unsupported tests with supported tests. 
Hypertension was the problem that generated the highest volume of pathology tests 
in Australian general practice. Further, the ageing population is expected to lead to 
an increase in the prevalence of hypertension, which in turn would generate more 
management of hypertension in general practice and increased associated pathology 
ordering. Therefore, achieving a reduction (even a modest reduction) in GPs’ 
pathology test (volumes or occasions of testing) ordering by reducing unnecessary 
tests would be worthwhile. 
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5.5 Type 2 diabetes 
5.5.1 Background 
The prevalence of diabetes in Australia has doubled over the last 20 to 30 years,180,181 
and is expected to continue to increase,180-182 a situation that is occurring in many 
countries.182,183 The expected increase is linked to increases in population, ageing of 
population, and increasing obesity.180-183  
Diabetes was made a National Health Priority Area in 1996 due to the burden it 
places on the health system.184 In 2003, diabetes was responsible for 5.5% of the total 
burden of disease and injury in Australia.156  
The majority of diabetes in Australia is Type 2 diabetes (T2D).154,181,185 The self-
reported prevalence of diagnosed T2D in the population was 3.5% in 2007–08.154 
However, measured prevalence is far higher—7.1% of adults aged 25 years and over 
in 1999–00—because it includes diagnosed and undiagnosed T2D (approximately 
half was undiagnosed).181  
There have been numerous national and state-based policies and initiatives 
introduced to identify undiagnosed diabetes, improve the care of people with 
diabetes, and prevent diabetes in those at risk in Australia. Examples of initiatives 
implemented in general practice include, the National Integrated Diabetes Program186 
(which included the MBS diabetes annual cycle of care items), the National Chronic 
Disease Strategy,187 the MBS Chronic Disease Management items,188 the Prevention 
of Type 2 Diabetes Program,189 and the Australian Primary Care Collaboratives 
Program.190  
General practice has been the focus of many initiatives because GPs hold the primary 
role in the diagnosis and management of T2D. For the majority of patients they are 
the health professional most often seen and they coordinate multidisciplinary care, 
through referrals and through the MBS multidisciplinary care plans. Diabetes is one 
of the most commonly managed problems in general practice.17 A 2009 SAND 
substudy of 3,021 patients estimated the prevalence of T2D to be 9.0% of patients at 
encounters in general practice.191 Pathology testing is used by GPs to diagnose T2D, 
to monitor glycaemic control and to identify morbidities associated with diabetes. 
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5.5.2 Management rate in Australian general practice 
In BEACH, T2D was managed at 22,935 patient encounters by 6,451 GPs in  
2000–08, at a rate of 2.9 per 100 encounters (Table 5.8). This equates to about 
3.2 million encounters per year where T2D was managed by GPs in Australia.  
As described in Chapter 4, the management rate of T2D increased significantly 
between 2000–02 and 2006–08. There was no change in the diagnosis or detection 
rate of new cases of T2D between 2000–02 and 2006–08 (Table 5.8). This indicates 
that the increased management rate largely reflected an increase in monitoring 
encounters for T2D rather than an increase in its detection or diagnosis rate. 
Table 5.8: Summary of T2D data set, 2000–08, 2000–02 and 2006–08 
 2000–08 2000–02 2006–08  
Variable Number 
Rate per 100 
encounters 
(95% CI) 
(n = 784,300) Number
Rate per 100 
encounters 
(95% CI) 
(n = 198,200) Number 
Rate per 100 
encounters 
 (95% CI) 
(n = 188,300) Change
General 
practitioners 
6,451 
 
. . 1,573 . . 864 
 
. . . . 
 
T2D encounters  22,935 . . 5,211 . . 6,171 . . . . 
T2D problems 
managed 
22,938 
 
2.9 
(2.9–3.0)
5,211 2.6 
(2.5–2.8)
6,172 
 
3.3 
(3.1–3.4)  
New T2D problems 
 
1,421 
 
0.2 
(0.2–0.2)
325 0.2 
(0.1–0.2)
369 
 
0.2 
(0.2–0.2) — 
Note: Data about T2D problems managed are drawn from Chapter 4, Table 4.3. T2D – Type 2 diabetes; CI – confidence 
interval. Shading indicates a statistically significant change between 2000–02 and 2006–08. The direction and type of 
change is indicated for each measure: / indicates a statistically significant change, and — indicates no change. 
5.5.3 Pathology ordered for T2D 
Pathology was ordered at a rate of 77.2 per 100 T2D problems in 2000–08. At almost 
one-third of T2D problem contacts (29.7%) at least one pathology test/battery was 
ordered by the GPs. Once the decision to order pathology was made, GPs ordered an 
average 2.59 tests/batteries per tested T2D problem (Table 5.9).  
As reported in Chapter 4, the rate of pathology ordering for T2D increased 
significantly between 2000–02 and 2006–08. This was due to significant increases in 
both the likelihood of pathology being ordered for T2D, and the number of tests 
ordered once the decision to order pathology was made (Table 5.9).  
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Table 5.9: Summary of pathology ordering for T2D, 2000–08, 2000–02 and 2006–08 
 2000–08 2000–02 2006–08  
Variable Number 
Per cent / 
Rate of T2D 
problems 
(95% CI) 
(n = 22,938) Number
Per cent / 
Rate of T2D 
problems 
(95% CI)
(n = 5,211) Number 
Per cent / 
Rate of T2D 
problems 
(95% CI)
(n = 6,172) Change
Pathology (Rate per 
100 T2D problems) 
17,709 
 
77.2
(75.0–79.5)
3,314 63.6
(59.6–67.6)
5,459 
 
88.4
(83.7–93.2)  
At least one pathology 
order (Per cent of T2D 
problems)  
6,818 
 
29.7
(29.0–30.5)
1,423 27.3
(25.8–28.8)
1,948 
 
31.6
(30.1–33.0)  
Number of tests/ 
batteries per 100 
tested T2D problems 
. . 
 
259.8
(255.7–263.8)
. . 232.9
(224.8–241.0)
. . 
 
280.2
(272.4–288.1)  
Note: Pathology ordering data from 2000–02 and 2006–08 are drawn from Chapter 4, Table 4.4. CI – confidence interval. 
Shading indicates a statistically significant change between 2000–02 and 2006–08. The direction and type of change 
is indicated for each measure: / indicates a statistically significant change. 
Types of pathology tests/batteries ordered  
Table 5.10 shows the rate of pathology tests/batteries ordered for T2D in 2000–08 by 
MBS groups and the most common individual types of tests ordered.  
Chemistry tests were the group most often ordered (68.5 per 100 T2D contacts) and 
the most common were:  
• HbA1c tests (23.0 per 100 T2D contacts) 
• lipid tests (11.7 per 100 contacts)  
• glucose/glucose tolerance tests (10.0) 
• EUC tests (7.2) 
• ‘other chemistry’ tests (6.2)—90% of this group were urine albumin tests  
• LFTs (4.5) (Table 5.10). 
Haematology tests (6.1 per 100 contacts), in particular FBCs (5.5 per 100), were also 
commonly ordered in the management of T2D (Table 5.10). 
Only 7% of pathology tests/batteries were ordered in the management of ‘new’ cases 
of T2D, the vast majority being ordered for ongoing management (Table 5.10). 
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Table 5.10: Rate of pathology test orders for T2D by MBS pathology groups and most 
frequent individual test orders within each group, 2000–08 
 All T2D problems New T2D problems 
Pathology test Number
Rate per 100 
T2D problems
(95% CI) 
(n = 22,938) Number
Per cent 
of test 
Rate per 100 new 
T2D problems 
(95% CI) 
(n = 1,421)
Chemistry  15,718 68.5 (66.5–70.6) 1,051 6.7 74.0 (67.6–80.3)
 HbA1c* 5,271 23 (22.3–23.7) 257 4.9 18.1 (16.0–20.1)
 Lipids*  2,681 11.7 (11.2–12.2) 124 4.6 8.7 (7.2–10.2)
 Glucose/glucose tolerance* 2,299 10.0 (9.5–10.5) 287 12.5 20.2 (18.1–22.3)
 EUC*  1,657 7.2 (6.8–7.6) 89 5.4 6.3 (4.9–7.6)
 Other chemistry*  1,418 6.2 (5.8–6.6) 110 7.8 7.7 (6.3–9.2)
 LFT*  1,040 4.5 (4.2–4.9) 60 5.8 4.2 (3.2–5.3)
 MBA*  803 3.5 (3.2–3.8) 46 5.7 3.2 (2.3–4.2)
 TFT*  235 1.0 (0.9–1.2) 47 20.0 3.3 (2.3–4.3)
Haematology  1,402 6.1 (5.7–6.5) 116 8.3 8.2 (6.6–9.7)
 FBC  1,266 5.5 (5.2–5.9) 106 8.4 7.5 (6.1–8.9)
Other tests NEC  401 1.8 (1.5–2.0) 31 7.7 2.2 (1.4–3.0)
Microbiology 164 0.7 (0.6–0.8) 23 14.0 1.6 (0.9–2.3)
Other pathology groups 24 . . 3 12.5 . .
Total pathology tests  17,710 77.2 (75.0–79.5) 1,224 6.9 86.1 (78.7–93.6)
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Only the groups of tests/individual tests accounting for  1% of all pathology tests for the selected problem are 
included. CI – confidence interval; NEC – not elsewhere classified; also see Abbreviations. 
Changes in the types of pathology tests/batteries ordered 
The pathology tests/batteries ordered for T2D problems in 2000–02 and 2006–08 are 
shown in Table 5.11. Listed below are the tests for which significant change in GPs’ 
order rate occurred between 2000–02 and 2006–08 (listed in decreasing test rate 
order). There were significant increases in the order rate of: 
• HbA1c tests—33% increase 
• lipid tests—53% increase 
• EUC tests—48% increase  
• ‘other chemistry’ tests—135% increase (due to a 125% rise in urine albumin 
tests) 
• LFTs—79% increase 
• MBA tests—83% increase 
• FBCs—89% increase (Table 5.11). 
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There was also a significant 28% decrease in the order rate of glucose/glucose 
tolerance tests between 2000–02 and 2006–08 (Table 5.11). 
Table 5.11: Rate of pathology test orders for T2D by MBS pathology groups and most 
frequent individual test orders within each group, 2000–02 compared with 2006–08 
 2000–02  2006–08  
Pathology test ordered Number
Rate per 100 
T2D problems 
(95% CI) 
(n = 5,211) Number
Rate per 100 
T2D problems 
(95% CI) 
(n = 6,172) Change
Chemistry  2,951 56.6 (53.0–60.2) 4,828 78.2 (73.9–82.5)  
 HbA1c* 994 19.1 (17.7–20.4) 1,566 25.4 (23.9–26.8)  
 Glucose/glucose tolerance* 641 12.3 (11.1–13.5) 550 8.9 (7.9–9.9)  
 Lipids*  478 9.2 (8.2–10.1) 869 14.1 (13.0–15.2)  
 EUC*  289 5.6 (4.8–6.3) 510 8.3 (7.4–9.1)  
 Other chemistry*  176 3.4 (2.8–4.0) 492 8.0 (7.1–8.8)  
 LFT*  170 3.3 (2.7–3.8) 363 5.9 (5.1–6.6)  
 MBA*  121 2.3 (1.8–2.9) 258 4.2 (3.5–4.9)  
 TFT*  43 0.8 (0.6–1.1) 69 1.1 (0.8–1.4) — 
Haematology  226 4.3 (3.7–5.0) 462 7.5 (6.6–8.4)  
 FBC  190 3.7 (3.1–4.2) 433 7.0 (6.2–7.8)  
Other tests NEC  94 1.8 (1.3–2.3) 123 2.0 (1.5–2.5) — 
 Other test NEC* 34 0.7 (0.4–0.9) 51 0.8 (0.5–1.1) — 
Microbiology 35 0.7 (0.4–0.9) 41 0.7 (0.5–0.9) — 
Other pathology groups 8 . . 5 . .  
Total pathology tests  3,314 63.6 (59.6–67.6) 5,459 88.4 (83.7–93.2)  
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: CI – confidence interval; NEC – not elsewhere classified; also see Abbreviations. Shading indicates a statistically 
significant change between 2000–02 and 2006–08. The direction and type of change is indicated for each measure: 
/ indicates a statistically significant change, and — indicates no change. 
Medications prescribed for T2D  
As pathology test recommendations often relate to the medications prescribed in the 
management of T2D, the most common prescribed medications for T2D are listed in 
Table 5.12.  
Between 2000–02 and 2006–08, there were significant increases in prescribing of the 
hypoglycaemic agents: thiazolinediones (glitazones), combination oral blood glucose 
lowering drugs, and long-acting insulin. There were simultaneous decreases in the 
prescribing rates of sulfonamides and fast acting insulins.  
The prescribing rates of statins, ACE inhibitors and aspirin also increased 
significantly between 2000–02 and 2006–08 (Table 5.12).  
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Table 5.12: Prescribed medications for T2D by Anatomical Therapeutic Chemical 
classification levels 3 and 4, 2000–02 and 2006–08 
 2000–02 2006–08  
ATC levels 3 and 4  Number
Rate per 100 T2D 
problems 
(95% CI) 
(n = 5,211) Number
Rate per 100 T2D 
problems  
(95% CI) 
(n = 6,172)  Change
Blood glucose lowering drugs, 
excluding insulins  3,058 56.7 (55.7–61.6) 3,207 52.0 (49.4–54.5)  
 Biguanides (e.g. metformin) 1,528 29.3 (27.6–31.0) 1,779 28.8 (27.3–30.3) — 
 Sulfonamides, urea  
 derivatives 1,480 28.4 (26.6–30.2) 1,088 17.6 (16.4–18.9)  
 Thiazolidinediones (i.e.  
 glitazones) 8 0.2 (0.0–0.3) 245 4.0 (3.4–4.5)  
 Combination oral blood  
 glucose lowering drugs 0
† 0† 75 1.2 (0.8–1.6)  
Insulins and analogues 297 5.7 (4.7–6.7) 395 6.4 (5.6–7.2) — 
 Intermediate combined with  
 fast-acting 186 3.6 (2.9–4.2) 269 4.4 (3.8–5.0) — 
 Long-acting 19 0.4 (0.2–0.5) 71 1.2 (0.8–1.5)  
 Fast-acting 92 1.8 (1.3–2.2) 55 0.9 (0.6–1.1)  
Lipid modifying agents, plain  59 1.1 (0.8–1.5) 260 4.2 (3.6–4.8)  
 HMG CoA reductase 
 inhibitors (i.e. statins) 54 1.0 (0.7–1.3) 242 3.9 (3.4–4.5)  
ACE inhibitors, plain  51 1.0 (0.7–1.3) 110 1.8 (1.4–2.1)  
Other analgesics and 
antipyretics (e.g. aspirin) 27 0.5 (0.3–0.7) 111 1.8 (1.3–2.3)  
Total prescribed 
medications 3,749 71.9 (68.7–75.2) 4,440 71.9 (68.7–75.2) — 
† Medication was not available in 2000–02. 
Note: Only the medications accounting for > 1% of prescribed medications in either of the data periods are included.  
ATC – Anatomical Therapeutic Chemical classification; CI – confidence interval; ACE – angiotensin converting 
enzyme. Shading indicates a statistically significant change between 2000–02 and 2006–08. The direction and type of 
change is indicated for each measure: / indicates a statistically significant change, and — indicates no change. 
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5.5.4 Guidance documents for T2D 
Twelve guidance documents were reviewed for T2D (Box 5.2).  
Box 5.2: Guidance documents reviewed for T2D 
Title Year Author  Abbreviated 
to 
Diabetes management in general 
practice: guidelines for Type 2 
diabetes 2008–09192 
2008 Diabetes Australia (DA) and Royal Australian 
College of General Practitioners (RACGP) 
DA & RACGP
National evidence based guidelines for 
the management of Type 2 diabetes 
mellitus193 
2005 Diabetes Australia Guideline Development 
Consortium (DAGDC)  
DAGDC 
Clinical practice guidelines for the 
prevention and management of 
diabetes in Canada194 
2008 Canadian Diabetes Association (CDA) CDA 
Type 2 diabetes: national clinical 
guideline for management in primary 
and secondary care195 
2008 National Collaborating Centre for Chronic 
Conditions, Royal College of Physicians. 
National Institute for Health and Clinical 
Excellence (NICE) guideline [United 
Kingdom] 
NICE 
Management of diabetes: a national 
clinical guideline196 
2001 Scottish Intercollegiate Guidelines Network 
(SIGN) 
SIGN 
Standards of medical care in 
Diabetes197 
2008 American Diabetes Association (ADA) ADA 
Clinical practice guidelines: Diabetes 
mellitus198 
2006 Ministry of Health (MoH) [Singapore] MoH 
Medical guidelines for clinical practice 
for the management of diabetes 
mellitus199 
2007 American Association of Clinical 
Endocrinologists (AACE) 
AACE 
Global guideline for Type 2 diabetes200 2005 International Diabetes Federation (IDF) IDF 
RCPA manual, diabetes mellitus 
section172 
2004 The Royal College of Pathologists of 
Australasia (RCPA) 
RCPA 
Murtagh’s general practice, diabetes 
mellitus diagnosis and management 
chapters173 
2007 Murtagh J [Australia] Murtagh 
Patient presentations in general 
practice, ‘diabetes mellitus’ and 
‘diabetes check-up’174 
1999 Steven I [Australia] Steven 
5.5.5 Extent of alignment between GP testing and guidance 
documents 
In Table 5.13, the frequently ordered pathology tests/batteries for T2D are 
categorised by level of support in the guidance documents listed in Box 5.2.  
Supported tests 
The five tests recommended in the majority of guidance documents were HbA1c, 
lipids, glucose/glucose tolerance, EUC, and urinary albumin or albumin:creatinine 
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(Table 5.13). Together these five tests accounted for 74.4% of tests/batteries ordered 
by GPs for T2D (Table 5.14). The rate at which supported tests were ordered for 
T2D increased significantly between 2000–02 and 2006–08 (Table 5.15). However 
individually, the rate of glucose/glucose tolerance tests decreased significantly while 
the other tests increased (Table 5.11).  
There was strong agreement among guidance documents for monitoring glycaemic 
control using the HbA1c test. Frequency of recommended testing was specified in 
the majority of guidance documents. However, three guidelines did not explicitly 
recommend testing of HbA1c.193,196,199 
Fasting glucose tests and oral glucose tolerance tests were recommended for the 
diagnosis of T2D by all guidance documents that provided diagnostic guidance. Only 
three documents194,195,200 recommended annual fasting plasma glucose testing to 
check the accuracy of the patient’s self-monitoring blood glucose machine. 
There was strong agreement among guidance documents for assessment of lipid 
levels. Frequency of testing and targets were provided in the majority of guidance 
documents. However, three guidance documents172,196,199 did not provide clear 
guidance on lipid testing.  
Annual assessment of kidney function was recommended in all documents with the 
exception of the DAGDC guideline. Serum creatinine (for calculation of estimated 
glomerular filtration rate) and urine albumin (albumin:creatinine ratio) were the tests 
specifically recommended. Annual testing of urea was also recommended in two 
documents.173,174  
Renal function was also often discussed in the context of medications. However, the 
DAGDC guideline only discussed renal function in the context of medications and 
blood pressure target—it did not discuss monitoring of creatinine or urine albumin to 
detect diabetic nephropathy.193  
Tests with conditional support 
LFT was classified as having conditional support (Table 5.13). LFT accounted for 
5.9% of tests ordered for T2D (Table 5.14) and their ordering increased significantly 
between 2000–02 and 2006–08 (Table 5.11). 
When LFT was mentioned in guidance documents it was most often in the context of 
medications, specifically in regard to monitoring glitazone use.192,198,199 In two 
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guidance documents liver function was discussed as a consideration in prescribing 
metformin but specific testing was not recommended.194,195 In contrast, NICE 
recommended against LFT testing when statins were prescribed.195 
Two documents recommended LFT as part of the initial assessment of T2D174,197 and 
one of these also recommended annual testing.174  
Support unable to be determined 
It was not possible to determine whether MBA and ‘other chemistry’ tests (excluding 
urine albumin tests) were recommended in the guidance documents (see Section 
5.3.4). Together these two tests accounted for 5.3% of pathology ordered for T2D 
(Table 5.14).  
With the exception of urinary albumin and albumin:creatinine (split from the ‘other 
chemistry’ group and discussed above), the remainder of the ‘other chemistry’ group 
was classified as having unclear guidance. 
The MBA test was not recommended in any guidance documents. However, some 
tests that may be considered part of the MBA, such as EUC and LFT, were partially 
or completely supported in the management of T2D (as discussed above). 
Unsupported tests 
The majority of guidance documents did not recommend testing of FBC and TFT 
(Table 5.13). These tests accounted for 8.5% of pathology ordered for T2D 
(Table 5.14). The order rate of FBC increased significantly between 2000–02 and 
2006–08 (Table 5.11).  
FBC monitoring was mentioned in two documents as a check for anaemia when 
chronic kidney disease was present.199,200 
TFT was not mentioned in the majority of guidance documents. Two documents did 
recommend TFT: DA & RACGP192 recommended it as part of the initial assessment 
if there was a family history or clinical suspicion of thyroid disease; and ADA197 
recommended TFT as part of the initial assessment if dyslipidaemia was present or 
the patient was female and over 50 years of age. 
Other tests mentioned in the guidance documents  
Other tests were mentioned in the guidance documents but each of these accounted 
for less than 1% of tests recorded by GPs for T2D.  
Urinalysis was recommended as part of the initial investigations in two sources.174,192  
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Urine M,C&S was recommended by DA & RACGP if risk of urine infection was 
high192 and was mentioned in RCPA in relation to diabetic nephropathy but the 
specific purpose of testing (whether to identify or monitor nephropathy) was not 
stated.172 
Parathyroid function tests were recommended in the presence of kidney disease by 
AACE.199 
Two guidance documents specifically recommended that routine monitoring of blood 
ketones198 and creatine kinase (CK) 195 should not be done.  
Key to Table 5.13 
Colour Description 
 The document specifically recommended this test. Any notes within the cell indicate 
further detail. For example, a specific disease to test for within subset of patients; a 
specific test within a group.  
 The document stated that this test should be considered. Any notes within the cell indicate 
further detail (e.g. a specific test to consider) 
 Unable to determine guidance (see Section 5.3.4).  
 The document specifically stated not to do this test. Additional information is supplied if 
certain conditions apply (e.g. specific clinical situations). 
 Guidance document does not mention this test 
 
 Table 5.13: Summary of guidance recommendations by most frequent individual test orders for T2D, 2000–08 
Pathology test  
Per cent of 
T2D path 
(n = 17,710) 
DA & 
RACGP192 DAGDC193 CDA194 NICE195 SIGN196 ADA197 MoH198 AACE199 IDF200 RCPA172 Murtagh173 Steven174  
HbA1c* 29.8  Implied   Implied   Implied     
Lipids*  15.1     Implied   Implied  Implied   
Glucose (excluding 
tolerance tests) 12.1 Diagnosis Diagnosis 
Diagnosis 
& annual Annual Diagnosis Diagnosis Diagnosis Diagnosis
Diagnosis 
& annual Diagnosis Diagnosis N/A 
EUC* 9.4  Implied           
Urine albumin/ 
albumin:creatinine ratio 7.2  Implied           
FBC  7.2        Kidney disease 
Kidney 
disease    
LFT*  5.9 Meds   Meds StatinsMeds  Diagnosis Meds Meds     
MBA* 4.5             
TFT*  1.3 
Diagnosis 
(Family Hx or 
symptoms) 
    
Diagnosis 
(dyslipidaemia 
or F > 50 years)
      
Glucose tolerance 0.9 Diagnosis Diagnosis Diagnosis N/A Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis Diagnosis N/A 
Other chemistry* 
(excluding urine albumin/ 
albumin:creatinine ratio) 
0.8             
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: T2D – Type 2 diabetes; path – pathology; N/A – not applicable; Meds – medications; Hx – history; F – female; also see Abbreviations. Any notes within the coloured cells are described in detail in  
Section 5.5.5, briefly: implied – indicates the use of the test is implied; Diagnosis – Test recommended at diagnosis; Meds – test recommended when specific medications are taken. 
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Evaluation of GP pathology ordering against guidance documents 
Table 5.14 provides a summary of the individual tests recorded in BEACH and the 
level of support provided in the guidance documents for each. Of the tests/batteries 
ordered for T2D in 2000–08: 
• 74.4% were supported  
• 11.2% had conditional support or support could not be determined 
• 8.5% were not supported (Table 5.14).  
The tests/batteries listed in Table 5.14 account for 94.1% of pathology ordered for 
T2D because only the most commonly ordered tests for T2D were evaluated.  
Table 5.14: Summary of support for GP pathology ordering for the most frequent 
individual test orders for T2D, 2000–08 
Pathology test  Number 
Per cent of all pathology 
for T2D 
Supported 13,184 74.4 
 HbA1c* 5,271 29.8 
 Lipids*  2,681 15.1 
 Glucose/glucose tolerance* 2,299 13.0 
 EUC*  1,657 9.4 
 Urine albumin/albumin:creatinine ratio 1,276 7.2 
Conditional/unclear support 1,985 11.2 
 LFT*  1,040 5.9 
 MBA*  803 4.5 
 Other chemistry*(a)  
 (excluding urine albumin/albumin:creatinine ratio) 142 0.8 
Unsupported 1,501 8.5 
 FBC  1,266 7.1 
 TFT*  235 1.3 
Subtotal (n, % of total tests) 16,671 94.1 
Total pathology tests  17,710 100.0 
(a) ‘Other chemistry’ after excluding albumin tests accounts for < 1% of total tests in 2000–08 but in 2006–08 it 
accounted for 1.6% of tests. It is included because as a whole group it accounted for  1% of tests for T2D.  
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Only the groups of tests/individual tests accounting for  1% of all pathology tests for the selected problem are 
included. See Abbreviations. 
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In 2000–08, GPs ordered supported pathology tests at a rate of 57.5 tests/batteries per 
100 T2D problems, followed by tests with conditional support (8.6 per 100), and 
unsupported tests (6.5). Tests ordered for T2D but not evaluated were ordered at a 
rate of 4.6 per 100 T2D problems. The rate at which GPs ordered tests in all ‘level of 
support’ groups increased significantly over time (Table 5.15). 
Table 5.15: Rate of pathology ordering for T2D by level of support, 2000–08, 2000–02 
and 2006–08 
 2000–08  2000–02  2006–08  
Level of support 
Rate per 100 T2D 
problems
 (95% CI) 
(n = 22,938)
Rate per 100 T2D 
problems
(95% CI) 
(n = 5,211)
Rate per 100 T2D 
problems 
 (95% CI) 
(n = 6,172) Change
Supported  57.5 (55.7–59.2) 49.1 (45.9–52.3) 63.7 (60.1–67.3)  
Conditional/unclear 
support  8.6 (8.2–9.1) 6.0 (5.2–6.7) 11.0 (10.0–12.0)  
Unsupported  6.5 (6.1–7.0) 4.5 (3.8–5.1) 8.1 (7.2–9.1)  
Not evaluated 4.6 (4.2–4.9) 4.1 (3.4–4.7) 5.7 (4.9–6.4)  
Note: CI – confidence interval. Shading indicates a statistically significant change between 2000–02 and 2006–08. The 
direction and type of change is indicated for each measure: / indicates a statistically significant change. 
GPs ordered only pathology tests that were supported or conditionally supported at 
22.6% (95% CI: 21.9–23.3) of T2D problems in 2000–08. A further 6.0% (95% CI: 
5.6–6.3) of T2D problems involved at least one unsupported test, and 71.4%  
(95% CI: 70.7–72.2) of problems involved either no pathology tests (70.3%) or tests 
that were not evaluated (1.1%) (results not tabled).  
There was no change in the proportion of T2D problems that involved supported 
testing between 2000–02 (22.2%, 95% CI: 20.7–23.6) and 2006–08 (22.7%, 95% CI: 
21.4–24.1). However the proportion involving at least one unsupported test increased 
significantly over this time, from 4.1% (95% CI: 3.5–4.7) to 7.4% (95% CI: 6.6–8.2) 
(results not tabled). 
When GPs ordered unsupported tests, the vast majority (98%) were accompanied by 
one or more supported/partially-supported tests. Unsupported tests were ordered 
alone at the remaining 2%. GPs ordered only tests that were unsupported at 0.1% of 
T2D problems in 2000–08, and this did not change over time (0.1% in 2000–02 and 
2006–08) (results not tabled). 
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5.5.6 Discussion 
More than 85% of pathology tests ordered by GPs in the management of T2D were 
recommended (with either partial or complete support) by guidance documents. The 
statistically significant increase in the rate of GPs total pathology ordering for T2D 
between 2000–02 and 2006–08 was reflected in significant increases in the rate of 
tests that were supported, partially supported, and unsupported in guidance 
documents. The largest increases were in the rate of partially supported and 
unsupported tests.  
Due to the increase in total rate of pathology ordering, the correlation between GPs’ 
ordering and level of support, as a proportion of total tests should be considered. 
Supported tests accounted for the largest proportion of total tests, but they accounted 
for a smaller proportion of total tests in 2006–08 than in 2000–02. Concomitantly 
there were small increases in the proportion of both the partially supported and 
unsupported tests. Overall the increase in total tests ordered by GPs for T2D 
suggested a small shift (approximately 2% of total pathology) to be ‘less’ in line with 
guidance recommendations. 
Comments on selected guidance documents 
The DAGDC, SIGN and AACE guidelines lacked clear recommendations for testing 
in (at least one of) three crucial aspects of T2D management: glycaemic control, lipid 
testing and renal function. 
Regular monitoring of glycaemic control (using the HbA1c test) was not 
recommended in any of these guidelines. SIGN and AACE both discussed the 
HbA1c target but specific recommendations for monitoring HbA1c were not 
given.196,199 The DAGDC guideline was published as seven stand-alone sections 
(each section focused on an aspect of T2D management), but there was no section on 
glycaemic control. It was only mentioned in the lipid section of the guideline in the 
context of the beneficial effect of glycaemic control on lipids, and specific test 
recommendations for HbA1c were not given.193 
Lipid test recommendations were lacking in the SIGN and AACE guidelines. SIGN 
discussed dyslipidaemia as a cardiovascular risk factor,196 and AACE provided the 
target for lipid levels,199 but neither included testing or monitoring recommendations.  
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The DAGDC guideline did not include a section on diabetic nephropathy. Renal 
function was only discussed as a consideration in choice of therapy and monitoring 
of medication side effects.193 
Since work for this chapter was completed, new SIGN and DAGDC guidelines have 
been published that supersede those reviewed in this study, and an additional AACE 
guideline about developing a diabetes care plan has been published (but this does not 
supersede the existing guidance). The new SIGN guideline does not correct the 
omissions noted above. In contrast, the new DAGDC guideline corrects the noted 
omissions, but it is worth mentioning that the structure of separate sections persists in 
the new version. Publishing the guideline in multiple sections makes it difficult to 
search for information and creates a very long guideline (the length of the 2005 
guideline reviewed in this chapter was more than 750 pages, easily the longest of the 
reviewed documents) making it difficult to use as a guidance document. 
Monitoring of T2D 
As T2D is a chronic condition, the majority of management provided and pathology 
ordered by GPs, was for its ongoing management. In most guidance documents there 
were clear recommendations on the use and frequency of tests to monitor glycaemic 
control, lipid levels and renal function in the ongoing management of T2D. However 
the role of fasting glucose tests, FBC and LFT in long-term management was not 
clear. 
The fasting glucose test was unanimously recommended to diagnose T2D, 
suggesting the majority would be associated with ‘new’ cases of T2D. However, 
BEACH data showed that most (87%) were ordered after the diagnosis of T2D. 
Glucose testing accounted for 12% of testing for T2D. While the order rate of fasting 
glucose tests did decrease between 2000–02 and 2006–08, the high proportion 
ordered for ongoing care suggests that GPs routinely use this test for ongoing 
management. Only three guidance documents recommended glucose testing in 
ongoing management, to annually assess the accuracy of the patient’s home glucose 
monitor. GPs’ rationale for ongoing use may reflect this recommendation or may be 
due to other reasons. Considering the volume of glucose testing, guidance on the role 
of fasting glucose testing in ongoing care of T2D should be clarified in future 
guidance documents. 
 126 
FBC testing was classified as unsupported in this study because only two guidance 
documents suggested it had a role in the management of T2D. However, GPs 
commonly ordered FBC for T2D (7% of total tests in 2000–08), and the order rate 
almost doubled between 2000–02 and 2006–08. This test was responsible for the 
small shift in GPs ordering being ‘less’ in line with guidance recommendations. 
Two guidance documents recommended FBC testing to check for anaemia when 
chronic kidney disease was present. The presence of chronic kidney disease as a 
comorbidity in T2D was not recorded in BEACH. Therefore whether the rate of FBC 
testing ordered by GPs reflects monitoring of kidney disease cannot be determined. 
However, the lack of guidance for the test, its increased ordering rate and the high 
proportion of tests it accounted for, suggest that the role of FBC in ongoing 
management of T2D needs to be clarified. 
Assessment of liver function was most often mentioned in regard to medications in 
guidance documents, either to identify liver dysfunction or to monitor potential 
adverse effects of medications. However, frequency and duration of monitoring were 
not specified, with one exception—Steven174 recommended annual monitoring. In 
the management of T2D, the order rate of LFTs increased significantly between 
2000–02 and 2006–08, as did the prescribing rate for medications for which LFT 
monitoring was recommended (statins and glitazones). Given these increases, the 
required frequency and duration of LFT for monitoring adverse effects of 
medications needs to be clarified (see ‘medication monitoring’ discussion below).  
For fasting glucose tests, FBC and LFT, in addition to the issues discussed above, 
there was a lack of guidance about interpretation of test results in the context of 
monitoring, even among tests with an established role in monitoring. While the target 
and testing interval were discussed, guidance was not provided on what represents a 
true change in repeated testing results. This is known as the ‘critical difference’ and 
incorporates the expected analytical and intra-individual variation of a test.201 An 
understanding of critical difference is necessary when making treatment decisions 
(e.g. titrating medications) as it determines the level at which a change in results 
represents a true change versus a chance finding.  
Previous studies have demonstrated that there is large variation in GPs estimation of 
critical difference201,202 and that there is limited guidance available to users of 
pathology testing about interpreting repeated results.201-203 As providing guidance 
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about critical difference is complex (due to the number of factors involved), disease-
specific guidelines may not be the best place to disseminate this information for 
monitoring tests. Nevertheless, authors of guidance should consider including at least 
some information about interpretation of the primary monitoring tests on which 
major treatment decisions for T2D are based (such as HbA1c).  
Medication monitoring 
The amount of information about pathology tests required when selecting medication 
(e.g. presence of impaired renal function) and identifying adverse effects, varied 
considerably among guidance documents. Some documents stated that medication 
information was outside the scope of the guidance and referred the reader to the 
relevant product information.194,195 In contrast, the AACE guideline provided a 
summary table for oral hypoglycaemic medications that described the monitoring 
required to determine medication response and presence of side effects, with 
information on time interval to test.199 
Recommendations regarding testing to measure response to therapy were clear in the 
guidance. However, the testing required to identify contraindications and to monitor 
adverse effects was not clear and these are discussed below. 
For metformin, renal impairment and liver disease were considerations in the 
appropriateness of the medication.179,192,194,198,199 Despite this, most guidance did not 
recommend testing prior to initiation of metformin. Based on pathology test 
recommendations in other parts of the guidance documents, GPs should have been 
aware of renal impairment as it would be tested in routine assessment of T2D, but 
this is not the case for liver function. As metformin is the first line medication 
recommended for T2D and the most commonly prescribed medication for T2D in 
this study, the high rate of LFTs ordered by GPs may be partially due to the need to 
assess presence of liver disease in these patients. Guidance about the need for testing 
prior to initiation of metformin should be clarified. 
In the use of glitazones, liver dysfunction/disease was stated as a consideration and 
monitoring of liver enzymes was recommended.192,198,199 The frequency of 
monitoring of liver enzymes was often not specified. In contrast, the Australian 
medication guideline, eTG, recommended LFT prior to initiation of glitazone, 
followed by 2-monthly monitoring for the first year of therapy and periodically 
thereafter.179 The prescribing rate of glitazones increased significantly between 
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2000–02 and 2006–08 and this may have contributed to the significant increase in 
LFT testing. 
Most T2D guidance documents included recommendations about the management of 
lipid levels and blood pressure. For the blood pressure medications—ACE inhibitors, 
angiotensin receptor blockers and diuretics—testing of electrolytes and creatinine 
were recommended.192,196-199  
Statins were the lipid lowering medication most often discussed in T2D guidance. 
The NICE guideline and a paper by the American Physicians Association specifically 
stated monitoring of liver function in statin use for T2D was not necessary.195,204 In 
contrast, the majority of guidance for management of lipid disorders reviewed in 
Section 5.6 recommended monitoring LFT in statin use. The eTG also recommended 
monitoring liver function after 4 weeks of statin use, but information on ongoing 
monitoring was not provided.179 In the management of T2D the prescribing rate of 
statins and ACE inhibitors increased significantly over the duration of this study 
(2000–02 to 2006–08) and this may have contributed to the significant increase in 
LFT and kidney function testing. 
In summary, pathology testing related to medication use may have contributed to 
increases in the rates of LFT, electrolyte and kidney function testing. Guidance 
documents need to provide clearer recommendations about when testing is required, 
whether monitoring of adverse effects is required, the interval between tests and the 
duration of monitoring needed. 
Other factors contributing to the increased management rate of T2D  
The recommended management of T2D has changed as our understanding of 
cardiovascular disease risk has improved. Guidance documents’ recommendations 
are based on evidence about the combined influence of multiple risk factors (such as 
lipid levels and blood pressure) on cardiovascular disease risk. GPs’ management of 
T2D recorded in BEACH suggests they manage the multiple risk factors (such as 
blood pressure and lipids) as part of T2D rather than as separate clinical problems, 
probably because the threshold at which they become a cardiovascular risk is lower 
than the level required for clinical diagnosis. 
As awareness of the threshold of risk (the level at which a factor contributes to risk) 
improved, the targets for a number of observable findings were changed in guidance 
documents (for example, lower HbA1c, low density lipoprotein [LDL] cholesterol 
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and blood pressure, and increased high density lipoprotein [HDL] cholesterol) for 
certain ‘at risk’ patients. Changes in these targets may have influenced GPs’ 
management rate of T2D and pathology ordering rates because these targets are 
potentially harder and take longer to achieve. Pathology testing to measure response 
is more frequent while actively trying to achieve a target (titrating medications, 
monitoring adverse-effects of medications). While the guidance documents 
acknowledge that targets should be adjusted to the individual patient, it is likely that 
a change in targets that requires intensifying management will result in increased 
testing rates.  
Basing treatment recommendations on multiple factors is likely to increase the 
number of patients requiring active treatment. For example, using conventional 
targets, a single risk factor in a patient with T2D may not need treatment—such as, a 
LDL level of 2.4 mmol/L, where the target is < 2.5mmol/L. However, it may require 
treatment when other risk factors are considered—such as, presence of coronary 
heart disease which lowers the recommended LDL target to < 2.0 mmol/L,192 
presence of other risk factors (age > 60 years, microalbuminuria) which require lipid-
lowering treatment regardless of lipid levels.176 
Management of cardiovascular disease risk factors in patients with T2D may have 
contributed to the increased management rate and pathology rate seen in this study. 
While these changes may increase the resources required to manage T2D they 
represent an increase in high quality evidence-based care. 
Past health initiatives aiming to improve detection of diabetes and care of patients 
with diabetes are also likely to have contributed to the increased management rate 
and pathology ordering rate for T2D in general practice. These initiatives provide 
funding for evidence-based clinical activities. For example the diabetes cycle of care 
(introduced as part of the National Integrated Diabetes Program186 in 2006) required 
patients to see the GP at least twice (in a 11–13 month period) and have HbA1c, 
lipids and microalbuminuria assessed at least once in the cycle.186 The success of 
these initiatives may have had an impact on the management rate and pathology 
ordering rate for T2D in a positive way – as they are evidence-based, the 
recommended activities reflect best practice in the management of T2D.  
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Summary 
The majority of tests ordered by GPs in the management of T2D were recommended 
in guidance documents. It can be concluded that much of the increase in the 
management rate and testing rate seen in BEACH was related to best practice 
management of T2D and has been stimulated through numerous evidence-based 
initiatives. The prevalence of T2D is expected to increase in the future due to the 
ageing population and increasing obesity prevalence.180-182 This would cause a 
concomitant increase in the management rate of T2D in general practice, and a 
corresponding increase in pathology ordering based on the current pattern of GPs’ 
pathology ordering for T2D. This study suggests that most of this ordering would be 
supported by guidance documents. 
These finding suggest that the main opportunity to reduce unsupported testing 
ordered for T2D lies in clarification of whether FBC has a role in T2D management. 
Monitoring recommendations should also be improved to clarify: the role (if any) of 
fasting glucose and LFT in long-term management of T2D; and testing required to 
monitor adverse effects of medications. The majority of T2D management and 
pathology ordered by GPs for T2D is for monitoring, reinforcing the need for clarity 
in recommendations regarding pathology testing in long-term management. 
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5.6 Lipid disorders 
5.6.1 Background 
Lipid disorder is national priority because it is a risk factor for cardiovascular 
disease.151 In 2003, ‘high blood cholesterol’ was responsible for 6.2% of the total 
burden of disease and injury in Australia.156  
The prevalence of measured elevated total cholesterol (> 5.5 mmol/L) was 51.2% of 
adults aged 25 years and over in 1999–00.157 The National Health Survey estimated 
the prevalence of self-reported high cholesterol to be 6% of the Australian population 
in 2007–08.154  
The link between lipid levels and cardiovascular disease has been known for many 
decades.205,206 However the management strategy has changed over time. Lipid levels 
are now assessed and managed in the context of the patient’s absolute cardiovascular 
risk.207 This incorporates multiple risk factors and allows identification of the 
patients who will benefit most from treatment rather than basing treatment decisions 
on lipid levels alone.178 In this context, the criteria for subsidised lipid-lowering 
medications (through the PBS) in Australia were broadened in October 2006 to allow 
access on the basis of cardiovascular risk rather than measured lipid levels alone.208  
Lipid disorder is one of the most commonly managed problems in general practice.17 
A SAND substudy of 2,960 patients estimated that 22% of patients at general 
practice encounters had diagnosed dyslipidaemia, and a further 5% had their lipid 
levels managed for other reasons (such as cardiovascular risk).209 Pathology tests are 
required for the diagnosis and monitoring of lipid disorders, and for the assessment 
of cardiovascular risk. 
5.6.2 Management rate in Australian general practice 
In BEACH, lipid disorder was managed at 25,231 patient encounters by 6,480 GPs, 
at a rate of 3.2 per 100 encounters in 2000–08 (Table 5.16). This equates to 
approximately 3.2 million encounters per year where lipid disorder was managed by 
GPs in Australia.  
As discussed in Chapter 4, the management rate of lipid disorders increased 
significantly between 2000–02 and 2006–08 (Table 5.16). There was a significant 
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increase in the diagnosis or detection rate of new cases of lipid disorder, from 0.35 
per 100 encounters in 2000–02 to 0.48 in 2006–08 (Table 5.16). This suggests that 
the increased management rate reflects increases in both detection and monitoring 
encounters for lipid disorders. 
Table 5.16: Summary of lipid disorders data set, 2000–08, 2000–02 and 2006–08 
 2000–08 2000–02 2006–08 
Variable Number 
Rate per 100 
encounters 
(95% CI) 
(n = 784,300) Number
Rate per 100 
encounters 
(95% CI) 
(n = 198,200) Number 
Rate per 100 
encounters 
(95% CI) 
(n = 188,300) Change
General 
practitioners 
6,480 
 
. . 1,629 . . 1,602 
 
. . . . 
 
Lipid 
encounters  
25,231 
 
. . 5,780 . . 6,624 
 
. . . . 
 
Lipid problems 
managed 
25,248 
 
3.2 
(3.2–3.3)
5,782 2.9 
(2.8–3.0)
6,629 
 
3.5 
(3.4–3.7)  
New lipid 
problems 
3,169 
 
0.40 
(0.39–0.42)
699 0.35 
(0.32–0.38)
902 
 
0.48 
(0.44–0.52)  
Note: Data about lipid disorder problems managed are drawn from Chapter 4, Table 4.3. CI – confidence interval. Shading 
indicates a statistically significant change between 2000–02 and 2006–08. The direction and type of change is 
indicated for each measure: / indicates a statistically significant change. 
5.6.3 Pathology ordered for lipid disorders 
Pathology was ordered at a rate of 62.5 per 100 lipid disorder problems managed in 
2000–08. Almost one-third of lipid disorder problem contacts (30.5%) resulted in at 
least one test/battery being ordered by GPs. Once the decision to order pathology 
was made, GPs ordered on average 2.05 tests/batteries per tested lipid problem 
(Table 5.17).  
As reported in Chapter 4, the rate of pathology ordering for lipid disorders increased 
significantly between 2000–02 and 2006–08. This was due to a significant increase 
in the number of tests ordered once the decision to order pathology was made. There 
was no change in the likelihood of pathology being ordered in the management of 
lipid disorders (Table 5.17). 
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Table 5.17: Summary of pathology ordering for lipid disorder, 2000–08, 2000–02 and 
2006–08 
 2000–08 2000–02 2006–08  
Variable Number 
Per cent / 
Rate of lipid 
problems 
(95%CI)
(n = 25,248) Number
Per cent / 
Rate of lipid 
problems 
(95%CI) 
(n = 5,782) Number 
Per cent / 
Rate of lipid 
problems 
(95%CI) 
(n = 6,629) Change
Pathology 
(Rate per 100 lipid 
problems) 
15,777 
 
62.5 
(60.6–64.4)
3,363 58.2 
(54.7–61.6)
4,410 
 
66.5 
(62.5–70.6)  
At least one 
pathology order 
(% of lipid problems)  
7,704 
 
30.5 
(29.8–31.3)
1,758 30.4 
(28.9–31.9)
2,010 
 
30.3 
(28.9–31.8) — 
Number of tests/ 
batteries per 100 
tested lipid problems 
. . 
 
204.8 
(201.2–208.4)
. . 191.4 
(184.6–198.2)
. . 
 
219.4 
(211.6–227.3)  
Note: Pathology ordering data from 2000–02 and 2006–08 are drawn from Chapter 4, Table 4.4. CI – confidence interval. 
Shading indicates a statistically significant change between 2000–02 and 2006–08. The direction and type of change 
is indicated for each measure: / indicates a statistically significant change, and — indicates no change. 
Types of pathology tests/batteries ordered  
Table 5.18 shows the rate of pathology ordered for lipid disorders in 2000–08 by 
MBS groups and the most common individual types of tests ordered. 
Chemistry tests were the group most often ordered (57.1 per 100 lipid disorder 
contacts) and the most common were:  
• lipid tests (31.4 per 100 lipid disorder contacts)  
• LFTs (7.8) 
• glucose/glucose tolerance tests (6.0) 
• EUC tests (3.2). 
Haematology tests (4.3 per 100 contacts), in particular FBCs (3.8), were also 
commonly ordered in the management of lipid disorders. 
Only 7.6% of pathology tests were ordered in the management of ‘new’ cases of lipid 
disorders, the vast majority being ordered for ongoing management (Table 5.18). 
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Table 5.18: Rate of pathology test orders for lipid disorder by MBS pathology groups 
and most frequent individual test orders within each group, 2000–08 
 All lipid disorder problems  New lipid disorder problems 
Pathology test  Number
Rate per 100 lipid 
problems 
(95% CI)
(n = 22,938) Number
Per cent 
of test 
Rate per 100 new 
lipid problems 
(95% CI) 
(n = 1,421)
Chemistry  14,414 57.1 (55.4–58.8) 1,104 7.7 34.8 (31.9–37.8)
 Lipids*  7,919 31.4 (30.5–32.3) 704 8.9 22.2 (20.4–24.0)
 LFT*  1,961 7.8 (7.3–8.2) 106 5.4 3.3 (2.7–4.0)
 Glucose/glucose tolerance* 1,520 6.0 (5.7–6.4) 107 7.0 3.4 (2.7–4.0)
 EUC*  801 3.2 (2.9–3.5) 42 5.2 1.3 (0.9–1.7)
 MBA*  683 2.7 (2.4–3.0) 37 5.4 1.2 (0.8–1.6)
 CK 671 2.7 (2.4–2.9) 44 6.6 1.4 (1.0–1.8)
 TFT*  318 1.3 (1.1–1.4) 27 8.5 0.9 (0.5–1.2)
 PSA* 157 0.6 (0.5–0.7) 4 2.5 0.1 (0.0–0.2)
Haematology  1,076 4.3 (3.9–4.6) 55 5.1 1.7 (1.2–2.2)
 FBC 949 3.8 (3.5–4.1) 48 5.1 1.5 (1.1–1.9)
Other tests NEC  210 0.8 (0.7–1.0) 16 7.6 0.5 (0.2–0.8)
Other pathology groups 77 . . 18 23.4 . .
Total pathology tests  15,777 62.5 (60.6–64.4) 1,193 7.6 37.7 (34.5–40.8)
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Only the groups of tests/individual tests accounting for  1% of all pathology tests for the selected problem are 
included. CI – confidence interval; NEC – not elsewhere classified; also see Abbreviations. 
Changes in the types of pathology tests/batteries ordered 
Table 5.19 shows the most common tests/batteries ordered for lipid disorders in 
2000–02 and 2006–08. Listed below are the tests for which significant change in 
GPs’ order rate occurred between 2000–02 and 2006–08 (listed in decreasing test 
rate order). There were significant increases in the order rate of: 
• FBCs—85% increase 
• EUC tests—110% increase  
• MBA tests—68% increase 
• CK tests—94% increase 
• TFTs—70% increase 
• PSA tests (a marginal increase)—60% increase (Table 5.19). 
In contrast, there was a significant 12% decrease in the order rate of lipid tests 
(Table 5.19).  
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Table 5.19: Rate of pathology test orders for lipid disorder by MBS pathology groups 
and most frequent individual test orders within each group, 2000–02 compared with 
2006–08 
2000–02  2006–08  
Pathology test  Number
Rate per 100 
lipid problems
(95% CI)
(n = 5,782) Number
Rate per 100 
lipid problems 
(95% CI) 
(n = 6,629) Change
Chemistry  3,124 54.0 (50.8–57.3) 3,954 59.7 (56.1–63.2) — 
Lipids*  1,932 33.4 (31.5–35.4) 1,957 29.5 (27.9–31.1)  
LFT*  408 7.1 (6.1–8.0) 550 8.3 (7.4–9.2) — 
Glucose/glucose tolerance* 305 5.3 (4.6–6.0) 417 6.3 (5.5–7.0) — 
EUC*  121 2.1 (1.6–2.5) 294 4.4 (3.8–5.1)  
MBA*  112 1.9 (1.4–2.4) 211 3.2 (2.6–3.8)  
CK 101 1.8 (1.2–2.3) 232 3.5 (2.9–4.1)  
TFT*  56 1.0 (0.7–1.2) 112 1.7 (1.3–2.1)  
PSA* 26 0.5 (0.3–0.6) 55 0.8 (0.6–1.1)  
Haematology  185 3.2 (2.6–3.8) 361 5.5 (4.7–6.2)  
FBC 156 2.7 (2.2–3.2) 333 5.0 (4.3–5.8)  
Other tests NEC  35 0.6 (0.4–0.8) 71 1.1 (0.7–1.4) — 
Other pathology groups 19 . . 24 . .  
Total pathology tests  3,363 58.2 (54.7–61.6) 4,410 66.5 (62.5–70.6)  
Note: CI – confidence interval; NEC – not elsewhere classified; also see Abbreviations. Shading indicates a statistically 
significant change between 2000–02 and 2006–08. The direction and type of change is indicated for each measure: 
/ indicates a statistically significant change (darker shading), / indicates a marginal change (lighter shading), 
and — indicates no change. 
Medications prescribed for lipid disorders  
Lipid lowering agents (plain and combination) accounted for more than 97% of 
medications prescribed in the management of lipid disorders, in 2000–08. Most of 
these were plain statins (91% of all prescribed medications for lipid disorders).  
There was a marginal increase in the rate of prescribed medications between  
2000–02 and 2006–08, from 63.0 per 100 contacts with lipid disorders (95% CI: 
61.1–64.8) to 66.5 per 100 (95% CI: 64.8–68.2). This increase was due GPs’ 
prescribing of ezetimibe and statin/ezetimibe medications, which were not available 
for purchase in 2000–02 and were prescribed at a rate of 4.0 per 100 lipid disorder 
contacts in 2006–08. There was no change between 2000–02 and 2006–08 in the 
prescribing rate of: statins; fibrates; and other lipid-lowering medications (results not 
tabled). 
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5.6.4 Guidance documents for lipid disorder 
Guidance documents for the management of lipid disorder and the lipid section of 
cardiovascular disease prevention guidelines were considered in this study. Twelve 
guidance documents were reviewed for lipid disorder (Box 5.3). 
Box 5.3: Guidance documents reviewed for lipid disorders 
Title Year Author  
Abbreviated 
to 
Position Statement on Lipid 
Management178 
2005 National Heart Foundation (NHF) of 
Australia and the Cardiac Society of 
Australia and New Zealand (CSANZ) 
NHF & 
CSANZ 
Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults - Adult 
Treatment Panel210 and the 2004 
update: Implications of recent clinical 
trials211 
2002 
(2004)
National Cholesterol Education Program 
(NCEP) Expert Panel [United States of 
America] 
NCEP 
Clinical Guidelines and Evidence 
Review for Lipid Modification: 
cardiovascular risk assessment and the 
primary and secondary prevention of 
cardiovascular disease212 
2008 National Collaborating Centre for 
Primary Care and Royal College of 
General Practitioners. National Institute 
for Health and Clinical Excellence 
(NICE) guideline [United Kingdom] 
NICE 
Risk estimation and the prevention of 
cardiovascular disease213 
2007 Scottish Intercollegiate Guidelines 
Network (SIGN) 
SIGN 
Medical Guidelines for Clinical Practice 
for the Diagnosis and Treatment of 
Dyslipidemia and Prevention of 
Atherogenesis214 
2002 American Association of Clinical 
Endocrinologists (AACE) 
AACE 
European guidelines on cardiovascular 
disease prevention in clinical practice215
2007 European Society of Cardiology (ESC) ESC 
Screening and Management of Lipids216 2009 Barrie WE, Harrison RV, Khanderia UB, 
Kiningham RB, Rosenson RS University 
of Michigan [United States of America]  
Barrie et al. 
Recommendations for the management 
of dyslipidemia and the prevention of 
cardiovascular disease217,218 
2003 Genest J, Frohlich J, Fodor G, 
McPherson R. Working Group on 
Hypercholesterolemia and Other 
Dyslipidemias [Canada] 
Genest et al. 
Clinical practice guidelines: Lipids219 2006 Ministry of Health (MoH) [Singapore] MoH 
Health Care Guideline: Lipid 
Management in Adults220 
2007 Woolley A, Kopecky S, Kottke T, 
O'Connor P, Hanson S, Conroy W et al. 
Institute for Clinical Systems 
Improvement (ICSI) guideline [United 
States of America] 
ICSI 
RCPA manual, hyperlipidaemia 
section172 
2004 The Royal College of Pathologists of 
Australasia (RCPA) 
RCPA 
Murtagh’s general practice, 
dyslipidaemia chapter173 
2007 Murtagh J [Australia] Murtagh 
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5.6.5 Extent of alignment between GP testing and guidance 
documents  
In Table 5.20, the frequently ordered tests/batteries for lipid disorder are categorised 
by level of support in the guidance documents listed in Box 5.3.  
Supported tests 
The five types of tests recommended in the majority of guidance documents were 
Lipid tests, LFT, glucose/glucose tolerance, EUC and TFT (Table 5.20). Together 
these tests accounted for 79.3% of pathology ordered by GPs for lipid disorder 
(Table 5.21). Between 2000–02 and 2006–08 the order rate of EUC and TFT 
increased significantly while the order rate of lipid tests decreased (Table 5.19). The 
latter represents a change in how GPs record the lipid test rather than a change in 
lipid ordering behaviour. GPs were more likely to record the specific lipid 
subfractions in 2000–02 (counted as multiple tests) whereas in 2006–08 they were 
more likely to record the lipid profile test (counted as a single test) (results not 
tabled). 
Lipid tests were unanimously recommended, including the need to test lipid 
subfractions (i.e. total cholesterol, LDL cholesterol, HDL cholesterol and 
triglycerides).  
Liver function testing was also recommended in all guidance documents to: 
determine presence of liver dysfunction as a cause of secondary lipid disorders,172,210-
212,214,216,219,220 as a consideration in medication selection and safety,173,178,210-
213,215,216,219,220 and/or in the monitoring of statin medications and selected other 
medications (e.g. combination therapy).173,210-214,216-220  
Glucose testing was recommended in most guidance documents to determine the 
presence of diabetes as a cause of secondary lipid disorder.172,173,210-214,216,219,220 
Diabetes was also discussed in regard to cardiovascular risk as its presence increases 
the patient’s risk and affects which lipid target is appropriate for the 
patient.178,210,211,213-220 
Assessment of renal function (EUC test) was recommended in most guidance 
documents to determine the presence of renal impairment as a cause of secondary 
lipid disorder.172,173,210-212,214,216,219,220 Renal function was also discussed as a 
consideration in medication selection,178,210-213,216-220 and in regard to cardiovascular 
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risk178,210,211,213,215,217,218 as this affects which lipid target is appropriate for the 
patient. 
Assessment of thyroid function was recommended in most guidance documents to 
determine the presence of hypothyroidism as a cause of secondary lipid 
disorder,172,173,210-212,214,216,219,220 and prior to initiating a statin.220  
Tests with conditional support 
The CK test was classified as having conditional support (Table 5.20). CK accounted 
for 4.3% of tests ordered for lipid disorders (Table 5.21) and increased significantly 
between 2000–02 and 2006–08 (Table 5.19). 
CK testing was discussed in regard to medication (primarily statin) use to detect 
myopathy. Most guidance stated that routine CK monitoring was not necessary, but 
CK testing was recommended in patients with muscle symptoms178,210-213,216,219,220 
and some guidance documents recommended taking a baseline measure prior to 
starting statins (or combination statin therapy) for future comparison in all 
patients173,178,210,211,220 or for high risk patients.213 
A few guidance documents recommended routine monitoring in certain high risk 
patients (e.g. renal disease, high dose statins, statin combination therapy).173,178,217-219 
In documents where guidance about CK testing was not given, the potential for 
myopathy as an adverse effect of statin use was discussed.214,215 
Support unable to be determined 
It was not possible to determine whether MBA were recommended in the guidance 
documents (see Section 5.3.4). MBA accounted for 4.3% of pathology ordered for 
lipid disorder (Table 5.21) and increased significantly over time (Table 5.19). 
The MBA test itself was not recommended in any guidance documents. However, 
some tests that may be considered part of the MBA, such as EUC and LFT, were 
partially or completely supported in the management of lipid disorder (as discussed 
above). 
Unsupported tests 
The guidance documents did not mention FBC and PSA testing (Table 5.20). These 
tests accounted for 7.0% of pathology ordered for lipid disorders (Table 5.21) and the 
order rate of both tests increased significantly between 2000–02 and 2006–08 
(Table 5.19). It may be possible that GPs ordered the FBC to assess the presence of 
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systemic lupus erythematosus,221 a possible cause of secondary lipid disorders 
(mentioned in two guidance documents214,220). 
Key to Table 5.20 
Colour Description 
 The document specifically recommended this test. Any notes within the cell indicate 
further detail. For example, a specific disease to test for within subset of patients; a 
specific test within a group.  
 The document stated that this test should be considered. Any notes within the cell 
indicate further detail (e.g. a specific test to consider) 
 Unable to determine guidance (see Section 5.3.4).  
 The document specifically stated not to do this test. Additional information is supplied if 
certain conditions apply (e.g. specific clinical situations). 
 Guidance document does not mention this test 
 
 Table 5.20: Summary of guidance recommendations by most frequent individual test orders for lipid disorder, 2000–08 
Pathology 
test  
Per cent of 
lipid disorders 
pathology 
(n = 15,777) 
NHF & 
CSANZ178 NCEP210,211 NICE212 SIGN213 AACE214 ESC215 
Barrie 
et al.216
Genest et 
al.217,218 MoH219 ICSI220 RCPA172 Murtagh173 
Lipids*  50.2             
LFT*  12.4 Medication safety      
Medication 
safety   Medication
 
 
 
Medication 
Glucose/glucose 
tolerance* 9.6 CV risk   CV risk    CV risk 
 
 
 
 
FBC  6.0     SLE     SLE   
EUC*  5.1 CV risk and medication       
CV risk and 
meds 
 
 
 
 
MBA*  4.3             
CK 4.3 Baseline & muscle sx 
Baseline & 
muscle sx 
Muscle 
sx 
Muscle sx & 
high risk pts Implied 
Medication 
safety  
Muscle 
sx 
High risk 
medication
High risk 
medication
Baseline & 
muscle sx
 Monitor in 
statin use  
TFT*  2.0             
PSA* 1.0             
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: CV risk – cardiovascular risk; SLE – systemic lupus erythematosus; sx – symptom; pts – patients. Also see Abbreviations. Any notes within the coloured cells are described in detail in Section 5.6.5. 
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Evaluation of GP pathology ordering against guidance documents 
Table 5.21 provides a summary of the individual tests recorded in BEACH and the 
level of support provided in the guidance documents for each. Of the tests/batteries 
ordered for lipid disorder in 2000–08: 
• 79.3% were supported 
• 8.6% had conditional support or support could not be determined 
• 7.0% were not supported by the guidance documents.  
The individual tests/batteries listed in Table 5.21 account for 94.9% of pathology 
ordered for lipid disorders because only the most commonly ordered tests for lipid 
disorder were evaluated.  
Table 5.21: Summary of support for GP pathology ordering for the most frequent 
individual test orders for lipid disorder, 2000–08 
Pathology test  Number 
Per cent of all pathology 
for lipid disorders 
Supported 12,519 79.3 
 Lipids*  7,919 50.2 
 LFT*  1,961 12.4 
 Glucose/glucose tolerance* 1,520 9.6 
 EUC*  801 5.1 
 TFT*  318 2.0 
Conditional/unclear support 1,354 8.6 
 MBA* 683 4.3 
 CK 671 4.3 
Unsupported 1,106 7.0 
 FBC  949 6.0 
 PSA* 157 1.0 
Subtotal (n, % of total tests) 14,980 94.9 
Total pathology tests  15,777 100.0 
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Only the groups of tests/individual tests accounting for  1% of all pathology tests for the selected problem are 
included. See Abbreviations. 
In 2000–08, GPs ordered supported pathology tests at a rate of 49.6 tests/batteries per 
100 lipid disorder problems, followed by tests with conditional support (5.4 per 100), 
and unsupported tests (4.4). Tests ordered for lipid disorder but not evaluated were 
ordered at a rate of 3.2 per 100 problems. The rate at which GPs ordered tests that 
were conditionally supported, unsupported and not evaluated increased significantly 
over time (Table 5.22). 
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Table 5.22: Rate of pathology ordering for lipid disorder by level of support, 2000–08, 
2000–02 and 2006–08 
 2000–08 2000–02 2006–08  
Level of support 
Rate per 100 lipid 
disorder problems
(95% CI) 
(n = 25,248)
Rate per 100 lipid 
disorder problems
(95% CI) 
(n = 5,782)
Rate per 100 lipid 
disorder problems 
 (95% CI) 
(n = 6,629) Change
Supported  49.6 (48.1–51.1) 48.8 (45.9–51.7) 50.3 (47.3–53.3) — 
Conditional/unclear 
support 5.4 (5.0–5.8) 3.7 (3.0–4.4) 6.7 (5.8–7.6)  
Unsupported  4.4 (4.0–4.7) 3.1 (2.6–3.7) 5.9 (5.0–6.7)  
Not evaluated 3.2 (2.9–3.4) 2.5 (2.0–3.0) 3.8 (3.1–4.4)  
Note: CI – confidence interval. Shading indicates a statistically significant change between 2000–02 and 2006–08.  
The direction and type of change is indicated for each measure: / indicates a statistically significant change,  
and — indicates no change. 
 
GPs ordered only pathology tests that were supported or conditionally supported at 
25.6% (95% CI: 24.9–26.3) of lipid disorder problems in 2000–08. A further 4.1% 
(95% CI: 3.8–4.4) of problems involved at least one unsupported test, and 70.3% 
(95% CI: 69.5–71.0) involved either no pathology tests (69.5%) or tests that were not 
evaluated (0.8%) (results not tabled).  
There was no significant change in the proportion of lipid disorder problems that 
involved supported testing between 2000–02 (26.8%, 95% CI: 25.3–28.2) and  
2006–08 (24.1%, 95% CI: 22.7–25.4). However the proportion of problems 
involving at least one unsupported test increased significantly over this time, from 
3.0% (95% CI: 2.5–3.5) to 5.4% (95% CI: 4.6–6.2) (results not tabled). 
When GPs ordered unsupported tests, the vast majority (98%) were accompanied by 
one or more supported/partially-supported tests. Unsupported tests were ordered 
alone at the remaining 2%. GPs ordered only tests that were unsupported at 0.1% of 
lipid disorder problems managed in 2000–08. This did not change over time (0.1% in 
2000–02 and 2006–08) (results not tabled). 
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5.6.6 Discussion 
GPs’ pathology testing aligned well with that recommended in guidance documents, 
with 88% of tests ordered by GPs in the management of lipid disorders being 
recommended (with either partial or complete support). The statistically significant 
increase in the rate of GPs total pathology ordering for lipid disorders between  
2000–02 and 2006–08 was reflected in the increased rate of tests that were partially 
supported, and unsupported in guidance documents. There was no change in the rate 
of supported tests.  
Due to the increase in total rate of pathology ordering, the correlation between GPs’ 
ordering and level of support, as a proportion of total tests should be considered. 
Supported tests decreased as a proportion of total tests between 2000–02 and 
2006–08, and was counteracted by increases in partially supported and unsupported 
tests. Overall this suggests that the increase in GPs ordering resulted in testing being 
‘less’ in line with recommendations.  
Part of the decrease in the proportion of supported tests was due to a change in the 
way GPs’ recorded lipid tests on the BEACH encounter forms. In 2000–02, GPs 
were more likely to record the specific lipid subfractions (counted as multiple tests) 
whereas in 2006–08 they were more likely to record the lipid profile test (counted as 
a single test). This may reflect the recommendation to test the entire lipid profile so 
that treatment decisions are based on all lipid subfractions. In the past, treatment 
recommendations were based on the total cholesterol level alone.178,222 
Criteria for funding may also contribute to changes in the pattern of lipid components 
being recorded by GPs in BEACH. Prior to November 2001, the MBS only funded 
HDL tests if the total cholesterol was found to be abnormal,223 suggesting that GPs 
ordered a HDL test separately after obtaining an abnormal total cholesterol result. 
Further, the limit of five pathology tests per BEACH recording form (see 
Section 5.10) may have an influence on recording. For example, as the number of 
tests recorded per problem has increased (see Chapter 4), GPs may record a lipid 
profile (one test) rather than specifying all the lipid subfractions (multiple tests) in 
order to have space available to record other tests. 
Monitoring lipid levels 
The treat-to-target approach to managing lipid levels was recommended (usually 
with LDL cholesterol targets) in most guidance documents.173,178,210,211,214-220 
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Recommendations for monitoring lipid levels were based on the phase of 
management: an ‘active’ phase of management while trying to achieve targets and a 
monitoring phase. 
In the active phase of managing lipid levels (response to diet and exercise and/or 
medications), most guidance documents recommended an interval of between 4 and 
12 weeks for measuring response (i.e. retesting lipid levels) until the recommended 
target lipid levels were achieved.210,211,214,216-218,220  
The NICE and SIGN guidelines did not adopt the usual treat-to-target approach to 
managing lipids. The NICE guideline recommended that patients taking statins for 
primary prevention of cardiovascular disease should not have their lipid levels 
measured in response to statin use unless clinical judgement or patient preference 
indicate the need to review the lipid profile. For secondary prevention of 
cardiovascular disease, the authors provided ‘desirable’ total cholesterol and LDL 
levels to guide the intensification of treatment rather than as targets.212  
The SIGN guideline authors found there was insufficient evidence to support 
recommending lipid targets. Instead they recommended “intensive lipid lowering 
therapy” for high-risk patients taking lipid-lowering therapy for secondary 
prevention and “lifetime treatment with simvastatin 40mg” for those taking it for 
primary prevention. The authors advocated the same total cholesterol target as 
recommended by the National Health Service for Scotland as a minimum standard of 
care.213 
In their review of available evidence, Smellie et al. recommended an interval of 
8 weeks (+/- 4 weeks) for monitoring lipid levels in the active phase of management, 
concluding that differences between guideline recommendations were unlikely to 
influence long-term outcomes.224 However, Bell et al. questioned the need to monitor 
patients taking lipid-lowering medications where randomised control trial data are 
available to give an indication of whether target will be achieved based on initial 
lipid levels.225 This approach assumes high levels of medication adherence and 
similarities between patients in everyday clinical settings and trial participants. There 
is concern that clinical trial data may not reflect the ‘real world’ clinical setting as 
trial participants are highly selected and levels of medication adherence are higher 
than in the general patient population. Smellie et al. concluded that further evidence 
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is needed before recommending changes in monitoring practices on the basis of 
clinical trial evidence.224  
The recommended interval for testing in the long-term monitoring phase varied 
between the guidance documents. For patients whose lipid levels were being 
managed (i.e. those on lipid-lowering medications or at high cardiovascular risk), the 
recommended monitoring interval ranged from 3 to 12 monthly, with individual 
guidance documents often suggesting a range for retesting such as 4–6 monthly,  
6–12 monthly.178,210,211,213,214,216-220  
Smellie et al., after reviewing available guidelines, recommended annual lipid tests 
for long-term monitoring. They also noted that most recommendations on testing 
intervals were consensus-based.224 In the guidance documents reviewed the level of 
evidence behind the recommended testing interval (for either the active or 
monitoring phase of management) was not stated. 
Although there were differences among the guidance documents, the most commonly 
recommended interval for long-term monitoring of lipid levels was 6–12 months. 
However, recent evidence suggests that in patients for whom lipid levels are stable 
(within 0.5 mmol/L of target) the interval for monitoring should be every 3–5 years 
because more frequent testing is more likely to reflect measurement error than true 
change.226  
This measurement error is a product of the analytical and intra-individual variation in 
lipid testing. Most of the guidance documents reviewed did not discuss intra-
individual and analytical variation of lipid testing. Only two guidance 
documents212,216 discussed the level of expected variance in lipid measurements and 
the need for at least two tests before starting therapy. The NICE guideline 
highlighted that repeated measurement improves precision of the lipid testing, and 
was the only guideline to mention this in the context of monitoring, stating that 
monitoring is often based on one measurement, multiple testing being impractical in 
practice. Murtagh, AACE and NCEP also stated the need for at least two tests before 
starting therapy but the reason for this was not provided.173,210,211,214  
The only time authors of guidance documents appear to consider precision is at the 
time of initial assessment of lipid levels before therapy is started. Although it is 
important to establish an accurate baseline measurement of lipid levels (because lipid 
lowering therapy is life-long), the recommendation to initiate lipid-lowering therapy 
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in guidance documents was usually based on a patient’s cardiovascular disease risk 
which incorporates multiple factors, lipid levels being just one of these factors. This 
puts less importance on the precision of the lipid measurement at initiation. 
However, in monitoring the response to therapy, lipid levels are usually the sole 
indicator.  
Further, the majority of management of lipid disorders in general practice, and lipid 
tests ordered in their management, are for monitoring. Therefore, information on 
variation in lipid levels is arguably of most importance in monitoring. The amount of 
intra-individual and analytical variation in monitoring lipid levels has been discussed 
by other authors,224,226-229 but not incorporated into guidance documents. More 
information on the degree of variation is needed in guidance documents to inform 
GPs of the likelihood of measurement error when monitoring lipid levels. 
Glaziou et al.’s (2008) finding that interval for monitoring lipid levels should be  
3–5 yearly226 is too recent to have been incorporated into the reviewed guidance 
documents or to be reflected in the lipid test order rate observed in this study. This 
evidence may be incorporated in future guidance. However, further investigation of 
the impact of a longer monitoring interval may be needed – particularly the impact 
on patient adherence as some guideline authors discussed frequent monitoring of 
lipid levels as a tool to aid improvement in patient adherence to therapy.178,220  
Monitoring statin use  
The majority of lipid-lowering medications prescribed in the management of lipid 
disorders in the current study were plain statins (91% of medications for lipid 
disorders). The guidance documents reviewed primarily referred to monitoring in 
relation to statin therapy. 
Liver function  
There was reasonable agreement among guidance documents on the need to test LFT 
before initiating statins, after commencing and after increasing dose. However, 
guidance varied on the need for ongoing monitoring. 
Other authors have published recommendations about testing in the context of statin 
use. The United States (US) National Lipid Association Statin Safety Assessment 
(NLASSA) taskforce recommended ongoing monitoring but noted there was little 
evidence to support it.230 Recognition of the lack of evidence for long-term 
monitoring was echoed by others.212,224,227 
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The NICE guideline provided a consensus recommendation that LFT testing was 
needed pre-treatment, within 3 months of starting medication, and a year after that. 
Further monitoring was not recommended unless clinically indicated. 
The majority of guidance documents recommended monitoring of LFT but offered 
no comment on frequency or duration of monitoring.173,178,214,220 This was also the 
case in the Australian medication guideline ‘eTG’.179 
The order rate of LFT did not change over the period of this study, suggesting GPs 
have not changed their behaviour in regard to monitoring LFTs in the management of 
lipid disorders. 
Creatine kinase  
CK testing was not recommended in routine monitoring of statin use in most 
guidance documents. The exception was Murtagh, who recommended ongoing 
monitoring of CK in statin use.173  
Other authors provided more detail. Smellie et al recommended a baseline CK test 
prior to initiating a statin for two reasons: if baseline CK is elevated statin should not 
be started, and if CK testing is indicated in the future (e.g. muscle symptoms 
develop) results can be compared with baseline.224,227 The NLASSA taskforce stated 
that baseline testing in patients at high risk for muscle toxicity may be considered but 
routine baseline testing for all patients commencing a statin was not 
recommended.230 
In the reviewed guidance documents, CK testing was commonly recommended in 
patients who develop muscle symptoms. The NLASSA taskforce stated that muscle 
symptoms or increased CK were likely to be caused by other aetiologies and should 
be investigated by health professionals.230 If rhabdomyolysis is suspected serum 
creatinine should also be measured. 
GPs ordering of CK increased significantly between 2000–02 and 2006–08, even 
though the vast majority of guidance recommended against routine monitoring of 
CK.  
Causes of secondary dyslipidaemia  
Testing for causes of secondary dyslipidaemia was recommended in most guidance 
documents prior to starting lipid-lowering therapy. The exceptions were: the 
Australian NHF & CSANZ guideline;178 and the cardiovascular prevention 
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guidelines from ESC215 and SIGN.213 The SIGN guideline recommended that 
clinicians ‘consider secondary causes of dyslipidaemia’ but details of these 
secondary causes were not listed.213 For the two cardiovascular prevention 
guidelines213,215 this omission is possibly because they did not solely provide 
guidance on the management of lipid disorder, but included all aspects of 
cardiovascular prevention (e.g. blood pressure, antiplatelet therapy).  
The conditions commonly listed as secondary causes that involved pathology tests 
were hypothyroidism, renal disease, liver disease and diabetes. Testing to identify 
causes of secondary dyslipidaemia were mentioned as part of the initial evaluation of 
the patient. In contrast, the majority (> 90%) of tests used to identify these conditions 
were ordered by GPs for ongoing management.  
Of the tests related to secondary causes of lipid disorders, the rate of thyroid and 
kidney function testing (TFT and EUC) increased significantly. The proportion of 
lipid problems that were newly diagnosed increased between 2000–02 and 2006–08 
and this may have contributed to some of the increased rates of EUC, and TFT as 
these were recommended as part of the initial investigations. However, this is 
unlikely to account for the entire increase in these tests. 
No guidance was provided on whether there is a need to periodically retest for these 
secondary causes of lipid disorders in the future. However, liver function testing was 
recommended in monitoring of medication use; and ongoing testing for diabetes or 
kidney disease may be undertaken as part of reassessment of cardiovascular risk (as 
these conditions increase cardiovascular risk) although the need to test glucose and 
kidney function was not explicitly stated. Kidney function testing, specifically 
creatinine levels were mentioned in guidance documents for diagnosis of 
rhabdomyolysis as a rare adverse effect of statin therapy. But the NLASSA taskforce 
stated that it is not necessary to monitor serum creatinine or proteinuria routinely 
during statin therapy.230 
Most guidance documents recommended thyroid testing in all patients regardless of 
initial lipid levels. In contrast, Smellie et al. recommended thyroid testing only if the 
initial total cholesterol level was > 8.0 mmol/L.231 The need to reassess thyroid 
function was not mentioned in any of the guidance documents. 
Authors of guidance documents should consider incorporating information on 
whether these conditions, particularly thyroid disease, are likely to occur in the future 
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(e.g. increasing prevalence with age) and whether subsequent diagnosis of the 
condition is likely to affect management of lipid disorders, to inform whether 
repeated testing is needed for patients without thyroid disease at initial assessment.  
Tests for which guidance was lacking 
The significant increases in GPs’ ordering rates of FBC and MBA tests and marginal 
increase in PSA tests are not directly related to guidance provided in the management 
of lipid disorders. It is unclear why the rates of these tests increased over the period 
of this study. GPs’ increased use of FBC and MBA tests are discussed further in 
Section 5.10.  
Other factors contributing to the increased management rate of lipid disorder  
The guideline documents recommended initiating lipid therapy and management of 
lipid levels in the context of the patient’s absolute cardiovascular risk. 
Lipid targets have become lower over time as knowledge about cardiovascular risk 
improved. The majority of guidance documents recommended LDL targets, with 
lower targets recommended for patients with higher cardiovascular risk. Lower 
targets may have influenced GPs’ management rate of lipid disorder problems and 
pathology ordering rates because they are potentially harder, and may take longer, to 
achieve. More frequent visits and pathology testing were recommended while 
actively trying to achieve a target (titrating medications). While the guidance 
documents acknowledged that targets may not be achievable in all patients and 
should be adjusted to the individual patient, it is likely that a change in target that 
requires intensifying treatment will result in increased management and testing rates. 
Changes in policies are also likely to have contributed to the increased management 
rate of lipid disorders seen in this study. In particular, the decision to broaden the 
PBS criteria for subsidised lipid-lowering medications in October 2006 to allow 
access on the basis of cardiovascular risk rather than measured lipid levels alone,208 
and the introduction of the MBS item for health checks in patients aged 45–49 years 
in February 2006 to prevent or delay the onset of chronic disease232 may have 
contributed to the increased management rate of lipid disorders. 
The increased focus on total cardiovascular risk does not appear to have altered GPs’ 
pathology ordering behaviour in the management of lipid disorders. The data suggest 
that GPs have not changed the rate at which they monitor lipids in response to 
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therapy. GPs have also not changed the rate of glucose testing (e.g. assessing 
presence of diabetes/impaired glucose tolerance) or liver function testing (i.e. 
presence of liver disorder/monitoring side effect of statin) when managing lipid 
disorder. Of the individual tests that increased (FBC, EUC, MBA, CK, TFT and 
PSA) for lipid disorder problems, only EUC (kidney function) may be associated 
with assessment or management of cardiovascular risk.  
Summary 
The majority of tests ordered by GPs in the management of lipid disorders were 
recommended in guidance documents. However, the increased rate of pathology tests 
ordered for lipid disorders reflected GPs’ increased use of tests that were partially 
supported and unsupported in guidance documents. This highlights the importance of 
targeting a reduction in unsupported tests, even if the absolute reduction in testing 
would be modest.  
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5.7 Health check 
5.7.1 Background  
Prevention is one of the cornerstones of Australian general practice. Promoting the 
prevention of disease was one of the founding objectives of the Australian College of 
General Practitioners (now the RACGP) in 1958.233  
Primary care is the health sector with the most contact with the population and the 
most opportunity to provide preventive care. In 2009–10, 83% of the population 
visited a GP at least once (DoHA, personal communication, June 2010) and per head 
of population there were an average 5.2 GP visits funded by Medicare Australia.13  
Through activities such as vaccination, health promotion, and risk management 
(identification and reduction) GPs have the opportunity to prevent disease, and to 
detect disease in its early stages. Therefore they are involved in all types of 
preventive care. 
In Australia, the recent focus of preventive care has been the prevention of chronic 
diseases because our ageing population is expected to increase the burden on the 
health system.234 Recent initiatives include the National Chronic Disease Strategy187 
(2005) and the National Preventative Health Strategy235 (2009), both acknowledged 
the role of primary health care in preventive care and provided funding to support 
GPs in preventing, detecting and managing chronic disease.187,235 
MBS item numbers for health assessments in general practice have been introduced 
to encourage preventive action in target population groups. Examples include: the 
annual health assessment in patients aged 75 years and over (1999);236 the health 
assessment for people aged 45–49 years who are at risk of developing chronic 
disease (2006);232 the assessment of people aged 40–49 years with a high risk of T2D 
(2008).18 Pathology tests are used by GPs in preventive activities to identify risk 
factors, and to diagnose and monitor disease. 
5.7.2 Management rate in Australian general practice 
In this section ‘health check’ problems include those labelled as unspecified health 
check-ups in patients aged 15 years and over.  
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In BEACH, ‘heath check’ was managed at 8,113 encounters by 3,707 GPs in  
2000–08, at a rate of 1.2 per 100 encounters (Table 5.23). This equates to 
approximately 1.0 million encounters per year with patients aged 15 years or  
more where health checks were managed by GPs in Australia. 
As reported in Chapter 4, there was a significant increase in the management rate  
of health checks, between 2000–02 and 2006–08 (Table 5.23). 
Table 5.23: Summary of health check data set in patients aged 15+ years, 2000–08, 
2000–02 and 2006–08 
 2000–08 2000–02 2006–08 
Variable Number 
Rate per 100 
encounters 
(95% CI) 
(n = 682,932) Number
Rate per 100 
encounters 
(95% CI) 
(n = 171,136) Number 
Rate per 100 
encounters 
(95% CI) 
(n = 165,439) Change
General practitioners 3,707 . . 872 . . 1,028 . . . . 
Health check 
encounters  
8,113 
 
. . 1,845 . . 2,463 
 
. . . . 
 
Health check 
problems managed 
8,120 
 
1.2 
(1.1–1.2)
1,846 1.1 
(1.0–1.2)
2,464 
 
1.5 
(1.4–1.6)  
Note: Data about health check problems managed are drawn from Chapter 4, Table 4.3. CI – confidence interval. Shading 
indicates a statistically significant change between 2000–02 and 2006–08. The direction and type of change is 
indicated for each measure: / indicates a statistically significant change. 
5.7.3 Pathology ordered for health check 
Pathology was ordered at a rate of 147.9 tests/batteries per 100 ‘health check’ 
contacts with patients aged 15 years and over in 2000–08. Almost half of the contacts 
(49.5%) resulted in at least one pathology order. Once the decision to order 
pathology was made the GP ordered on average 2.99 tests/batteries per tested ‘health 
check’ contact (Table 5.24).  
The increase in the rate of pathology ordering between 2000–02 and 2006–08 was 
due to a significant increase in the number of tests ordered once the decision to order 
tests was made (as reported in Chapter 4). There was no change in the likelihood that 
at least one pathology test would be ordered in the management of health check 
problems (Table 5.24). 
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Table 5.24: Summary of pathology ordering for health check (patients 15+ years), 
2000–08, 2000–02 and 2006–08 
 2000–08 2000–02 2006–08 
Variable Number 
Per cent / 
Rate of 
health check
problems
(95%CI) 
(n = 8,120) Number
Per cent / 
Rate of 
health check
problems
(95%CI) 
(n = 1,846) Number 
Per cent / 
Rate of 
health check
problems
(95%CI) 
(n = 2,464) Change
Pathology 
(Rate per 100 health 
check problems) 
12,008 147.9 (142.2–153.6) 2,252
122.0 
(110.7–133.3) 4,407 
178.9 
(167.3–190.4)  
At least one 
pathology order  
(% health check 
problems)  
4,023 49.5 (48.0–51.1) 900
48.8 
(45.1–52.5) 1,319 
53.5 
(50.7–56.3) — 
Number of tests/ 
batteries per 100 
tested health check 
problems 
. . 298.5 (291.6–305.3) . .
250.1 
(236.1–264.2) . . 
334.1 
(322.8–345.4)  
Note: Pathology ordering data from 2000–02 and 2006–08 are drawn from Chapter 4, Table 4.4. CI – confidence interval. 
Shading indicates a statistically significant change between 2000–02 and 2006–08. The direction and type of change 
is indicated for each measure: / indicates a statistically significant change. 
Types of pathology tests/batteries ordered  
Table 5.25 shows the rate of pathology tests/batteries ordered for ‘health check’ 
problems in patients aged 15 years and over in 2000–08 by MBS groups and the 
most common individual types of tests ordered. 
Chemistry tests were the group most often ordered (102.2 per 100 health check 
contacts) and the most common were:  
• lipid tests (29.7 per 100 ‘health check’ contacts)  
• glucose/glucose tolerance tests (18.5) 
• LFTs (11.7)  
• EUC tests (10.3) 
• MBA tests (8.7). 
Haematology tests (25.3 per 100 contacts), in particular FBC (22.7), and 
cytopathology tests (9.2), in particular Pap smear (9.1), were commonly ordered as 
part of the management of ‘health check’ (Table 5.25). 
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Table 5.25: Rate of pathology test orders for health check (patients 15+ years) by MBS 
groups and most frequent individual tests within each group, 2000–08 
Pathology test Number 
Rate per 100 health check problems 
(95% CI) (n = 8,120) 
Chemistry  8,301 102.2 (97.8–106.6) 
 Lipids*  2,413 29.7 (28.4–31.1) 
 Glucose/glucose tolerance* 1,500 18.5 (17.3–19.6) 
 LFT*  952 11.7 (10.7–12.7) 
 EUC*  839 10.3 (9.5–11.2) 
 MBA*  705 8.7 (7.8–9.6) 
 PSA* 663 8.2 (7.5–8.9) 
 TFT*  583 7.2 (6.5–7.9) 
 Ferritin* 203 2.5 (2.1–2.9) 
 Other chemistry*  144 1.8 (1.2–2.3) 
Haematology  2,055 25.3 (23.9–26.7) 
 FBC  1,839 22.7 (21.4–23.9) 
 ESR 153 1.9 (1.5–2.2) 
Cytopathology 745 9.2 (8.0–10.4) 
 Pap smear* 740 9.1 (7.9–10.3) 
Microbiology 574 7.1 (5.8–8.4) 
 Hepatitis serology* 161 2.0 (1.5–2.5) 
Other tests NEC  199 2.5 (2.0–2.9) 
Other pathology groups 134 . . 
Total pathology tests  12,008 147.9 (142.2–153.6) 
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Only the groups of tests/individual tests accounting for  1% of all pathology tests for the selected problem are 
included. CI – confidence interval; NEC – not elsewhere classified; also see Abbreviations. 
Changes in types of pathology tests/batteries ordered 
Table 5.26 shows the most common pathology tests/batteries ordered for health 
check in 2000–02 and in 2006–08. Listed below are the tests for which significant 
change in GPs’ order rate occurred between 2000–02 and 2006–08 (listed in 
decreasing test rate order). There were significant increases in the order rate of: 
• lipid tests—36% increase 
• FBCs—72% increase  
• glucose/glucose tolerance—40% increase 
• LFTs—100% increase 
• EUC tests—128% increase  
• MBA tests—60% increase 
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• TFTs—121% increase 
• PSA tests—95% increase  
• ‘other chemistry’ tests—233% increase  
• occult blood tests—280% increase (Table 5.26). 
There was also a significant 58% decrease in the order rate of Pap smears as part of 
health checks between 2000–02 and 2006–08 (Table 5.26).  
Table 5.26: Rate of pathology test orders for health check (patients 15+ years) by MBS 
groups and most frequent individual tests within each group, 2000–02 compared with 
2006–08 
 2000–02  2006–08  
Pathology test Number
Rate per 100 
health check 
problems (95% CI) 
(n = 1,846) Number
Rate per 100
 health check 
problems (95% CI) 
(n = 2,464) Change
Chemistry  1,423 77.1 (68.9–85.3) 3,182 129.1 (120.3–138)  
 Lipids*  484 26.2 (23.4–29.1) 877 35.6 (33.1–38.1)  
 Glucose/glucose tolerance* 278 15.1 (12.6–17.5) 519 21.1 (18.8–23.3)  
 LFT*  149 8.1 (6.1–10.0) 399 16.2 (14.0–18.4)  
 EUC*  107 5.8 (4.5–7.1) 324 13.2 (11.4–14.9)  
 MBA*  124 6.7 (5.0–8.4) 264 10.7 (8.9–12.5)  
 PSA* 101 5.5 (4.1–6.8) 263 10.7 (9.2–12.1)  
 TFT*  86 4.7 (3.2–6.1) 255 10.4 (8.8–11.9)  
 Ferritin* 33 1.8 (1.0–2.5) 82 3.3 (2.4–4.3) — 
 Other chemistry*  17 0.9 (0.4–1.4) 74 3.0 (1.5–4.5)  
Haematology  369 20.0 (17.1–22.9) 779 31.6 (28.8–34.4)  
 FBC  312 16.9 (14.4–19.4) 716 29.1 (26.4–31.7)  
 ESR 41 2.2 (1.5–2.9) 42 1.7 (1.0–2.4) — 
Microbiology 130 7.0 (4.5–9.6) 161 6.5 (4.4–8.6) — 
 Hepatitis serology* 37 2.0 (1.1–2.9) 49 2.0 (0.9–3.1) — 
Cytopathology 270 14.6 (11.4–17.8) 149 6.1 (4.3–7.8)  
 Pap smear* 270 14.6 (11.4–17.8) 149 6.1 (4.3–7.8)  
Other tests NEC  42 2.3 (1.4–3.2) 78 3.2 (2.1–4.2) — 
Simple basic tests 10 0.5 (0.2–0.9) 46 1.9 (1.2–2.5)  
 Occult blood test 10 0.5 (0.2–0.9) 46 1.9 (1.2–2.5)  
Other pathology groups 18 . . 58 . .  
Total pathology tests  2,252 122.0 (110.7–133.3) 4,407 178.9 (167.3–190.4)  
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: CI – confidence interval; NEC – not elsewhere classified; also see Abbreviations. Shading indicates a statistically 
significant change. The direction and type of change is indicated for each measure between 2000–02 and 2006–08: 
/ indicates a statistically significant change, and — indicates no change. 
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5.7.4 Guidance documents for health check 
The five preventive health guidance documents reviewed for health check are listed 
in Box 5.4.  
 
Box 5.4: Guidance documents reviewed for health checks 
Title Year Author  
Abbreviated 
to 
Guidelines for preventive activities in 
general practice (The Red Book)177 
2009 Royal Australian College of General 
Practitioners (RACGP) 
RACGP 
US Preventive Services Task Force 
recommendations237 
2008 United States Preventive Services Task 
Force (USPSTF) 
USPSTF 
Health Care Guidelines: Preventive 
services for adults238 
2008 Grenz K, Mortinsen R, Pine D, Solberg L, 
Wilkinson JM, Harvey L et al. Institute for 
Clinical Systems Improvement (ICSI) 
guideline [United States of America] 
ICSI 
Canadian Task Force on Preventive 
Health Care recommendations239 
1994–
2005 
Canadian Task Force on Preventive Health 
Care (CTFPHC) 
CTFPHC 
Health Screening240 2004 Health Promotion Board, Ministry of Health 
(MoH) [Singapore] 
MoH 
5.7.5 Extent of alignment between GP testing and guidance 
documents  
In Table 5.27, the frequently ordered pathology tests/batteries for health check are 
categorised by level of support in the guidance documents listed in Box 5.4.  
Supported tests 
The three tests that were recommended in the majority of guidance documents were 
lipids, Pap smears and faecal occult blood tests (Table 5.27). Together these tests 
accounted for 26.3% of tests/batteries ordered by GPs for health checks (Table 5.28). 
Between 2000–02 and 2006–08, the order rate of lipid and faecal occult tests 
increased significantly, but the order rate of Pap smears for health check problems 
decreased (Table 5.26). While the rate of Pap smears decreased for health checks, the 
total rate of Pap smears (for all problems) increased between 2000–02 and 2006–08 
(see Chapter 4).  
There was strong agreement among the guidance documents that lipids should be 
measured in selected patients. Recommendations were made on the basis of 
identifying patients who are at increased risk of cardiovascular disease and are 
therefore most likely to benefit from testing. The evidence for screening in male 
patients is stronger than for females.177,237 Recommendations for screening intervals 
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were made in three guidance documents.177,237,240 The RACGP and USPSTF 
recommended intervals based on risk, 5 yearly for the lower risk group and  
1–2 yearly for the higher risk groups.177,237 The MoH guideline recommended an 
interval of 3 years if lipid levels were within the ‘desirable’ range.240 
The CTFPHC239 was the only document to conclude that there was insufficient 
evidence to recommend lipid testing. However, this guideline was released in 1994 
and considering the new evidence and new pharmacological treatments now 
available, can be considered out of date.  
There was unanimous agreement among guidance documents that cervical cancer 
screening should be routinely undertaken in all sexually active females until the age 
of 65 or 69 years. Testing older women was recommended if patients were not 
previously screened177,237 or they had a new sexual partner.238 Frequency of 
recommended Pap smear testing varied based on risk. For average risk patients 
testing every 2 years177 or 3 years237-240 was recommended.  
Guidance documents also unanimously recommended that colorectal cancer 
screening should be routinely undertaken in patients aged 50 years and over and 
earlier for those at increased risk. The faecal occult blood test (FOBT) was the only 
pathology test that GPs could order for colorectal screening. Other screening options 
given in guidance documents were sigmoidoscopy or colonoscopy. The type, 
frequency, and age of onset of screening depended on the patient’s risk of colorectal 
cancer. For patients at average risk, all guidance documents recommended FOBT 
from the age of 50 years either annually237-240 or biannually.177,237,239 Alternatively 
sigmoidoscopy or colonoscopy were also recommended.237-239 For patients at higher 
risk (e.g. family history of bowel cancer) the primary screening tools were 
colonoscopy or sigmoidoscopy.177,237,239 In high risk patients the potential need for 
genetic testing was discussed in two guidance documents.177,237 
Tests with conditional support 
There were three types of tests that had conditional support or mixed levels of 
support in the guidance documents: glucose/glucose tolerance, hepatitis tests and 
tests for other sexually transmitted infections (STI) (Table 5.27). Together these tests 
accounted for 15.4% of the tests ordered for health checks (Table 5.28). Over the 
period of this study, the order rate of glucose/glucose tolerance tests increased 
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significantly, and the rate of hepatitis testing (Table 5.26) and other STI tests did not 
change significantly (results not tabled). 
Testing for diabetes mellitus (using glucose testing) was recommended for selected 
high risk patients in three guidance documents.177,237,239 MoH provided stronger 
support, recommending screening for all patients from the age of 40 years and for 
patients with known risk factors from 30 years.240 In contrast, ICSI stated that testing 
was not recommended in asymptomatic patients but did not provide further 
guidance.238  
Screening for STIs (including chlamydia, HIV, and hepatitis) was recommended in 
most guidance documents for high risk patients.177,237-240 Most also recommended 
chlamydia testing for all females aged less than 25 years in addition to other high risk 
groups.177,237-239 The USPSTF recommended against routine screening for 
Hepatitis B or C. For Hepatitis B this was because screening strategies have poor 
predictive value due to difficulty in accurately identify at risk individuals, and for 
Hepatitis C there was insufficient evidence to recommend screening.238  
Support unable to be determined 
It was not possible to determine whether MBA and ‘other chemistry’ tests were 
recommended in the guidance documents (see Section 5.3.4). Together these two 
tests accounted for 7.1% of GP pathology ordered for health checks (Table 5.28). 
Both increased significantly between 2000–02 and 2006–08 (Table 5.26). 
The ICSI guideline specifically recommended against use of routine laboratory 
testing (including blood chemistry panels) without clinical suspicion of disease.238 
Unsupported tests 
The guidance documents did not recommend testing of FBC, LFT, EUC, PSA, TFT, 
ferritin and ESR (Table 5.27). These tests accounted for 43.6% of pathology ordered 
by GPs in the management of health check (Table 5.28). Between 2000–02 and 
2006–08, the order rate of most of these tests increased significantly (with the 
exception of ferritin and ESR tests). 
All guidance documents recommended against routine testing of PSA to detect 
prostate cancer.177,237-240 RACGP recommended against the test but stated that men 
should be informed of risks and benefits to make an informed choice.177 Both 
USPSTF and RACGP highlighted that PSA testing was not recommended in men 
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aged 75 years and over,177,237 and USPSTF stated that there was insufficient evidence 
to make a recommendation in men aged less than 75 years.237 MoH recommended 
screening in high risk men aged more than 50 years who have had close relatives 
diagnosed with prostate cancer when aged less than 60 years.240 
EUC tests were supported in only one document, the RACGP recommending annual 
screening using the estimated glomerular filtration rate for high risk patients. High 
risk patients were defined as those with hypertension, obesity, diabetes, family 
history of kidney disease, and Indigenous patients aged more than 35 years.177 The 
other guidelines did not discuss EUC testing nor kidney disease with one exception. 
The 1993 CTFPHC recommended against screening asymptomatic adults using a 
dipstick to identify chronic renal failure because there was no efficacious, non 
harmful treatment available for early stages of the disease course.239  
Screening for thyroid disease was not supported in most guidance. RACGP 
specifically recommended against the use of TFT as a screening test.177 USPSTF, 
CTFPHC and ICSI stated that there was insufficient evidence to make a 
recommendation for or against screening in asymptomatic adults.237-239 
LFT, ferritin and ESR were not mentioned in any of the guidance documents. FBC 
was also not directly mentioned in any document. However, ICSI recommended 
against use of routine laboratory testing (including “haemoglobulin and haematocrit 
screening”) without clinical suspicion of disease.238 These would be considered part 
of the FBC in Australia, suggesting that ICSI did not support routine use of the FBC. 
Key to Table 5.27 
Colour Description 
 The document specifically recommended this test. Any notes within the cell indicate further 
detail. For example, a specific disease to test for within subset of patients; a specific test 
within a group.  
 The document stated that this test should be considered. Any notes within the cell indicate 
further detail (e.g. a specific test to consider) 
 Unable to determine guidance (see Section 5.3.4).  
 The document specifically stated not to do this test. Additional information is supplied if 
certain conditions apply (e.g. specific clinical situations). 
 Guidance document does not mention this test 
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Table 5.27: Summary of guidance recommendations by most frequent individual test orders for health check, 2000–08 
Pathology test  
Per cent of path 
(n = 12,008) RACGP177 USPSTF237 ICSI238 CTFPHC239 MoH240 
Lipids*  20.1 > 45 yrs or high risk Not in F without CHD risk M > 34 yrs & F > 45 yrs Insufficient evidence (1994) > 40 yrs or high risk 
FBC  15.3   Not as screening   
Glucose/glucose 
tolerance* 12.5 
Patients at increased risk Yes in HT. Consider for CVD 
and dyslipidaemia  
Not in asymptomatic pts 
Not recommended in 
asymptomatic pts  
Yes in HT and  
dyslipidaemia (2005) 
> 40 yrs or > 30 yrs 
and risk factors 
LFT*  7.9      
EUC*  7.0 High risk pts     
Pap smear* 6.2 Sexually active until 69 yrs Sexually active until 69 yrs 21 to 64 yrs & 65+ if new sexual partner 
Sexually active until 65 yrs 
(1994) 
F > 25 yrs 
MBA* 5.9   Not as screening   
PSA* 5.5 Not recommended. Pt choice (50–75 yrs) informed of risk & benefit.
Insufficient evidence in  
M<75 yrs and NO in M>75 yrs 
Not recommended Not recommended (1994) FHx onset < 60 yrs 
TFT*  4.9 Low prevalence even with FHx Insufficient evidence Insufficient evidence Insufficient evidence (1994)  
Ferritin* 1.7      
STI tests (excluding 
hepatitis)(a) 1.6 
High risk pts and Chlamydia  
in F < 25 yrs 
High risk pts and Chlamydia 
in F < 25 yrs 
High risk pts and 
Chlamydia in F < 25 yrs
High risk pts (1994) and 
Chlamydia in F < 25 yrs (1996)
High risk pts 
Hepatitis serology* 1.3 High risk / request STI check Only in pregnant women High risk pts   
ESR 1.3      
Other chemistry* 1.2      
Occult blood test(b) 0.9 > 50 to 75 yrs or  > 25 yrs in high risk pts 
> 50 to 75 yrs > 50 yrs or > 45 yrs in 
high risk pts 
> 50 yrs or earlier in high risk 
pts (2001) 
> 50 yrs 
(a) STI tests include tests for chlamydia, HIV, and ‘STI screen’. Hepatitis is excluded because it is listed separately. 
(b) Occult blood tests accounted for < 1% of pathology in 2000–08. It is included because the order rate increased significantly between 2000–02 and 2006–08. In 2006–08 it accounted for 1.0% of pathology. 
* Includes multiple ICPC-2 PLUS codes (see Appendix 7).  
Note: Path – pathology; M – male; F – female; yrs – years; pts – patients; HT – hypertension; CVD – cardiovascular disease; FHx – family history; STI – sexually transmitted infection; also see Abbreviations. Any 
notes within the coloured cells are described in detail in Section 5.7.5. 
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Evaluation of GP pathology ordering against guidance documents  
Table 5.28 provides a summary of the individual tests and the level of support 
provided in the guidance for each. Of the tests/batteries ordered by GPs for health 
check in 2000–08: 
• 26.3% were supported 
• 22.5% had conditional support or support could not be determined  
• 43.6% were not supported by the guidance documents (Table 5.28).  
The individual tests/batteries listed in Table 5.28 account for 93.2% of pathology 
ordered by GPs for health checks because only the most common tests ordered for 
health checks were evaluated.  
Table 5.28: Summary of support for GP pathology ordering for the most frequent 
individual test orders for health check (patients aged 15+ years), 2000–08 
Pathology test Number 
Per cent of pathology 
for health check 
Supported 3,152 26.3 
 Lipids*  2,413 20.1 
 Pap smear* 740 6.2 
 Occult blood test(a) 104 0.9 
Conditional/unclear support 2,707 22.5 
 Glucose/glucose tolerance* 1,500 12.5 
 MBA*  705 5.9 
 Other STI testing (including Chlamydia, HIV, STI screen) 197 1.6 
 Hepatitis serology* 161 1.3 
 Other chemistry*  144 1.2 
Unsupported 5,232 43.6 
 FBC  1,839 15.3 
 LFT*  952 7.9 
 EUC*  839 7.0 
 PSA* 663 5.5 
 TFT*  583 4.9 
 Ferritin* 203 1.7 
 ESR 153 1.3 
Subtotal (n, % of total tests) 11,196 93.2 
Total pathology tests  12,008 100.0 
(a) Occult blood tests accounted for < 1% of pathology in 2000–08. It is included because the order rate increased 
significantly between 2000–02 and 2006–08. In 2006–08 it accounted for 1.0% of pathology. 
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Only the tests/individual tests accounting for  1% of all pathology tests for the selected problem are included. See 
Abbreviations. 
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In 2000–08, GPs ordered unsupported pathology tests at a rate of 64.5 tests/batteries 
per 100 health check problems, followed by supported tests (40.1 per 100), and tests 
with conditional support (33.4). Tests ordered for health check but not evaluated 
were ordered at a rate of 10.1 per 100 problems. The rate at which GPs ordered 
unsupported and conditionally supported tests increased significantly over time 
(Table 5.29). 
Table 5.29: Rate of pathology ordering for health check by level of support, 2000–08, 
2000–02 and 2006–08 
 2000–08 2000–02 2006–08  
Level of support 
Rate per 100 health 
check problems
 (95% CI) (n = 8,120)
Rate per 100 health 
check problems
 (95% CI) (n = 1,846)
Rate per 100 health 
check problems 
 (95% CI) (n = 2,464) Change
Supported  40.1 (38.3–41.9) 41.4 (37.1–45.6) 43.5 (40.4–46.6) — 
Conditional/unclear 
support 33.4 (31.5–35.2) 26.4 (23.3–29.6) 39.1 (35.7–42.6)  
Unsupported  64.5 (61.1–67.9) 44.9 (38.4–51.4) 84.5 (77.4–91.6)  
Not evaluated 10.1 (9.0–11.1) 9.3 (7.0–11.6) 11.8 (9.8–13.9) — 
Note: CI – confidence interval. Shading indicates a statistically significant change between 2000–02 and 2006–08.  
The direction and type of change is indicated for each measure: / indicates a statistically significant change,  
and — indicates no change. 
 
GPs ordered only pathology tests that were supported or conditionally supported at 
17.1% (95% CI: 15.8–18.3) of health check problems in 2000–08. A further 30.2% 
(95% CI: 28.8–31.5) of health check problems involved at least one unsupported test, 
and 52.8% (95% CI: 51.2–54.4) involved either no pathology tests (50.4%) or tests 
that were not evaluated (2.4%) (results not tabled).  
The proportion of health check problems that involved supported testing decreased 
significantly from 23.9% (95% CI: 20.9–26.9) in 2000–02 to 12.6% (95% CI:  
10.8–14.5) in 2006–08. In parallel, the proportion of problems involving at least one 
unsupported test increased from 22.3 % (95% CI: 19.6–25.0) to 38.5% (95% CI: 
35.7–41.2) (results not tabled). 
When GPs ordered unsupported tests, the majority (89%) were accompanied by one 
or more supported/partially supported tests. Unsupported tests were ordered alone at 
the remaining 11%. GPs ordered only tests that were unsupported at 3.3% of health 
check problems in 2000–08. This did not change significantly over time 2.7% (95% 
CI: 1.9–3.5) in 2000–02 and 3.4% (95% CI: 2.6–4.2) in 2006–08 (results not tabled). 
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5.7.6 Discussion 
GPs’ pathology testing did not align well with that recommended in guidance 
documents, only about half of tests ordered by GPs for health checks (in patients 
aged 15 years and over) being partially or completely supported. The statistically 
significant increase in the rate of GPs’ total pathology ordering for health checks 
between 2000–02 and 2006–08 was reflected in the increased rate of tests that were 
partially supported, and those that were unsupported in guidance documents. There 
was no change in the order rate of supported tests. 
Due to the increase in total rate of pathology ordering, the relationship between GPs’ 
ordering and level of support, as a proportion of total tests should be considered. 
Supported tests decreased as a proportion of total tests between 2000–02 and  
2006–08, and was counteracted by an increase in unsupported tests. Overall this 
suggests that the increase in GPs’ ordering resulted in testing being ‘less’ in line with 
recommendations.  
Comments on guidance documents 
There were relatively few guidance documents for preventive health care available 
for review. Further, of the five guidance documents reviewed, two239,240 would be 
considered out of date. 
The CTFPHC239 guideline recommendations dated from 1994, 1996, 2001 and 2005. 
The year of each recommendation is provided in Table 5.27, and those from the 
earlier years were out of date (although not formally withdrawn). Despite this, the 
CTFPHC recommendations were extensively referenced throughout the literature.  
MoH guidelines are withdrawn after 5 years (unless updated), as the MoH 
guideline240 (published in June 2004) was not updated it was withdrawn in June 
2009.  
Unsupported pathology tests in guidance documents 
Prostate cancer screening 
Screening for prostate cancer (involving the PSA test) in the general male population 
was not recommended in any of the reviewed guidance documents (including the 
Australian RACGP guideline177). Since these documents were released, interim 
results from two clinical trials on prostate cancer screening outcomes have been 
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published (in 2009 and 2012). The US and European studies provided inconclusive 
evidence of whether screening for prostate cancer was worthwhile. 
In 2009, the European study reported after an average 9-year follow-up that 
screening reduced deaths from cancer by 20% (2.94 deaths per 1,000 in the screened 
men compared with 3.65 per 1,000 in the control group). However, there was a high 
rate of over-diagnosis: 1,410 patients would need to be screened and 48 patients 
treated, in order to save one life.241 In contrast, the US study reported no difference 
in mortality from prostate cancer was seen in the screened group compared with the 
control group after a 7–9 year follow-up.242 The differences in the results of the two 
studies are partially explained by differences in the screening protocol used (PSA 
was tested annually in the US study and every 4 years in the European study), and 
the proportion of the control group who received PSA testing as part of ‘usual care’, 
which was higher in the US study.  
In early 2012, results from both the above European and US studies were published 
using data after a longer follow-up period—both reported no significant change from 
the results reported in 2009.243,244 Independent reviews of the 2009 and 2012 
publications concluded that the results were unlikely to change recommendations for 
prostate cancer screening, nor current practice.245-247 
Authors of the guidance documents reviewed in the current study have not changed 
their recommendations in response to these publications. Similarly other 
organisations (e.g. Cancer Council of Australia,248 international governments) still 
recommend against routine screening for prostate cancer.249 Despite this, the media 
coverage of prostate screening often incorrectly reports the evidence250 and 
encourages screening.251 
Further, there are organisations that support prostate cancer screening. For example, 
the Prostate Cancer Foundation of Australia recommends annual screening (PSA test 
and digital rectal exam) in all men commencing at 50 years of age for those with no 
family history or at 40 years of age with a family history.252 The RCPA and others 
have recommended use of the PSA test to predict long-term risk in men, first testing 
around the age of 45 years253,254 and using the result to guide the frequency of future 
PSA monitoring. This approach has been criticised.255 However, the purpose of the 
RCPA recommendation was to provide guidance on the ‘optimal use of PSA testing’, 
accepting that there is existing widespread use of the PSA test.254,256 
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The current study confirms this, demonstrating that GPs commonly order PSA 
testing during health checks. Further, use of the test increased significantly between 
2000–02 and 2006–08. In fact, total PSA testing (for all problems) increased 
significantly over the duration of this study (see Chapter 4, Table 4.2). This increase 
occurred without change in the guidance documents’ recommendations. Contributing 
factors may include: increased patient requests for testing; ‘pro-screening’ media 
coverage;251 and increased number of men in the population aged 50–75 years.15 
Further, increased incidence of prostate cancer may also play a role. As incidence in 
the population increases,257 the number of men with a family history of the disease 
also increases. As family history increases the risk of prostate cancer,177,240 it may 
influence the patient’s decision to request PSA testing. However, the increased 
number of men being tested has contributed to increased incidence of prostate 
cancer,249 creating the potential for perpetuating the ‘screening–diagnosis’ cycle. 
Thyroid function test 
The majority of guidelines reviewed in this study stated that there was insufficient 
evidence to make a recommendation regarding screening of thyroid function in 
asymptomatic patients. The RACGP guideline recommended against the testing of 
thyroid function in asymptomatic adults (regardless of family history) due to low 
prevalence and lack of evidence of benefit.177  
Other reviews/authors have recommended that opportunistic thyroid testing is not 
supported in the healthy population.258-262 However, as thyroid disease is most 
prevalent in older women263 some guidance suggested that screening in menopausal 
women may be cost-effective.258,261,262,264 The American Thyroid Association 
guidelines for detection of thyroid dysfunction was the only guideline to recommend 
routine screening (every 5 years, using the thyroid-stimulating hormone test) in all 
adults from the age of 35 years.265  
Despite this lack of support or evidence the BEACH data demonstrated a significant 
increase in the rate of TFTs. Between 2000–02 and 2006–08, the order rate increased 
significantly both in the management of health checks and in the management of all 
problems (see Chapter 4, Table 4.2). 
Pathology tests not referenced in guidance documents  
Most guidance documents did not mention the use of FBC, MBA, LFT, EUC, ferritin 
and ESR tests for health checks or screening, which together accounted for 39% of 
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tests. Despite this lack of guidance, GPs’ order rate of FBC, MBA, LFT, and EUC 
increased significantly in the management of health checks. 
It is important to note that GPs may use the ‘health check’ label to refer to preventive 
checks done in a diverse range of clinical situations. While health checks ordered for 
a specific disease were excluded in this study, it is possible that some tests were 
appropriate for the patient’s individual clinical circumstance but were not 
recommended in guidance documents. This is discussed in more detail in Section 
5.10 (see ‘Prevention’), and may explain why GPs order tests not referenced in 
guidance documents.  
The FBC was the second most commonly ordered test for health checks (15% of 
tests). A FBC is often requested as a routine screening blood test in general 
practice.221 However, the guidance documents did not mention FBC testing.  
Screening for kidney disease was only recommended in the Australian RACGP 
guideline. Annual screening of glomerular filtration rate estimated from serum 
creatinine was recommended for high risk patients. The prevalence among high risk 
patients may have increased, as the prevalence of conditions associated with high 
risk have increased (e.g. diabetes,180,181 obesity154). This in turn may have contributed 
to increased rates of EUC testing. 
The ICSI guideline provided a consensus recommendation against ordering routine 
testing in preventive health care, particularly the use of blood chemistry panels, 
haemoglobulin/haematocrit screening and urinalysis without clinical suspicion of an 
underlying condition.238 This suggests that routine ordering of MBA and FBC tests 
were not supported by the ICSI. 
The high proportion of tests ordered by GPs for health checks but not mentioned in 
guidance documents is concerning. Investigation of the clinical usefulness of these 
pathology tests for health checks is needed. The results of this investigation should 
be used to improve guidance documents, and this guidance promoted to GPs to 
improve test ordering (if necessary). 
Changes in order rate of tests that were supported  
The reduction in the rate of Pap smears ordered for health checks reflects a change in 
the problem label recorded by GPs (from ‘check-up’ to ‘well woman check-up’, the 
latter was not included in the analysis for this chapter) rather than a reduction in 
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cervical cancer screening. The pathology ordering data for all problems (Chapter 4) 
showed that the total rate of Pap smear testing increased significantly over the 
duration of this study (2000–02 to 2006–08).  
In addition to being supported for health checks, lipid and glucose testing were 
supported in guidelines for the assessment of cardiovascular risk176,213,215 (see 
Section 5.6). GPs might consider assessment of cardiovascular risk as part of the 
health check. Contributing factors to the increased ordering rate of these tests when 
doing health checks include the increasing number of patients in the target age group 
for screening due to Australia’s ageing population,15 and the increase in the 
proportion of patients with known risk factors for lipid disorders or diabetes (e.g. 
hypertension,157 metabolic syndrome,266 chronic kidney disease267) particularly if the 
diagnosed prevalence of risk factors increases with age. 
The increase in the rate of occult blood tests between 2000–02 and 2006–08 may be 
partially attributed to the introduction of the National Bowel Cancer Screening 
program in August 2006.268 Tests conducted in the screening program do not require 
GPs to order FOBTs (as test packs are supplied directly to screening participants). 
However, the program has been introduced slowly and currently provides a ‘one-off’ 
test per person turning either 50, 55 or 65 years of age, far less often than the 
biannual screening recommendation in the Australian guideline for people aged 50 to 
75 years.177 The increased rate of FOBTs may reflect GPs’ biannual testing (as per 
the guideline recommendation) for patients not targeted in the screening program. 
Another contributor may be the increased number of people in the target age group 
for screening due to Australia’s ageing population.15 
Other factors contributing to the increased management rate of health checks 
Check-ups are an important preventive activity and the community is encouraged to 
have a regular check-up with a GP.269 To a large extent, the increased management 
rate of health checks was due to the introduction and subsequent uptake of MBS 
items funding specific age or risk-based health assessments.18,232,236 
Australia’s ageing population may have contributed to the increased rate of health 
checks provided by GPs. Over the decade 2000 to 2010, the proportion of the 
population aged 40 years and above increased.15 These older adults are the age-group 
in whom routine disease screening (e.g. colorectal cancer, diabetes, lipid disorders) 
was recommended (commencing at 40–50 years) and for whom many of the MBS 
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health assessments were designed.18,232,236 It can be assumed that the increased 
number of older Australians may have contributed to the past growth in the rate of 
health checks provided by GPs. It may also contribute to future growth in rates of 
health checks, as the growth in the older population is expected to continue over the 
coming decades.137 A corresponding increase in volume of GPs’ pathology ordering 
(based on the current pattern of pathology test ordering) would be likely. 
Summary 
Less than half the pathology tests ordered by GPs for health checks were supported 
by the guidance documents. Further, the increased rate of pathology tests ordered for 
health checks primarily reflected GPs’ increased use of tests that were unsupported 
in guidance documents. Of particular importance is the need to determine the role of 
tests commonly ordered by GPs but not referenced in guidance documents. There is 
significant discord between guidance recommendations and GPs’ ordering practice 
for health checks that should be investigated further. 
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5.8 Weakness / tiredness 
5.8.1 Background 
Tiredness or fatigue is a common presentation in general practice. Studies have 
reported its prevalence as a presenting symptom in 6–14% of general practice 
patients,270-272 and as a secondary symptom in 19% of patients.270  
In BEACH, patients presented with weakness/tiredness as a reason for encounter at a 
rate of 1.4 per 100 encounters in 2006–08,273 and it was managed as a clinical 
problem at a rate of 0.7 per 100 encounters (Chapter 4, Table 4.3). The difference 
between the presentation and management rates indicates that at the encounter GPs 
were able to apply a more specific diagnostic label to about half of the 
weakness/tiredness presentations. 
Tiredness or fatigue has been described as the most common medically unexplained 
condition managed in general practice.274 It represents a diagnostic challenge for GPs 
due to the broad range of conditions for which it may be a symptom, including 
psychological disorders, sleep problems, chronic disorders and serious 
disease.271,272,275-279 Pathology testing is often ordered by GPs in an attempt to 
identify the underlying cause (and/or exclude serious disease as the cause) of 
tiredness. 
5.8.2 Management rate in Australian general practice 
In BEACH, weakness/tiredness problems were managed at 5,624 patient encounters 
with 3,279 GPs in 2000–08, at a rate of 0.7 per 100 encounters (Table 5.30). This 
equates to approximately 710,000 encounters per year where weakness/tiredness 
problems are managed by GPs in Australia.  
As described in Chapter 4, there was no change in the management rate of 
weakness/tiredness between 2000–02 and 2006–08. There was also no significant 
change in the rate of new cases per 100 encounters (Table 5.30).  
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Table 5.30: Summary of weakness/tiredness data set, 2000–08, 2000–02 and 2006–08 
 2000–08 2000–02  2006–08 
Variable Number
Rate per 100 
encounters 
(n = 784,300) Number
Rate per 100 
encounters 
(n = 198,200)
 
Number 
Rate per 100 
encounters 
(n = 188,300)
General practitioners 3,279 . . 853 . .  788 . . 
Weakness/tiredness 
encounters  
5,624 . . 1,507 . .  1,372  
. .
Weakness/tiredness 
problems managed 
5,627 0.7 
(0.7–0.8)
1,509 0.8 
(0.7–0.8)  
1,373 
 
0.7 
(0.7–0.8)
New weakness/ 
tiredness problems 
2,456 0.31 
(0.30–0.33)
597 0.30 
(0.27–0.33)  
657 
 
0.35 
(0.32–0.38)
Note: Data about the weakness/tiredness problems managed are drawn from Chapter 4, Table 4.3. CI – confidence 
interval. 
5.8.3 Pathology ordering for weakness/tiredness 
Pathology was ordered at a rate of 205.4 tests/batteries per 100 weakness/tiredness 
contacts in 2000–08, and more than half of contacts (56.6%) resulted in at least one 
pathology order. Once the decision to order pathology was made, the GP ordered on 
average 3.63 tests/batteries per tested contact (Table 5.31).  
As described in Chapter 4, the rate of pathology ordering increased significantly 
between 2000–02 and 2006–08. This was due to a significant increase in the 
likelihood of pathology being ordered in the management of weakness/tiredness 
problems. There was no statistically significant change in the number of tests ordered 
once the decision to order tests was made (Table 5.31). 
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Table 5.31: Summary of pathology ordering for weakness/tiredness, 2000–08, 2000–02 
and 2006–08 
 2000–08 2000–02 2006–08 
Variable Number 
Per cent / 
Rate of 
weak/tired
problems
(95%CI)
(n = 5,627) Number
Per cent / 
Rate of 
weak/tired
problems
(95%CI)
(n = 1,509) Number 
Per cent / 
Rate of 
weak/tired
problems
(95%CI)
(n = 1,373) Change
Pathology (Rate per 
100 weak/tired 
problems) 
11,559 
 
205.4 
(197.2–213.6)
2,684 177.9 
(164.0–191.8)
3,199 
 
233.0 
(217.3–248.7)  
At least one pathology 
order (% of weak/tired 
problems)  
3,187 
 
56.6 
(54.7–58.6)
759 50.3 
(46.7–53.9)
854 
 
62.2 
(58.5–65.9)  
Number of tests/ 
batteries per 100 tested 
weak/tired problems 
. . 
 
362.7 
(357.0–368.3)
. . 353.6 
(343.2–364.0)
. . 
 
374.6 
(363.5–385.7) — 
Note: Pathology ordering data from 2000–02 and 2006–08 are drawn from Chapter 4, Table 4.4. Weak/tired – weakness/ 
tiredness; CI – confidence interval. Shading indicates a statistically significant change between 2000–02 and  
2006–08. The direction and type of change is indicated for each measure: / indicates a statistically significant 
change, and — indicates no change. 
Types of pathology tests/batteries ordered  
Table 5.32 shows the distribution of pathology tests/batteries ordered for 
weakness/tiredness in 2000–08 by MBS groups and the most common individual 
types of tests ordered. 
Chemistry tests were the group most often ordered (135.7 per 100 weakness/ 
tiredness contacts) and the most common were:  
• TFTs (32.3 per 100 contacts) 
• ferritin tests (21.0)  
• LFTs (17.4)  
• EUC tests (15.5) 
• MBA tests (11.6)  
• glucose/glucose tolerance tests (11.5) (Table 5.32). 
Haematology tests (53.9 per 100 contacts), in particular FBCs (45.7), and 
microbiology tests (9.7) were also commonly ordered in the management of 
weakness/tiredness (Table 5.32). 
Almost 60% of pathology tests were ordered by GPs for ‘new’ cases of weakness/ 
tiredness and the order rate for ‘new’ problems was significantly higher than average 
(Table 5.32). The likelihood of pathology being ordered at new weakness/tiredness 
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contacts was high, with at least one pathology test ordered for 74.3% (95% CI:  
72.4–76.1) of new cases (results not tabled). 
Table 5.32: Rate of pathology test orders for weakness/tiredness by MBS groups and 
most frequent individual tests within each group, 2000–08 
 All weakness/tiredness problems New weakness/tiredness problems 
Pathology test Number
Rate per 100 
weak/tired problems
(95%CI) (n = 5,624) Number
Per cent 
of test 
Rate per 100 new 
weak/tired 
problems
(95%CI) (n = 2,456)
Chemistry  7,636 135.7 (130.0–141.5) 4,558 59.7 185.6 (178.9–192.3)
 TFT*  1,819 32.3 (30.5–34.1) 1,113 61.2 45.3 (43.1–47.5)
 Ferritin* 1,183 21.0 (19.6–22.5) 727 61.5 29.6 (27.6–31.6)
 LFT*  979 17.4 (16.1–18.7) 589 60.2 24.0 (22.1–25.8)
 EUC*  872 15.5 (14.3–16.7) 510 58.5 20.8 (18.9–22.6)
 MBA*  650 11.6 (10.5–12.6) 405 62.3 16.5 (14.8–18.2)
 Glucose/glucose 
 tolerance* 647 11.5 (10.5–12.5) 391 60.4 15.9 (14.3–17.6)
 Lipids*  329 5.9 (5.1–6.6) 184 55.9 7.5 (6.4–8.6)
 Vitamin B12* 311 5.5 (4.8–6.2) 171 55.0 7.0 (5.9–8.1)
 Other chemistry*  213 3.8 (3.0–4.6) 99 46.5 4.0 (3.0–5.0)
 Hormone assay* 197 3.5 (2.7–4.3) 117 59.4 4.8 (3.4–6.1)
 CRP 147 2.6 (2.1–3.1) 91 61.9 3.7 (2.9–4.5)
Haematology  3,034 53.9 (51.5–56.3) 1,832 60.4 74.6 (71.9–77.3)
 FBC  2,572 45.7 (43.7–47.7) 1,561 60.7 63.6 (61.5–65.7)
 ESR 430 7.6 (6.9–8.4) 250 58.1 10.2 (8.9–11.4)
Microbiology 543 9.7 (8.6–10.7) 311 57.3 12.7 (11–14.3)
 Monospot* 153 2.7 (2.2–3.2) 95 62.1 3.9 (3.1–4.7)
 Urine M,C&S* 127 2.3 (1.8–2.7) 79 62.2 3.2 (2.5–3.9)
Other tests NEC  181 3.2 (2.6–3.8) 100 55.2 4.1 (3.1–5.1)
Immunology 147 2.6 (2.1–3.1) 74 50.3 3.0 (2.2–3.8)
Other pathology groups 18 . . 10 55.6 . .
Total pathology tests  11,559 205.4 (197.2–213.6) 6,885 59.6 280.3 (271.6–289.0)
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Only the groups of tests/individual tests accounting for  1% of all pathology tests for the selected problem are 
included. CI – confidence interval; NEC – not elsewhere classified; also see Abbreviations. 
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Changes in types of pathology tests/batteries ordered  
The most common pathology tests/batteries ordered for weakness/tiredness in  
2000–02 and 2006–08 are shown in Table 5.33. Listed below are the tests for which 
significant change in GPs’ order rate occurred between 2000–02 and 2006–08 (listed 
in decreasing test rate order). There were significant increases in the order rate of: 
• FBCs—20% increase  
• TFTs—35% increase 
• ferritin tests—64% increase 
• LFTs—33% increase 
• vitamin B12 tests—105% increase 
• CRP tests—281% increase (there was trend for a corresponding decrease in the 
order rate of ESR tests but this trend did not reach statistical significance) 
• ‘other immunology’ tests—600% increase, due to an increased number of 
immunoglobulin and anti-endomysial antibody tests (Table 5.33). 
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Table 5.33: Rate of pathology test orders for weakness/tiredness by MBS groups and 
most frequent individual tests within each group, 2000–02 compared with 2006–08 
 2000–02  2006–08  
Pathology test Number
Rate per 100 
weak/tired
problems
(95% CI) (n = 1,509) Number
Rate per 100 
weak/tired 
problems
(95% CI) (n = 1,373) Change
Chemistry  1,696 112.4 (102.9–121.9) 2,163 157.5 (146.1–168.9)  
 TFT*  406 26.9 (24.1–29.7) 498 36.3 (32.9–39.7)  
 Ferritin* 245 16.2 (13.9–18.5) 365 26.6 (23.6–29.5)  
 LFT*  232 15.4 (13.2–17.6) 282 20.5 (17.9–23.2)  
 EUC*  199 13.2 (10.9–15.5) 221 16.1 (13.8–18.4) — 
 MBA*  154 10.2 (8.3–12.1) 167 12.2 (10.0–14.3) — 
 Glucose/glucose tolerance* 174 11.5 (9.6–13.4) 154 11.2 (9.1–13.3) — 
 Vitamin B12* 59 3.9 (2.8–5.0) 110 8.0 (6.3–9.7)  
 Lipids*  65 4.3 (3.2–5.4) 91 6.6 (5.1–8.2) — 
 Other chemistry*  47 3.1 (2.0–4.2) 76 5.5 (3.7–7.4) — 
 CRP 17 1.1 (0.6–1.7) 58 4.2 (2.9–5.5)  
 Hormone assay* 45 3.0 (1.8–4.2) 46 3.4 (2.0–4.7) — 
Haematology  778 51.6 (47.3–55.9) 782 57.0 (52.5–61.4) — 
 FBC  629 41.7 (38.3–45.1) 689 50.2 (46.4–53.9)  
 ESR 138 9.2 (7.5–10.8) 85 6.2 (4.8–7.6) — 
Microbiology 135 9.0 (6.9–11.0) 131 9.5 (7.5–11.6) — 
 Monospot* 37 2.5 (1.6–3.4) 44 3.2 (2.2–4.2) — 
 Urine M,C&S* 33 2.2 (1.4–3.0) 30 2.2 (1.4–3.0) — 
Immunology 18 1.2 (0.6–1.8) 69 5.0 (3.5–6.6)  
 Other immunology* 6 0.4 (0.1–0.7) 38 2.8 (1.6–3.9)  
Other tests NEC 56 3.7 (2.4–5.0) 47 3.4 (2.1–4.7) — 
 Blood test 29 1.9 (1.0–2.8) 29 2.1 (1.1–3.2) — 
Other pathology groups 1 . . 7 . .  
Total pathology tests  2,684 177.9 (164.0–191.8) 3,199 233.0 (217.3–248.7)  
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Weak/tired – weakness/tiredness; CI – confidence interval; NEC – not elsewhere classified; also see Abbreviations. 
Shading indicates a statistically significant change, the direction and type of change is indicated for each measure 
between 2000–02 and 2006–08: / indicates a statistically significant change, and — indicates no change. 
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5.8.4 Guidance for weakness/ tiredness 
Guidance documents for the management of tiredness and fatigue were reviewed in 
this study, but guidance for chronic fatigue syndrome was excluded.  
The Dutch College of General Practitioners (DCGP) guideline for blood testing in 
‘medically unexplained’ complaints was also reviewed because fatigue is the most 
common unexplained complaint managed in general practice.274 Medically 
unexplained complaints were defined as ‘those complaints for which a GP, after 
clarifying the reason for the encounter, taking the patient’s history, and performing a 
physical examination, is unable to establish a diagnosis.’280 There were no guidance 
documents that specifically addressed management of ‘weakness’, but it was covered 
in the DCGP guideline. 
In total eight guidance documents were reviewed (Box 5.5). However there was 
some duplication as two authors produced two guidance documents each. These 
documents (written by the same author) were independent of each other and were 
therefore reviewed. 
Box 5.5: Guidelines and guidance documents reviewed for weakness/tiredness 
Title Year Author  
Abbreviated 
to 
Investigating fatigue of less than 6 
months' duration: Guidelines for 
family physicians276 
1999 Godwin M, Delva D, Miller K, Molson J, 
Hobbs N, MacDonald S et al. [Canada] 
Godwin et al. 
Dutch College of General 
Practitioners guideline for blood 
testing in medically unexplained 
complaints281 
1994 
(2009)
Dutch College of General Practitioners 
(DCGP), cited in Koch et al. because the 
original guideline is published in Dutch 
[The Netherlands] 
DCGP 
Fatigue – a general diagnostic 
approach282 
2003 Murtagh J [Australia] Murtagh 2003
Murtagh’s general practice, 
tiredness chapter173 
2007 Murtagh J [Australia] Murtagh 
Patient presentations in general 
practice, ‘I feel tired’174 
1999 Steven I [Australia] Steven 
Laboratory investigation of 
tiredness283 
2006 bpac (Best practice advocacy centre) 
[New Zealand] 
bpac 
ABC of psychological medicine: 
Fatigue284 
2002 Sharpe M and Wilks D [United Kingdom]  Sharpe & 
Wilks 
RCPA manual, chronic fatigue 
section172  
2004 The Royal College of Pathologists of 
Australasia (RCPA) 
RCPA 
There must be something wrong’—
primary presentation in the scenario 
is fatigue of a chronic duration  
> 6 months285 (RCPA case scenario)
2003 The Royal College of Pathologists of 
Australasia (RCPA) and The University 
of Sydney (USyd) Department of 
Medical Education 
RCPA & 
USyd 
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5.8.5 Extent of alignment between GP testing and guidance 
documents 
In Table 5.34, the frequently ordered pathology tests/batteries for weakness/tiredness 
are categorised by level of support in the guidance documents listed in Box 5.5.  
Overview 
Some guidance documents consistently referred to the same clinical situation or 
conditions when recommending pathology testing. These conditions are summarised 
here and referred to in the next sections. 
Godwin et al.,276 Steven174 and DCGP281 only provided conditional support for the 
use of any pathology tests in the management or investigation of tiredness. Each 
document consistently recommended testing in the following circumstances: 
• if indicated by the physical examination (Godwin et al.)276 
• ‘if felt to be required’ by the GP (Steven)174  
• tests should be postponed until 4 weeks after the first presentation of the 
unexplained complaint (of which fatigue is the most common) (DCGP).281  
In the bpac guidance, test recommendations were based on patient age, sex, presence 
of risk factors and/or duration of tiredness. After relevant clinical review, specific 
tests were recommended: 
• for all patients (after relevant clinical review) 
• if the duration of tiredness was longer than 1 month or the patient was aged more 
than 50 years, or  
• for those patients aged less than 50 years who had additional risk factors for a 
specific disease.283  
In the following text when Godwin et al.,276 Steven174 DCGP281 and bpac283 are 
mentioned as giving conditional support, the conditions refer to those listed above. 
Supported tests 
The tests that were recommended in the majority of guidance documents were FBC, 
TFT, ferritin, LFT, EUC, glucose/glucose tolerance and ESR (Table 5.34). Together 
these tests accounted for 73.6% of tests/batteries ordered by GPs for 
weakness/tiredness (Table 5.35). The order rate of FBC, TFT, ferritin, and LFT 
increased significantly between 2000–02 and 2006–08 (Table 5.33). 
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FBC testing was recommended in all guidance documents. Godwin et al.,276 
DCGP281 and Steven174 provided conditional support (as described above), but the 
DCGP281 only recommended the haemoglobin test, a component of the FBC battery 
in Australia, rather than the full battery. 
TFT was also supported in all guidance documents. Though four documents 
provided conditional support—as described above for Godwin et al.,276 DCGP,281 
Steven,174 and in bpac for patients at risk of thyroid problems.283  
Ferritin testing was recommended to identify iron deficiency anaemia in five of the 
guidance documents and not mentioned in the other four documents—of these four, 
two discussed anaemia as a common cause of tiredness/fatigue276,284 but did not 
recommend ferritin testing. 
LFT was supported in the majority of guidance documents. Conditional support was 
provided by Steven174 and in bpac for patients at risk of liver dysfunction.283 
EUC was recommended in seven guidance documents. Three of these provided 
conditional support: Godwin et al.,276 Steven,174 and in bpac for patients at risk of 
renal problems.283 
Glucose testing was recommended in most guidance documents. Conditional support 
was provided in Godwin et al.276 and DCGP,281 and in bpac for patients at risk of 
diabetes.283 
ESR testing was recommended in the majority of guidance documents. Godwin et 
al.,276 DCGP281 and Steven174 gave conditional support. 
Tests with conditional support 
There were two tests that had conditional support or mixed levels of support in the 
guidance documents: Monospot and CRP (Table 5.34). Together these tests 
accounted for 2.6% of tests ordered for weakness/tiredness (Table 5.35). Between 
2000–02 and 2006–08 the rate of CRP increased significantly but the order rate for 
Monospot tests did not change (Table 5.33) 
CRP was recommended in four guidance documents,172,173,283,284 two of which 
recommended use of either CRP or ESR.173,284 The bpac guidance recommended 
CRP testing if the patient was over 50 years of age or tiredness had lasted longer than 
a month.283 
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Epstein Barr Virus (Monospot testing) was mentioned in most guidance documents 
as a possible cause of tiredness. The limitations of the test in diagnosing the 
condition were also discussed. RCPA and USyd recommended testing only if there 
was recent infection because approximately 90% of patients will have positive results 
due to previous infection,285 and bpac specifically recommended against testing.283 
Support unable to be determined 
It was not possible to determine whether MBA and ‘other chemistry’ tests were 
recommended in the guidance documents (see Section 5.3.4). Together these two 
tests accounted for 7.4% of pathology ordered for weakness/tiredness (Table 5.35). 
Their order rate did not change between 2000–02 and 2006–08 (Table 5.33). 
The MBA test itself was not recommended in any guidance documents. However, 
some tests that may be considered part of the MBA, such as EUC and LFT, were 
partially or completely supported in the management of weakness/tiredness (as 
discussed above). 
Unsupported tests 
Most guidance documents did not recommend testing of lipids, vitamin B12, 
hormone assay and Urine M,C&S (Table 5.34). These four tests accounted for 8.3% 
of pathology ordered for weakness/tiredness (Table 5.35). Vitamin B12 was the only 
test within this group to increase significantly between 2000–02 and 2006–08 
(Table 5.33).  
Lipid tests were not mentioned by any of the guidance documents in the management 
of weakness/tiredness. 
Vitamin B12 testing was only recommended by Steven174 if anaemia was suspected. 
Other documents discussed anaemia as a cause of tiredness/fatigue, but did not 
mention vitamin B12 testing even though vitamin B12 deficiency is one possible 
cause of anaemia. 
The ‘hormone assay’ test group in BEACH represented orders for sex hormones in 
> 90% of cases. Testing sex hormones was not mentioned in any of the guidance 
documents, but testing the cortisol hormone was mentioned in four documents if 
Cushing’s syndrome was suspected (a rare disease that may cause tiredness). 
However, because cortisol was rarely ordered and ‘hormone assay’ largely reflected 
sex hormone testing, this test group was classified as unsupported. 
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Urine M,C & S test was recommended in the two Murtagh documents; however, it 
was not mentioned in any of the other guidance documents. 
Other tests mentioned in the guidance documents  
Other tests were mentioned in the guidance documents but each of these accounted 
for less than 1% of tests recorded by GPs for weakness/tiredness. 
Urinalysis was recommended in six documents,174,276,282-285 three174,276,283 of which 
gave conditional support.  
Calcium testing was commonly recommended173,174,282,283 often with 
magnesium173,282 or phosphate testing.283 
Other recommendations included testing for autoimmune diseases (e.g. antinuclear 
antibody test),173,283,285 testing for chronic infections (e.g. HIV, hepatitis),173,174,283 
muscle enzymes (e.g. CK)173,284,285 and cancer antigens.173 
Key to Table 5.34 
Colour Description 
 The document specifically recommended this test. Any notes within the cell indicate further 
detail. For example, a specific disease to test for within subset of patients; a specific test 
within a group.  
 The document stated that this test should be considered. Any notes within the cell indicate 
further detail (e.g. a specific test to consider) 
 Unable to determine guidance (see Section 5.3.4).  
 The document specifically stated not to do this test. Additional information is supplied if 
certain conditions apply (e.g. specific clinical situations). 
 Guidance document does not mention this test 
 
 Table 5.34: Summary of guideline/guidance recommendations by most frequent individual test orders for weakness/ tiredness, 2000–08 
  Fatigue/tiredness  Chronic fatigue (> 6 months) 
Pathology test 
Per cent of 
weak/tired 
pathology 
(n = 11,559) 
 Godwin 
et al.276 DCGP281 
Murtagh 
2003282 Murtagh173 Steven174 bpac283 
Sharpe & 
Wilks284  RCPA172 
RCPA & 
USyd285 
FBC  22.3   Wait 4 weeks Hb only         
TFT*  15.7   Wait 4 weeks    At risk/ > 50 yrs/ 1+month     
Ferritin* 10.2     Anaemia      
LFT*  8.5       At risk/ > 50 yrs/ 1+month     
EUC*  7.5       At risk/ > 50 yrs/ 1+month     
MBA* 5.6           
Glucose/glucose  
tolerance* 5.6 
  Wait 4 weeks    At risk/ > 50 yrs/ 1+month     
ESR 3.7  Wait 4 weeks  or CRP   or CRP    
Lipids*  2.9           
Vitamin B12* 2.7     Anaemia      
Other chemistry* 1.8           
Hormone assay* 1.7   Cortisol Cortisol Cortisol     Cortisol 
Monospot* 1.3      Not in diagnosis    Recent infection 
CRP 1.3    or ESR  > 50 yrs/ 1+month or ESR    
Urine M,C&S* 1.1           
* Includes multiple ICPC-2 PLUS terms (see Appendix 7) 
Note: Weak/tired – weakness/tiredness; Hb – haemoglobulin; > 50 yrs – aged more than 50 years; 1+ month – duration of one month or more; also see Abbreviations. Any notes within the coloured cells are 
described in detail in Section 5.8.5. Only the groups of tests/individual tests accounting for  1% of all pathology tests for the selected problem are included.  
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Evaluation of GP pathology ordering against guidelines/guidance  
Table 5.35 provides a summary of the individual tests and the level of support 
provided in the guidance for each. Of the tests/batteries ordered by GPs for 
weakness/tiredness in 2000–08:  
• 73.6% were supported  
• 10.1% had conditional support or support could not be determined 
• 8.3% were not supported by the guidance documents (Table 5.35).  
The individual tests/batteries listed in Table 5.35 account for 92.0% of pathology 
tests/batteries ordered for weakness/tiredness because only the most commonly 
ordered were evaluated.  
Table 5.35: Summary of support for GP pathology ordering for the most frequent 
individual test orders for weakness/tiredness, 2000–08 
Pathology test Number 
Per cent of all pathology 
for weakness/tiredness 
Supported 8,502 73.6 
 FBC  2,572 22.3 
 TFT*  1,819 15.7 
 Ferritin* 1,183 10.2 
 LFT*  979 8.5 
 EUC*  872 7.5 
 Glucose/glucose tolerance* 647 5.6 
 ESR 430 3.7 
Conditional/unclear support 1,163 10.1 
 MBA*  650 5.6 
 Other chemistry*  213 1.8 
 Monospot* 153 1.3 
 CRP 147 1.3 
Unsupported 964 8.3 
 Lipids*  329 2.9 
 Vitamin B12* 311 2.7 
 Hormone assay* 197 1.7 
 Urine M,C&S* 127 1.1 
Subtotal (n, % of total tests) 10,629 92.0 
Total pathology tests  11,559 100.0 
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Only the groups of tests/individual tests accounting for  1% of all pathology tests for the selected problem are 
included. See Abbreviations. 
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In 2000–08, GPs ordered supported pathology tests at a rate of 151.0 tests/batteries 
per 100 weakness/tiredness problems, followed by tests with conditional support 
(20.5 per 100), and unsupported tests (17.0). Tests ordered for weakness/tiredness 
but not evaluated were ordered at a rate of 16.9 per 100 problems. The rate at which 
GPs ordered tests in all ‘level of support’ groups increased significantly over time 
(Table 5.36). 
Table 5.36: Rate of pathology ordering for weakness/tiredness by level of support, 
2000–08, 2000–02 and 2006–08 
 2000–08 2000–02 2006–08  
Level of support 
Rate per 100 
weak/tired
problems
(95%CI) (n = 5,627)
Rate per 100 
weak/tired
 problems
 (95% CI) (n = 1,509)
Rate per 100 
weak/tired 
problems 
 (95% CI) (n = 1,373) Change
Supported  151.0 (144.5–157.5) 134.1 (122.7–145.6) 166.8 (153.9–179.7)  
Conditional/unclear 
support 20.5 (19.2–21.9) 16.9 (14.3–19.4) 24.9 (21.8–28.0)  
Unsupported  17.0 (15.6–18.5) 13.3 (11.1–15.6) 20.0 (17.0–23.0)  
Not evaluated 16.9 (15.3–18.4) 13.5 (11.2–15.7) 21.4 (17.9–24.8)  
Note: CI – confidence interval. Shading indicates a statistically significant change between 2000–02 and 2006–08. The 
direction and type of change is indicated for each measure: / indicates a statistically significant change. 
GPs ordered only pathology tests that were supported or conditionally supported at 
38.5% (95% CI: 37.0–40.1) of weakness/tiredness problems in 2000–08. A further 
15.4% (95% CI: 14.1–16.6) of problems involved at least one unsupported test, and 
46.1% (95% CI: 44.2–48.0) involved either no pathology tests (43.3%) or tests that 
were not evaluated (2.8%) (results not tabled). 
There was no change in the proportion of weakness/tiredness problems that involved 
supported testing, 36.2% (95% CI: 33.1–39.4) in 2000–02 and 40.5% (95% CI:  
37.4–43.7) in 2006–08. However the proportion of problems involving at least one 
unsupported test increased significantly over this time, from 11.8% (95% CI:  
9.9–13.6) to 18.3% (95% CI: 15.6–21.0) (results not tabled). 
When GPs ordered unsupported tests, the vast majority (95%) were accompanied by 
one or more supported/partially supported tests, unsupported tests being ordered 
alone at the remaining 5%. GPs ordered only tests that were unsupported for 0.8% of 
weakness/tiredness problems in 2000–08. This did not change significantly over time 
0.7% (95% CI: 0.3–1.1) in 2000–02 and 1.2% (95% CI: 0.2–2.1) in 2006–08 (results 
not tabled). 
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5.8.6 Discussion 
GPs pathology testing aligned well with that recommended in guidance documents, 
with approximately 85% of tests ordered by GPs in the management of 
weakness/tiredness being recommended (with either partial or complete support). 
The statistically significant increase in the rate of GPs total pathology ordering for 
weakness/tiredness between 2000–02 and 2006–08 was reflected in significant 
increases in the rate of tests that were supported, partially supported, and 
unsupported in guidance documents.  
As a proportion of total tests ordered there was very little change in the proportion 
that were supported (either completely or partially) or unsupported for 
weakness/tiredness, indicating that the increase in GPs’ testing did not reflect a 
change to be ‘more’ or ‘less’ in line with guidance recommendations. 
This study includes weakness/tiredness when recorded as a problem under 
management by GPs. It does not reflect all patient presentations of 
weakness/tiredness, as GPs at encounters were able to apply a more specific 
diagnostic label to about half of these presentations.273 In BEACH, GPs were 
instructed to record the problem at the highest diagnostic level possible with the 
information available at the encounter. Therefore the management of 
weakness/tiredness represents either: a diagnostic process (i.e. a symptom under 
investigation), or an undifferentiated problem (i.e. following investigation a 
‘diagnosis’ is unable to be determined).  
Pathology tests would be considered part of the diagnostic process. Guidance 
documents discussed them in the context of the entire diagnostic process, that is, in 
combination with an appropriate medical history and physical examination. This was 
also emphasized in the literature, Cornuz et al. stated that ‘in the absence of positive 
history or physical examination laboratory tests are rarely helpful’.286 This approach 
was recommended to focus testing because of the broad range of conditions linked to 
tiredness. 
In this study, only guidance documents for fatigue and tiredness were reviewed for 
weakness/tiredness because no guidance documents were found for weakness. This is 
unlikely to impact significantly on the results of the study because the majority of 
problems classified to the ICPC-2 ‘weakness/tiredness’ group were recorded by GPs 
as tiredness or related synonyms such as fatigue or malaise.  
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In the guidance documents reviewed, pathology recommendations were consensus-
based rather than evidence-based because there is very little evidence available. 
Recommendations were based on the conditions in general practice that commonly 
involve fatigue/tiredness as a symptom, and on the likelihood of underlying disease.  
Underlying disease 
Prevalence of underlying disease in general practice patients with fatigue is low. 
Three prospective studies investigating outcomes of fatigue in general practice 
patients reported diagnosis of a somatic disease as the (known or likely) cause of 
fatigue in 8% of patients.275,278,281 Two of these studies specifically linked diagnosis 
of somatic diseases to pathology tests.275,281 An Australian retrospective study 
examined medical records where tiredness was recorded as a symptom or diagnosis, 
and identified a ‘significant diagnosis’ as the likely cause of tiredness in 9% of 
patients, but only 4% of patients were diagnosed as a result of pathology testing.287 
While three of the studies linked the diagnosis of somatic diseases to pathology 
tests,275,281,287 only two recommended the most useful tests in making these 
diagnoses.281,287 Koch et al.281 compared the tests recommended in the DCGP’s 
guideline with a separate panel of tests developed by expert consensus, and 
concluded that the four blood tests in the DCGP’s guideline (FBC, TFT, glucose and 
ESR) were most useful. In contrast Gialamas et al. in their retrospective study 
concluded that the most useful tests were FBC, glucose and EUC.287 The five tests 
(from these two studies) were evaluated as supported in this study, but only represent 
a subset of the supported tests (74% of the supported tests ordered by GPs, 55% of 
total tests ordered). The results of these studies suggest authors of future guidance 
documents should consider a more focussed approach to pathology testing than is 
currently recommended.  
Abnormal results and false positive results 
The low prior probability of underlying disease in patients with weakness/tiredness 
and high rates of pathology testing ordered by GPs are likely to generate high rates of 
abnormal test results, many of which will be false positive test results. This is 
demonstrated in results of the three studies that investigated the role of pathology 
tests in diagnosing somatic diseases in general practice.275,281,287 
In the retrospective study, 14% of 1,046 tests had abnormal results, but 90% of these 
were not clinically significant.287 In the British prospective study, 33% of patients 
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had an abnormal test result, but for 72% of these patients the abnormal result was not 
clinically relevant.275 In the Dutch prospective study, at least one false positive result 
was recorded for 23% of 192 patients with medically unexplained fatigue with the 
limited DCGP set of tests and for 56% of patients with the expanded test panel.281 
The issue of abnormal results and false positive results is discussed in greater depth 
in Section 5.10. 
Delaying testing 
The desire to reduce false positive test results, the low probability of underlying 
disease and the self-limiting nature of most medically unexplained complaints such 
as fatigue led the DCGP to recommend a limited set of tests and to delay testing until 
4 weeks after first presentation of the complaint. The study by Koch et al. designed 
to test the DCGP recommendation, could not assess the impact of delaying pathology 
testing in patients with medically unexplained fatigue, because most patients 
randomised to wait 4 weeks did not return for a follow-up consultation – 78% (of 
111 patients) did not return. An additional 27 patients were excluded because GPs 
were unable to delay testing. Whether this was due to patient or GP factors was not 
investigated.281 Even though there was insufficient follow-up data, Koch et al. 
concluded there was value in delaying pathology testing, on the basis of similar rates 
of somatic diseases in the delayed versus immediate testing groups.281  
It is possible that the low level of follow-up consultations in Koch et al.’s study 
could indicate that these patients experienced a self-limiting episode of fatigue that 
resolved within 4 weeks, making a follow-up visit and testing unnecessary. The 
likelihood of patients requiring multiple visits for management of weakness/tiredness 
may be relatively low regardless of the pathology testing strategy used. The 
retrospective study of medical records conducted by Gialamas et al. reported that the 
majority of patients (55%) required only one GP visit to manage tiredness.287 The 
current study also supports this: the high proportion of new weakness/tiredness 
contacts (44%) suggests that the rate of follow-up contacts was relatively low (when 
compared with the chronic diseases investigated in this chapter). However, because 
this study used cross-sectional data, I was not able to assess the number of GP 
consultations patients required to manage weakness/tiredness.  
Even though each episode of tiredness may not require many GP visits, pathology 
tests are frequently initiated at the first visit. In this study, three-quarters of new 
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weakness/tiredness problems had at least one pathology test ordered. Similarly, in a 
small study of medically unexplained complaints, 83% of 59 patients with fatigue 
had tests initiated at the first GP visit,288 and in the study by Gialamas et al. 
likelihood of ordering at the first contact was not reported but 67% of test orders 
were initiated at the first contact.287 This suggests that application of a 
recommendation to ‘delay testing’ would require a significant change in GPs’ current 
pathology ordering behaviour for weakness/tiredness.  
The DCGP was the only guideline to recommend delaying testing at the first GP 
visit. However, duration of tiredness was mentioned as a component of medical 
history to be considered prior to ordering pathology testing in many guidance 
documents.172,173,276,281,283-285 It may be that GPs incorporate patients’ duration of 
tiredness in their decision to order pathology testing, and patients’ duration of 
symptoms at their first GP visit was sufficient to warrant pathology testing.  
Given that over the period of this study the likelihood of ordering pathology 
increased and likelihood of ordering was high for new cases of weakness/tiredness, 
delaying pathology testing as per the DCGP’s recommendation may achieve a 
reduction in the likelihood of testing. Delaying testing has been found not to have an 
impact on patient satisfaction and anxiety levels when compared with immediate 
testing for medically unexplained complaints.289 However, further research needs to 
be conducted to determine the clinical outcomes of patients in whom testing is 
delayed. Such research would also need to compare cost effectiveness of delaying 
testing versus immediate testing, for example, the cost of pathology tests, GP visits 
required, and the time taken to explain the reasons for delaying testing. 
Summary  
The majority of tests ordered by GPs for weakness/tiredness were recommended in 
guidance documents. The measured increase in pathology testing was due to an 
increased likelihood that GPs would initiate testing in the management of 
weakness/tiredness. There was no contributing increase in the management rate of 
weakness/tiredness and no clear cause for the increase in likelihood of testing. But 
importantly the extent to which GPs’ testing aligned with recommendations did not 
change. 
Results from some small studies have suggested that limiting the number of 
pathology tests ordered, at least initially, for weakness/tiredness may have a role in 
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reducing clinically insignificant abnormal test results. It has also been recommended 
that GPs should delay testing in patients with tiredness. Both of these suggestions 
may reduce pathology testing for weakness/tiredness, but the level of evidence is 
weak. Further research is needed to increase the evidence base and to ensure 
recommendations to delay testing would not adversely affect patient outcomes, and 
that any associated change in clinical practise is cost-effective.  
The evidence-base available to support recommendations for pathology ordering in 
the management of weakness/tiredness is weak. Consequently many of the 
recommendations in guidance documents were consensus-based. Increasing the 
research in this area could improve the robustness of future guidance documents for 
weakness/tiredness. 
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5.9 Overweight/obesity 
5.9.1 Background 
In most developed countries, including Australia, the high and increasing prevalence 
of overweight and obesity has a significant economic and health impact.109 
Recognising the burden of chronic disease caused by obesity, it was named a 
National Health Priority Area in April 2008290 and is targeted in the current National 
Preventative Health Strategy.235 
The 2007–08 National Health Survey, estimated that 61.3% of Australian adults were 
overweight/obese (measured BMI  25). Prevalence was higher among males (68%) 
than females (55%), and had increased from 56.3% in 1995.154 In a SAND substudy 
of adult patients (aged 18 years and over) attending general practice, prevalence of 
overweight/obesity (calculated BMI from self-reported height and weight) increased 
from 54.3% in 2000–01 to 59.3% in 2007–08.273 
In 2003, high body mass was responsible for 7.5% of total burden of disease and 
injury in Australia.156 In 2005, the direct cost (health care and non-health care costs) 
of overweight and obesity (in adults aged 30 years and over) was $21 billion, $6.5 
billion for overweight and $14.5 billion for obesity.291 Three-quarters of these direct 
costs were health care costs.  
Obesity and overweight are associated with many diseases including T2D, cancer 
and cardiovascular diseases.292 Research suggests that about two-thirds of 
overweight/obese patients seen in general practice have at least one obesity-related 
cardiovascular comorbidity,293 and likelihood of comorbidities increases with 
increasing BMI.293,294 
Pathology testing has a role in the diagnosis, assessment and management of many of 
these associated diseases and is one small component of the health cost burden 
attributed to overweight/obesity. GPs’ management of overweight/obesity generated 
the smallest amount of pathology of the six problems investigated in this study (see 
Chapter 4). It was prioritised for investigation because it is the focus of much current 
public health policy. There have been several national and state-based programs that 
aim to reduce the prevalence of overweight and obesity. Recent national examples 
include the ‘Measure Up’ campaign295 and the ‘Swap it’ campaign.296 With 
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increasing public awareness it is likely that the management rate of overweight and 
obesity in general practice will increase. If this occurs it would create a 
corresponding increase in pathology orders. 
5.9.2 Management rate in Australian general practice 
In BEACH, obesity or overweight was managed at 7,797 encounters with adult 
patients (aged 18 years and over) by 3,677 GPs in 2000–08, at a rate of 1.2 per 100 
adult encounters (Table 5.37). This equates to approximately 1.0 million adult 
encounters nationally per year where overweight/obesity was managed by GPs. 
Obesity accounted for 71.8% of overweight/obesity problems managed and 
overweight for the remaining 28.2% (Table 5.37).  
As discussed in Chapter 4, there was no significant change in the management rate of 
overweight/obesity between 2000–02 and 2006–08. There was also no change in the 
diagnosis or detection rate of new cases of overweight/obesity (Table 5.37).  
Table 5.37: Summary of overweight/obesity data set (adult patients), 2000–08, 2000–02 
and 2006–08 
 2000–08 2000–02  2006–08 
Variable Number 
Rate per 100 
adult encounters 
(95% CI) 
(n = 666,135) Number
Rate per 100 
adult encounters 
(95% CI) 
(n = 166,770) 
 
Number 
Rate per 100 
adult encounters 
(95% CI) 
(n = 161,571)
General 
practitioners 
3,677 . . 954 . .  864 . .
Overweight/obesity 
encounters  
7,797 
 
. . 1,975 . .  1,935 . .
Overweight/obesity 
problems managed 
7,797 1.2 
(1.1–1.2)
1,975 1.2 
(1.1–1.3)  
1,935 1.2 
(1.1–1.3)
 Obesity 5,598 0.8 (0.8–0.9)
1,458 0.9 
(0.8–1.0)  
1,418 0.9 
(0.8–1.0)
 Overweight 2,199 0.3 (0.3–0.4)
517 0.3 
(0.3–0.4)  
517 0.3 
(0.3–0.4)
New overweight/ 
obesity problems 
1,141 0.17 
(0.16–0.18)
292 0.18 
(0.15–0.20)  
242 0.15 
(0.12–0.18)
Note: Data about overweight/obesity problems managed are drawn from Chapter 4, Table 4.3. CI – confidence interval. 
Figure 5.1 compares the age-specific rates of management of overweight/obesity 
among adult patients and the age-specific prevalence of overweight/obesity among 
patients encountered in general practice. The latter uses calculated BMI from self-
reported height and weight drawn from a subsample of 31,062 patients at BEACH 
encounters in 2007–08 (see Section 3.2.6). 
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Figure 5.1 should be interpreted as follows—for patients aged 45–64 years, 1.6% had 
obesity or overweight managed as a clinical problem at the encounter, whereas 
68.1% of patients attending in this age group were obese or overweight.  
There is a huge gap between the proportion of patients who are overweight/obese and 
the management rate of overweight/obesity. The combination of prevalence and 
encounter data suggests there were 51 overweight/obese adult patients seen by GPs 
per 1 management encounter for overweight/obesity. This illustrates that there is 
huge scope for an increase in the management rate of overweight/obesity.  
 
 
 
Note: Management is the per cent of encounters with patients in each age group involving management of overweight or 
obesity. Prevalence is the per cent of patients in the subsample surveyed who are overweight/obese (BMI  25, 
n = 31,062). 
Figure 5.1: Age-specific rate of management of overweight/obesity (2000–08) and 
age-specific prevalence of overweight/obesity (2007–08) in adult patients 
Age group (years) 
Per cent 
 
5.9.3 Pathology ordering for overweight/obesity 
Pathology was ordered at a rate of 37.4 per 100 overweight/obesity problems in 
2000–08 for adult patients. More than one in ten overweight/obesity problem 
contacts (13.6%) resulted in at least one pathology order. Once the decision to order 
was made the GP ordered on average 2.75 tests per tested problem (Table 5.38).  
As reported in Chapter 4, the rate of pathology ordering for overweight/obesity 
increased significantly between 2000–02 and 2006–08, due to an increase in the 
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likelihood of at least one test/battery being ordered. There was no significant change 
in the number of tests ordered per tested overweight/obesity problem (Table 5.38).  
Table 5.38: Summary of pathology ordering for overweight/obesity (adult patients), 
2000–08, 2000–02 and 2006–08 
 2000–08 2000–02 2006–08  
 Number 
Per cent / 
Rate of ov/ob 
problems 
(95% CI) 
(n = 7,797) Number
Per cent / 
Rate of ov/ob 
problems 
(95% CI) 
(n = 1,975) Number 
Per cent / 
Rate of ov/ob 
problems
(95% CI) 
(n = 1,935) Change
Pathology (Rate per 
100 ov/ob problems) 
2,916 
 
37.4 
(34.4–40.4)
605 30.6 
(24.6–36.7)
912 
 
47.1 
(39.9–54.4)  
At least one 
pathology order (% 
of ov/ob problems) 
1,062 
 
13.6 
(12.6–14.6)
231 11.7 
(9.7–13.7)
319 
 
16.5 
(14.1–18.9)  
Number of tests/ 
batteries per 100 tested 
ov/ob problems 
. . 
 
274.7 
(265.5–283.8)
. . 262.3 
(241.4–283.3)
. . 
 
285.9 
(268.2–303.6) — 
Note: Pathology ordering data from 2000–02 and 2006–08 are drawn from Chapter 4, Table 4.3. Ov/ob – overweight/ 
obesity; CI – confidence interval. Shading indicates a statistically significant change between 2000–02 and 2006–08. 
The direction and type of change is indicated for each measure: / indicates a statistically significant change, and 
— indicates no change. 
Types of pathology tests/batteries ordered  
Table 5.39 shows the rate of pathology tests/batteries ordered for overweight/obesity 
in 2000–08 by MBS groups and the most common individual types of pathology tests 
ordered. Chemistry tests were the group most often ordered (30.9 per 100 
overweight/obesity management contacts) and the most common were:  
• lipid tests (8.7 per 100)  
• glucose/glucose tolerance tests (7.1 per 100)  
• TFTs (5.0) (Table 5.39). 
Haematology tests (5.2 per 100 contacts), in particular FBCs (4.7), were also 
commonly ordered in the management of overweight/obesity (Table 5.39). 
One-quarter of pathology tests (26.5%) were ordered for ‘new’ cases of 
overweight/obesity. Tests were ordered at a higher rate for ‘new’ overweight/obesity 
problems (67.7 per 100 new problems) than average for all overweight/obesity 
problems (37.4 per 100 problems). However, the majority of pathology tests ordered 
were for ongoing management or monitoring of overweight/obesity (Table 5.39). 
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Table 5.39: Rate of pathology test orders for overweight/obesity by MBS pathology 
groups and most frequent individual test orders within each group, 2000–08 
 
All overweight/obesity 
problems  New overweight/obesity problems 
Pathology test Number
Rate per 100 
overweight/obesity 
problems (95% CI) 
(n = 7,797) Number
Per cent 
of test 
Rate per 100 new 
overweight/obesity 
problems (95% CI) 
(n = 1,141)
Chemistry  2,411 30.9 (28.4–33.5) 643 26.7 56.4 (48.5–64.2)
 Lipids*  676 8.7 (7.8–9.5) 178 26.3 15.6 (13.1–18.1)
 Glucose/glucose 
 tolerance* 550
7.1 (6.3–7.8) 144 26.2 12.6 (10.1–15.1)
 TFT*  392 5.0 (4.5–5.6) 119 30.4 10.4 (8.5–12.3)
 LFT*  248 3.2 (2.7–3.6) 70 28.2 6.1 (4.5–7.7)
 EUC*  197 2.5 (2.1–2.9) 47 23.9 4.1 (2.9–5.4)
 MBA*  149 1.9 (1.6–2.3) 47 31.5 4.1 (2.9–5.4)
 Hormone assay* 53 0.7 (0.4–0.9) 16 30.2 1.4 (0.6–2.2)
 Other chemistry*  46 0.6 (0.4–0.8) 8 17.4 0.7 (0.2–1.2)
 Ferritin* 30 0.4 (0.2–0.6) 3 10.0 0.3 (0.0–0.6)
Haematology  408 5.2 (4.6–5.8) 112 27.5 9.8 (7.8–11.8)
FBC  369 4.7 (4.2–5.3) 101 27.4 8.9 (7.1–10.6)
ESR  30 0.4 (0.2–0.5) 9 30.0 0.8 (0.3–1.3)
Other tests NEC  53 0.7 (0.5–0.9) 10 18.9 0.9 (0.3–1.4)
Other pathology groups 44 . . 7 15.9 . .
Total pathology tests  2,916 37.4 (34.4–40.4) 772 26.5 67.7 (58.6–76.7)
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: CI – confidence interval; NEC – not elsewhere classified; also see Abbreviations. Only the groups of tests/individual 
tests accounting for  1% of all pathology tests for the selected problem are included.  
Changes in the types of pathology tests/batteries ordered  
Table 5.40 shows the most common pathology tests/batteries ordered for 
overweight/obesity in 2000–02 and 2006–08. Listed below are the tests for which 
significant change in GPs’ order rate occurred between 2000–02 and 2006–08 (listed 
in decreasing test rate order). There were significant increases in the order rate of: 
• TFTs—70% increase 
• FBCs—68% increase 
• ‘other chemistry’ tests—450% increase. 
There was also a marginal increase in the order rate of MBA (Table 5.40). 
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Table 5.40: Rate of pathology test orders for overweight/obesity by MBS pathology 
groups and most frequent individual test orders within each group, 2000–02 compared 
with 2006–08 
 2000–02  2006–08  
Pathology test Number
Rate per 100 
ov/ob problems 
(95% CI) 
(n = 1,975) Number
Rate per 100 
ov/ob problems 
(95% CI) 
(n = 1,935) Change
Chemistry  498 25.2 (20.2–30.2) 754 39.0 (32.7–45.2)  
 Lipids*  153 7.8 (6.0–9.5) 208 10.8 (8.8–12.7) — 
 Glucose/glucose tolerance* 127 6.4 (4.8–8.0) 164 8.5 (6.7–10.3) — 
 TFT*  72 3.7 (2.7–4.6) 122 6.3 (5.0–7.6)  
 LFT*  45 2.3 (1.3–3.2) 78 4.0 (2.9–5.1) — 
 EUC*  38 1.9 (1.3–2.6) 63 3.3 (2.3–4.2) — 
 MBA*  25 1.3 (0.7–1.8) 50 2.6 (1.8–3.4)  
 Other chemistry*  4 0.2 (0.0–0.4) 21 1.1 (0.6–1.6)  
 Hormone assay* 13 0.7 (0.2–1.1) 14 0.7 (0.3–1.2) — 
 Ferritin* 8 0.4 (0.1–0.7) 12 0.6 (0.1–1.1) — 
 PSA* 6 0.3 (0.0–0.6) 9 0.5 (0.2–0.8) — 
Haematology  83 4.2 (3.0–5.4) 135 7.0 (5.6–8.4)  
 FBC  75 3.8 (2.7–4.9) 123 6.4 (5.1–7.6)  
 ESR  6 0.3 (0.1–0.5) 11 0.6 (0.2–0.9) — 
Other tests NEC  17 0.9 (0.3–1.4) 17 0.9 (0.5–1.3) — 
 Other test NEC* 5 0.3 (0.0–0.5) 12 0.6 (0.3–1.0) — 
 Blood test  10 0.5 (0.1–0.9) 4 0.2 (0.0–0.4) — 
Other pathology groups 7 . . 6 . .  
Total pathology tests  605 30.6 (24.6–36.7) 912 47.1 (39.9–54.4)  
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Ov/ob – overweight/obesity; CI – confidence interval; NEC – not elsewhere classified; also see Abbreviations. 
Shading indicates a statistically significant change between 2000–02 and 2006–08. The direction and type of change 
is indicated for each measure: / indicates a statistically significant change (darker shading), / indicates a 
marginal change (lighter shading), and — indicates no change. 
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5.9.4 Guidance documents for overweight/obesity 
Eleven guidance documents were reviewed for overweight/obesity (Box 5.6). Only 
documents for overweight and/or obesity in adults were included. 
Box 5.6: Guidance documents reviewed for overweight/obesity 
Title Year Author  
Abbreviated 
to 
Clinical practice guidelines for the 
management of overweight and 
obesity in adults297 
2004 National Health and Medical Research 
Council (NHMRC) [Australia] 
NHMRC 
 Overweight and obesity in adults:
 a guide for general practitioners  
 (GP)298 
2004 NHMRC [Australia] NHMRC GP 
Canadian clinical practice guidelines 
on the management and prevention 
of obesity in adults and children299 
2006 Obesity Canada Clinical Practice Guidelines 
(OCCPG) Expert Panel 
OCCPG 
Guidelines on management of adult 
obesity and overweight in primary 
care300 
2006 National obesity forum (NOF) [United 
Kingdom] 
NOF 
 In depth assessment resource for 
 health professionals301 
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5.9.5 Extent of alignment between GP testing and guidance 
documents 
In Table 5.41, the frequently ordered pathology tests/batteries for overweight/obesity 
are categorised by level of support in the guidance documents listed in Box 5.6.  
Supported tests 
The four types of tests that were recommended in the majority of guidance 
documents were lipids, glucose/glucose tolerance, LFT and hormone assay 
(Table 5.41). Together these four tests accounted for 52.4% of tests/batteries ordered 
by GPs for overweight/obesity (Table 5.42). The order rate of these tests did not 
change between 2000–02 and 2006–08 (Table 5.40). 
Guidance documents unanimously recommended lipid testing to identify lipid 
disorders and glucose testing to identify diabetes or impaired glucose tolerance.  
Liver function testing was recommended in six guidance documents, four 
documents173,297-299 recommended testing all patients and two indicated it could be 
considered.300,304 When provided, the rationale for LFT was to identify non-alcoholic 
fatty liver disease and other liver disorders.297-299,304 
Of the ‘hormone assay’ test group for overweight/obesity, sex hormones accounted 
for about 80% and cortisol tests for the remaining 20%. Three documents 
recommended testing sex hormones for all female patients,297-299 and two listed it as 
a test to consider.173,300 The rationale for testing was to identify polycystic ovary 
syndrome and infertility problems. In five documents, cortisol testing was 
recommended if symptoms of Cushing’s syndrome were present.172-174,300,301 
Tests with conditional support 
There was mixed support for TFT in the management of overweight/obesity 
(Table 5.41). TFT accounted for 13.4% of tests ordered (Table 5.42) and the ordering 
rate increased significantly between 2000–02 and 2006–08 (Table 5.40). 
Thyroid disease was discussed in guidance as a possible cause of overweight/obesity 
in seven guidance documents.172-174,298,300,301,304 Only two guidance documents 
recommended routine thyroid testing in the assessment of overweight/obesity, one of 
which recommended ordering TFT,174 and the other recommended the thyroid-
stimulating hormone test.301 There were two occasions where guidance documents 
produced by the same authors (the NHMRC guideline and GP guide,297,298 and the 
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NOF guideline and assessment document300,301) provided inconsistent 
recommendations for thyroid function assessment. This is discussed in more detail in 
Section 5.9.6. 
Support unable to be determined 
It was not possible to determine whether MBA and ‘other chemistry’ tests were 
recommended in the guidance documents (see Section 5.3.4). Together these two 
tests accounted for 6.7% of pathology ordered for overweight/obesity (Table 5.42). 
Between 2000–02 and 2006–08, the rate of MBA increased marginally and the rate 
of ‘other chemistry’ tests increased significantly (Table 5.40). 
The MBA test itself was not recommended in any guidance documents. However, 
some tests that may be considered part of the MBA, such as LFT, were partially or 
completely supported in the management of overweight/obesity (as discussed above). 
Unsupported tests 
The guidance documents did not recommend testing of FBC, EUC, ferritin and ESR 
(Table 5.41). Together these tests accounted for 21.4% of all pathology ordered by 
GPs in the management of overweight/obesity (Table 5.42). FBC was the only test 
within this group to increase significantly between 2000–02 and 2006–08 
(Table 5.40).  
EUC testing or assessment of kidney function was not mentioned in most guidance 
documents. Murtagh173 recommended testing kidney function in all patients and 
NOF300 and NHLBI304 listed it as a consideration. 
The FBC, ferritin and ESR tests were not mentioned in most of the guidance 
documents, with the exception of the NHLBI guideline, that stated that FBC should 
be considered.304  
Other tests mentioned in the guidance documents  
Other tests were mentioned in the guidance documents but each of these accounted 
for less than 1% of tests recorded by GPs for overweight/obesity.  
Urinalysis was recommended in two sources,299,300 and two documents recommended 
testing for gout/hyperuricaemia.297-299 The most common test for gout is urate/uric 
acid. While it was not among the most common individual tests, it may have been a 
part of the MBA test.  
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Key to Table 5.41 
Colour Description 
 The document specifically recommended this test. Any notes within the cell indicate 
further detail. For example, a specific disease to test for within subset of patients; a 
specific test within a group.  
 The document stated that this test should be considered. Any notes within the cell indicate 
further detail (e.g. a specific test to consider) 
 Unable to determine guidance (see Section 5.3.4).  
 The document specifically stated not to do this test. Additional information is supplied if 
certain conditions apply (e.g. specific clinical situations). 
 Guidance document does not mention this test 
 
 Table 5.41: Summary of guidance recommendations by most frequent individual test orders for overweight/obesity, 2000–08 
Pathology test  
Per cent of 
ov/ob path 
(n = 2,917) NHMRC297 
NHMRC 
GP298 OCCPG299 NOF300 NOF assess301 NICE302
NICE 
NHS303 NHLBI304 RCPA172 Murtagh173 Steven174 
Lipids*  23.2            
Glucose/glucose 
tolerance*  18.9 
           
TFT*  13.4 
  Only if 
clinically 
indicated 
 Thyroid-
stimulating 
hormone  
      
FBC  12.7            
LFT*  8.5            
EUC*  6.8            
MBA* 5.1            
Hormone assay* 1.8 
Polycystic 
ovary and 
fertility 
Polycystic 
ovary and 
fertility 
Polycystic 
ovary 
Cortisol 
and sex 
hormones
Cortisol    Cortisol Cortisol 
and sex 
hormones
Cortisol 
Other chemistry*  1.6            
Ferritin* 1.0            
ESR  1.0            
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Ov/ob – overweight/obesity; also see Abbreviations. Any notes within the coloured cells are described in detail in Section 5.9.5. Only the groups of tests/individual tests accounting for  1% of all pathology 
tests for the selected problem are included. 
 
198 
 199 
Evaluation of GP pathology ordering against guidance documents 
Table 5.42 provides a summary of the individual tests ordered for overweight/ 
obesity and the level of support provided in the guidance for each. Of the tests 
ordered by GPs in 2000–08: 
• 52.4% were supported  
• 20.1% had conditional support or support could not be determined 
• 21.4 were not supported by the guidance documents (Table 5.42).  
The individual tests/batteries listed in Table 5.42 account for 93.9% of pathology 
tests/batteries ordered for overweight/obesity because only the most commonly 
ordered tests for overweight/obesity were evaluated.  
Table 5.42: Summary of support for GP pathology ordering for the most frequent 
individual test orders for overweight/obesity, 2000–08 
Pathology test supported by guidance Number
Per cent of all pathology tests
for overweight/obesity 
Supported 1,527 52.4
 Lipids*  676 23.2
 Glucose/glucose tolerance*  550 18.9
 LFT*  248 8.5
 Hormone assay* 53 1.8
Conditional/unclear support 587 20.1
 TFT*  392 13.4
 MBA* 149 5.1
 Other chemistry* 46 1.6
Unsupported 625 21.4
 FBC  369 12.7
 EUC*  196 6.8
 Ferritin* 30 1.0
 ESR  30 1.0
Subtotal (n, % of total tests) 2,739 93.9
Total pathology tests  2,916 100.0
* Includes multiple ICPC-2 PLUS codes (see Appendix 7). 
Note: Only the groups of tests/individual tests accounting for  1% of all pathology tests for the selected problem are 
included. See Abbreviations. 
In 2000–08, GPs ordered supported pathology tests at a rate of 19.6 tests/batteries per 
100 overweight/obesity problems, followed by unsupported tests (8.0) and those with 
conditional support (7.5). Tests ordered for overweight/obesity but not evaluated 
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were ordered at a rate of 2.3 per 100 problems. The rate at which GPs ordered 
unsupported and conditionally supported tests increased significantly over time 
(Table 5.43). 
Table 5.43: Rate of pathology ordering for overweight/obesity by level of support, 
2000–08, 2000–02 and 2006–08 
 2000–08 2000–02 2006–08  
Level of support 
Rate per 100 
overweight/obesity
problems
(95%CI) (n = 7,797)
Rate per 100 
overweight/obesity
problems
(95%CI) (n = 1,975)
Rate per 100 
overweight/obesity 
problems 
(95%CI) (n = 1,935) Change
Supported  19.6 (17.7–21.4) 17.1 (13.2–21.0) 24.0 (19.4–28.6) — 
Conditional/unclear 
support 7.5 (6.7–8.3) 5.1 (3.9–6.4) 9.8 (8.0–11.7)  
Unsupported  8.0 (7.1–8.9) 6.4 (4.7–8.2) 10.8 (8.6–13.0)  
Not evaluated 2.3 (2.0–2.7) 2.0 (1.3–2.7) 2.5 (1.8–3.3) — 
Note: CI – confidence interval. Shading indicates a statistically significant change between 2000–02 and 2006–08. The 
direction and type of change is indicated for each measure: / indicates a statistically significant change,  
and — indicates no change. 
 
GPs ordered only pathology tests that were supported or conditionally supported at 
7.1% (95% CI: 6.4–7.9) of overweight/obesity problems in 2000–08. A further 5.9% 
(95% CI: 5.2–6.5) of problems involved at least one unsupported test, and 87.0%  
(95% CI: 86.1–88.0) of problems involved either no pathology tests (86.4%) or tests 
that were not evaluated (0.6%) (results not tabled). 
Between 2000–02 and 2006–08 there was no change in the proportion of 
overweight/obesity problems that involved supported testing, 6.1% (95% CI:  
4.8–7.4) in 2000–02 and 8.1% (95% CI: 6.2–9.9) in 2006–08. However the 
proportion of problems involving at least one unsupported test increased significantly 
over this time, from 4.8% (95% CI: 3.5–6.0) to 7.7% (95% CI: 6.3–9.2) (results not 
tabled). 
When GPs ordered unsupported tests, the vast majority were accompanied by one or 
more supported/partially supported tests (96.6% of occasions). Unsupported tests 
were ordered alone at the remaining 3.4%. GPs ordered only tests that were 
unsupported at 0.2% of overweight/obesity problems in 2000–08, and this did not 
change over time (0.1% in both 2000–02 and 2006–08) (results not tabled).  
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5.9.6 Discussion 
GPs’ pathology test ordering for overweight/obesity problems (in adult patients) 
aligned moderately well with that recommended in guidance documents, with 72% 
of tests partially or completely supported. The statistically significant increase in the 
rate of GPs total pathology ordering for overweight/obesity problems between  
2000–02 and 2006–08 was reflected in the increased rate of tests that were partially 
supported, and in those unsupported in guidance documents. There was no change in 
the rate of supported tests. 
Due to the increase in total rate of pathology ordering, the correlation between GPs’ 
ordering and level of support, as a proportion of total tests should be considered. 
Supported tests accounted for the largest proportion of total tests, but they accounted 
for a smaller proportion of total tests in 2006–08 than in 2000–02. Concomitantly 
there was an increase in the proportion of partially supported tests and a small 
increase in unsupported tests. Overall the increase in total tests ordered by GPs for 
overweight/obesity suggested a small shift (less than 2% of total pathology) towards 
being ‘less’ in line with guidance recommendations. However, there was a more 
pronounced shift in GPs’ ordering, from supported to partially supported tests that 
warrants further investigation. 
Comments on guidance documents 
Guidance documents for management of overweight/obesity logically followed the 
‘normal’ management pathway from identification, to assessment, to management, to 
monitoring. 
Most documents had no clear section for recommended pathology tests. Mixed 
terminology was used to refer to testing e.g. ‘diagnostic testing’, ‘laboratory 
investigations’, ‘diagnostic investigations’, ‘assessment’, the specific test name, or 
the disease to be tested for—making identification of recommended testing within 
the lengthy documents (often over 200 pages) difficult. The Australian NHMRC 
guideline (and related GP guide) did not specifically recommend any pathology tests, 
conditions associated with obesity being listed by relative risk of developing the 
condition with the statement ‘standard procedures are used to test for these’.297,298 
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Contradictory statements 
Recognising that size, complexity and structure of guidance documents was a barrier 
to them being utilised, some authors created an abbreviated guidance document. 
However, there were inconsistencies between the full and abbreviated guidance. 
There were also conflicting statements made within the same guidance document.  
The Australian NHMRC guideline and the related GP guide provided contradictory 
advice for thyroid disease. In the full guideline thyroid disease was not mentioned as 
a disease to consider in assessment. However, hypothyroidism was mentioned in two 
other places in the guideline: as a condition that places people at risk of obesity with 
the statement that it generally shows up earlier in life; and, in the alternative 
treatment section it was noted that it caused “very few cases” of obesity.297 These 
comments suggest that the authors of the full guideline do not consider thyroid 
disease testing to be a routine part of the assessment of overweight/obesity. In 
contrast, the GP guide stated “Medical conditions: Certain medical conditions, for 
example, hypothyroidism, are known causes of overweight” and goes on to 
recommend that these medical conditions should be assessed by clinicians.298 This 
suggests support for thyroid testing in the GP guide, though not in the full guideline. 
The recommended pathology tests in the NOF guideline and separate ‘full 
assessment’ did not align. In the NOF guideline300 a number of blood tests were 
listed ‘if appropriate’, suggesting they would not be necessary in all patients. In 
contrast, the assessment document recommended a smaller number of tests for all 
patients.301 
Authors of two guidance documents made inconsistent recommendations within the 
document. The NHLBI guideline listed the lipids and glucose tests as recommended 
tests in one section of the guideline and as tests to be considered in another 
section.304 The NHRMC GP guide listed conditions to test for in the assessment 
phase using “standard testing”, but also included as an appendix a Weight 
Management Plan, which prompted for specific test results. These were: 
triglycerides, cholesterol, insulin, glucose, LFT, and endocrine tests. However, 
insulin is not a recommended standard pathology test to use for testing any of the 
conditions. 
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Testing for phase of management 
Pathology tests were, in the main, only recommended in the assessment phase of 
management (i.e. prior to starting treatment) to identify the presence/absence of other 
morbidities associated with overweight/obesity, and/or possible medical causes for 
overweight/obesity. It is likely that GPs ordered pathology tests/batteries for the 
assessment of overweight/obesity at the time of its ‘diagnosis’ as a new clinical 
problem, which explains the higher pathology order rate at these new cases than the 
average rate for overweight/obesity problems. 
Multiple guidance documents acknowledged the chronic nature of 
overweight/obesity and the need for long-term management.297-299,302-304 The majority 
of GP-patient contacts for overweight/obesity management (85%) were for its 
ongoing management, as were the majority of pathology tests/batteries ordered 
(74%). However, only one guidance document made a recommendation about 
pathology testing in ongoing management: the Canadian guideline made a consensus 
recommendation to retest glucose and lipid levels ‘at regular intervals’.299 
There was a lack of guidance about whether there is a need for pathology testing in 
ongoing management to reassess the absence or presence of associated morbidities. 
As the majority of contacts and pathology testing were provided by GPs for ongoing 
management of overweight/obesity this is an area authors of future guidance 
documents should improve. 
Tests for which guidance was lacking 
There was a significant discord between guidance documents’ recommendations and 
GPs’ ordering for overweight/obesity for three tests: FBC, TFT and MBA.  
FBC was only mentioned in one guidance document, as a possible inclusion in initial 
assessment, and the MBA was not recommended in any guidance documents. Only 
TFT was commonly mentioned in guidance documents. However, due to the 
variation between recommendations in guidance documents TFT was judged as 
‘partially supported’ in this study. However, when it was recommended it was only 
in the initial assessment of overweight/obesity, but GPs usually ordered it in ongoing 
management (70% of occasions). The increase in the proportion of GP-ordered tests 
classified as ‘partially supported’ (mentioned earlier in this discussion) was mainly 
due to increases in the rate of TFT and MBA tests. 
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The three tests (FBC, TFT and MBA) accounted for one-third of total tests ordered 
for overweight/obesity in 2000–08. GPs’ ordering of these tests increased 
significantly between 2000–02 and 2006–08, and the increases in order rates of TFT 
and FBC were the main contributors to the total increase in GPs’ pathology ordering 
for overweight/obesity. 
Investigation of whether the FBC and TFT tests are clinically useful in the 
management of overweight/obesity and at which stage of management (including for 
ongoing monitoring) is needed. The results of this investigation should be used to 
improve guidance documents, and this guidance promoted to GPs to improve test 
ordering. 
Evidence base for overweight 
A lot of the available evidence, on which recommendations in the documents were 
based, was for obesity only. For example, the studies referenced in guidance 
documents that identified links to associated morbidities and causative 
conditions/diseases were among obese patients, not in the overweight. However, 
recommendations were made for overweight and obese patients based on this 
evidence though the causative links may be less clear in overweight patients.  
Factors influencing the future management rate of overweight /obesity  
The prevalence of overweight/obesity is high and increased over the period of this 
study (between 2000 and 2008) in the Australian population,154 and in the Australian 
general practice patient population.273 However, there was no change in the 
management rate of overweight/obesity as a clinical problem in general practice. It 
remained very low. In 2000–08, on average, GPs saw 51 overweight/obese patients 
for every one management occasion.  
Multiple studies have similarly noted the discord between prevalence of obesity and 
its management in primary care. The proportion of obese patients who recall 
receiving weight management or have it documented in the record varies from 19% 
to 49%.305-308 GPs acknowledge the importance of management of overweight and 
obesity and most report feeling well prepared to manage it.309 However, they also 
perceive that they are unlikely to be very effective in influencing the factors driving 
obesity in patients,310,311 despite evidence that patients who receive weight loss 
counselling are more likely to attempt weight loss.305 
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As the current management rate is low, the amount of total pathology accounted for 
by overweight/obesity is also small. However, with public awareness campaigns 
underway to address overweight/obesity at a population level it is likely that its 
management rate in general practice will increase as it is the usual first point of 
contact Australians have with the health care system. The potential for increased 
management is huge and would create a corresponding increase in pathology, which 
would occur without any change in GPs’ current pathology ordering behaviour. 
However, GP’s pathology ordering for overweight/obesity has increased and may 
continue to do so, which would further increase future pathology test rates for 
overweight/obesity. 
The inclusion of obesity as a National Health Priority Area290 and as part of the 
National Preventative Health Strategy235 reflects the urgency and scale of the 
overweight/obesity problem. The Strategy’s Obesity Working Group 
recommendation to ‘strengthen, skill and support primary healthcare and public 
health workforce to support people in making healthy choices’235 is timely.  
The Australian NHMRC guideline and GP guide were created seven years ago and 
are overdue for revision, providing an opportunity to improve the overweight/obesity 
guidance available to GPs addressing the deficiencies highlighted in this study. It is 
clear from the Working Group’ recommendation that primary care workers will 
continue to have a role key in the management of obesity in the future. 
Summary 
More than 70% of pathology ordered by GPs in the management of 
overweight/obesity were recommended in guidance documents. Based on the current 
prevalence-management pattern and increases in GP’s pathology ordering for 
overweight/obesity there is potential for future growth in pathology ordering 
associated with overweight/obesity. Future guidance developed for GPs should 
address the gaps and limitations highlighted in this study, particularly in long-term 
management. Addressing the appropriateness of GP test ordering in management of 
overweight/obesity may decrease some future costs associated with its management. 
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5.10 Discussion 
GP adherence to guidance documents 
Pathology tests/batteries ordered by GPs in the management of hypertension, T2D, 
lipid disorders and weakness/tiredness aligned well with those recommended in 
guidance documents, with at least 85% of tests ordered for these problems being 
completely or partially supported. This was not the case for ‘health check’ and 
overweight/obesity problems, with 50% and 70% of tests, respectively, being 
completely or partially supported in guidance documents. 
Although only six problems were investigated in this chapter, they accounted for 
one-quarter (25%) of the total pathology tests/batteries recorded by GPs in 2000–08. 
When viewed as one group, 66% of the pathology ordered for the six conditions were 
supported in guidance documents, 15% were partially supported, 13% were 
unsupported and 6% were not evaluated. When described in terms of the total 
volume of pathology ordered 17% of tests were supported for the six problems, 4% 
were partially supported, and 3% were unsupported. 
Over the period of this study, GPs’ pathology ordering for the six problems 
increased, and this represented a shift to be ‘less’ in line with recommendations in 
guidance documents. The proportion of tests ordered by GPs that were supported 
decreased (from 70% in 2000–02 to 61% in 2006–08), counteracted by increases in 
the proportion that were partially supported (13% to 17%) and unsupported (11% to 
16%). The proportion of tests that were not evaluated in this study remained constant 
(6% in 2000–02 and 2006–08). Although the proportion of unsupported tests 
increased, it is important to note that the increase of 5% was relatively modest over 
the 8 years of the study. Inappropriate pathology ordering was not the major 
contributor to the increased rates of GPs’ pathology ordering, as increases occurred 
in all ‘level of support’ groups.  
The results in Chapter 4 suggest that 13.6 million tests/batteries were ordered for the 
six problems in 2006–08 in Australia. This is the extrapolated number of pathology 
tests ordered across the country and incorporates GPs pathology ordering for the 
problems, the management rate of the problems and the number of national GP 
encounters. Of these tests, 10.7 million (78.2%) were completely or partially 
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supported in guidance documents, 2.1 million (16.6%) were not supported and 
850,000 (6.2%) were not evaluated in this study. 
It is interesting to note that most of the pathology tests evaluated as unsupported in 
the current study were not mentioned in the guidance documents, rather than being 
specifically recommended against. In other words, guidance documents were 
prescriptive in encouraging the necessary pathology tests and rarely proscriptive in 
recommending against use of pathology tests.  
It may be that some of the tests not mentioned in guidance documents, and therefore 
evaluated as unsupported, have a role in the management of the clinical problem. 
Prior to implementing interventions to curb these ‘unsupported’ tests, further 
investigation of the clinical value of such tests may be needed. 
When GPs ordered unsupported tests this was primarily in addition to ordering 
supported tests. It was rare that an order for pathology for any of the six problems 
included only unsupported tests. This aligns with the study by van Wijk et al.79 that 
found the most common cause of ‘non-compliant’ pathology ordering by GPs was 
the addition of tests. However, it was also found that half of the tests considered 
‘non-compliant’ were subsequently recommended in the revised guidelines, leading 
van Wijk et al. to conclude that GPs were early adopters of new evidence.79 This 
does not appear to be the case in the current study. The eight years of data evaluated 
and the range of publication dates of the reviewed guidance documents suggest that 
if GPs’ ordering of unsupported tests was pre-empting changes in guidance this 
would have been noted.  
The fact that unsupported tests were rarely ordered alone has significant implications 
in the context of the current MBS funding structure of pathology tests ordered by 
GPs in Australia. In studies evaluating the cost-effectiveness of implementing 
pathology interventions in other countries, cost-effectiveness was favourable on the 
basis of the saved testing costs.76,78,312 However, because of the coning structure in 
the current funding arrangement, only the three most expensive MBS pathology item 
numbers per testing episode are funded by the Australian Government. This means 
that reducing the ordering of inappropriate tests may not achieve a reduction in cost 
of the tests at an episode, unless they fall in the three most expensive pathology items 
ordered on that occasion. 
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Limitations 
Essentially this study assesses the appropriateness of GPs’ pathology test selection in 
the management of the six investigated problems, with appropriateness judged on 
recommendations for testing provided in guidance documents. It was not the purpose 
of this study to determine whether GPs performed all the recommended tests for each 
problem. There are circumstances where GPs’ use of appropriate tests may be 
suboptimal.  
There were a few occasions where guidance documents recommended pathology 
tests that GPs did not order. These tests were not strongly recommended, that is, 
there was not consensus among guidance documents for these tests. The only 
exception was the urinalysis test, which was supported in guidance documents for 
hypertension and weakness/tiredness. It is likely that urinalysis was not recorded by 
GPs participating in BEACH because GPs are instructed not to record dipstick tests. 
Urinalysis includes a dipstick and microbiology test. Therefore, low rates of 
urinalysis may reflect a limitation of the BEACH pathology data. However, in 
general, GPs’ failure to order tests that were not strongly supported in guidance 
document is not likely to be a concern.  
There are limitations related to the type of data available in this study. The cross-
sectional and encounter-based nature of the data meant some clinical information 
(e.g. presence of clinical signs, comorbidities, test results, interval between repeated 
tests) was not known. When a guidance document recommended a test in a selected 
clinical circumstance, GPs’ ordering of the test was evaluated as ‘supported’ in the 
current study. This is a somewhat lenient approach to assessing the appropriateness 
of testing. It is possible that a test that was evaluated as supported in this study may 
not be appropriate in the circumstances of the individual patient. It is also possible 
that a test not recommended in guidance may be appropriate in the circumstances of 
the individual patient.  
The measure used to assess ‘appropriateness’ in this study, is just one possible 
measure. Others have used different measures (such as unnecessary repetition of 
tests313) although most of these have been applied in settings other than general 
practice.52 
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There are also limitations to the pathology data recorded in the BEACH study. As 
discussed in Chapter 3, there are a maximum of five pathology tests/batteries of tests 
that can be recorded per encounter. Each test may relate to more than one problem 
being managed and the analysis in this chapter is based on these problem–pathology 
linkages. It was possible for a single pathology test/battery to be linked to more than 
one problem, and therefore evaluated in this study for more than one problem, but 
this was rare. 
Some of the guidance documents reviewed in this study were published subsequent 
to the data being recorded. However, the relative consistency of recommendations 
between guidance documents and consistency in the types of tests ordered by GPs for 
each problem suggest that differences in publication dates of the guidance documents 
would not have affected the conclusions of this study. 
Guidance documents 
Guidance documents, in particular guidelines, have been shown to be successful in 
improving care when produced, disseminated and implemented successfully.11,85,314 
However uptake of guidance is often poor for a variety of reasons. Barriers to 
guideline adherence may relate to the individual patient, clinicians attitudes to 
guidelines, the characteristics of the guidance (e.g. the source, evidence base and 
practical features such as length), and characteristics of the individual 
recommendations.153,315-323 In this study, while acknowledging that these barriers 
exist, guidance documents are viewed as summaries of the best available evidence 
and reflect the guidance available to GPs for pathology testing. 
As a whole, the quality of the guidance documents reviewed in this study was highly 
variable. For example, it is likely that some of the guidelines reviewed would not 
meet the indicators for high quality using the Appraisal of Guidelines for Research 
and Evaluation (AGREE) instrument.324 However, it was not the purpose of this 
study to assess the quality of the guidance documents in this respect. Nor was it 
within the scope of this thesis to determine the accuracy or appropriateness of the 
pathology recommendations made by authors of guidance documents (e.g. that the 
evidence was correctly interpreted). Instead guidance documents were viewed to 
determine what is available to GPs in terms of guidance about pathology testing. 
 210 
I may not have identified and reviewed all the relevant guidance documents available 
for the six problems investigated in this study. Also as the study was limited to 
guidance documents available in English, most of the Dutch College of General 
Practitioners guidelines could not be evaluated, despite being widely referenced in 
the literature.76,79,86,88,95,281 
Locating relevant Australian guidelines and other guidance documents was not 
straightforward as several organisations produce guidance documents.325 At the time 
this study was conducted there was no central listing of Australian guidelines or 
other guidance documents. In contrast, other countries had organisations responsible 
for guideline creation and dissemination (such as NICE in the UK) and/or central 
listings of guidelines (e.g. the US National guideline clearinghouse). Since this study 
was completed, a web-based ‘National clinical practice guidelines portal’ has been 
launched326 which should facilitate locating guidelines in the future. 
The guidance documents reviewed, commonly guidelines, were usually not designed 
for GPs. Many of the documents were lengthy (frequently 200+ pages) in order to 
include all the evidence. The size and number of guidelines applicable to diseases 
commonly managed in general practice has been acknowledged as a barrier to their 
use by GPs.153,319,322,323 
In addition, locating information about recommended pathology testing in the 
guidance documents was often difficult. There was mixed terminology used to refer 
to testing e.g. ‘diagnostic testing’, ‘laboratory investigations’, ‘diagnostic 
investigations’, ‘assessment’, and the specific test name, or the disease that testing 
aims to identify or exclude. Implementing common terminology to refer to pathology 
tests in guidance documents would be one easy way to help clinicians identify 
relevant recommendations in these lengthy documents. 
This study identified quite a few inconsistencies in pathology recommendations both 
within and between guidance documents for equivalent clinical situations. 
Incomplete pathology test recommendations were also identified, particularly in the 
context of long-term management (this is discussed in more detail below in ‘Chronic 
conditions’).  
I found one other study that investigated the quality of blood test recommendations 
in guidelines. Van Wijk et al.327 reported only a few instances of incomplete blood 
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test recommendations in the guidelines of the Dutch College of General 
Practitioners. Van Wijk’s study suggests a better quality of recommendations in the 
Dutch guidelines than found in the current study. This is probably because the 
guidelines reviewed were all from one source. Additionally these guidelines have 
been extensively used in studies to improve GPs’ pathology ordering in the 
Netherlands76,79,86,88,95,281 over several decades and it is likely that any inconsistencies 
have been corrected over time. 
The problems investigated  
The six problems included in this study can be considered to represent three broad 
groups: chronic conditions, diagnostic problems and preventive care. Lipid disorders, 
T2D, hypertension, and overweight/obesity are chronic conditions. Health check, as 
a problem under management, represents a preventive process of care and the 
management of weakness/tiredness problems represents a diagnostic process. There 
were different issues raised in this study that were common to each of these three 
broad groups. 
Chronic conditions 
The study highlights that the majority of GP management and pathology 
tests/batteries ordered (70–90% of pathology) for the four chronic conditions were 
for the long-term management of the conditions. Despite this, recommendations 
regarding pathology testing in long-term management of conditions were frequently 
omitted or incomplete in guidance documents. 
Guidance documents often included recommendations about monitoring the key 
indicator(s) for the disease (e.g. lipid levels for lipid disorders, HbA1c for diabetes). 
However, recommendations regarding the monitoring of other factors including 
medication side effects were frequently omitted or incomplete. For example, 
guidance documents recommended monitoring liver function in the use of statin 
medications but gave no advice on the frequency and duration of monitoring. 
For hypertension, lipid disorders and overweight/obesity a number of pathology tests 
were only recommended as part of the initial assessment of new cases of disease (e.g. 
those recommended to identify possible underlying causes of the disease). In this 
study, the level of support may be over-estimated for such tests. 
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GPs continued to order these pathology tests in the ongoing management of the 
problems, that is, beyond the initial assessment. No guidance was provided on the 
need (or not) to periodically reorder tests recommended in the initial assessment. For 
example, guidance is needed on whether the secondary causes of disease 
(recommended for testing in the initial assessment) are likely to occur in the future 
(e.g. increasing prevalence with age), and therefore whether these secondary causes 
need to be reassessed. Such guidance should inform GPs whether subsequent 
diagnosis of the condition is likely to affect management of the disease and whether 
repeated testing is needed.  
In addition to incomplete guidance about pathology tests needed for monitoring 
chronic conditions, there was also a lack of information on interpretation of repeated 
testing. Even among tests with an established role in monitoring chronic conditions, 
the expected variation of test results (i.e. the expected analytical and intra-individual 
variation in repeated test results) was not discussed in guidance documents. 
Knowledge of this variance is essential for GPs to accurately interpret results, to 
determine the level at which clinical intervention (e.g. increase medication dose) is 
required to maintain ‘control’ and avoid progression of disease.328 
Lipid testing is a good example to highlight the issues around recommendations for 
monitoring. In this study lipid testing was supported for the four chronic conditions, 
but the level of detail provided in guidance documents about reassessing or 
monitoring lipid levels varied. No guidance documents discussed interpretation of 
repeated lipid results (i.e. expected variation of results), although its variability is 
well studied.224,226-229 Recommendations to monitor lipid levels and the interval 
between repeated testing were usually complete in guidance documents for lipid 
disorders and T2D. However this was not the case for hypertension and 
overweight/obesity. On the few occasions where recommendations for repeated lipid 
testing were made, they were vague, such as reassess ‘regularly’ or ‘at regular 
intervals’. GPs’ ordering of lipid tests is further investigated in a substudy in 
Chapter 6. 
The current study suggests that there is scope for improvement in pathology ordering 
guidance in the long-term management of chronic diseases. Complete guidance is 
needed on tests required in ongoing management particularly beyond the primary 
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monitoring test(s) for conditions. These improvements should include whether other 
tests have an ongoing role in the long-term management of the condition (such as 
those recommended in the initial management) and monitoring of medication side 
effects. Specifically these recommendations should be complete and include the 
recommended interval between tests and the duration that testing should persist.  
It has been said that monitoring practices are understudied,328 and that quality 
evidence in monitoring protocols in health care is lacking.56,329 This may explain why 
the monitoring recommendations in guidance documents are not ideal. Improving 
recommendations about the testing interval for monitoring is not straightforward 
because frequency may depend on the phase of management.328,329 Never-the-less 
making improvements in recommendations for monitoring tests (including interval 
and interpretation) is worthwhile considering the volume of testing generated by 
monitoring chronic disease in general practice.  
Multiple morbidity  
Managing patients with multiple chronic problems has become part of everyday 
practice for GPs.330,331 Prevalence of multimorbidity increases with age330,331 and as 
the Australian population ages the proportion of people with multiple chronic 
morbidities will increase.  
Both guidance documents and this study are disease-specific. This is necessary 
because much of the evidence is disease-specific. However disease-specific guidance 
documents do not reflect the real world experience of managing patients with 
multiple diseases in general practice.153,332,333 A similar limitation applies in this 
study when comparing disease-specific recommended testing with actual clinical 
practice.  
There is a need for improved guidance for pathology testing in patients with multiple 
morbidities. As many individual chronic diseases require pathology testing in their 
ongoing management, producing guidance relating to appropriate pathology in 
multiple morbidity situations may benefit GPs. However, since the number of 
possible combinations of chronic diseases is almost innumerable, realistically such 
guidelines should concentrate on the most prevalent combinations of disease. 
 214 
Testing for a diagnostic purpose  
Pathology tests are usually ordered by GPs for diagnostic purposes in the 
management of weakness/tiredness. The low prior probability of disease in these 
patients and the high rates of pathology ordering mean that the likelihood of 
receiving false positive or false negative tests results is common.  
Even though GPs’ test selection aligned well with that recommended in guidance 
documents, most of these recommendations were based on consensus because there 
is little available evidence. The few studies conducted suggest that limiting the 
number of tests (so that fewer than that currently recommended in guidance 
documents are ordered) may reduce the likelihood of false positive results with no 
change in the diagnostic yield of pathology testing for fatigue.281,287 However, the 
study by Koch et al.281 suggested that even with a limited set of pathology tests, the 
chances of false positive results are relatively high. Increasing the number of tests 
ordered per testing occasion and the characteristics of tests ordered (such as 
sensitivity) contribute to the likelihood of false positive results.  
In the current study, the odds of false positive test results are not likely to have 
increased over the study period, as the number of tests ordered per testing occasion 
and the types of tests ordered for weakness/tiredness did not change significantly 
between 2000–02 and 2006–08. Therefore, the odds of false positive results are 
unlikely to have contributed to the increased rate of pathology testing for 
weakness/tiredness. The increase rate of GPs’ pathology ordering in the management 
weakness/tiredness was due to an increased likelihood that GPs would initiate 
pathology testing (i.e. an increased proportion of patients with weakness/tiredness 
problems were being tested).  
Increasing the number of patients being tested may create a cascade of effects that 
contribute to more pathology testing. For example, assuming that the odds of 
receiving false positive results stay the same and GPs react to these abnormal results 
in the same way (with the same rate of follow-up pathology tests), an increase in the 
volume of patients being tested will flow on to an increased volume of patients 
experiencing false positive results and receiving follow-up testing. This is not to 
suggest that this is clinically inappropriate testing – but simply demonstrating the 
cascade that may be triggered by increasing GP likelihood of testing.  
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Based on the low probability of disease and high rates of testing (as described 
above), it can be assumed that receiving false positive results or clinically 
insignificant abnormal results is a common occurrence in general practice for 
weakness/tiredness. It may be that GPs’ management of abnormal results in the 
management of weakness/tiredness changed and this contributed to increased rates of 
pathology testing. Certainly the management rate of abnormal tests results (as a 
clinical problem) in Australian general practice has increased, so too has GPs’ 
pathology ordering in managing these abnormal results (as described in Chapter 4). 
A high probability of clinically insignificant abnormal test results in diagnostic 
situations is not unique to weakness/tiredness—GPs deal with similar situations on a 
regular basis. Authors have discussed the potential harms of clinically insignificant 
abnormal test results, such as cascades of investigations and testing, unnecessary 
procedures and patient anxiety.9,53,144,334 However, Houben et al. found that in 
diagnostic situations where probability of disease is low (as is the case for tiredness) 
GPs interpreted most abnormal tests results as ‘normal’ or clinically insignificant,335 
and cascades of unnecessary investigations, referrals and treatments were 
uncommon.336 The small sample of GPs (n = < 90) in these studies may limit the 
generalisability of the results, particularly as other studies have reported considerable 
variation in GPs’ pathology ordering behaviour.43-51,71-73,337 
Patient experiences of abnormal results are not well understood, but it is likely that 
they will also be highly variable. An interesting contradiction is apparent when you 
consider that one of the motivations cited by GPs36,37,338 for ordering pathology tests 
(and cited by patients for wanting to be tested33,339) in diagnostic situations is to 
reassure, but abnormal results may achieve the opposite effect, leading to patient 
anxiety—a conundrum considering that clinically insignificant abnormal results are a 
common occurrence in these diagnostic situations.338 Future investigation of the 
flow-on effects of abnormal pathology results in Australian general practice for 
weakness/tiredness, or similar diagnostic problems, would identify the frequency of 
the discussed ‘harms’ and whether interventions (such as education) either for GPs, 
patients or both are needed. 
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Prevention 
Health checks are considered a valuable tool in providing preventive care. Their use 
has been shown to improve use of cholesterol tests, Pap smears and faecal occult 
blood testing.340 However, there is a significant amount of literature that shows 
performance of preventive health activities in primary care is suboptimal.92,341-343 The 
Australian Government has introduced several MBS items for health 
assessments18,232,236 among other initiatives to “ensure that we encourage GPs to 
deliver quality preventative health.”344  
Health checks had the poorest alignment between GPs’ pathology ordering and 
guidance recommendations of the six problems investigated. This may be partially 
due to the diverse range of clinical situations that GPs may face when using the 
‘health check’ label. For example, MBS items were introduced to encourage 
preventive care in a range of selected high risk patient groups, such as older patients 
aged 75 years and over,236 patients at risk of chronic disease,232 and patients at risk of 
T2D.18 While the definition of health checks used in this study excludes those related 
to established disease, it is possible that the patient’s individual clinical 
circumstances call for different pathology tests than those recommended in guidance 
documents. As discussed in the limitations section above, the cross-sectional 
encounter-based nature of this study meant that some data about the patient’s 
individual clinical circumstance was not available. Therefore a conservative 
approach was used; all pathology tests recommended in guidance documents for 
preventive care were included as supported tests. However, as discussed below, the 
difference between tests required for an individual patient’s clinical situation and 
tests recommended in preventive care guidance documents may be more pronounced 
than for the other 5 problems evaluated in this study. 
In considering appropriateness of pathology ordering Lundberg states that we need to 
consider the effect of the test in terms of whether “it was useful for the patient or for 
the public's health”.42 Of course a test may be useful to both the patient and the 
public. However, the concept of individual benefit versus public benefit may 
partially explain the discord between pathology tests ordered by GP’s for health 
checks and those recommended in preventive care guidelines.  
Prevention is a core population health strategy, and as such guidelines for preventive 
care have their basis in public health benefit. By contrast the interaction between a 
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GP and patient is primarily about the patient’s individual benefit. Beaulieu et al. 
found that both physicians and patients were as concerned with usefulness of a 
preventive intervention to the individual as to the general population.341 The lack of 
applicability of guidelines to the individual patient has been identified as a barrier to 
guideline adherence particularly for GPs.153,316,317,319-321 Potentially this may be more 
pronounced for guidelines based on population benefit (such as preventive care) than 
those created for a specific morbidity. 
Over the study period, there was an increase in the number of tests ordered by GPs 
per ordering occasion for health checks. This may have increased the likelihood of 
false positive results, particularly among well patients.142-144  
One of the limitations of the cross-sectional data is that we don’t know the nature of 
the ‘health check’ being provided (e.g. presence of other risk factors or morbidities) 
and cannot determine the type of preventive care likely to be represented.  
The RACGP guideline states that health checks must “involve preventive 
interventions for which there is clear evidence of their effectiveness.”177 It appears 
that the Government’s initiatives to increase the number of health checks were 
successful but this has also increased the rates of both supported and unsupported 
pathology tests for preventive care.  
Only a few guidance documents were available for preventive care and the tests that 
were unsupported for health checks were usually not mentioned in guidance 
documents rather than specifically recommended against. This suggests that further 
research is needed to determine whether there is evidence to support the pathology 
tests that were unsupported in this study but commonly ordered by GPs for health 
checks. 
Specific tests of interest 
There were a few tests identified in this study which were commonly ordered in 
management of the six problems, but for which GPs ordering and recommendations 
in guidance documents frequently did not align. These tests were FBC, TFT and 
MBA. 
These tests are highlighted because the GP ordering rate increased significantly, they 
account for a significant proportion of pathology ordered for these six conditions but 
guidance documents frequently did not support use of the tests.  
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Further investigation is needed to determine the clinical indications for ordering 
FBC, TFT and MBA tests, particularly to investigate their role in the long-term 
monitoring of the chronic conditions. GPs’ ordering of FBCs are investigated in a 
separate study in Chapter 6. 
Conclusion 
The majority of pathology ordered for the six problems were supported in guidance 
documents. The significant increases in GPs’ rates of pathology ordering for these 
problems were reflected in significant increases in tests at all levels of support. Thus 
GPs’ pathology ordering in these six problems does not reflect significant amounts of 
inappropriate tests, nor does it support the assertion that increases in pathology 
ordering are caused by disproportionate increases in unsupported tests. 
As a proportion of total tests, there was an increase in the proportion of unsupported 
tests over time, suggesting a shift toward GPs’ pathology ordering being less in line 
with recommendations over time. However, this was a modest change in the context 
of the increases in total pathology rates.  
There is scope for improvements in GPs’ pathology ordering for the six problems 
investigated. However there are considerable differences between the problems. GPs’ 
pathology test ordering aligned well with recommendations for pathology testing in 
guidance documents for hypertension, T2D, lipid disorders and weakness/tiredness. 
However, due to the lack of guidance on pathology testing in ongoing management, 
the level of support for some tests may be over-estimated, particularly for 
hypertension and lipid disorders. Pathology tests/batteries ordered by GPs for ‘health 
checks’ and overweight/obesity problems did not align well with recommended 
testing. 
Pathology recommendations in guidance documents could be improved in multiple 
ways. Removing inconsistent pathology test recommendations, and standardising 
terminology used to refer to pathology testing would help GPs locate relevant 
information within the lengthy guidance documents. The most important 
improvements needed are for guidance in the long-term monitoring of chronic 
problems. Guidance documents need to include detail about: which tests need to be 
monitored, the frequency and duration of monitoring required; and the interpretation 
of results of repeated tests. 
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6 Investigation of FBC and lipid 
testing 
6.1 Background 
In previous chapters of this thesis, the focus of the research has been the problems 
for which GPs order high volumes of pathology tests and, for a selection of these 
problems, the extent to which GPs’ test selection represents that recommended in 
evidence-based guidelines and guidance documents. In contrast, the focus in this 
chapter is the pathology test. Specifically the study investigated the use of the two 
most commonly ordered pathology test types in Australian general practice as 
previously identified in Chapter 4: the FBC and the lipid test. 
The FBC test (also known as a ‘complete blood count’) and lipid tests are ‘low cost, 
high volume’ pathology tests. Despite the high volume at which they are ordered,37 
they are not the most commonly funded MBS pathology items.345 This is due to the 
effect of the MBS payment structure: the iso-resource item numbers, and the coning 
rule which limits MBS funding to the three most expensive MBS items from each 
episode of GP-ordered pathology tests (as described in Chapter 2).  
The extent of ‘coned out’ or missing MBS data was investigated in 2010, using data 
from pathology laboratories. Of the FBCs ordered by GPs only 45–55% were 
charged to the MBS, the remainder being ‘coned out’. For lipid tests, HDL was the 
only lipid component that could be investigated (because it has its own MBS item 
number) and just 20–30% of these were charged to the MBS.19,346 It was not possible 
to investigate the effect of coning on the remaining lipid components because these 
are in MBS items that are structured as iso-resource chemistry groups, and the 
specific tests ordered cannot be identified. This study demonstrated that MBS data do 
not reflect GPs actual pathology ordering patterns for FBC and lipid tests.  
GPs’ rate of FBC and lipid test ordering increased significantly between 2000–02 
and 2006–08 (see Chapter 4). These tests were among the most commonly ordered 
tests for the six problems investigated in Chapter 5, although the extent to which 
their use was supported varied. While lipid tests were generally supported for the 
investigated problems, this was not the case for FBC tests.  
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The purpose of this chapter is to investigate issues raised in the literature review and 
during research undertaken in previous chapters that could not be investigated using 
the cross-sectional BEACH encounter data. These issues and the objectives for this 
study are summarised below. 
Who initiates the tests 
The literature suggests that general practice patients frequently wish to have their 
blood tested.33-35 Not all patients communicate a request for testing,347 but when they 
do, GPs have described this as a contributing factor in their decision to order 
pathology tests.36,37 However, few studies have quantified the proportion of tests 
perceived by GPs to be generated by patient request. A SAND substudy conducted in 
2002, found that 15.1% of pathology tests ordered at general practice encounters 
were initiated by patient requests for testing.348  
Purpose of tests 
While the clinical problem for which a pathology test was ordered was recorded in 
the BEACH data set, the specific clinical purpose of the test (whether for monitoring, 
diagnostic or preventive purposes) was not requested. However, as discussed in 
Chapter 5, this has a bearing on the appropriateness of ordering specific tests and the 
interpretation of the result.  
Interval between repeat testing 
The cross-sectional nature of the BEACH encounter data meant that the interval 
between testing was not known. The review of guidance documents undertaken in 
Chapter 5 revealed that recommendations on the ideal interval between tests were 
often lacking, particularly when tests were used for monitoring purposes and, the 
majority of lipid and FBC tests were ordered by GPs for the long-term management 
of the chronic conditions. For monitoring of lipid levels, there has also been debate 
as to whether the commonly recommended monitoring interval of 6–12 months 
should be lengthened or whether there is a need for monitoring at all.224-226,349  
Status of FBC testing 
The clinical purpose for GP ordering of FBCs was unclear for most of the six 
problems investigated in Chapter 5. They appeared to be ordered opportunistically or 
routinely when GPs ordered pathology tests in the management of the problems 
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investigated. Others have described clinician’s use of the FBC as ‘indiscriminate’, 
‘reflexive’ or ‘routine’ in various inpatient and outpatient health settings.350-354 
Even though the FBC was the most commonly ordered pathology test in general 
practice, it has not been the subject of much ‘independent’ discussion in the 
literature. In contrast, there is a wealth of literature about lipid testing in primary 
care.83,226-228,355,356 
The use of FBC tests has been discussed in the outpatient352-354 (including the 
emergency department357,358) and inpatient health settings.67 Outcomes of these 
studies suggest that FBC tests either were not supported in the specific setting 
studied67,352,353 or that improved appropriateness of ordering would reduce the 
number of FBCs.357,358 Only one study recommended the routine use of FBCs in 
ambulatory care because they ‘contributed to the wellbeing of the population’.354 
I could find only one small study discussing use of FBCs in general practice and it 
was conducted more than 20 years ago.350 This study introduced an intervention to 
improve appropriateness of ordering that reduced use of FBCs and improved 
appropriateness of their use.350 Other studies in general practice would have included 
evaluation of GPs’ use of FBC tests in the context of a broader intervention, 
76,82,86,88,281 but these publications did not report information specifically about FBC 
ordering. 
While GPs’ use of FBC tests is rarely discussed in the literature, there is no shortage 
of articles recommending GPs use the test, most frequently for diagnostic purposes 
for a range of problems (such as, fatigue,276,282,284 unexplained complaints,281,359 
nausea and vomiting360) and for the diagnosis and management of haematological 
diseases (such as anaemia173,361). 
Medication status and morbidity profile of patients with lipid tests 
The cardiovascular risk associated with lipid levels means that testing lipids and 
management of lipid levels is recommended for prevention and secondary prevention 
of cardiovascular disease in the management of related chronic diseases (see 
Chapter 5). The BEACH encounter data set provides a snapshot of the characteristics 
of patients and the details of the clinical problems for which lipid tests are ordered. 
However, this snapshot does not provide a complete profile of the morbidities that 
the patient has nor information about whether the patient currently takes lipid-
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lowering medication. Both of these factors may influence the decision to order lipid 
tests. In this chapter I aim to fill the gaps in the available information highlighted 
above. 
6.2 Objectives  
The objectives of this study were: 
• to measure the extent to which FBC and lipid tests are initiated by patients 
• to investigate the purpose of ordering FBC and lipid tests for all problems, and 
specifically for the six problems investigated in Chapter 5 
• to describe the interval between repeated FBC and lipid tests, and specifically the 
interval between these tests when used for monitoring purposes. 
Additional objectives that are unique to either FBC or lipid tests are: 
• to describe the differential diagnosis or diagnoses investigated by GPs when 
FBC tests were ordered for diagnostic purposes 
• to investigate the morbidity profile, and lipid lowering medication use among 
patients for whom lipid tests were ordered. 
6.3 Method  
This study used the SAND method as described in Section 3.2.6. Ethics approval for 
this SAND study was obtained from the Ethics Committee of the Australian Institute 
of Health and Welfare, and the Human Research Ethics Committee of the University 
of Sydney. Data in this study were collected over two periods: July–August 2008 
(Sample A), and September–October 2009 (Sample B).  
At each encounter where the GP had ordered a FBC or lipid test they were asked a 
series of questions. I designed these questions to elicit information for each test on: 
who initiated the test; the clinical purpose of the test; whether the patient had been 
tested in the past, and (where applicable) the time since previous testing. Box 6.1 
shows the SAND form designed for this study. These questions were attached to the 
bottom of the BEACH encounter form (see Appendix 2) and the SAND data 
collected can be linked to data (such as patient age and sex) recorded in the 
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encounter form. Additionally the linkages between the FBC and lipid test and the 
problem(s) for which they were ordered were drawn from the encounter form. 
The ‘purpose of test’ categories were based on a previous study conducted in 2002 
that defined tests as investigative, monitoring and/or preventive.348 The preventive 
category was further broken down into tests for primary and secondary prevention. 
The purpose of tests were defined as: 
• investigative or diagnostic for a new condition 
• monitoring of an existing diagnosed condition 
• primary prevention, i.e. screening in an otherwise healthy patient (e.g. following 
RACGP red book guidelines177 for preventive activities)  
• secondary prevention, i.e. screening in a patient with established risk factors for 
a condition but without the condition (Box 6.1).  
GPs were also asked whether ordering the FBC or lipid test was ‘opportunistic’, i.e. 
the test was added to the pathology order once the decision to order another test had 
already been made. 
In circumstances where FBC tests were ordered for investigative purposes, GPs were 
asked to specify the differential diagnosis or diagnoses for which the FBC was 
ordered. Selecting a differential diagnosis was defined as ‘the process of weighing 
the probability of one disease versus that of other diseases possibly accounting for a 
patient’s illness’.362 These differential diagnoses were recorded by the GPs as free 
text and coded using ICPC-2 PLUS.113 
When lipid tests were ordered, GPs were asked whether the patient was currently 
taking lipid lowering medication, and to indicate which conditions the patient had 
from a short list of conditions or risk factors (tick boxes). The listed conditions/risk 
factors were: dyslipidaemia, family history of dyslipidaemia, obesity, diabetes, 
hypertension and ‘other cardiovascular disease’ (Box 6.1). 
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Box 6.1: Example of SAND form completed by participating GPs (with instructions) 
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6.4 Results 
6.4.1 The sample 
Table 6.1 shows the age and sex distributions of patients in: each of the two samples 
(A and B) included in this study; the combined sample (A + B); and, all encounters 
recorded in BEACH in 2008–09.122  
There was no statistically significant difference in the patient age and sex 
distributions in samples A and B did not differ significantly, indicating that the 
samples were homogenous (Table 6.1). Therefore, the samples were combined for 
the remaining analysis. In the combined sample, 193 GPs recorded details of FBC 
and lipid testing for 5,629 patients who visited them when participating in this study.  
The patients in this study were a subsample of all patients in the BEACH study. The 
age-sex distribution of the combined SAND sample was compared with that of all 
patients in the BEACH study (Table 6.1). There was no difference in the sex 
distribution, but there were significant differences in the age distribution. 
Significantly more patients were aged 1–4 years, and fewer were aged 75 years and 
over, in the SAND sample than in the total BEACH sample (Table 6.1). 
Table 6.1: Characteristics of patients in the FBC and lipid study sample 
 Sample A Sample B Combined sample  BEACH 2008–09122
Variable 
Per cent(a)
(95% CI)
(n = 2,940)
Per cent(a)
(95% CI)
(n = 2,689)
Per cent(a) 
(95% CI) 
(n = 5,629) 
 Per cent(a)
 (95% CI) 
(n = 101,000)
Sex (missing n) (14) (16) (30)  (781)
 Male 41.8 (38.6–45.0) 41.2 (38.5–43.9) 41.5 (39.4–43.6)  41.5 (40.7–42.3)
 Female 58.2 (55.0–61.4) 58.8 (56.1–61.5) 58.5 (56.4–60.6)  58.5 (57.7–59.4)
Age (missing n) (19) (15) (34)  (626)
 < 1 years 2.1 (1.6–2.7) 2.6 (1.8–3.4) 2.3 (1.9–2.8)  1.9 (1.8–2.0)
 1–4 years 4.8 (3.7–5.8) 6.4 (5.1–7.8) 5.6 (4.7–6.4)  4.0 (3.8–4.2)
 5–14 years 5.8 (4.6–7.0) 4.8 (3.9–5.7) 5.3 (4.6–6.1)  5.1 (4.8–5.3)
 15–24 years 8.0 (6.7–9.4) 9.6 (8.1–11.0) 8.8 (7.8–9.8)  8.1 (7.7–8.4)
 25–44 years 22.2 (19.9–24.5) 23.8 (21.0–26.6) 23.0 (21.2–24.7)  20.7 (20.1–21.3)
 45–64 years 29.0 (27.0–30.9) 28.0 (25.6–30.5) 28.5 (27.0–30.1)  29.1 (28.5–29.6)
 65–74 years 13.3 (11.5–15.1) 11.1 (9.2–13.0) 12.3 (11.0–13.6)  13.8 (13.4–14.2)
 75+ years 14.8 (12.4–17.1) 13.6 (10.8–16.5) 14.2 (12.4–16.1)  17.5 (16.7–18.3)
(a) Missing data removed.  
Note: FBC – full blood count; CI – confidence interval. 
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6.4.2 FBC testing 
GPs ordered a FBC test for 9.4% (95% CI: 8.4–10.5) of sampled patients. This 
equates to an estimated 10.6 million FBC tests ordered by GPs at the 113 million 
MBS paid GP encounters that occurred in Australia in 2008–09. There was no 
statistical difference in the order rate of FBC tests by patient sex: 9.6% (95% CI: 
8.1–11.0) of males and 9.3% (95% CI: 8.0–10.5) of female patients (results not 
tabled). 
The age-specific rate of FBC testing is shown in Figure 6.1. The likelihood of GPs 
ordering a FBC was constant across age groups for patients aged 15 years and over, 
approximately 10% of patients in each adult age group receiving an order for a FBC 
test. Ordering FBC tests for children aged less than 15 years was uncommon 
(Figure 6.1). 
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Figure 6.1: Patient age-specific rate of FBC orders (95% confidence intervals)  
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Test initiation 
Of the 530 patients for whom GPs ordered a FBC test, responses to who initiated or 
suggested the test were recorded for 486. In most cases the GP initiated the FBC test 
(92.2%), but the patient initiated 6.0% and an ‘other health professional’ 1.9% 
(Table 6.2).  
Purpose of test 
It was possible to record multiple reasons for ordering FBC tests and at least one 
reason was recorded for 500 patients. In most cases (94.4% of patients) GPs listed 
only one reason. Two reasons were recorded for 4.8% of patients, and three reasons 
for 0.8% of patients (results not tabled).  
An investigative or diagnostic purpose was the most common reason for ordering 
FBC tests, indicated for 48.0% of patients for whom a FBC was ordered. Monitoring 
was a recorded reason for 35.0% of patients, opportunistic testing (i.e. adding the test 
to a pathology order once the decision to order was already made) for 10.6%, 
primary prevention (i.e. screening in an otherwise healthy patient) for 8.0%, 
secondary prevention (i.e. screening in a patient with known risk factors) for 4.8% 
(Table 6.2). 
Previous testing and interval between repeat testing 
Most patients with a FBC test ordered at the recorded encounter had previously had a 
FBC test (80.6%), 12.4% were tested for the first time at the recorded encounter, and 
for 7.0% of patients previous testing status was not known (Table 6.2). 
The time since the last test was ordered was recorded for 396 of the 404 patients who 
had a previous FBC test. The last test was ordered > 12 months ago for 39.7% of 
patients, 7–12 months ago for 22.2%, 3–6 months ago for 19.7%, < 3 months ago for 
16.4%, and was not known for 2.0% of patients (Table 6.2). 
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Table 6.2: FBC testing in general practice patients 
Variable Number
Per cent(a)
 (n = 530)
95% 
LCL
95% 
UCL 
Initiation of testing (missing) (44)    
 GP 448 92.2 89.8 94.6 
 Patient 29 6.0 3.9 8.0 
 Other health professional 9 1.9 0.7 3.0 
Purpose of ordering(b) (missing) (30)  
 Investigative 240 48.0 42.8 53.2 
 Monitoring 175 35.0 29.4 40.6 
 Primary prevention 40 8.0 5.3 10.7 
 Secondary prevention 24 4.8 2.6 7.0 
 Opportunistic 53 10.6 6.7 14.5 
Prior testing status (missing) (29)  
 Previously tested 404 80.6 76.6 84.7 
 Never tested 62 12.4 8.9 15.8 
 Unknown 35 7.0 4.6 9.3 
Time since previous test(c) (missing) (8)  
 < 3 months 65 16.4 12.0 20.9 
 3–6 months 78 19.7 14.8 24.6 
 7–12 months 88 22.2 18.1 26.4 
 > 12 months 157 39.7 34.2 45.1 
 Unknown 8 2.0 0.5 3.5 
(a) Missing data removed. 
(b) Multiple responses allowed. 
(c) Proportion of patients who had been tested previously. 
Note: FBC – full blood count; LCL – lower confidence limit; UCL – upper confidence limit. 
 
The interval since the previous FBC test was recorded for 170 of the 175 patients 
who had a FBC ordered for monitoring purposes. Almost half (48.3%) of those 
patients with a monitoring FBC had been tested in the previous six months. When 
compared with FBC tests ordered for non-monitoring purposes, monitoring FBC 
tests were significantly more likely to have been ordered within the previous 
12 months (Table 6.3). 
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Table 6.3: Time since previous FBC test when ordered for monitoring versus other 
purposes 
 Monitoring FBC test FBC test for other purposes 
Time since 
previous test Number 
Per cent(a)
 (n = 170)
95% 
LCL
95% 
UCL Number
Per cent(a) 
 (n = 218) 
95% 
LCL 
95% 
UCL 
< 3 months 37 21.8 14.8 28.8 25 11.5 6.3 16.6 
3–6 months 45 26.5 18.6 34.4 33 15.1 9.5 20.8 
7–12 months 47 27.6 20.4 34.9 40 18.3 13.4 23.3 
> 12 months 41 24.1 17.4 30.8 112 51.4 44.0 58.8 
Unknown 0 . . . . . . 8 3.7 1.0 6.4 
(a) Missing data removed. Of the 404 patients with a previous FBC test data were missing for 16 patients. 
Note: FBC – full blood count; LCL – lower confidence limit; UCL – upper confidence limit. 
Problems for which FBC tests were ordered 
The SAND data were linked to the data recorded on the encounter form to 
investigate the problems for which GPs ordered FBC tests. The problem or problems 
for which the test was ordered were linked for 466 of the 530 patients for whom a 
FBC was ordered. There were 64 patients for whom the FBC test was not linked to a 
problem on the encounter form. Where the FBC test and problem(s) was linked, GPs 
indicated that the 466 tests were ordered in the management of 492 problems 
(Table 6.4). 
There was a broad range of problems for which FBC tests were ordered by GPs. The 
most common problems were hypertension (8.5%), weakness/tiredness (6.1%), 
health checks (4.9%), Type 2 diabetes (4.9%), pregnancy (3.5%), problems described 
as blood tests (3.0%), and lipid disorders (2.8%) (Table 6.4). The 23 problems listed 
in Table 6.4 accounted for 57% of all problems linked to FBC and the three most 
common problems accounted for less than 20%. 
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Table 6.4: Most common problems for which GPs ordered a FBC test 
Problem managed Number
Per cent of 
problem–FBC test links 
(n = 492) 
95% 
LCL 
95% 
UCL
Hypertension (non-gestational)* 42 8.5 6.1 11.0
Weakness/tiredness 30 6.1 3.7 8.5
Health check (15+ years)* 24 4.9 2.8 6.9
Type 2 diabetes 24 4.9 2.8 6.9
Pregnancy* 17 3.5 1.8 5.1
Blood test – all* 15 3.0 1.2 4.9
Lipid disorders 14 2.8 1.4 4.3
Anaemia* 13 2.6 1.3 4.0
Vitamin/nutritional deficiency 10 2.0 0.7 3.4
Menstrual problems* 9 1.8 0.5 3.1
Anxiety* 8 1.6 0.4 2.9
HIV infection/AIDS 7 1.4 0.0 4.2
Abdominal pain* 7 1.4 0.4 2.5
Depression* 7 1.4 0.3 2.6
Rheumatoid arthritis 7 1.4 0.4 2.5
Upper respiratory tract infection 7 1.4 0.1 2.7
Abnormal test results* 6 1.2 0.3 2.2
Ischaemic heart disease* 6 1.2 0.3 2.2
Cough 6 1.2 0.1 2.3
Urinary disease, other 6 1.2 0.3 2.2
Back complaint* 5 1.0 0.2 1.9
Vertigo/dizziness 5 1.0 0.1 1.9
Acute bronchitis/bronchiolitis 5 1.0 0.1 1.9
Subtotal 280 56.9 . . . .
Total 492 100.0 . . . .
* Includes multiple ICPC-2 PLUS codes (see Appendix 6). 
Note: Only problems accounting for > 1% of problem–FBC test links. FBC – full blood count; LCL – lower confidence limit; 
UCL – upper confidence limit; HIV – human immunodeficiency virus; AIDS – acquired immune deficiency syndrome. 
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Differential diagnoses of investigative FBC tests 
When FBC tests were ordered for investigative purposes, GPs were asked to describe 
the differential diagnosis/diagnoses. Of the 240 FBC test ordered for investigative 
purposes, GPs recorded differential diagnoses for 230 patients. More than one 
differential diagnosis could be recorded per patient and a total of 349 diagnoses were 
recorded: 60% of patients had one differential diagnosis recorded, 28.3% had two 
and 11.7% had three recorded (results not tabled).  
There was a wide range of problems listed as differential diagnoses. The most 
common were:  
• anaemia (29.2% of diagnoses) 
• infectious disease (8.0%), which was primarily expressed by GPs as ‘infection’ 
• vitamin/nutritional deficiency (4.0%), primarily expressed as ‘iron deficiency’ 
• viral disease (3.7%), primarily expressed as ‘viral illness’  
• infectious mononucleosis (2.9%) 
• other disease of the digestive system, recorded by GPs as coeliac disease, colitis 
or pancreatitis (2.3%) (Table 6.5).  
Table 6.5: Most common differential diagnoses for investigative FBC tests 
Differential diagnoses Number
Per cent 
(n = 349) 
Anaemia*  102 29.2 
Infectious disease, other/NOS 28 8.0 
Vitamin/nutritional deficiency 14 4.0 
Viral disease, other/NOS 13 3.7 
Infectious mononucleosis 10 2.9 
Other disease of the digestive system 8 2.3 
Pneumonia 7 2.0 
Purpura/coagulation defect 7 2.0 
Abnormal test results* 6 1.7 
Acute bronchitis/bronchiolitis 6 1.7 
Subtotal 201 57.6 
Total 349 100.0 
* Includes multiple ICPC-2 PLUS codes (see Appendix 6). 
Note: FBC – full blood count; NOS – not otherwise specified. 
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Purpose of FBC test when ordered for selected problems 
Table 6.6 reports the purpose of FBC tests ordered for each of the six problems 
investigated in Chapter 5. It was possible for multiple purposes to be recorded for 
each problem. 
The majority of FBCs ordered for hypertension, Type 2 diabetes and lipid disorders 
were ordered for monitoring (Table 6.6). These three chronic conditions accounted 
for almost one-third (31.4%) of the monitoring FBCs ordered (results not tabled).  
There were insufficient numbers of cases where GPs ordered FBCs for 
overweight/obesity to draw conclusions about the purpose of testing (Table 6.6). 
FBCs for weakness/tiredness were almost exclusively ordered for investigative 
purposes (Table 6.6). It was the clinical problem for which GPs most often ordered 
investigative FBCs (11.7% of investigative FBC tests) (results not tabled). For the 28 
patients with an investigative FBC ordered for weakness/tiredness, GPs listed 45 
differential diagnoses for weakness/tiredness (12.9% of all differential diagnoses). 
The most common were anaemia (n = 22), infectious diseases (n = 6), and 
vitamin/nutritional deficiency (n = 4) (results not tabled).  
When FBCs were ordered as part of the health check, the three main purposes were 
monitoring (27.3%), primary prevention (27.3%) and investigative (22.7%). There 
was no primary purpose for which GPs ordered FBCs for health checks (Table 6.6). 
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Table 6.6: Purpose of ordering FBC tests for selected problems  
Problem managed(a) Purpose of FBC Number
Per cent of 
problem-specific 
FBC test links 
95% 
LCL 
95% 
UCL
Investigative 7 17.1 4.5 29.6Hypertension (non-gestational)* 
Monitoring 24 58.5 42.4 74.6
 Primary prevention 5 12.2 0.0 24.4
 Secondary prevention 4 9.8 0.3 19.2
 Opportunistic 6 14.6 3.6 25.7
Weakness/tiredness Investigative 28 96.6 89.3 100.0
 Monitoring 1 3.4 0.0 10.7
 Primary prevention 0 . . . . . .
 Secondary prevention 0 . . . . . .
 Opportunistic 0 . . . . . .
Type 2 diabetes Investigative 2 8.3 0.0 20.5
 Monitoring 20 83.3 67.5 99.2
 Primary prevention 1 4.2 0.0 12.9
 Secondary prevention 4 16.7 0.0 36.2
 Opportunistic 1 4.2 0.0 12.9
Health check (15+ years)* Investigative 5 22.7 3.0 42.4
 Monitoring 6 27.3 6.2 48.3
 Primary prevention 6 27.3 7.5 47.1
 Secondary prevention 2 9.1 0.0 21.7
 Opportunistic 3 13.6 0.0 27.8
Lipid disorders Investigative 0 . . . . . .
 Monitoring 11 91.7 72.9 100.0
 Primary prevention 0 . . . . . .
 Secondary prevention 0 . . . . . .
 Opportunistic 1 8.3 0.0 27.1
Overweight/obesity (adults)* Investigative 2 66.7 0.0 100.0
 Monitoring 1 33.3 0.0 100.0
 Primary prevention 0 . . . . . .
 Secondary prevention 0 . . . . . .
 Opportunistic 0 . . . . . .
(a) Multiple purposes for ordering FBC tests could be ordered per problem. There were cases where the purpose of the 
FBC was missing for the problem. The purpose of FBC was known for: 41 hypertension problems (missing n = 1); 29 
weakness/tiredness problems (missing n = 1); 24 Type 2 diabetes problems (missing n = 0); 22 health check 
problems (missing n = 2); 12 lipid disorder problems (missing n = 2); 3 overweight/obesity problems (missing n = 0). 
* Includes multiple ICPC-2 PLUS codes (see Appendix 6). 
Note: FBC – full blood count; LCL – lower confidence limit; UCL – upper confidence limit. 
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6.4.3 Lipid testing 
GPs ordered a lipid test for 8.3% (95% CI: 7.3–9.2) of sampled patients. This equates 
to an estimated 9.4 million lipid tests ordered at GP encounters in Australia in  
2008–09. GPs were more likely to order lipid tests for male patients (9.9%, 95% CI: 
8.4–11.4) than for female patients (7.0%, 95% CI: 5.9–8.1) (results not tabled). 
The age-specific rate of lipid testing is shown in Figure 6.2. Lipid tests were most 
likely to be ordered for patients aged 45–64 years (14.2%), followed by patients aged 
65–74 years (10.5%), and those aged 75 years and over (8.2%). GPs rarely ordered 
lipid tests for patients aged less than 25 years of age (Figure 6.2). 
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Figure 6.2: Patient age-specific rate of lipid orders (95% confidence intervals)  
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Test initiation 
Of the 465 patients for whom GPs ordered a lipid test, the person who initiated or 
suggested the test was recorded for 456 patients. In most cases the GP initiated the 
lipid test (87.1%), followed by the patient (11.2%), and an ‘other health professional’ 
(1.8%) (Table 6.7).  
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Purpose of test 
The purpose(s) of the test was provided for 455 patients. It was possible to record 
multiple reasons for ordering lipid tests. However, in most cases (83.7% of patients) 
GPs recorded only one reason for ordering lipid tests. Two reasons were recorded for 
13.4% of patients, and three reasons for 2.9% of patients. 
The most common purpose was monitoring (58.5% of patients). Prevention was 
recorded as the purpose for 35.8% of patients: 18.0% being for primary prevention 
(i.e. screening in an otherwise healthy patient), and 17.8% for secondary prevention 
(i.e. screening in a patient with known risk factors). An investigative or diagnostic 
purpose was recorded for 18.2% of patients, and the lipid test was opportunistic (i.e. 
adding the test to a pathology order once the decision to order was already made) for 
7.3% (Table 6.7). 
The most common combinations of indications were: monitoring and secondary 
prevention (5.9%), monitoring and primary prevention (2.9%), and investigative and 
primary prevention (1.3%) (results not tabled). 
Previous testing and interval between repeat testing 
Most patients with a lipid test ordered at the recorded encounter had previously had 
their lipid levels assessed (86.0% of 458 respondents), 10.5% were tested for the first 
time today, and for 3.5%, previous testing status was not known (Table 6.7). 
Of the 394 patients who had previously had their lipid levels assessed, the time since 
the last test was ordered was recorded for 391 patients. The last test was ordered 
> 12 months ago for 42.2% of patients, 7–12 months ago for 26.6% of patients,  
3–6 months ago for 22.0%, < 3 months ago for 7.4%, and was not known for 1.8% of 
patients (Table 6.7). 
Table 6.8 shows the interval since the previous lipid test, recorded for 259 of the 266 
patients who had a lipid test ordered for monitoring purposes. The last test was 
ordered more than 12 months ago for 31.3% of patients, 7–12 months ago for 30.1% 
of patients, 3–6 months ago for 29.3%, and < 3 months ago for 8.5% of patients. 
When compared with lipid tests ordered for non-monitoring purposes, monitoring 
lipid tests were significantly more likely to have been ordered within the previous 
12 months (Table 6.8). 
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Medication status and morbidity profile 
Current lipid lowering medication status was specified for 447 patients for whom 
lipid tests were ordered and almost 40% were currently taking a lipid lowering 
medication (Table 6.7). Of the 174 patients taking a lipid lowering medication, 
80.4% had dyslipidaemia (with or without any of the other listed conditions). The 
remaining 19.6% of patients had at least one of the other listed cardiovascular 
diseases or risk factors (results not tabled).  
Details on the presence/absence of the listed morbidities and risk factors were 
provided for 452 patients: 43.8% had dyslipidaemia, 43.1% had hypertension, 25.7% 
were obese, 18.8% had diabetes, 18.8% had a family history of dyslipidaemia, and 
12.2% had an ‘other cardiovascular disease’ (Table 6.7).  
At least one of these morbidities/risk factors was present in 84.3% (95% CI:  
80.7–87.9) of patients who had a lipid test ordered and multiple morbidities/risk 
factors were common (44.5% of patients with lipid tests). Of the 381 patients with at 
least one of the listed morbidities/risk factors, 47.2% had only one, 24.9% had two, 
18.6% had three morbidities and 9.2% had four or more. The most common 
morbidities/risk factors and combinations were: dyslipidaemia alone (13.6%, 95% 
CI: 9.6–17.7 of patients with morbidities/risk factors), hypertension alone (10.0%, 
95% CI: 6.7–13.3), family history of dyslipidaemia alone (8.9%, 95% CI: 5.9–12.0), 
dyslipidaemia + hypertension (7.3%, 95% CI: 4.4–10.3), obesity only (7.1%, 95% 
CI: 4.5–9.7), dyslipidaemia + diabetes + hypertension (5.0%, 95% CI: 2.8–7.2), and 
diabetes alone (4.7%, 95% CI: 2.2–7.1) (results not tabled). 
Of the 198 patients with dyslipidaemia who had a lipid test ordered, 73.7% (95% CI: 
66.5–81.0) had at least one of the other listed morbidities/risk factors, and 71.4% 
were taking a lipid lowering medication. Of patients with dyslipidaemia: 55.1% 
(95% CI: 47.0–63.1) had hypertension; 28.3% (95% CI: 20.9–35.6) obesity; 24.2% 
(95% CI: 17.7–30.8) diabetes; 17.7% (95% CI: 10.6–24.8) family history of 
dyslipidaemia; 16.2% (95% CI: 11.3–21.0) other cardiovascular disease, and 26.3% 
had none of the other listed morbidities/risk factors (results not tabled).  
There were 183 patients (40.5% of those with a lipid test ordered at the current 
encounter) with at least one of the listed morbidities or risk factors who did not have 
dyslipidaemia. Of these patients: 47.0% (95% CI: 39.0–55.0) had hypertension; 
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32.8% (95% CI: 24.6–41.0) obesity; 27.3% (95% CI: 19.6–35.0) family history of 
dyslipidaemia; 20.2% (95% CI: 13.9–26.6) diabetes; and 12.6% (95% CI: 7.5–17.6) 
had an other cardiovascular disease (results not tabled). 
Table 6.7: Lipid testing in general practice patients 
Variable Number
Per cent(a)
 (n = 465)
95% 
LCL 
95% 
UCL 
Initiation of testing (missing) (9)   
 GP 397 87.1 83.6 90.6 
 Patient 51 11.2 7.9 14.4 
 Other health professional 8 1.8 0.6 3.0 
Purpose of ordering(b) (missing) (10)   
 Monitoring 266 58.5 53.5 63.5 
 Investigative 83 18.2 13.9 22.6 
 Primary prevention 82 18.0 13.5 22.5 
 Secondary prevention 81 17.8 13.0 22.6 
 Opportunistic 33 7.3 4.3 10.2 
Prior testing status (missing) (7)   
 Previously tested 394 86.0 82.6 89.4 
 Never tested 48 10.5 7.4 13.6 
 Unknown 16 3.5 1.9 5.1 
Time since previous test(c) (missing) (3)   
 < 3 months 29 7.4 4.4 10.5 
 3–6 months 86 22.0 17.1 26.9 
 7–12 months 104 26.6 21.9 31.3 
 > 12 months 165 42.2 36.6 47.8 
 Unknown 7 1.8 0.5 3.1 
Medication status (missing) (18)   
 Taking lipid lowering medication 174 38.9 33.9 43.9 
Presence of associated morbidities(b) (missing) (13)   
 Dyslipidaemia 198 43.8 38.9 48.8 
 Hypertension 195 43.1 37.6 48.7 
 Obesity 116 25.7 21.0 30.4 
 Diabetes 85 18.8 15.0 22.6 
 Family history of dyslipidaemia 85 18.8 14.0 23.6 
 Other cardiovascular disease 55 12.2 9.0 15.3 
(a) Missing data removed. 
(b) Multiple responses allowed. 
(c) Proportion of patients who had been tested previously. 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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Table 6.8: Time since previous lipid test when ordered for monitoring versus other 
purposes 
 Monitoring lipid test Lipid test for other purposes 
Time since 
previous test Number 
Per cent(a)
 (n = 259)
95% 
LCL
95% 
UCL Number
Per cent(a) 
 (n = 128) 
95% 
LCL 
95% 
UCL 
< 3 months 22 8.5 4.7 12.3 6 4.7 1.0 8.3 
3–6 months 76 29.3 22.9 35.8 9 7.0 2.4 11.7 
7–12 months 78 30.1 24.1 36.2 26 20.3 12.8 27.8 
> 12 months 81 31.3 24.8 37.7 82 64.1 54.9 73.2 
Unknown 2 0.8 0.0 1.8 5 3.9 0.6 7.3 
(a) Missing data removed. Of the 394 patients with a previous lipid test data were missing for 7 patients. 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
Problems for which lipid tests were ordered 
The SAND data were linked to the data recorded on the encounter form to 
investigate the problems for which GPs ordered lipid tests. Of the 465 patients for 
whom a lipid test was ordered, the problem or problems for which the test was 
ordered were linked for 401 patients. There were 64 patients where the lipid test was 
not linked to a problem on the encounter form. Where the lipid test and problem(s) 
was linked, GPs indicated that the 401 tests were ordered in the management of 427 
problems (Table 6.9). 
The most common problems for which GPs ordered lipid tests were lipid disorders 
(20.8%), hypertension (15.9%), Type 2 diabetes (11.9%), health checks (6.9%) and 
problems labelled as blood tests (5.9%). Approximately half of all lipid test-problem 
linkages were accounted for in the three most common problems: lipid disorders, 
hypertension and diabetes (Table 6.9). 
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Table 6.9: Most common problems managed with a lipid test 
Problem managed Number
Per cent of 
problem–lipid test links 
(n = 427) 
95% 
LCL 
95% 
UCL
Lipid disorders 89 20.8 16.7 25.0
Hypertension (non-gestational)* 68 15.9 12.2 19.7
Type 2 diabetes 51 11.9 8.6 15.3
Health check (15+ years)* 29 6.9 4.1 9.7
Blood test – all* 25 5.9 3.1 8.6
Ischaemic heart disease* 13 3.0 1.4 4.7
Weakness/tiredness 11 2.6 0.8 4.4
Overweight/obesity (adults)* 11 2.6 1.0 4.2
Risk factor NOS 8 1.9 0.6 3.1
Prescription – all* 7 1.6 0.4 2.8
Abnormal test results* 7 1.6 0.4 2.8
Cardiovascular check-up* 6 1.4 0.3 2.5
HIV infection/AIDS 5 1.2 0.0 3.5
Subtotal 330 77.3 . . . .
Total 427 100.0 . . . .
* Includes multiple ICPC-2 PLUS codes (see Appendix 6). 
Note: Only problems accounting for > 1% of problem–lipid test links. LCL – lower confidence limit; UCL – upper confidence 
limit; NOS – not otherwise specified; HIV – human immunodeficiency virus; AIDS – acquired immune deficiency 
syndrome. 
Purpose of lipid test for selected problems 
Table 6.10 reports the purpose of lipid tests ordered for the six problems investigated 
in Chapter 5. It was possible for multiple purposes to be recorded for each problem. 
The majority of the lipid tests ordered for hypertension, Type 2 diabetes and lipid 
disorders were ordered for monitoring (Table 6.10). These three chronic conditions 
accounted for 60.5% of the monitoring lipids ordered (results not tabled).  
Secondary prevention was also a common reason for ordering lipid tests for 
hypertension, Type 2 diabetes and overweight/obesity. When lipid tests were ordered 
as part of the health check, the main purposes were primary prevention (42.9%), and 
monitoring (35.7%) (Table 6.10). 
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Table 6.10: Purpose of ordering lipid tests for selected problems  
Problem managed(a) Purpose of lipid test Number
Per cent of 
problem-specific 
lipid test links 
95% 
LCL
95% 
UCL
Lipid disorders Monitoring 78 87.6 79.1 96.2
 Investigative 3 3.4 0.0 7.3
 Primary prevention 10 11.2 3.2 19.3
 Secondary prevention 12 13.5 4.8 22.2
 Opportunistic 3 3.4 0.0 7.3
Monitoring 40 60.6 47.4 73.8Hypertension (non-gestational)* 
Investigative 9 13.6 2.8 24.5
 Primary prevention 7 10.6 2.0 19.2
 Secondary prevention 17 25.8 14.1 37.4
 Opportunistic 2 3.0 0.0 7.3
Type 2 diabetes Monitoring 43 89.6 80.5 98.6
 Investigative 4 8.3 0.4 16.3
 Primary prevention 3 6.3 0.0 15.5
 Secondary prevention 15 31.3 15.3 47.2
 Opportunistic 0 . . . . . .
Health check (15+ years)* Monitoring 10 35.7 16.8 54.6
 Investigative 5 17.9 2.0 33.7
 Primary prevention 12 42.9 20.6 65.1
 Secondary prevention 2 7.1 0.0 17.2
 Opportunistic 2 7.1 0.0 16.8
Weakness/tiredness Monitoring 4 36.4 1.7 71.0
 Investigative 6 54.5 20.6 88.5
 Primary prevention 0 . . . . . .
 Secondary prevention 0 . . . . . .
 Opportunistic 1 9.1 0.0 30.9
Overweight/obesity (adults)* Monitoring 3 27.3 0.0 60.4
 Investigative 4 36.4 0.0 72.7
 Primary prevention 3 7.3 0.0 60.4
 Secondary prevention 5 45.5 5.9 85.0
 Opportunistic 1 9.1 0.0 27.8
(a) Multiple purposes for ordering lipid tests could be ordered per problem. There were cases where the purpose of the 
lipid was missing for the problem. The purpose of lipid testing was known for: 89 lipid disorder problems (missing n = 
0); 66 hypertension problems (missing n = 2); 48 Type 2 diabetes problems (missing n = 3); 28 health check problems 
(missing n = 1); 11 weakness/tiredness problems (missing n = 0); 11 overweight/obesity problems (missing n = 0). 
* Includes multiple ICPC-2 PLUS codes (see Appendix 6). 
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6.5 Discussion 
FBC tests were widely ordered by GPs for a broad range of problems, most often for 
investigative or diagnostic purposes. The results suggest GPs generate an estimated 
10.6 million FBC tests in Australia annually. Lipid tests were predominately ordered 
for a small number of chronic problems, usually for the purposes of monitoring lipid 
levels, and in total GPs’ orders for lipid tests generate an estimated 9.4 million tests 
per annum in Australia. 
Initiation of testing 
FBC and lipid testing was primarily initiated by the GP. While patient desire to have 
pathology tests has been described as a factor influencing GPs’ pathology 
ordering,36,37 GPs perceived patients as initiating FBC and/or lipid testing at 
relatively few encounters (5% of FBC orders and 11% of lipids). There was no 
statistically significant difference between the proportion of FBC and lipid tests that 
were patient-initiated. However, when compared with an earlier SAND study 
conducted in 2002, the proportion of patient-initiated FBC tests was significantly 
smaller than the average for all pathology tests (15.1%).348 This suggests that the 
decision to order FBC tests was more likely to be initiated by the GP than average 
for all tests, but this was not the case for lipid tests.  
If an intervention or policy regarding FBC and/or lipid testing was to be introduced, 
then GPs should be the primary focus of the intervention or policy as the majority of 
testing is initiated by them.  
Patient demand for testing has been described as one of the possible factors 
contributing to the increased use of pathology testing.28,29,363 Comparison of the 
results of the current study with the 2002 BEACH study suggests that there has been 
no increase over time in the proportion of testing that was initiated by patient 
requests. However, the current study measures ‘successful’ communicated requests 
for testing, not the total patient demand for testing.  
Demand for testing has been assessed as expectations of testing32-35 and 
communicated requests to be tested.347,364,365 Other studies report that 14–39% of 
patients in general practice have an expectation of pathology or imaging testing 
being ordered at their visit.32-35 But only 7.5–9.4% of patients in outpatient settings 
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actually requested tests,364,365 a smaller proportion than those expecting to be 
tested.347 Both the proportions of patients expecting and requesting tests are larger 
than those whose request for testing is successful (as measured here). 
The fact that a low proportion of patients in this study initiated pathology testing, 
together with the finding from other studies that fulfilment of expected or requested 
tests does not affect patient satisfaction,32,35,347 suggests that patient demand for 
testing is managed successfully by GPs. 
Full blood count  
Pattern of use of FBC tests 
GPs’ use of the FBC test was widespread, with GPs ordering FBCs for one-in-ten 
contacts with all patients aged 15 years and over, regardless of patient sex. There was 
a wide range of problems for which FBCs were ordered, reflecting the distribution of 
ordering across patient age groups.  
Other authors have described clinician’s ordering of FBCs as ‘indiscriminate’, 
‘reflexive’ or ‘routine’ on the basis of patterns of ordering.350-354 The increased rate 
of GPs’ FBC ordering over time for all problems (see Chapter 4), and specifically for 
the six problems investigated in Chapter 5, also raised concerns about GPs patterns 
of use of FBC tests.  
The breadth and frequency of FBC testing in this study may be suggestive of routine 
ordering, but the purposes recorded by GPs for ordering FBC tests do not support 
this conclusion. GPs were able to describe a clinical purpose for 90% of FBCs 
ordered, the remainder being ordered ‘opportunistically’. A FBC was described as 
‘opportunistic’ if it was added to the pathology order after the decision to order was 
made. It is possible these opportunistic tests represent occasions of ‘routine’ or 
‘reflexive’ ordering. 
Investigative/diagnostic FBC tests 
GPs indicated that the most common purpose for ordering FBCs was 
investigative/diagnostic, accounting for half of FBC testing in this study. GPs 
recorded the differential diagnoses being assessed with these investigative FBCs. The 
differential diagnoses were most commonly haematological disorders (e.g. anaemia) 
and infections, which aligns with FBC test ordering recommendations in the 
literature.173,276,281,282,284,359-361,366 Weakness/tiredness was the most common problem 
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investigated with an FBC, but it accounted for only 12% of the investigative tests, 
reflecting the breadth of problems for which investigative FBC was ordered. The 
purpose of ordering FBC for weakness/tiredness was almost exclusively 
investigative, and the differential diagnoses recorded by GPs reflected those for 
which FBC testing was recommended in guidance documents (see Chapter 5).  
Monitoring FBC tests  
Monitoring was the second most common reason GPs ordered FBC tests, 35% of 
them being ordered for this purpose. The need to monitor the FBC in management of 
diseases where the result of the test directly reflects the disease status (e.g. anaemia, 
infections231,366) is logical. In contrast, the reason for monitoring FBC in the 
management of hypertension, Type 2 diabetes and lipid disorders is unclear because 
the FBC result is unlikely to monitor variables directly related to these diseases. GPs 
indicated the main purpose of ordering FBCs for these conditions was monitoring, 
confirming the hypothesis I made in Chapter 5, that GPs’ use of FBC tests for these 
conditions was for monitoring. 
Monitoring tests for these three problems accounted for one-third of all monitoring 
FBCs. As discussed in Chapter 5, guidelines for these conditions do not recommend 
FBC monitoring. It is possible that for patients with chronic conditions, GPs’ ordered 
FBC tests opportunistically. For example, if patients have comorbidities (such as 
anaemia) which require FBC testing, that were not managed at the current encounter, 
GPs may have ordered the test opportunistically when ordering other pathology tests 
for the condition under management. However, this may well not be the case. Further 
investigation is needed to gain a better understanding of the reasons GPs order FBC 
tests. 
FBCs were ordered frequently when ordered for monitoring, patients being 
monitored were significantly more likely to have been tested within the previous 
12 months (76%) than those ordered for other purposes (45%). It is unclear whether 
or not this represents an ideal monitoring interval because no general information is 
available to Australian GPs about use of FBC tests for monitoring. 
I could find only one document giving GPs guidance on the use of the FBC test and 
the follow-up of abnormal FBC results.366 This New Zealand document provided 
consensus-based guidance on interpretation and follow-up of minor abnormal results 
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of the components of the FBC, because this was an area in which GPs indicated they 
needed guidance. As such, the guidance it contains is more relevant to FBCs ordered 
for investigative/diagnostic purposes than those ordered for monitoring. 
It may be too difficult to provide general recommendations about FBC monitoring 
because the ideal frequency of monitoring will be influenced by the characteristics of 
the individual patient, the problem being monitored, and the expected variation of the 
test.366 Data on ideal monitoring intervals and interpretation of repeated FBC testing 
may be included in the guidance documents for the individual problems for which 
monitoring FBCs were ordered rather than in the general literature. However, as 
discussed above, this was not the case for hypertension, Type 2 diabetes and lipid 
disorders. 
Given the volume of FBC tests ordered by GPs for monitoring it is of concern that 
there is no published guidance available to GPs on what constitutes the best 
monitoring strategy. There is also limited guidance available on the interpretation of 
monitoring FBC tests. As such, GPs would be guided by their clinical experience 
when ordering and interpreting FBCs used for monitoring. There is a need for 
guidance on the use of FBCs for monitoring, particularly for chronic disease.  
Preventive FBC tests 
GPs reported a purpose of primary or secondary prevention for 13% of FBCs ordered 
in this study, a proportion small enough to challenge the assumption that FBCs are 
usually used as a screening test.221,352,353 The use of FBCs for primary or secondary 
prevention was not supported in guidelines for preventive care (see Section 5.7). 
Similarly, studies investigating routine use of the FBC for case finding (i.e. primary 
prevention) in outpatient care recommended against the use of the FBC for this 
purpose because it generates a very low diagnostic yield (less than 1% of tests 
identified new cases of disease).352,353 Given this lack of support for FBC as a 
preventive test it is reassuring that it was not the main reason for GPs’ use of the 
FBC test. However it represents an area in which FBC ordering may be 
inappropriate.  
The ‘health check’ in general practice is considered a preventive care activity. 
Therefore, it was expected that FBCs ordered for ‘health check’ patients would be 
ordered for preventive purposes. While this was the case for 36% of FBC tests 
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(primary prevention 27%, secondary prevention 9%), GPs also frequently reported 
monitoring (27%) and investigation (23%) as the purpose(s) of ordering FBCs for 
health checks. 
The variety of purposes given for ordering FBCs for health check problems may 
indicate that the patients receiving health checks were not ‘well’ patients. They may 
have had symptoms requiring investigation with a FBC test or a disease (or history of 
disease) for which monitoring with a FBC was indicated. Caution is needed in 
interpreting the purpose of FBCs ordered for health checks as there were small 
numbers of health checks recorded in this study. However, the results demonstrate 
that the reason for ordering a test for a problem that is considered preventive cannot 
be assumed to be for prevention. If an intervention was implemented to discourage 
GPs from using FBC tests for preventive purposes, then targeting preventive health 
problems (such as the health check) to deliver this intervention would not be an 
effective strategy.  
Due to the high volume of FBC tests ordered by GPs, the 13% ordered for prevention 
equated to approximately 1.4 million FBC tests ordered in Australia in 2008–09, a 
considerable volume of tests nationally that were not supported by current evidence-
based guidelines. 
Reducing the ordering of FBCs for prevention has the potential to substantially 
decrease the volume of FBC tests. But this will not necessarily translate directly into 
reduced cost of FBC tests funded through Medicare because of the coning funding 
rule (approximately 45–55% of FBCs ordered by GPs were ‘coned out’ and therefore 
were not Medicare-funded19,346). It is unclear whether a similar proportion of FBCs 
ordered for prevention would be coned out. The argument about effectiveness of any 
future intervention aiming to reduce inappropriate FBC ordering must be based on 
the ability of the intervention to improve quality of ordering rather than cost-
effectiveness. The cost-effectiveness argument does not hold in this instance due to 
the coning effect. However, reduction of FBC ordering for prevention represents an 
opportunity to improve the quality of pathology ordering and has the potential to 
generate savings in terms of resource use and manpower required for this testing. 
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Lipid testing 
Pattern of use of lipid tests 
GPs ordered lipid tests most frequently at encounters with adult patients aged  
45–64 years, followed by those aged 65–74 years and 75 years and over. The peak in 
testing in middle age reflects the age group in which lipid levels in the population are 
at their highest;367 and the age from which lipid screening is recommended for 
cardiovascular risk assessment.176,177 It also reflects the age group targeted by MBS 
items for health assessments in patients at risk of chronic disease.18,232 
GPs ordered lipid testing more often at encounters with male patients than at those 
with females. This may be due to the increased risk of cardiovascular disease177,237 
and mortality in males in the population compared with females.368 However, there 
were no corresponding sex-specific differences in the prevalence of dyslipidaemia or 
other conditions requiring management of lipid levels in patients attending general 
practice.209 This suggests that the difference seen in this study was not due to 
differences in the sex-specific prevalence of disease requiring lipid management.  
However, differences in sex-specific attendance patterns in general practice may 
explain some of the difference in rates of lipid testing. Men visit GPs less frequently 
than women,369 and so to maintain a comparable level (by sex) of lipid screening in 
the patient population, GPs would have to test males at a higher proportion of their 
attendances than females. The data imply that GPs are being proactive in ensuring 
male patients have their lipid levels tested rather than suggesting that females are 
being tested at a lower rate, and it is therefore unlikely that the difference is of 
concern. 
GPs ordered lipid tests for a relatively focussed group of problems compared with 
the breadth seen for FBC tests. Lipid disorders, hypertension, Type 2 diabetes, and 
health checks accounted for 55% of lipid testing, and the majority of these tests were 
ordered for monitoring. This is not surprising as guidelines recommended that the 
best practice management of each of these problems requires assessment of lipid 
levels and, if necessary, their subsequent management and monitoring (see 
Sections 5.4–5.7). 
The most common reason for testing lipid levels was for monitoring of an existing 
disease, recorded for almost 60% of lipid tests. Other purposes for ordering lipid tests 
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were also commonly recorded: an investigative/diagnostic purpose was recorded for 
18% of lipid tests; primary prevention for 18%, and secondary prevention 18%. It 
was possible for GPs to record multiple purposes, and this occurred most often when 
testing for secondary prevention, with half also having ‘monitoring’ recorded as a 
reason for ordering. 
Monitoring of lipids 
GPs ordered lipid tests for monitoring more frequently than for other purposes, and 
generated approximately 5.6 million orders for monitoring lipid tests in 2008–09. 
The majority (59%) of lipid monitoring by GPs in the current study was repeated at 
an interval of 3–6 or 7–12 months, indicating that GPs are following current 
guideline recommendations that advocate 6–12 monthly monitoring (see 
Section 5.6). 
Recent evidence from two studies suggests that monitoring lipid levels at an interval 
of less than 3 years is likely to represent measurement error, rather than true change, 
because the signal-to-noise ratio in cholesterol testing is weak.226,349 In other words, 
the amount of short-term biological and analytical variation (noise) makes it difficult 
to detect small changes in cholesterol levels (signal) when tests are repeated too 
frequently.  
Only one of the above studies was published prior to the conduct of the current 
study. Glasziou et al. used data from the ‘LIPID’ clinical trial, and recommended that 
among patients in whom lipid levels are stable (within 0.5 mmol/L of target) the 
interval for monitoring should be every 3–5 years.226 A move toward such a testing 
interval would represent a major change to GPs’ current lipid monitoring practices. 
The fact that this represents a change to GPs’ existing behaviour is of itself a barrier 
to the adoption of the new evidence.321 
One of the commonly stated barriers to adoption of guideline recommendations is 
disagreement with the evidence or lack of applicability of the evidence to the patient 
population.153,316-319,321 This includes the perception that clinical trial evidence does 
not reflect the real world clinical setting. This ‘barrier’ can be applied to the LIPID 
trial: it included patients had a history of acute coronary syndrome, who were taking 
pravastatin and had high total cholesterol.226 Using the first criteria alone—acute 
coronary syndrome—would represent (at most) 12% of general practice patients in 
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the current study, assuming that all patients who had an ‘other cardiovascular 
disease’ had an acute coronary syndrome. GPs may be hesitant to adopt this new 
evidence, perceiving that the study findings would be relevant to a small minority of 
their patients. 
The second study that recommended an interval of at least 3 years between repeated 
lipid measures was conducted in Japan and published in 2010. Takahashi et al.349 
investigated the signal-to-noise ratio of lipid measures taken in adults receiving an 
annual health check-up (excluding those who were taking a lipid lowering 
medication), and provided further evidence supporting the recommendation for a 
longer interval between repeated lipid measures in a broader group of patients.349 
GPs’ may accept this ‘real world’ evidence more readily than the clinical trial data 
from the earlier study. Takahashi’s study was published after my research was 
completed, therefore I could not measure its subsequent impact (if any) on GPs’ 
ordering behaviour. GPs have been shown to adopt new evidence in their pathology 
ordering behaviour quickly (before it is incorporated in guidelines).88 However, to do 
so they need to trust the evidence itself, and its applicability to their 
patients.153,316,317,319-321 
Another factor is that GPs may believe that monitoring lipid levels has an effect on 
patient behaviour. The outcomes of testing in terms of patients’ emotional, social, 
cognitive and behavioural responses to testing are not well studied.63 It is possible 
that these outcomes could be beneficial to the patient (such as, improved adherence 
to medication, reassurance) or detrimental (such as increased anxiety).63 
Numerous studies have shown that patient adherence to lipid lowering medications, 
particularly statins, is poor and decreases over time.370-372 For example, non-
adherence of statins in patients aged 65 years and over were 38%, 42% and 56% 
after 1 year, 2 years and 5 years respectively.371 Patient adherence is important to 
ensure the health benefits of lipid lowering medication are realised and cost-
effectiveness is maintained.370,373,374  
Thus patient adherence to medication is a valid concern for GPs, but it is unclear 
whether monitoring lipids will improve adherence. A few studies have shown an 
association between lipid testing (monitoring) and improved adherence to lipid 
medication, but the causality of this relationship is unproven.375 The results of 
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monitoring lipid tests have been found to have only limited ability to detect patients’ 
lipid medication adherence.355 Hence it appears that the action of monitoring may 
have an effect on patient adherence even though the results of these tests may not 
accurately measure adherence.  
Despite the lack of robust evidence, guidelines for the management of lipid disorders 
recommend frequent monitoring of lipid levels as a tool to improve patient adherence 
to therapy.178,220 GPs may be guided by these recommendations and their clinical 
experience of whether or not testing has a desirable impact on patient adherence. 
The extent to which a change in the lipid testing interval would influence the volume 
of lipid tests analysed in laboratories can be seen in a UK study. Doll et al. found that 
if lipids were tested only once every 3 years then 79% of the lipid tests ordered in 
primary and secondary care in 2005–07 would not have been needed. Alternatively if 
lipid levels were tested once per year, as recommended for high risk patients in 
guidelines, then 42% of lipid tests would not have been needed.367 The current study 
shows that most patients (84%) for whom GPs ordered lipid tests had cardiovascular 
conditions or risk factors for which current guidelines recommend annual testing. 
Therefore the lower estimate is likely to be a closer reflection of the amount of lipid 
testing that may be surplus in general practice based on current guideline 
recommendations. 
The study by Doll et al. is likely to overestimate the amount of lipid testing that was 
‘unnecessary’ by applying a simple measure of repeat testing to all patients. Further 
details about these patients (such as their diseases, risk factors or the reason for 
ordering a lipid test) were not available, yet may have an influence on the ideal 
interval between repeated testing. The longer interval of 3-5 yearly testing was not 
recommended for all patients.226,349 It would only apply to patients being monitored, 
and the current study shows that only 60% of lipid tests were ordered for monitoring. 
Recommendations for a long interval between repeated testing would be applicable 
to only a subset of patients. Further research is needed to identify the subset of 
patients for whom GPs could implement a longer monitoring interval. 
Lipid tests ordered by GPs generate a substantial volume of testing—an estimated 
9.4 million lipid tests were ordered at GP encounters in Australia in 2008–09. Of 
these, 5.5 million were ordered for monitoring purposes. A change in monitoring 
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practices has the potential to substantially reduce the volume of lipid testing ordered 
by GPs. Further research is needed to determine: whether a lengthening in 
monitoring interval is acceptable to GPs and patients, for which subset patients this 
would be applicable, and whether it would adversely affect patient outcomes. While 
a reduction in volume of lipid testing generated by GP orders would generate savings 
in terms of resources required for testing, the extent of cost savings to the MBS is not 
known because of the current iso-resource items and coning funding model. 
Limitations 
The lipid and FBC testing activity for patients aged 75 years and over may not be 
accurately assessed in the study due to an under-representation of patients in this age 
group.  
In this study, the definition of secondary prevention provided to participating GPs 
was ‘screening in a patient with established risk factors for a condition but without 
the condition’ and was based on the definition of the US Preventive Task Force that 
states “secondary preventive measures identify and treat asymptomatic persons who 
have already developed risk factors or preclinical disease but in whom the condition 
has not become clinically apparent.”101 The definition used in this study should have 
stated that the patient had not already been diagnosed with disease rather than stating 
that the patient did not have the disease. There is some contention around the 
definition of secondary prevention throughout the literature and confusion about the 
application of these definitions.376,377 Therefore, readers may wish to combine 
primary and secondary prevention and view results as being indicative of FBC and 
lipid tests ordered for preventive purposes. 
The interval between FBC and lipid tests is a single measure of the time between the 
patient’s current and most recent FBC or lipid test. When the purpose of the test is 
monitoring this interval between FBC or lipid tests has been interpreted as the usual 
monitoring interval, but this may not reflect the patient’s regular pattern of testing.  
The FBC is a battery of tests which includes multiple components that are ordered 
together for convenience but have different clinical uses. The components of interest 
will vary based on the clinical situation. For example, when investigating anaemia 
the red cell count and red cell morphology are the components of interest. As such 
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the GPs’ purpose for ordering the FBC test may reflect only part of the included 
tests.  
Conclusion 
FBC is the most commonly ordered test in general practice, yet there was a 
surprising lack of data and guidance available about the use of the test. This study 
partially fills this gap by providing data about GPs’ use of FBC tests. GPs regularly 
ordered FBC tests for adult patients, for a broad range of problems, and most tests 
were ordered for investigative/diagnostic or monitoring purposes. Patients initiated 
only a small proportion of FBC tests, most of this testing being generated by the 
GPs’ judgement that testing was needed. 
There is a need for further research on the use of the FBC test for monitoring, 
including the situations in which it needs to be monitored, and the appropriate 
monitoring strategy. In contrast, FBC tests ordered for prevention represent a clinical 
use that is not supported in evidence-based guidelines. Prevention was not a major 
reason that GPs ordered FBCs, but due to the large volume of FBC tests ordered it 
represents a considerable number of tests that are potentially unnecessary, and is an 
area in which interventions could be targeted. Further, given the breadth of problems 
for which GPs’ ordered the FBC, it would be better to target an intervention at the 
test and purpose (e.g. FBC tests used for prevention) than at the use of the test for a 
particular problem.  
This chapter also describes GPs’ ordering of lipid tests, the second most frequently 
ordered test in general practice. Most lipid testing was generated by the GPs’ 
judgement that testing was needed. Lipid tests were ordered primarily for chronic 
problems, and most tests were ordered for monitoring purposes. New evidence 
suggests GPs may order monitoring tests more frequently than is needed. Introducing 
a longer interval between monitoring tests has the potential to significantly reduce 
the volume of lipid tests ordered by GPs. However, further research is needed to 
determine for which general practice patients this change in monitoring strategy 
could be applied, and to ensure it would not result in adverse outcomes for patients. 
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7 Predictors of GPs’ pathology 
ordering 
7.1 Background 
The increasing use and cost of pathology services in general practice in Australia,5 
and internationally,8-10 have prompted concern about the quality of GPs’ pathology 
ordering. In Chapter 5, I assessed quality of ordering by measuring the 
appropriateness of GP pathology ordering for selected morbidities. In this chapter I 
investigate factors that contribute to variance in GPs’ pathology ordering rates 
because the presence of variance among GPs is often regarded as an indicator of poor 
quality.  
The presence of considerable variance among GPs in their use of pathology testing 
services has been established in Australia and internationally.43-51,71-73,337 There is a 
huge range of reasons for which clinicians (including GPs) order pathology tests, 
including: diagnostic factors; therapeutic and prognostic factors; to monitor illness 
and drug therapy; for screening; patient-related factors; doctor-related factors; and 
policy and organisational factors.36,37,40,41 All of these factors have the potential to 
account for variance among GPs’ in terms of their pathology ordering and multiple 
factors may simultaneously influence this variance. Therefore studies seeking to 
investigate the variance among GPs’ ordering of pathology tests aim to determine the 
independent predictors of the variance, using multivariate analysis.43-51,71-73  
The most common factors investigated to identify the independent causes of 
variation are doctor-related factors or policy and organisational factors, followed by 
factors related to the patients. Other studies have found behavioural factors (such as 
GP attitude to risk and malpractice claims,378,379 and communication style380) 
independently influenced GPs’ pathology ordering behaviour, but these cannot be 
addressed through methods adopted in this thesis. The non-behavioural variables 
found to be independently associated with GPs’ pathology ordering are summarised 
below. 
Studies that found an association between GP sex and pathology testing reported that 
female GPs ordered more tests.43,46-48 In other studies there was a univariate 
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association between GP sex and pathology testing45,49,51 but with modelling this 
relationship disappeared44,45,49 or was unclear.51 Other studies did not test the 
influence of GP sex.50,71 
Increased GP age or more years of experience were found to be independent 
predictors of lower rates of pathology ordering in some studies.43-45 Others found a 
non-linear relationship between years of experience and testing in young GPs.46,48 In 
other cases no effect of GPs’ age or experience has been shown47,49 or it was not 
tested.50,71 
Country of graduation was found be a factor in some studies43,46,47 but not others.45 
An effect related to education was found in one study in which variation was related 
to the training hospital attended by young GPs,48 but ‘medical school attended’ did 
not have an effect in a separate study.49 This suggests a possible effect of training, 
but the consistency of this result is affected by the health system of the country being 
studied.  
Geographic location of the practice appeared to have an independent relationship 
with pathology ordering but the results were inconsistent as were the variables 
assessed. Rural areas were associated with lower47,49 and higher43,45 rates of testing. 
A relationship between increased distance to laboratory and lower rates of testing 
was found in one study46 but not another.50 Associations with size of the local 
population,46 geographic region50 and country51 have also been found. 
The number of GPs working at a practice was associated with higher45 and lower50 
rates of pathology ordering. A number of other GP variables were found to be 
independently associated with testing. Examples include: involvement with guideline 
development,50 number of auxiliary staff,46 and use of problem orientated order 
forms.50 These were not frequently investigated in studies and may reflect 
associations unique to the study population.  
In some studies, the type of work or workload associated with pathology ordering 
was assessed at an aggregated level and related to the GP. Factors associated with 
increased testing were high frequency of visits per patient,44 high proportion of 
(age-adjusted) patients,47 higher proportion of services performed in the office 
(versus the hospital),49 lower rates of psychotherapy services,49 and higher rates of 
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long (Level C) Medicare consultations.45 These variables may reflect differences in 
pathology testing based on the types of patients seen by GPs.  
Most authors incorporated patient age and sex in their studies but only a small 
number measured the effect of this on variation in GPs’ pathology ordering. Patient 
age was incorporated in most,43-47,49,51,72,73 but not all50,71 studies. Older patients were 
independently associated with more testing,43,46 as was management of patients aged 
15–64 years.45 Hartley et al. found age a predictor of pathology testing but did not 
describe the nature of the relationship.73 
Similarly, patient sex was incorporated in most,43-46,49,51,72,73 but not all47,50,71 studies. 
Management of female patients was independently associated with higher testing 
levels in some studies43,46 and had no effect in others.45,73 
Ferrier et al. incorporated the proportion of female patients aged 15–49 years in their 
study and found this group of patients were independently associated with higher 
rates of testing. Two studies adjusted the outcome measure of the study (rate of 
pathology testing) by patient age and sex.44,51 
Adjustment for patient morbidity was only made in three studies.45,72,73 In one of 
these studies the amount of variation explained by morbidity was not stated.72 
However, in the other two, it was the variable that accounted for the greatest 
proportion of variation in GPs’ pathology ordering.45,73 In many studies it is possible 
that data about patient morbidity was not available. Despite this lack of data, some 
authors have assumed that casemix has little effect and variability is due to the 
individual GPs’ clinical requesting practices.50 
Some of the studies investigating variation in GPs’ pathology ordering did not 
specify the variables that were significant predictors or did not describe the nature of 
the relationship, instead stating that a relationship existed.44,51,72,73 In another study 
the multivariate model did not identify any statistically significant predictors of GPs’ 
pathology ordering.71 
There is some inconsistency between studies in the variables found to be 
independently associated with GPs’ pathology ordering. There are several possible 
causes for this inconsistency. The outcome variable used in the studies varied. 
Outcomes used include: total pathology ordering per GP; 43-46,71,73 rates of pathology 
adjusted by patient age-sex;51 ordering rates of a selected group of the most common 
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individual tests;47,50 a mixture of pathology and imaging tests;46,50,72 ratio of 
pathology services to all services claimed by the GP;48 quintiles of GPs’ testing from 
low to high;47 number and cost of tests per patient;49 and presence or absence of 
testing (i.e. a binary variable).72 To some extent these outcome measures were due to 
differences in the data sources used, such as laboratory data,47,50,71 billing data,43,48,49 
and data collected at the GP encounter.44-46,51,72,73 
Further, the number of variables included in multivariate analyses differed 
considerably and this also may be due, in part, to the source data. In particular, the 
lack of inclusion of morbidity or casemix variables in the studies may reflect data 
limitations.  
Authors often had a narrow objective or specific hypothesis that the study was 
designed to address (e.g. to assess the effect of attending medical schools of different 
universities49), in terms of determining whether a specific variable was an 
independent predictor of pathology ordering.46,48-50 In some cases this led to authors 
choosing a limited number of variables to include in the multivariate models, but the 
basis for selection was not provided.49,50 Consequently variables were omitted that 
others had found were independent predictors of variation (such as GPs’ sex50) even 
when these variables were available in the data set.50 This calls into question the 
quality of some of the models used. 
Several studies involved a local sample44,46,48,49,71-73 and/or were not representative of 
the GP population within the respective country.46,48-51,72 In addition, the majority of 
studies were either published more than 10 years ago, or, though published more 
recently, used data more than 10 years old,43,44,46,48-51,71-73 and can be considered out 
of date. The limitations of previous studies, including inconsistent methodology, 
poor quality of the multivariate models, lack of representativeness and age of the 
data severely limit their reliability. 
Only two studies included data that were collected since 2000 from nationally 
representative samples.45,47 The most recent of these was conducted by Vinker et al. 
in Israel in 2003 using laboratory data for 16 common pathology tests ordered by 
primary care physicians.47 The limited number of tests, lack of data on morbidity and 
differences in health systems between Israel and Australia meant that this study 
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could not provide a reliable indication of factors likely to account for variation in 
GPs’ pathology ordering in Australia.  
The second study used data collected in the BEACH study (the same study as used in 
this thesis) from a representative Australian sample in 1998–2001 to investigate 
variation in GPs’ pathology ordering.45 This previous BEACH study is relevant and 
relatively contemporary. However, there has been significant growth in the rate of 
GPs’ pathology ordering since the study was done—it increased by 31%, from 29.7 
tests/batteries of tests per 100 encounters in 2000–01 to 43.2 in 2007–08.273 Due to 
this growth, and the limitations of previous research, I have investigated predictors of 
GP pathology ordering in this thesis. Identifying factors that are independent 
predictors of pathology ordering has the potential to inform future patterns of 
pathology ordering, particularly if these predictors relate to expected changes in the 
characteristics of the GP workforce and population characteristics. 
7.2 Objective 
This chapter investigates the extent to which the variance in GPs’ pathology ordering 
rates can be explained by a number of factors including GP, practice, and patient 
characteristics, the clinical problem under management, and the type of encounter.  
7.3 Method 
The simple and multiple regression analyses were performed on data collected in 
BEACH from April 2007 to March 2008. In these analyses the GP was the unit of 
analysis and the outcome variable was total number of pathology tests/batteries of 
tests ordered per GP—referred to as rate of GP pathology ordering throughout this 
chapter. The statistical software package SAS 9.1.3129 was used for univariate and 
multivariate analyses.  
The data were unweighted because the variables used for weighting (GP age and GP 
sex) were adjusted for in the analyses (see Section 3.2.10).  
In BEACH, problems under management and pathology tests ordered are coded at 
the GP terminology level using ICPC-2 PLUS and classified to the ICPC-2 (see 
Section 3.2.7). In this chapter problems managed were analysed at the classification 
chapter level using the 17 ICPC-2 chapters. As the analysis conduced in this chapter 
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investigates GPs’ total pathology ordering, the types of pathology tests ordered by 
GPs were not investigated.  
Simple linear regression was used to determine the proportion of variance in GP 
pathology ordering rates explained by each individual variable. Explanatory 
variables investigated are listed by ‘family’ in Box 7.1.  
Variables listed in Box 7.1 were included in both the univariate and multivariate 
analysis, except where variables were highly correlated. This was the case for GP age 
and years in general practice, hence only GP age was fitted in the multivariate 
analysis. 
In the analysis of variance, most variables were assigned a reference group. This 
group (or category) is clearly labelled for each variable in the results, and results are 
interpreted in relation to the reference group. However, a static reference group was 
not assigned for three variables: proportion of encounters by patient age, rate of 
problems managed in each ICPC-2 chapter, and the proportion of encounters with 
MBS item consultations classified as level A, B, C and D. Instead, for these 
categorical variables, each category was compared with the remainder of the 
categories in that variable. In effect the ‘remainder of the categories’ becomes the 
reference group to the category being examined. For example, when investigating the 
variance explained by MBS consultation levels: level A MBS consultations are 
compared with, as one group, level B, C and D consultations; level B MBS 
consultations are compared with level A, C and D consultations, and so on. 
Multiple regression using stepwise (backward) elimination was used to find the 
independent predictors of GP pathology ordering rates. Predictor variables were 
fitted into the model in ‘families’ in the following order: GP demographics, practice 
characteristics, consultation type, patient demographics, and problems managed. The 
model was reduced by each family in turn, starting with problems managed, 
adjusting for all other families. Variables within problems managed were kept if 
significant (alpha=0.05) or improved the fit of the model. The next family (patient 
demographics) was then reduced, and so on, until all retained variables are (to some 
degree) significant.381 
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Box 7.1: Variables included in univariate and multivariate analysis 
• GP characteristics 
– Sex  
– Age 
– Years in general practice 
– Fellowship of the Royal Australian College of General Practitioners 
(FRACGP) (yes/no)(a) 
– Workload (number of sessions worked per week)(a) 
– Country of graduation (international medical graduates)(a) 
• Practice characteristics 
– Size of practice (number of full-time [FTE] equivalent GPs)(a) 
– State or Territory of practice location  
– Rurality of practice location using the Australian Standard Geographical 
Classification (ASGC) remoteness areas(a) 
– Accreditation‡ status (yes/no) 
– Teaching status (undergraduate or registrar training) (yes/no)(a) 
• Patient characteristics 
– Proportion of encounters by patient sex 
– Proportion of encounters by patient age 
– Proportion of encounters with new patients‡ 
– Proportion of encounters with patients with a health concession card‡  
(Health care card‡ or Repatriation health card‡) 
• Problems managed 
– Rate of problems managed in each ICPC-2 chapter‡ 
• Consultation type 
– Proportion of encounters with MBS GP consultation service items classified 
as level A, B, C and D.‡  
(a) These variables are described in the data elements section of the method (Section 3.2.5). 
‡ Definition of term is included in glossary. 
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7.4 Results  
7.4.1 The sample 
A total of 953 randomly sampled GPs participated in BEACH in 2007–08 and 
recorded data about 95,300 encounters.  
The representativeness of the GPs and encounters sampled in 2007–08 has been 
demonstrated and published elsewhere.121 The assessment of representativeness of all 
annual BEACH samples included in this thesis are discussed in detail in 
Section 3.2.10. In summary, in 2007–08, the sampled GPs were representative of 
Australian GPs in the sample frame in terms of their sex, age, and distribution across 
states. However, participants who graduated in a country other than Australia were 
slightly under-represented (26.5%) when compared with the total sample (30.2%) 
(2 = 5.72, p = 0.017).121  
The age-sex distribution of patients at BEACH encounters where MBS general 
practice consultation service items were recorded as claimable was compared with 
that of patients at all Australian encounters claimed as MBS general practice 
consultation service items in the 2007–08 study period. There is an excellent fit of 
the MBS and BEACH age-sex distribution, with no age-sex category varying by 
more than 15% from the population distribution. The range of precision ratios  
(0.91–1.14) indicates that the BEACH sample of encounters is a good representation 
of Australian GP–patient encounters.121 
GPs who participated in BEACH in 2007–08 ordered 45,597 pathology 
tests/batteries. An average of 47.8 pathology tests/batteries were ordered per GP per 
100 encounters (standard deviation: 29.6), and 95% of GPs ordered between 9 and 97 
pathology tests/batteries per 100 encounters (Table 7.1). The outcome variable (rate 
of GP pathology ordering) showed a normal distribution (results not shown). 
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Table 7.1: Description of pathology ordering per 100 encounters with GPs 
Variable  
Number of pathology tests per 100 
encounters from each GP 
(n = 45,597 tests/batteries of tests) 
Mean (standard deviation) 47.8 (29.6) 
Range 0–263 
Percentile of distribution  
 5% 9 
 25%–1st quartile  27 
 50%–Median 43 
 75%–3rd quartile 64 
 95% 97 
 
7.4.2 Univariate analysis 
The results of the univariate analysis are shown in Table 7.2. The number of GPs 
analysed for each variable differs due to the removal of missing data, and the number 
used in the analysis of each variable is specified. Of the 17 variables investigated, 15 
were found to be significant univariate predictors of GP pathology ordering rates 
when fitted alone. 
GP characteristics 
Female GPs had significantly higher pathology ordering rates than male GPs. 
Similarly those with Fellowship of the Royal Australian College of General 
Practitioners (FRACGP) had higher pathology ordering rates than their non-
FRACGP colleagues (Table 7.2). 
The rate of ordering decreased significantly with increasing age, GPs aged 55 years 
and over having the lowest ordering rates. Correspondingly, GPs with more than 
20 years experience in general practice had the lowest ordering rates. Lower rates of 
ordering were also generated by GPs with a high workload (more than 10 sessions 
per week) compared with GPs who worked 1–5 sessions per week, and those who 
obtained their primary medical degree in Asia compared with Australian graduates 
(Table 7.2). 
Practice characteristics 
Compared with GPs in small practices with less than 2.0 full-time equivalent (FTE) 
GPs, those in moderately sized practices (with 2.0–4.9 and 5.0–9.9 FTE GPs) had 
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higher rates of pathology ordering. GPs in practices that were accredited and in those 
that provided undergraduate and registrar training also had higher rates of ordering 
than their counterparts in non-accredited, and in non-teaching practices (Table 7.2). 
Location of practice by rurality was significantly associated with ordering rates. In 
particular, GPs in major cities had lower rates of ordering than GPs in inner and 
outer regional areas. The state or territory in which the GPs’ practice was located 
showed a statistically significant association with pathology ordering rates 
(p = 0.045), but this association was not reflected in any individual state or territory 
(Table 7.2). 
Patient characteristics 
Higher ordering rates were associated with management of female patients, and of 
patients aged 45–64 years compared with patients in all other age groups. In contrast, 
management of children (aged less than 15 years) was associated with lower ordering 
rates of pathology (Table 7.2). 
Problems under management 
Higher rates of ordering were associated with management of problems classified in 
the following ICPC-2 chapters (in order of predictive value): female genital; 
endocrine, metabolic and nutritional; general and unspecified; urological; blood and 
blood-forming organs; pregnancy and family planning; psychological; circulatory; 
digestive; male genital; and social. Management of problems classified as respiratory 
was associated with lower pathology ordering rates (Table 7.2). 
Types of consultations 
General practice consultations claimable as standard (level B) were associated with 
lower ordering rates, whereas those claimable as long (level C) or prolonged 
(level D) were associated with higher ordering rates (Table 7.2). 
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Table 7.2: Univariate analysis of GP pathology ordering(a)  
Variable  
Regression 
Coefficient 
Effect size 
(standard Beta) 
Per cent of 
variance 
explained 
(R2*100) P value 
GP characteristics     
Sex (n = 945)  
(reference = Male) . . . . 10.86 <0.001 
 Female 20.18 0.33 . .  
Age (n = 953)  
(reference = < 35 years) . . . . 5.44 <0.001 
 35–44 years  -8.07 -0.11 . . 0.039 
 45–54 years -9.83 -0.16 . . 0.008 
 55+ years -21.72 -0.35 . . <0.001 
Years in general practice (n = 946) 
(reference = 1–4 years) . . . . 2.59 <0.001 
 5–9 years  -1.65 -0.02 . . 0.675 
 10–19 years -2.48 -0.03 . . 0.490 
 20+ years -11.14 -0.19 . . 0.001 
FRACGP (n = 948)  
(reference = FRACGP) . . . . 0.81 0.006 
 Not FRACGP -5.32 -0.09 . .  
Workload (n = 944)  
(reference = 1–5 sessions per week) . . . . 1.65 <0.001 
 6–10 sessions per week -6.55 -0.10 . . 0.015 
 11+ sessions per week -15.07 -0.16 . . <0.001 
International medical graduate (n = 950) 
(reference = Australian graduates) . . . . 2.49 <0.001 
 UK / Ireland / New Zealand -5.21 -0.05 . . 0.136 
 Asia -15.52 -0.16 . . <0.001 
 Other -1.91 -0.02 . . 0.577 
Practice characteristics     
Size of practice (number FTE GPs) (n = 930) 
(reference < 2 FTE GPs) . . . . 3.54 <0.001 
 2.0–4.9 9.36 0.16 . . 0.001 
 5.0–9.9 14.87 0.23 . . <0.001 
 10+  0.93 0.01 . . 0.811 
 (continued) 
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Table 7.2 (continued): Univariate analysis of GP pathology ordering(a)  
Variable  
Regression 
Coefficient 
Effect size 
(standard Beta) 
Per cent of 
variance 
explained 
(R2*100) P value 
Location by state/territory (n = 952) 
(reference = Australian Capital Territory)  . . . . 1.51 0.045 
 New South Wales 8.25 0.13 . . 0.323 
 Victoria 10.55 0.16 . . 0.209 
 Queensland 16.72 0.22 . . 0.049 
 South Australia 10.27 0.10 . . 0.239 
 Western Australia 16.52 0.15 . . 0.063 
 Tasmania 11.22 0.07 . . 0.254 
 Northern Territory 18.60 0.08 . . 0.101 
Rurality of practice by ASGC (n = 952)
(reference = Major cities) . . . . 1.04 0.007 
 Inner/outer regional 6.70 0.10 . . 0.002 
 Remote/very remote 6.90 0.03 . . 0.340 
Accreditation (n = 948) 
(reference = accredited practice) . . . . 1.27 0.001 
 Not accredited -9.71 -0.11 . . . . 
Teaching practice (n = 948) 
(reference = teaching practice) . . . . 1.80 <0.001 
 Not a teaching practice -7.99 -0.13 . . . . 
Patient characteristics     
Sex (n = 953)  
(reference = Female) . . . . 11.87 <0.001 
 Male patients -0.75 -0.34 . . . . 
Age (n = 953)     
 Patients < 5 years -0.49 -0.09 0.85 0.004 
 Patients 5–14 years -1.46 -0.20 4.07 <0.001 
 Patients 15–24 years -0.23 -0.05 0.25 0.123 
 Patients 25–44 years 0.06 0.02 0.04 0.524 
 Patients 45–64 years 0.40 0.11 1.25 0.001 
 Patients 65+ years 0.05 0.03 0.09 0.352 
Health concession card (n = 940)  
(reference = no card) . . . . 0.39 0.054 
 Health concession card holders -0.08 -0.06 . . . . 
New patient (n = 953)  
(reference = not new patient) . . . . 0.16 0.222 
 New patients -0.10 -0.04 . . . . 
(continued) 
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Table 7.2 (continued): Univariate analysis of GP pathology ordering(a)  
Variable 
Regression 
Coefficient 
Effect size 
(standard Beta) 
Per cent of 
variance 
explained 
(R2*100) P value 
Rate of problems managed (ICPC-2 
chapter) (n = 953)     
 General and unspecified (A chapter) 0.90 0.31 9.56 <0.001 
 Blood and blood-forming organs  
(B chapter) 3.11 0.23 5.13 <0.001 
 Digestive (D chapter) 1.07 0.16 2.68 <0.001 
 Eye (F chapter) 0.47 0.03 0.08 0.385 
 Hearing (H chapter) -0.35 -0.03 0.08 0.372 
 Circulatory (K chapter) 0.45 0.17 2.77 <0.001 
 Musculoskeletal (L chapter) 0.06 0.02 0.04 0.562 
 Neurological (N chapter) 1.27 0.10 1.01 0.002 
 Psychological (P chapter) 0.62 0.19 3.43 <0.001 
 Respiratory (R chapter) -0.57 -0.17 2.98 <0.001 
 Skin (S chapter) 0.11 0.04 0.18 0.185 
 Endocrine, metabolic and nutritional 
(T chapter) 1.42 0.41 16.6 <0.001 
 Urological (U chapter) 3.13 0.23 5.35 <0.001 
 Pregnancy and family planning  
(W chapter) 1.18 0.20 4.00 <0.001 
 Female genital (X chapter) 1.57 0.44 18.96 <0.001 
 Male genital (Y chapter) 2.55 0.15 2.20 <0.001 
 Social (Z chapter) 2.33 0.11 1.28 0.001 
MBS item(b) (n = 942)     
 Level A – short -0.02 -0.00 0.00 0.959 
 Level B – standard -0.25 -0.17 2.85 <0.001 
 Level C – long 0.93 0.36 12.78 <0.001 
 Level D – prolonged 2.76 0.25 6.42 <0.001 
(a) Missing data were removed from the analysis. There were 953 GPs in the total sample and the numbers available for 
each variable are specified next to the variable label. 
(b) The MBS items are content-based GP consultation descriptors ranging from Level A (attendance for an obvious 
problem, no time specifications) to D (exhaustive consultation, minimum of 40 minutes) see glossary. 
Note: FRACGP – Fellowship of the Royal Australian College of General Practitioners; ASGC – Australian Standard 
Geographical Classification; ICPC-2 – International Classification of Primary Care, Version 2; MBS – Medicare 
Benefits Schedule. Also see glossary.  
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7.4.3 Multivariate analysis 
The independent predictors of pathology ordering rates are shown in Table 7.3. The 
final model explained 50.4% (F21,880=42.65, p <0.001) of the variance in GPs’ 
pathology ordering. This model included data from 902 GPs (94.6% of the original 
sample), for whom all data variables were complete. Of the 16 variables investigated, 
nine were found to be significant multivariate predictors of GP pathology ordering 
rates, results for which are described below. 
GP characteristics 
The association with GP sex and age seen in the univariate analysis persisted after 
adjusting for all other variables in the model. After adjustment, female GPs had 
significantly higher pathology ordering rates than their male counterparts, whereas 
GPs aged 45 years and over (particularly those aged 55 years and over) had lower 
ordering rates relative to GPs aged less than 35 years. In contrast, the association 
with workload and country of graduation found in the univariate analysis did not 
persist after adjustment (Table 7.3). 
Practice characteristics 
The effect of practice size and rurality persisted after adjustment. GPs in moderately 
sized practices with 5 to 10 FTE GPs had higher rates of ordering than those in 
practices with less than 2 FTE GPs. GPs in practices located in inner and outer 
regional areas had higher order rates than those in major city practices. However, the 
effect of state/territory of practice location, and medium practice size (2.0–4.9 FTE 
GPs) were no longer significant after adjustment (Table 7.3). 
Patient characteristics 
Although not significant in the univariate analysis, after adjustment, management of 
new patients was associated with higher ordering; and management of patients with a 
health concession card was associated with lower ordering. This suggests the effect 
of each of these variables on pathology ordering was associated with other variables 
in the model (Table 7.3). 
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Both before and after adjustment, management of patients aged less than 5 years was 
associated with lower ordering rates. The effect of the proportion of female patients 
and patients aged 45–64 years did not persist in the multivariate analysis (Table 7.3).  
Problems under management 
In the multivariate analysis, higher rates of ordering were associated with 
management of problems classified in the following ICPC-2 chapters: (in order of 
predictive value) endocrine, metabolic and nutritional; male genital; general and 
unspecified; female genital; urological; and blood and blood-forming organs 
(Table 7.3). 
The effects of the management of problems classified as pregnancy and family 
planning, circulatory, respiratory, psychological and social, identified in the 
univariate analysis were not significant after adjustment (Table 7.3). 
Types of consultations 
General practice consultations claimable as long (Medicare level C) and to a lesser 
extent those claimable as standard (level B) were independently associated with 
higher rates of pathology ordering. The effect of the proportion of prolonged 
(level D) consultations did not persist after adjustment (Table 7.3).  
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Table 7.3: Final multivariate model of independent predictors of GP pathology 
ordering(a) 
Predictor variables 
Regression 
coefficient 
T-Value 
(F-partial) P value 
Effect size 
(standard 
Beta) 
Unique 
variance 
(per cent) 
GP characteristics      
GP sex (reference = Male)      
 Female 5.86 2.92 0.004 0.10 0.48 
GP age (reference = < 35 years)      
 35–44 years -4.43 -1.52 0.129 -0.06 0.13 
 45–54 years -6.22 -2.23 0.026 -0.10 0.28 
 55+ years -13.37 -4.49 <0.001 -0.22 1.14 
Practice characteristics      
Practice size (reference = < 2 FTE GPs)      
 2.0–4.9 3.79 1.86 0.064 0.06 0.19 
 5.0–9.9 7.90 3.68 <0.001 0.13 0.76 
 10+ 1.54 0.53 0.594 0.02 0.02 
Rurality of practice by ASGC  
(reference = Major cities)      
 Inner/outer regional 6.22 3.73 <0.001 0.09 0.78 
 Remote/very remote 5.16 0.91 0.363 0.02 0.05 
Patient characteristics      
Patients < 5 years -0.40 -2.88 0.004 -0.08 0.47 
Health concession card holders -0.09 -2.81 0.005 -0.08 0.44 
New patients 0.19 3.02 0.003 0.08 0.52 
Rate of problems managed (ICPC-2 chapter)     
General and unspecified (A chapter) 0.53 6.96 <0.001 0.18 2.73 
Blood and blood-forming organs  
(B chapter)  1.18 3.54 <0.001 0.09 0.71 
Endocrine, metabolic and nutritional 
(T chapter)  1.10 11.23 <0.001 0.32 7.10 
Urological (U chapter)  1.21 3.63 <0.001 0.09 0.74 
Female genital (X chapter)  0.72 6.36 <0.001 0.20 2.28 
Male genital (Y chapter)  3.11 7.09 <0.001 0.19 2.83 
MBS item(b)      
Medicare level B – standard 0.11 2.56 0.011 0.07 0.37 
Medicare level C – long 0.35 4.18 <0.001 0.13 0.98 
(a) Missing data were removed from the analysis. 902 GPs had all data variables available and were included in the final 
multivariate data. 
(b) The MBS items are content-based GP consultation descriptors ranging from Level A (attendance for an obvious 
problem, no time specifications) to D (exhaustive consultation, minimum of 40 minutes) see glossary. 
Note: ASGC – Australian Standard Geographical Classification; ICPC-2 – International Classification of Primary Care, 
Version 2; MBS – Medicare Benefits Schedule. Also see glossary. 
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7.5 Discussion 
This study demonstrated that there was considerable variation among GPs in their 
use of pathology tests, with 95% of GPs ordering between 9 and 97 tests/batteries per 
100 encounters. This variation is consistent with that reported in other 
studies.44,46,47,50,51,72,82,337 The multivariate model used in this study explained just 
over half of the variance in the rate of GPs’ pathology ordering. A number of 
variables were found to be independent explanatory predictors of pathology ordering. 
The strongest was the type of problem under management, followed by variables 
related to the GP, the practice, the patients and the types of consultations. 
This study investigated variables that were independent predictors of the volume of 
GPs’ pathology ordering in Australia. While these variables do not explain the 
increase in GPs’ pathology ordering seen in recent years,5 comparison of results with 
those of previous studies can inform whether these independent predictors have 
changed over time or new predictors emerged that may have contributed to the 
increase. In addition, the significant predictors identified in the current study can be 
viewed in the context of expected changes in the characteristics of the Australian GP 
workforce and population to predict likely future pressures on the utilisation of 
health resources for pathology testing. 
GP characteristics 
GP sex and age were the only GP characteristics associated with pathology ordering 
after adjustment in this study. Female GPs were found to order significantly more 
pathology tests than their male counterparts. Previous studies have either found a 
similar result,43,46-48 or no independent association with GP sex.44,45,49 Reasons for 
this discrepancy are unclear, but differences in the models used in each of the studies 
may have contributed—particularly the extent to which patient characteristics and 
problems managed by GPs were included. For example, compared with male GPs, 
Australian female GPs manage significantly more encounters with female patients 
and consequently manage more female-specific problems, such as female genital 
checks for Pap smears.382 These factors are not independent of each other. Therefore, 
interpreting the effect of GP sex on pathology ordering reported in these studies after 
adjustment requires consideration of which variables were included in the 
multivariate model.  
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Of the four studies that found female GPs ordered more tests than male GPs, only 
two included adjustment for patient sex,43,46 and none adjusted for morbidity.43,46-48 
Three earlier studies found no association of pathology ordering with GP sex, all 
three included patient sex,44,45,49 and two also included morbidity in the multivariate 
models.44,45 Consequently, the only two earlier studies that adjusted for patient sex 
and morbidity (one of which was the previous study using BEACH data from 1998–
2001), as I did in this study, did not support the finding that female GPs ordered 
more pathology tests. However, a recent study investigating sex-specific differences 
in GPs’ practising style, using BEACH data from 2009–10, found that female GPs 
ordered more pathology tests after adjustment for patient sex and morbidity.382 This 
supports the findings of the current study, and suggests that a relationship between 
GP sex and ordering may have developed over time. 
GP age and years of experience are commonly related to GPs’ pathology ordering 
rates. Increasing age could be assumed to be synonymous with increasing 
experience. In this study age and experience were highly correlated, therefore only 
GP age was analysed—and found to be inversely associated, as age increased the rate 
of testing decreased. This supports the findings of three previous studies,43-45 two of 
which were representative Australian studies.43,45 In contrast, one representative 
international study found no effect of GP age or years since graduation on pathology 
testing.47 Other small studies either reported a non-linear independent effect46,48 or no 
effect49 of GP age on pathology testing after adjustment. 
In the context of the Australian GP workforce the relationship of GP sex and age to 
pathology ordering raises potential concerns. The GP workforce has become 
increasingly feminised and is ageing.16 In 2008, one-third of GPs were aged 55 years 
and over and 38.4% were female.16 There have been considerable efforts to increase 
the number of medical graduates entering general practice383 to replace the ageing 
workforce, and the majority (62% in 2008) of GP registrars (i.e. medical graduates 
currently training to become GPs) are female.383 The results of this study suggest this 
group of young female GPs could be expected to order disproportionately more 
pathology tests. Therefore, the focus on identifying gaps in GP registrars’ education 
about quality use of pathology services384 is timely. 
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Practice variables 
This study showed that GPs practising in rural locations classified as inner and outer 
regional areas ordered more tests than those in urban areas. This finding is consistent 
with two earlier Australian studies: one used BEACH data;45 and the other used MBS 
pathology billing data.43  
However, this finding was not echoed in international studies. In two of these, the 
opposite effect was found, with pathology ordering being higher in urban areas;47,49 
and in another, no association between rurality of practice and pathology ordering 
was found.50 The small geographic size of the country or region(s) investigated in 
these studies may explain differences in the effect of rurality on pathology ordering 
between the studies and compared with the current study.47,49,50 Some international 
studies assessed whether geographic location of the practice had an independent 
effect of pathology ordering using variables other than rurality (e.g. distance to 
laboratory from practice location), but a consistent effect did not emerge.46,50,51 
The effect of rural location in the current and past Australian studies43,45 is likely to 
be related to the frequency of GP–patient attendance in these areas. In 2006–07, 
fewer GP services per person were claimed through Medicare with increasing 
geographic remoteness,385 possibly related to lack of access in the more rural areas. 
The three Australian studies that reported higher ordering in rural areas (after 
adjustment) all used encounter-based data about GPs’ pathology ordering, and were 
therefore affected by attendance patterns (e.g. in encounter-based studies, the lower 
the rate of attendance the lower the likelihood of being sampled). A population group 
which attends less frequently (such as those living in rural areas), assuming a similar 
need for pathology, would be more likely to have pathology ordered because they 
have fewer GP visits in which the opportunity to order can arise. Therefore, it is 
unlikely the higher rate of pathology of GPs in rural locations seen in this study is a 
concern. However, this could be tested in future studies by adjusting for attendance 
patterns of patients in different rural areas or by using data not affected by attendance 
patterns. 
Australian GPs’ practising in larger practices had higher rates of pathology ordering 
than those in small practices in the current and past studies using BEACH data.45 In 
contrast, Verstappen et al.50 found that GPs in the Netherlands who worked in group 
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practices (> 2 GPs) ordered fewer tests than those in solo practice. No other studies 
investigated practice size as a predictor of pathology ordering.  
Verstappen et al.50 hypothesized that lower ordering in group practices was due to 
clinical support provided by the opportunity to discuss a case with colleagues. It is 
conceivable that the behaviour of peers could influence GPs’ pathology ordering 
behaviour. Several studies have used feedback comparing GPs’ test utilisation with 
their peers as part of interventions to improve quality of pathology ordering.82,92,96,386 
Often these interventions achieve a reduction in pathology ordering.92,96,386 However, 
it is possible that peer influence may be multi-directional, depending on the 
behaviour of peers. In the current study, GPs practicing in larger practices ordered 
more tests than those in smaller practices, and this may reflect exposure to colleagues 
with higher rates of pathology ordering behaviour. 
Another possible explanation for the effect of practice size is corporate ownership of 
general practices within Australia. General practices owned by corporations tend to 
be large and incorporate other health services (such as pathology and imaging 
services) which are also commonly owned by the corporation, in one medical 
centre.387,388 Since the mid 1990’s corporate ownership of general practices in 
Australia has increased, raising concerns about the potential for influence on GPs’ 
use of health services in which corporations have a shared interest.387-391 Catchlove 
acknowledged this risk, but argued there was no evidence that GPs’ service use had 
been unduly influenced by corporation status.388 Instead he believed that simply by 
locating health services together, the proximity would provide the opportunity for the 
corporations to profit from GP referrals without the need for inducements.388  
Studdert et al.392 sought to investigate whether proximity to the pathology industry as 
indicated by presence of pathology collection centres in or adjacent to the practice 
influenced GPs pathology ordering in Australia. During the data period for this study 
(2000–09) the number and distribution of these collection centres was regulated.393 
Due to this restriction they were commonly located in larger practices due to the high 
volume of patients. Studdert et al. found no independent effect of practice proximity 
to collection centres (in Sydney and Melbourne) on GP pathology ordering.392 While 
no evidence has emerged of inducements in regard to GPs’ pathology ordering, the 
concern about the potential390,391 for such led the Australian Government to 
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strengthen the legislation on activities that are (and are not) acceptable between 
requesters (such as GPs) and providers of pathology services to ensure no 
inducements are made in regard to pathology services.394  
Defining ‘corporate ownership’ in Australian general practice is difficult as there is a 
wide range of possible ownership models, and so the extent to which practice size 
represents corporate ownership is uncertain. If the higher pathology rate at larger 
practices represents higher rates of testing at practices that are corporate owned, this 
may be a concern. It must be kept in mind that this higher testing does not provide 
any measure of the quality of the pathology testing. It may be that larger practices, 
whether corporately owned or not, have more resources available to them to ensure 
that patients are tested appropriately (e.g. through patient recall for monitoring or 
preventive care). It is unclear why GPs in larger practices order more pathology tests. 
Further investigation is needed to determine what causes this effect and whether it 
represents a cause for concern. 
Characteristics of GP workload 
Variables related to the patient, the types of problems managed and types of 
consultations are all indicators of the GPs clinical workload.  
In the current study, after adjustment, GPs’ pathology ordering was not associated 
with management of patients of a particular sex, and only management of young 
patients (aged less than 5 years) was associated with lower rates of testing. This 
suggests that the significant effect of patient age and sex reported in the univariate 
analysis was counteracted by other variables in the multivariate model. In particular, 
there is likely to be an interaction between patient age, sex and problems that 
generate high volumes of pathology testing. For example, the management of sex-
specific problems classified to the female genital (such as Pap smear) and male 
genital (such as prostate problems) ICPC-2 chapters, together explained 5% of the 
variance in this study. The inclusion of sex-specific morbidities is likely to have 
contributed to negating any independent effect of patient sex on GPs pathology 
ordering. Therefore the fact that many studies did not incorporate patient and 
casemix characteristics, other than age and sex into multivariate models used to 
investigate independent predictors of pathology ordering should be borne in mind 
when comparing results of studies.  
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The results of the current study, when compared with those of past studies using a 
similar method and multivariate model (incorporating patient age, sex and morbidity 
variables, among others), support earlier findings that patient sex is not an 
independent predictor of GPs’ pathology ordering.45,73 However, there were not 
similar findings for patient age. The current study found management of young 
patients resulted in fewer tests and no age groups were associated with higher testing. 
In contrast, Britt et al. reported higher ordering associated with management of 
patients aged 15–64 years.45 Hartley et al.73 stated that patient age explained 3.3% of 
variation in British GPs’ pathology ordering but not which age groups explained the 
variation. 
Adjustment for patient age and/or sex was made in several other 
studies,43,44,46,47,49,51,72 but the effect of these variables was only reported in two of 
these.43,46 Kristiansen et al.46 and Calcino43 both reported that management of older 
patients and female patients were each independently associated with increased rates 
of pathology testing, but neither study incorporated morbidity in their analysis.  
In the current study the types of problems managed by GPs were the strongest 
predictor of GPs pathology ordering. Very few studies adjusted for patient morbidity 
in their investigation of independent predictors of pathology ordering. Yet the two 
past studies that did, also found that it was the strongest independent explanatory 
predictor of GPs’ rates of pathology ordering.45,73  
Management of problems related to the endocrine system, those of a general and 
unspecified nature, and those related to the male and female genital systems were the 
strongest problem predictors of higher pathology ordering rates. Management of 
problems classified to these four chapters explained almost 15% of the variance in 
GPs’ testing rates. 
The individual conditions in Chapter 4 that contributed to the majority of pathology 
tests ordered by GPs may provide some insight into the conditions within these 
chapters which have the greatest potential to explain the variation. For example, the 
conditions classified in the general and unspecified chapter include health check-ups, 
weakness/tiredness, abnormal test results and viral illness. The endocrine and 
metabolic conditions include diabetes, lipid disorders, overweight/obesity, and 
thyroid problems. The chronic endocrine and metabolic conditions are perhaps an 
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area of concern in the context of Australia’s ageing population395 as many of these 
conditions are more prevalent in older patients.154 
The higher rate of pathology associated with level C Medicare consultations may 
reflect increased complexity and length of the consultation. In order to qualify for 
level C reimbursement the consultation must be a minimum of 20 minutes and may 
involve taking a detailed history, a clinical examination, arranging any necessary 
investigations and/or implementing a management plan in relation to one or more 
problems.23 The number of problems managed at general practice encounters and the 
proportion of encounters with older patients is increasing.103 In the context of an 
ageing population,395 it might be expected that GP workload will become more 
complex involving more older patients with multiple chronic conditions—the 
management of which is likely to require pathology testing. The future impact of 
Australia’s ageing population on the volume of pathology ordered by GPs is 
investigated in Chapter 8 of this thesis. 
New patients were significantly more likely to receive pathology testing in the 
current study. Kravitz et al.365 found that new patients were independently more 
likely to directly request imaging and pathology tests from their physician and also to 
receive tests. Establishing a thorough medical history for a new patient is accepted 
practice and this often involves pathology tests. Lack of access to previous pathology 
results may also be a factor. In our current health system, GPs would usually only 
have access to previous records and test results if a new patient brought a copy to 
their first encounter.  
Lower rates of pathology testing were associated with management of patients 
holding health concession cards. Concession cards incorporate: health care cards, 
which give access to health care through a higher Government subsidy level for those 
on lower incomes; and Repatriation health cards for returned servicemen and women 
and their families. The lower rate of GPs’ ordering could be due to higher attendance 
patterns in this group, or to physicians’ or patients’ perception of affordability. 
Patients with a lower socio-economic index attend general practice more often396 and 
therefore (as discussed above) in an encounter sample they would have a higher 
chance of being included in the sample and a lower chance of having pathology 
recorded at the sampled encounter (because they have more opportunities to be 
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tested). Lower rates of pathology in health concession card holders may also indicate 
an access problem to pathology services. If patients or physicians perceive barrier(s) 
to ordering pathology (e.g. cost) at an encounter this may influence the decision to 
order testing. However the high rates of bulk-billing of Medicare pathology services 
(86.1% of pathology services were bulk-billed in 2007–085) mean that cost is 
unlikely to be a barrier to the majority of patients.  
Amount of variance explained 
The final predictive model explained 50% of the variance in GPs’ pathology 
ordering. This is a larger proportion of variance than that explained by previous 
studies with a similar method (i.e. models including GP and patient characteristics, 
and morbidity data collected at patient encounters).45,72 One of these studies used 
BEACH data and was able to explain 33% of the variance in pathology ordering in 
1998–2001.45 Davis et al.72 were able to explain 21% of the variance in New Zealand 
GPs’ pathology and imaging ordering, but did not describe the specific variables 
contributing to this variation.  
Another three studies that primarily investigated GP and practice variables reported 
markedly different amounts of explained variation in multivariate analysis: 10%,46 
30%50 and 49%.51 The first two studies investigated GPs’ ordering of both pathology 
and imaging and neither had representative GP samples.46,50 The study that was able 
to explain 49% of the variance, investigated blood tests ordered by GPs in eight 
European countries, and the main contributor was the country variable, accounting 
for 45% of the variation.51 Several authors did not describe the proportion of 
variance explained in the final multivariate models used in their studies. Of the 
studies that did, only the current and previous study using BEACH data had a 
representative sample. 
Factors found elsewhere to independently GPs’ pathology ordering behaviour (e.g. 
GP attitude to risk and malpractice claims,378,379 and communication style380) were 
not measured in this study. The extent to which they are applicable in the Australian 
general practice setting is not known, and further research in this area could 
determine the effect of these factors in the Australian setting. 
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Conclusion 
This study has demonstrated that much of the variation in GPs’ pathology ordering is 
due to the GPs’ workload, particularly the types of problems managed. The 
observation by Smellie et al. that “clinical practice is often assumed to account for 
differences in the use of pathology tests, but there is little published evidence to 
support this” is pertinent.337 This study provides this evidence, and demonstrates that 
the key factor within ‘clinical practice’ is differences in the types of clinical 
problems dealt with by individual GPs. The problems that are prevalent in older 
patients are likely to place the greatest pressure on future use of pathology services 
as the Australian population ages. 
There were some GP and practice characteristics independently associated with use 
of pathology services. These accounted for a much smaller amount of the variation, 
but the finding that young GPs, and female GPs, had higher pathology rates has 
implications for future pathology utilisation, due to expected increases in the number 
of trainee GPs (registrars) and continued feminisation of the workforce. 
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8 Pathology generated by GP orders 
in the future 
The previous chapters of this thesis have investigated the historical growth in GPs’ 
pathology ordering, the morbidities that contributed to the increase and some of the 
explanatory factors contributing to variance in their pathology ordering. This chapter 
considers likely future growth in GPs’ pathology ordering based on the expected 
growth in, and ageing of, the Australian population. 
8.1 Objective 
The objective of this work is to assess the effect of the projected population growth 
and ageing on GP’s future pathology ordering in Australia. 
8.2 Background 
In the past, growth in the volume of pathology tests ordered in Australia has been 
associated with the ageing population (i.e. growth in the proportion of the population 
in older age groups).26,27 Population projections indicate continued increases in the 
number of people in older age groups.137 As the use of pathology services increases 
with age,27 it is likely this will continue to be a contributing factor to future growth in 
pathology ordering. 
The Australian Government has described the ageing population as a major challenge 
facing the future of the country because of its associated fiscal pressure.234 Health 
care costs are described as the major contributor to this fiscal pressure, contributing 
two-thirds of the expected increase in Government spending from 2010 to 2050.234 
The population projections published by the Australian Bureau of Statistics (ABS) 
demonstrate both the expected ageing of the population and population growth.137 In 
June 2010, Australia’s population was 22.3 million and 13.6% of people were aged 
65 years and over.15 The ABS have made three population projections based on 
different assumptions about fertility rates, longevity and migration rates. In 2050 the 
population is projected to be between 30.2 million and 39.6 million, with 22.2% to 
24.3% aged 65 years and over. In all three projections the proportion of the 
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population accounted for by older people aged 65 years and over from 2010 to 2050 
grows faster than does the total population.137  
Australia is not the only country facing fiscal pressure from an ageing population. A 
number of developed countries face similar pressures and the associated burden of 
expected increases in public health expenditure. Per capita health service use 
(including pathology27 and GP service136 use) and cost increase with age.234,397 
Growth will be driven by demographic trends and technological advances, including, 
new drugs, tests and medical interventions,234,397 leading the Organization for 
Economic Co-operation and Development (OECD) to describe the pressure for 
increasing health spending in the future to be “unrelenting, fuelled by technological 
changes, population expectations and ageing.”397 
Factors contributing to ageing populations include declining fertility rates and 
increased life expectancy. Many countries will experience pronounced increases in 
the proportion of the population that is aged 65 years and over due to the baby boom 
following World War II. Much of this increase is expected to occur over the next 3 
decades as the ‘baby boomers’ age.398 In Australia, the resulting population age 
structure is expected to persist to (at least) 2050 (assuming fertility rates and 
longevity do not change significantly),395 carrying with it the ongoing fiscal 
challenge of an increased dependency ratio (i.e. fewer working people per older 
people in the population). The long-term nature of the change in population age 
structure and dependency ratio translates to ongoing health expenditure pressures as 
outlined by the Australian Government and other OECD nations.234,397 
All areas of Australia’s health budget will face scrutiny as the Government prepares 
to meet the fiscal challenges caused by ageing to ensure that “spending on health is 
sustainable, affordable and provides maximum benefit to the greatest number of 
people.”20 Public expenditure on pathology services is one important aspect of the 
public health budget. In 2009–10, Medicare outlays on pathology services were 
$2 billion, 13% of total Medicare outlays.5 At the time the research for this chapter 
was conceptualised and analysis undertaken, the Australian Government was in the 
process of reviewing Medicare funding arrangements for MBS pathology services. 
One of the primary tasks of the review, which commenced in mid 2009 (and was 
completed in 2011), was to identify suitable alternate funding models.20,399 
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Regardless of the outcome of this review, demographic changes in the population 
will contribute to growth in the volume and cost of pathology services. This chapter 
attempts to estimate the amount of pathology that will be ordered by GPs for the 
Australian population in the future, based on recent rates of GP pathology ordering 
and recent patterns of GP service use, in combination with projected estimates of the 
future population. 
8.3 Method 
Patient age-sex patterns of GP pathology ordering and GP service use are used to 
estimate the future number of GP contacts involving pathology testing, and volume 
of pathology testing generated by GP orders for the Australian population. National 
data from three sources are used to calculate projected estimates for 2015 to 2050, 
using data from 2005–06 and 2009–10.  
Data sources 
The three types of national data used are: (i) the population of Australia; (ii) the 
number of GP services in Australia; and (iii) GPs’ pathology ordering rates 
(summarised in Box 8.1). 
 
Box 8.1: Summary of source data  
 2005–06 2009–10
Number of people in the Australian population(a)  20.4 million 22.0 million
Number of GP services(b)  107.7 million 120.0 million
BEACH(c)  
 Number of participating GPs 1,017 988
 Number of GP–patient encounters recorded 101,933 101,349
 Number of pathology tests/batteries of tests recorded by GPs 39,358 45,594
Sources: 
(a) Australian Bureau of Statistics published estimated resident population for 2005 and 2009.15 
(b) General practice services funded by Medicare Benefits Schedule and Department of Veterans’ Affairs. Data supplied by 
the Australian Government Department of Health and Ageing, and the Australian Government Department of Veterans’ 
Affairs. 
(c) The BEACH study annual data set published in General practice activity in Australia 2005–06123 and General practice 
activity in Australia 2009–10.17 
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Population data 
Australian population data were sourced from the ABS and are based on census data. 
Population estimates are formally updated each year,15 and population projections to 
2101 are also produced.137 Data on the number of people by age (single year) and sex 
are published by the ABS for population estimates and projections.15,137 
The estimated resident population from 30th June 200515, 30th June 200915, and the 
projected estimated population for 30th June for each 5th year from 2015 to 2050137 
are used.  
The estimated number of residents in the Australian population was 20.4 million in 
2005 and 22.0 million in 2009 (Box 8.1). The 2005 estimate was based on the 2001 
census data, adjusted for births, deaths and migration in subsequent years, and further 
adjusted following the 2006 census.15 The 2009 population estimate was based on 
2006 census data, adjusted for births, deaths and migration in subsequent years.15 
Three series of future projections of the Australian population are produced by the 
ABS: Series A, B and C.137 These series are based on past trends and on different 
assumptions about future fertility rates, life expectancy and migration.137 The 
projected estimates used in this chapter are summarised in Box 8.2. Series A 
projections predict the greatest growth in the population and Series C the lowest 
growth. 
Box 8.2: Australian projected population 2015 to 2050 (millions) 
 2015 2020 2025 2030 2035 2040 2045 2050 
Series A 24.0 26.1 28.3 30.5 32.7 35.0 37.3 36.6 
Series B 23.6 25.3 26.9 28.5 30.0 31.3 32.7 34.0 
Series C 23.3 24.5 25.7 26.9 27.8 28.7 29.5 30.2 
Source: Australian Bureau of Statistics population projections.137 
 
General practice services data 
The numbers of GP services provided to the Australian population were estimated 
using claims data. These data were provided by DoHA and the Department of 
Veterans’ Affairs (DVA); the two Australian Government organisations that fund the 
majority (95%17) of GP services in Australia. Each GP service is defined as a single 
GP-patient-date combination in the claims data. There were approximately 
107.7 million GP services in 2005–06 and 120.0 million in 2009–10 (Box 8.1). GP 
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services data were supplied by patient age (single year) and sex. These data are not 
publicly available with the required patient age and sex specificity and were provided 
directly by DoHA (DoHA, personal communication, June 2010) and DVA (DVA, 
personal communication, September 2009). 
DoHA provided the number of Medicare-funded GP services funded for two 
12 month time periods—April 2005 to March 2006, and April 2009 to March 2010. 
The majority of Australia’s GP services were funded by Medicare (100.6 million in 
2005–06 and 112.8 million in 2009–10). 
DVA provided the number of GP services funded via the Veterans’ Entitlements Act 
for Repatriation health card holders (including veterans and eligible dependents) for 
the 12 month period, April 2005 to March 2006. However, the April 2009 to March 
2010 data were not available from DVA. Therefore the 2005–06 DVA data 
(7.1 million GP services) were applied in the calculations that use 2009–10 data.  
GPs’ pathology ordering  
GPs’ pathology ordering data were drawn from the BEACH study. Annual weighted 
data are used for two 12 month time periods—April 2005 to March 2006, and April 
2009 to March 2010. As discussed in Section 3.2.10, the representativeness of these 
two annual data sets has been assessed, both before and after weighting, and the 
application of weighting marginally improved the precision of the encounter data 
set.17,123 Weighting is applied to ensure the estimates are based on nationally 
representative data. 
In the BEACH study, there were a total of 101,993 encounters recorded by 1,017 
participating GPs in 2005–06, and 101,349 encounters recorded by 988 GPs in  
2009–10. Details about 39,358 pathology tests/batteries were recorded at these 
encounters in 2005–06 and 45,594 tests/batteries in 2009–10 (Box 8.1). 
Two measures of GP pathology ordering are used—the rate of pathology 
tests/batteries ordered at GP–patient encounters, and the proportion of encounters 
that involve at least one pathology test/battery. For each measure the point estimate 
and 95% confidence limits were calculated. These measures can be analysed by 
patient age (single year) and sex groups as needed.  
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Calculation of national estimates 
This section describes how data from the three national sources described above are 
used to calculate: 
• the number of pathology tests/batteries of tests that were, and in the future are 
estimated to be, ordered by GPs for the total Australian population. 
• the number of GP contacts that involved, and in the future are estimated to 
involve, at least one pathology test/battery of tests for the total population. 
To ensure calculations were robust, patient or population data from each source were 
grouped:  
• 5-year age-sex groups were created for patients/people aged 0 to 84 years  
(e.g. males aged 0–4 years, females aged 0–4 years, males 5–9 years, females 
aged 5–9 years)  
• two age-sex groups were created for patients/people aged 85 years and over 
(males aged  85 years, females aged  85 years).  
Data where age or sex was missing were excluded from the analysis. 
The method used to calculate the number of tests/batteries in the population is 
described in detail below. The same method was used to calculate the number of GP 
contacts that involve pathology testing—by using the proportion of encounters with 
at least one pathology test/battery in steps 2 to 4 instead of the rate of pathology 
ordering. 
Box 8.3 provides a worked example of the method applied to both measures of GP 
pathology ordering for one age-sex group, female patients aged 40–44 years. 
Step 1: The average number of GP contacts per person in the population 
The average number of GP contacts per person is calculated by dividing the number 
of GP services in each age-sex cohort by the number of people in the population in 
the corresponding age-sex group. This is repeated using data from 2005–06 and 
2009–10. Referring to the example in Box 8.3 the average number of GP encounters 
per female head of population aged 40–44 years in 2005–06 was 5.0, and in 2009–10 
it was 5.4. 
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Step 2: The average number of pathology tests/batteries ordered by GPs per person in the 
population 
The average number of pathology tests/batteries per person is calculated by 
multiplying the rate of GPs’ pathology tests/batteries ordered per encounter (the rate 
per 100 encounters divided by 100) by the number of GP contacts per person (as 
calculated in step 1) in each age-sex cohort. This calculation was repeated using data 
from 2005–06 and 2009–10, and repeated for each time point using the lower and 
upper 95% confidence limits of the rate of pathology tests/batteries per encounter. 
For example, per woman aged 40–44 years, GPs ordered (on average) 2.4 tests/ 
batteries (95% CI: 2.2–2.7) in 2005–06, and 3.2 (95% CI: 2.9–3.5) in 2009–10  
(Box 8.3). 
Step 3: The total number of pathology tests/batteries ordered by GPs for the population 
The total number of pathology tests/batteries ordered by GPs for the population is 
calculated by multiplying the number of people in the population by the average 
number of tests/batteries per person (as calculated in step 2) in each age-sex cohort. 
This calculation was repeated using data from 2005–06 and 2009–10, and repeated 
using the lower and upper 95% confidence limits (calculated in step 2). Referring to 
the example in Box 8.3, there were approximately 1.88 million (95% CI: 
1.70 million–2.06 million) tests/batteries ordered by GPs for females aged  
40–44 years in 2005–06, and 2.46 million (95% CI: 2.25 million–2.68 million) in 
2009–10. 
Adding the estimates for all age-sex cohorts provides the total number of pathology 
tests/batteries ordered by GPs for the total Australian population in 2005–06 and 
2009–10. 
Step 4: The total number of pathology tests/batteries ordered by GPs for the projected 
population 2015 to 2050 
The total number of pathology tests/batteries ordered by GPs for the projected 
population is calculated by multiplying the expected number of people in the 
population in each age-sex cohort by the average number of tests/batteries per person 
(as calculated in Step 2).  
The number of pathology tests/batteries ordered by GPs was calculated for the 
projected population at 5 yearly intervals from 2015 to 2050 (that is, 2015, 2020, 
2025… etc). For each of the projected estimates of the annual population used (2015 
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to 2050) there are two estimates of the average number of tests/batteries per person 
(one based on 2005–06 data and a second based on 2009–10 data) applied to each 
series of population projections at each time point. Applying the three series of 
population projections (A, B and C) to the 2005–06 and 2009–10 data gives six 
estimates (each with 95% CI) of the projected total number of pathology 
tests/batteries ordered by GPs for each age-sex cohort, and (when the age-sex cohorts 
are added) for the total Australian population in each year used in the calculations. 
The projections based on 2005–06 data assume that in the future the population 
continues to have the same average number of GP contacts (per person in the 5-year 
age-sex cohorts) as they did in 2005–06, and that GPs continue to order pathology 
tests/batteries at the same rate at GP encounters (for patients in the 5-year age-sex 
cohorts) as they did in 2005–06. Similarly the projections based on 2009–10 data 
repeat these two assumptions, on the basis of 2009–10 GP contact and ordering rates.  
The example in Box 8.3 uses the estimated number of females aged 40–44 years in 
the population in 2020 to illustrate the method for Step 4. There are three 2005–06-
based estimates of the number of tests/batteries ordered by GPs for females aged  
40–44 years in 2020:  
• Series A: 2.02 million (95% CI: 1.83 million–2.22 million)  
• Series B: 1.97 million (95% CI: 1.78 million–2.16 million) 
• Series C: 1.92 million (95% CI: 1.73 million–2.11 million).  
Similarly there are three 2009–10-based estimates:  
• Series A: 2.68 million (95% CI: 2.44 million–2.91 million) 
• Series B: 2.61 million (95% CI: 2.38 million–2.84 million) 
• Series C: 2.54 million (95% CI: 2.32 million–2.76 million).  
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 Box 8.3 Calculation example of GP ordered pathology (number of tests/batteries and GP contacts involving testing) for females aged 40–44 years 
Source data (females aged 40–44 years) 2005–06 2009–10 
Number of people in the population  776,908 769,345 
Number of GP services 3,881,819 4,127,491 
Rate of pathology tests/batteries ordered by GPs per 100 encounters (95% CI) 48.39 (43.68–53.10) 59.66 (54.44–64.87) 
Per cent of encounters with at least 1 pathology test/battery ordered by GPs (95% CI)  21.75 (19.87–23.62) 23.73 (22.01–25.46) 
Step 2:  2005–06 2009–10
Average number of GP contacts with at least one  1.09 1.27
pathology test/battery per person (95% CI) (0.99–1.18) (1.18–1.37)
Step 2:  2005–06 2009–10 
Average number of pathology tests/batteries  2.42 3.20
per person (95% CI) (2.18–2.65) (2.92–3.48) 
Step 3: 2005–06 2009–10 
Number (millions) of pathology tests/batteries 1.88 2.46
for the population (95% CI) (1.70–2.06) (2.25–2.68) 
Step 4: Series 2005–06 2009–10
A: 2.02 
(1.83–2.22)
2.68 
(2.44–2.91)
B: 1.97 
(1.78–2.16)
2.61 
(2.38–2.84)
C: 1.92 
(1.73–2.11)
2.54 
(2.32–2.76)
Step 1:  2005–06 2009–10 
Average number of GP contacts per person 5.00 5.36 
Step 3: 2005–06 2009–10 
Number (millions) of pathology  
tests/batteries of tests ordered by 
GPs for the population in 2020  
(95% CI) 
Number (‘000’s) of GP contacts with at 844 980 
least one pathology test/battery for (771–917) (909–1,051) 
the population (95% CI) 
Number of GP contacts with at least one pathology test ordered in 
the population 
Number of pathology tests ordered by GPs in the population 
Step 4: Series 2005–06 2009–10
A:Number (‘000’s) of GP contacts 
with at least one pathology 
test/battery for the population in 
2020 (95% CI) 
909 
(831–987)
1,065
(988–1,142)
B: 886 
(810–962)
1,038
(963–1,113)
C: 863 
(789–938)
1,011
(938–1,085)
Note: Figures are rounded to two decimal points for presentation (Calculations were made with the total number). CI – confidence interval. 
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8.4 Results 
In the BEACH data set there were 100,566 GP–patient encounters recorded in  
2005–06 and 99,843 encounters in 2009–10 for which patient’s age and/or sex were 
known (Table 8.1). The total rate of pathology ordered by GPs increased 
significantly from 36.6 tests/batteries per 100 encounters in 2005–06 to 45.1 per 100 
in 2009–10. Similarly the proportion of encounters that involved at least one 
pathology test/battery increased from 16.4% in 2005–06 to 17.8% in 2009–10 
(Table 8.1). 
Table 8.1: Overview of pathology ordering data from the BEACH study 2005–06 and 
2009–10  
Data element 2005–06 2009–10
Number of GP–patient encounters(a) 100,566 99,843
Number of pathology tests/batteries of tests(a) 38,855 45,062
Rate of pathology tests/batteries of tests ordered per  
100 encounters (95% confidence interval) 
36.6 
(36.9–40.4) 
45.1
(43.3–47.0)
Per cent of encounters with at least 1 pathology test/battery of 
tests ordered (95% confidence interval) 
16.4 
(15.8–17.0) 
17.8 
(17.2–18.4)
(a) Data for which patient’s age and/or sex were not known were excluded. Therefore data do not match that reported in Box 8.1.  
In 2005–06, there were an estimated 41.0 million pathology tests/batteries ordered by 
GPs for the Australian population. This increased significantly to 53.3 million 
tests/batteries in 2009–10 (Table 8.2). The growth between 2005–06 and 2009–10 in 
the number of pathology tests/batteries ordered by GPs for the population was due to 
increases in both the rate at which GPs order pathology tests (as described above) 
and the number of GP contacts per head of population (4.9 per person in 2005–06 
and 5.2 in 2009–1013). 
At least one pathology test/battery was ordered by GPs at 17.5 million GP contacts in 
2005–06, and at 21.1 million GP contacts in 2009–10 (Table 8.3). This was not a 
statistically significant change. Although there was a statistically significant increase 
in the proportion of encounters with at least one pathology test/battery recorded in 
BEACH, when the age-sex specific rates of GP service use were included in the 
calculation no population-based change was apparent between 2005–06 and  
2009–10. 
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Table 8.2: Total number of pathology tests/batteries of tests ordered by GPs for the 
Australian population 
Time period 
Number pathology 
tests/batteries 95% LCL 95% UCL
2005–06 40,990,000 35,950,000 46,030,000
2009–10 53,310,000 47,160,000 59,460,000
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
Table 8.3: Number of GP contacts involving the ordering of at least one pathology 
test/battery of tests in the Australian population 
Time period 
Number of GP contacts with at least 
one pathology test/battery 95% LCL 95% UCL
2005–06 17,460,000 15,650,000 19,270,000
2009–10 21,100,000 19,040,000 23,160,000
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
The average number of tests/batteries ordered by GPs per person in each 5-year 
age-sex cohort in 2005–06 is shown in Figure 8.1, and in 2009–10 in Figure 8.2. The 
age-sex specific average number of GP contacts per person involving at least one 
pathology test/battery in 2005–06 and 2009–10 are shown in Figures 8.3 and 8.4, 
respectively.  
The average number of tests/batteries ordered by GPs per head of population 
increased with age in 2005–06 and 2009–10. Australians aged less than 15 years had 
an average of < 1 test/battery per person, and those aged 75 years and over had an 
average of 5.5 to 7.2 tests/batteries per person. There were also significant 
differences between males and females in the number of tests/batteries per person. 
GPs ordered significantly more tests for females aged between 15 and 54 years than 
for males, in both 2005–06 and 2009–10 (Figures 8.1 and 8.2). 
The statistically significant increase in number of tests ordered for the entire 
population from 2005–06 to 2009–10 was not reflected in all age-sex groups. For 
people aged 75 years and over, the average number of tests/batteries ordered by GPs 
increased significantly, from 2005–06 to 2009–10: for females from 5.5 (95% CI 
5.0–6.0) to 6.5 (95% CI: 6.1–7.1); and for males from 6.0 (95% CI: 5.5–6.5) to 7.2 
(95% CI: 6.6–7.8). There was also a marginal increase for people aged 50–54 years: 
for females from 2.9 (95% CI: 2.7–3.2) to 3.6 (95% CI: 3.2–3.9); and for males from 
2.1 (95% CI: 1.9–2.4) to 2.7 (95% CI: 2.4–3.0). Further, for females aged 40–44 and 
45–49 years the number of tests per head increased from 2.4 (95% CI: 2.2–2.7) in 
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both age groups in 2005–06 to: 3.2 (95% CI: 2.9–3.5) for those aged 40–44 years; 
and 3.1 (95% CI: 2.8–3.3) for those aged 45–49 years in 2009–10. For females aged 
5–9 years the number of tests per head increased marginally from 0.3 (95% CI:  
0.2–0.4) to 0.6 (95% CI: 0.4–0.7) (results not tabled). 
The average number of GP contacts per person involving at least one pathology 
test/battery also increased with age in 2005–06 and 2009–10 (Figures 8.3 and 8.4). 
Australians aged less than 20 years had an average of < 1 GP contact that involved 
pathology testing, and those aged 75 years and over had an average of 2.4 to 2.9 GP 
contacts per person that involved at least one pathology tests/battery. Between the 
ages of 15 and 50 years, females had more GP contacts per person that involved 
pathology testing than did males, in both 2005–06 and 2009–10 (Figures 8.3 and 
8.4). 
As reported earlier, there was no statistically significant increase in the number of 
GP contacts that involved at least one pathology order for the total population from 
2005–06 to 2009–10. However there was an increase (between these years) in  
the number of GP contacts per person that involved pathology for females aged  
5–9 years (0.2, 95% CI: 0.2–0.2 compared with 0.3, 95% CI: 0.3–0.4), and a 
marginal increase for females aged 40–44 years (1.1, 95% CI: 1.0–1.2 in 2005–06 
compared with 1.3 95% CI: 1.2–1.4 in 2009–10) (results not tabled). 
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Figure 8.1: Age-sex–specific average number of pathology tests/batteries of tests ordered by 
GPs per person in the Australian population in 2005–06 (95% confidence intervals) 
 
 
 
Figure 8.2: Age-sex–specific average number of pathology tests/batteries of tests ordered by 
GPs per person in the Australian population in 2009–10 (95% confidence intervals)  
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Figure 8.3: Age-sex–specific average number of GP contacts involving at least one 
pathology test/battery of tests per person in the Australian population in 2005–06 
(95% confidence intervals)  
 
 
 
Figure 8.4: Age-sex–specific average number of GP contacts involving at least one 
pathology test/battery of tests per person in the Australian population in 2009–10 
(95% confidence intervals)  
Number GP contacts with pathology
Age group (years)
Number GP contacts with pathology
Age group (years)
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The projected estimated number of pathology tests/batteries that will be ordered by 
GPs and the estimated number of GP contacts that will involve at least one pathology 
order for the Australian population in the coming decades are shown in Figures 8.5 
and 8.6. In each figure there are six estimates for each projected population time 
point.  
The first two column blocks in Figure 8.5 show estimated numbers of pathology 
tests/batteries based on the Series A population projections. The first column block is 
based on 2005–06 data (referred to as 2005-based) about GP pathology ordering per 
person and the second column block is based on 2009–10 data (referred to as 
2009-based). Series A estimates have the highest number of people in the Australian 
population, therefore they produce the highest estimates of future pathology 
ordering. From 2015 to 2050 the 2005-based Series A calculations suggest an 
increase of 91.0%—from 50.3 million tests/batteries ordered by GPs in 2015 to 
96.2 million in 2050. Over the same period, the 2009-based Series A estimate 
increased by 89.0% from 59.9 million tests/batteries ordered by GPs in 2015 to 
113.2 million in 2050 (Figure 8.5). 
The middle two column blocks are based on the Series B population projections, the 
intermediate estimates of population growth. From 2015 to 2050 the 2005-based 
Series B calculations suggest an increase of 63.4%—from 49.9 million tests/batteries 
ordered by GPs in 2015 to 81.5 million in 2050. Over the same period, the 2009-
based Series B estimate increased by 62.6%, from 59.3 million tests/batteries ordered 
by GPs in 2015 to 96.5 million in 2050 (Figure 8.5). 
The last two column blocks are based on the Series C population projections, the 
lowest estimates of population growth. From 2015 to 2050 the 2005-based Series C 
calculations suggest an increase of 53.6%—from 49.5 million tests/batteries ordered 
by GPs in 2015 to 76.0 million in 2050. Over the same period, the 2009-based 
Series C estimate increased by 52.6% from 58.9 million tests/batteries ordered by 
GPs in 2015 to 89.8 million in 2050 (Figure 8.5). 
The estimated numbers of GP contacts that involve at least one pathology test/battery 
in the future are shown in Figure 8.6. From 2015 to 2050 the 2005-based Series A 
calculations suggest an increase of 91.7%—from 21.4 million GP contacts involving 
at least one pathology test/battery in 2015 to 41.1 million in 2050. Over the same 
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period, the 2009-based Series A estimate increased by 90.6% from 23.7 million GP 
contacts involving at least one pathology test/battery in 2015 to 45.2 million in 2050 
(Figure 8.6).  
From 2015 to 2050 the 2005-based Series B calculations suggest an increase of 
63.7%—from 21.2 million GP contacts involving at least one pathology test/battery 
in 2015 to 34.7 million in 2050. Over the same period, the 2009-based Series B 
estimate increased by 63.2%, from 23.5 million GP contacts involving at least one 
pathology test/battery in 2015 to 38.3 million in 2050 (Figure 8.6). 
From 2015 to 2050 the 2005-based Series C calculations suggest an increase of 
53.7%—from 21.0 million GP contacts involving at least one pathology test/battery 
in 2015 to 32.3 million in 2050. Over the same period, the 2009-based Series C 
estimate increased by 53.1% from 23.3 million GP contacts involving at least one 
pathology test/battery in 2015 to 35.6 million in 2050 (Figure 8.6). 
When comparing the 2005-based and 2009-based results presented in Figures 8.5 and 
8.6, there were no statistically significant differences between projections when 
comparing equivalent time points. For example, the projections for 2015 of the 
estimated number of pathology tests/batteries that will be ordered and the estimated 
number of GP contacts that will involve at least one pathology order, based on  
2005–06 data were not significantly different to those based on 2009–10 data.
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Figure 8.5: Estimated number (millions) of pathology tests/batteries of tests ordered by GPs for the projected Australian population 2015 to 
2050 based on per head GP service use and GPs’ pathology ordering in 2005–06 and 2009–10 (95% confidence intervals) 
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Figure 8.6: Estimated number (millions) of GP contacts involving at least one pathology test/battery of tests for the projected Australian 
population 2015 to 2050 based on per head GP service use and GPs’ pathology ordering in 2005–06 and 2009–10 (95% confidence intervals) 
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8.5 Discussion 
The results presented in this chapter demonstrate that per capita, pathology generated 
by GP orders increases with age in the Australian population. This echoes the pattern 
of increased per capita health resource use, and total pathology service use associated 
with increased age.27,234,397 
The volume of pathology generated by GP orders and the number of occasions of 
testing for the population are projected to grow faster than would be expected with 
population growth alone. The same result is found for all series of projections and 
regardless of whether the calculations are based on 2005–06 or 2009–10 rates of GP 
pathology ordering and GP utilisation. This is because the proportion of older people 
in the population is projected to increase137 and, as age increases, so too does per 
capita GP pathology ordering. Therefore the excess growth (above that generated by 
population growth) is due to the effect of the ageing population. 
There are limitations that need to be kept in mind when considering the long-term 
projections made in this chapter. The projections of GPs’ pathology ordering are 
reliant on the robustness of the three types of national data (population projections, 
GPs’ pathology ordering and GP services) used.  
There is inherent uncertainty in estimating population projections. Projections were 
made by the ABS based on assumptions about life expectancy, fertility rates and 
migration rates. An unanticipated change in any of these factors would render the 
population projections unreliable. This uncertainty is why three series of population 
projections are published and why I have used these three series to project GPs’ 
pathology ordering. 
The number of pathology tests/batteries recorded in the BEACH study is limited by 
the space available on the recording form. A maximum of five tests/batteries can be 
recorded per encounter. This cap may lead to an underestimation in the projections of 
the number of pathology tests/batteries that will be ordered by GPs. This limitation 
does not affect the projected number of GP contacts that involve at least one 
pathology order because it is based on the proportion of encounters that involve at 
least one pathology test/battery, not on a count of tests/batteries.  
Pathology ordering recorded by GPs (in BEACH) reflects their intention that the 
patient will be tested. Inevitably a proportion of pathology ordered by GPs will never 
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be conducted, because the patient chooses not to be tested. Therefore the projections 
made in this chapter may overestimate the pathology testing that will be performed in 
the population in response to GPs’ ordering.  
The number of GP services provided to the community in 2005–06 and 2009–10 
were based on services funded through Medicare and the DVA. As the 2009–10 
DVA data were not available, the 2005–06 DVA data and 2009–10 Medicare data 
were combined to calculate the number of GP services per person in 2009–10. The 
number of GP services funded through Medicare (per capita) increased over the 
period of this investigation (2005–06 to 2009–10).13 As the total per capita use of 
DVA funded medical services (including GP, specialist and dental services) 
increased over this period,400,401 it is likely that DVA funded GP services (when 
viewed alone) also increased. Given these increases, the lack of 2009–10 DVA data 
may cause an underestimation of the number of GP services per person in 2009–10, 
particularly as most DVA funded GP services are for veterans’ aged 80 years and 
over and GP service use increases with age.136 In turn this means that the pathology 
projections based on 2009–10 data may be underestimated. 
The projections created in this chapter were based on 2005–06 and 2009–10 data 
because over this time there were significant increases in: the number of GP services 
per capita;13 the rate of GPs’ pathology ordering at encounters; and the proportion of 
GP encounters that involved at least one pathology test. Despite these increases, 
when the projections were calculated there were no statistically significant 
differences in the pathology projections based on 2005–06 data versus those based 
on 2009–10 data (when comparing equivalent projection time points). Theoretically 
it would be more reliable to use the 2005–06 based estimates because of the lack of 
2009–10 DVA data. However the pathology projections based on 2009–10 were 
consistently above those based on 2005–06 data and (while not statistically 
significant) this has economic ramifications for funding pathology services. 
Therefore the 2009–10 projections are the focus of the discussion below. 
The estimated projected number of pathology tests/batteries that will be ordered by 
GPs for the Australian population (based on 2009–10 data) was 58.9–59.9 million 
tests/batteries in 2015 and 89.8–113.2 million in 2050—an increase of 53–89%  
from 2015 to 2050. The estimated number of GP contacts that will involve at least 
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one pathology order for the Australian population (based on 2009–10 data) was 
23.3–23.7 million in 2015 and 35.6–45.2 million in 2050—an increase of 53–91% 
over this period. 
These projections assume that per head in each age-sex group the number of GP 
visits stays constant and the rate and likelihood of GPs’ ordering pathology stays 
constant. For example (referring to Box 8.3), these assumptions mean that an average 
40–44 year old female would have the same number of GP visits (5.4 per head), 
pathology tests/batteries (3.2) and GP visits involving pathology testing (1.3) in 
2009–10, as a 40–44 year old female will have in 2015, 2020…and so on to 2050. 
The current age-sex–specific pattern of pathology ordered by GPs for the population 
has potential to change considerably over the coming decades. In order for pathology 
rates to stay constant in the age-sex cohorts of the population in the future and 
therefore for the projections of future pathology ordering to be correct, the use of GP 
services, and GPs’ pathology ordering within the age–sex groups would need to stay 
constant. At a minimum, this would require prevalence of diseases and patterns of 
multiple morbidities in any one age-sex cohort of the population to remain constant 
in the future. Knowledge, guidance and rules about the role of pathology testing in 
the management of these morbidities would also need to be constant. However, in 
reality, changes within these variables will be inevitable over the coming decades 
because there are many factors that could create change. Some examples are given 
below. 
The prevalence of overweight/obesity may change and consequently generate 
changes in GP service use and GPs’ pathology ordering. The proportion of 
Australian adults who are overweight/obese has increased from 54% in 2004–05 to 
62% in 2007–08.154,402 High body mass is a risk factor for a number of chronic 
conditions including (but not limited to) dyslipidaemia and diabetes mellitus. Both of 
these conditions are usually managed by GPs and require pathology for diagnosis 
and monitoring. If the proportion of the population who are overweight/obese were 
to increase (as suggested by the historical trend) it is likely that this would generate a 
subsequent increase in pathology ordered by GPs. Alternatively if the ongoing public 
health initiatives295,296 that aim to reduce the prevalence of overweight/obesity are 
successful it is likely that there would be a subsequent reduction in pathology testing. 
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Significant changes in the extent to which GPs used pathology tests in the 
management of selected conditions were demonstrated from 2000–02 to 2006–08 in 
Chapter 4. Changes in what we know about a condition, and the best way to treat it 
(such as, new scientific knowledge, technological developments including new tests, 
and new medications), contribute to changes in the role of pathology in its 
management. These changes have the potential to change the management of 
conditions and are considered by both the OECD and the Australian Government to 
be a likely source of future growth in health costs.234,397 For example, genetic testing 
has been highlighted as a potential area of growth during the Government’s recent 
review of pathology funding, due to the rapid developments occurring in the genetics 
discipline.399 
Alternatively technological advances may reduce the need for pathology testing in 
the future. An example is the development of a vaccine for the human papillomavirus 
(HPV) and the subsequent vaccination program that was implemented in Australia in 
2007.403 The vaccine prevents the types of HPV that cause 70% of cervical cancer403 
and therefore it is likely to reduce the incidence of cervical cancer. Australia’s 
comprehensive national program for cervical cancer screening currently recommends 
screening with a Pap smear every 2 years for women aged 18 to 70 years, but this 
screening protocol is under review due to the introduction of the HPV vaccine, 
availability of new tests for screening, and emergence of evidence about the 
screening age and interval.404 It is expected that the screening interval will be 
increased and the age-groups covered in the program reduced.404 Consequently, the 
ordering of Pap smears, one of the most common tests ordered by GPs (see 
Chapter 4), may decrease. 
If the likelihood and rate of GPs’ pathology ordering stay constant, projected 
population growth and ageing will produce substantial future growth in the number 
of pathology tests/batteries and number of GP contacts involving pathology in the 
population. However, if the historic growth in the likelihood and rate of GPs’ 
pathology ordering continued in the future, then any projected estimates (based on 
2009–10 data) of GP-ordered pathology in the population would be too low.  
Governments internationally face uncertainties in estimating future health costs as 
changes in population, the prevalence of conditions and technological advances are 
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difficult to accurately predict. While it has limitations, basing projections on past 
patterns of health resource use is the best tool available to plan for future 
requirements. The projections of pathology in this chapter were made to 2050 as the 
growth in the proportion of the population in older age groups is expected to 
continue over the next four decades.395 In addition, the sustainability of health 
spending to 2050 is the Australian Government’s current focus.234  
The Australian Government has estimated that public health spending will increase 
by 77.5%, from 4.0% of gross domestic product in 2009–10 to 7.0% in 2049–50.234 
Forty per cent of this expected growth is due to population growth and ageing (i.e. 
demographic changes).234 The population projection used by the Government to 
predict this growth lies between the Series A and Series B population projections 
published by the ABS. In this chapter, the estimated growth in the volume of 
pathology tests/batteries ordered by GPs and the GP contacts that involve pathology 
from 2009 to 2050 is approximately 80% based on Series B population projections 
and 110% based on Series A projections. These pathology projections are based only 
on demographic changes (i.e. population growth and ageing). In contrast, the 
Government’s estimate of future health spending also incorporates growth in non-
demographic health spending (such as increased use of doctors, tests and 
medicines).234  
In this chapter, even without attempting to estimate the affect of non-demographic 
factors, growth in GPs’ projected pathology ordering is considerably larger that the 
Government’s expected growth in total health spending over the same timeframe. 
Comparing these estimates suggests that pathology generated by GP orders is likely 
to grow faster than total health care spending. Whether this means that the cost of 
pathology (ordered by GPs) will grow at the same rate as the projected pathology 
ordering is another matter. As the majority of GPs’ pathology ordering is funded 
through Medicare, the magnitude of cost growth will be affected by the Medicare 
funding rules, in particular the episode coning rule which restricts payment to the 
three most expensive pathology items (as described in Chapter 2). Therefore the 
Medicare cost of funding pathology tests ordered by GPs only partially reflects the 
tests ordered by GPs. It is not possible to replicate the effect of the episode cone 
using the data presented in this chapter. However, it is reasonable to conclude that 
projected growth in GPs pathology ordering is likely to produce growth in Medicare 
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pathology outlays, but under the current Medicare funding structure the growth in 
cost and growth in GPs’ ordering will not be equivalent. 
The review of Medicare funding arrangements for MBS pathology services, 
undertaken by the Australian Government (underway when the study in this chapter 
was conceptualised and data analysed), was completed in early 2011. The outcome 
was that the funding arrangements remained largely unchanged. A new funding 
agreement between the pathology industry and the Australian Government covering 
July 2011 to June 2016 was introduced. This covered Medicare outlays and growth 
in these outlays from pathology services ordered by all requestors (i.e. GPs and other 
specialist doctors),25 in a similar arrangement to the three previous MoUs that were 
in operation from 1996 to 2009 (the Government chose not to renew the previous 
MoU pending the outcome of this review). The new funding agreement includes a 
fixed annual range of funding growth, between a minimum of 4.4% and maximum of 
5.2% each year (subject to review).25 
During the period of the Government’s review, a pathology industry group, the 
Australian Association of Pathology Practices (AAPP) commissioned an analysis of 
the expected future growth in outlays for MBS pathology services. This analysis 
estimated an average annual growth rate in outlays of 6.2% (a range of 3.1% to 
7.0%) over the five years 2010–11 to 2014–15, based on historical growth in per 
person pathology usage, costs of services, and projected growth and ageing of  
the population.27 The annual growth in outlays attributed to the population was  
1.4–1.5%. In comparison, I estimated a growth of between 2.1% and 2.5% per 
annum in the volume of pathology tests/batteries generated by GPs’ orders, and 
number of GP contacts that involve pathology testing over the 5 years from 2009–10 
to 2015 based on population changes. The AAPP-commissioned report differs from 
the current study as it focussed on the growth in cost of pathology services generated 
by orders from GP and other medical specialists whereas I estimated the growth in 
volume and occasions of pathology testing generated from GP orders. However, my 
study may indicate a greater influence of population changes than suggested in the 
AAPP-commissioned report. 
It is likely that due to demographic changes alone there will be upward pressure on 
Medicare outlays for pathology services generated by GPs’ pathology ordering, 
 301 
suggesting that the Australian Government’s concern about future growth in the cost 
of pathology services is justified. Based only on the expected demographic changes 
in the population, future growth in GPs’ pathology ordering is inevitable. However if 
the historical trends of increased per capita use of GP services and increased number 
and likelihood of GP pathology ordering continue, they will compound the impact of 
these demographic changes. Together these factors will put significant upward 
pressure on future costs of pathology services. 
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9 Discussion 
Major findings 
This research provides a detailed picture of GPs’ pathology ordering and how it has 
changed from 2000 to 2008. The total increase in volume of GPs’ pathology ordering 
between 2000–02 and 2006–08 was influenced by increases in three factors, each of 
which can operate independently: the rate of pathology ordered in the management 
of clinical problems (due to increased likelihood of ordering and increased number of 
tests ordered per testing occasion), the number of problems managed at GP–patient 
encounters, and the total number of encounters provided to the Australian population. 
The majority of the volume and growth in GPs’ pathology ordering was attributable 
to a relatively small group of pathology tests and clinical problems. Just 22 problems 
accounted for 59% of the growth in testing between 2000–02 and 2006–08.  
Variance among GPs’ in the volume of pathology ordered is often used as an 
indicator of poor quality. In investigating factors that contribute to variance, I was 
able to explain 50% of the variance in GPs’ testing rates. Significant independent 
predictors of volume included some GP and practice characteristics, but the strongest 
determinate was the type of problem being managed. 
In this thesis, appropriateness of GPs’ pathology ordering for six selected problems 
was assessed by measuring alignment with recommendations in guidance documents. 
Overall GPs’ ordering aligned well, and increases in ordering over time for the six 
problems reflected increases in both ‘appropriate’ and ‘inappropriate’ ordering. I 
found no evidence to support concerns raised in the literature about widespread 
inappropriate ordering, or assertions that increases in ordering reflect 
disproportionate increases in inappropriate ordering. 
Based on the growth and ageing of the population alone, future growth in the volume 
of GPs’ pathology ordering is inevitable. The ageing of the population will increase 
the prevalence of diagnosed chronic disease and therefore increase its management 
and associated pathology testing. During my review of guidance documents I found 
that pathology test recommendations for long-term monitoring of chronic diseases 
were poor. Improving this guidance would support GPs in the appropriate ordering of 
pathology tests in this high growth area. 
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Limitations  
As with all observational studies there are limitations in the studies described here. 
The BEACH data used in this thesis are cross-sectional and encounter-based. As 
such, they are affected by the frequency with which patients see their GP. I have no 
way of knowing how often individual patients at the sampled encounters return to see 
a GP. Attendance patterns vary according to patient age and sex.136,369 Distance from 
care and the GP:population ratio which affects availability of GP appointments also 
have a bearing, as the management provided by GPs may be affected by the patient’s 
access to care. For example, the likelihood of a GP ordering pathology at an 
encounter may be higher for a patient who has not seen a GP for some time than for 
one who is seen regularly.  
The encounter data presented in this thesis will be affected by attendance patterns but 
the extent of this affect varies. In Chapters 4–6 there is minimal impact on the 
conclusions drawn as the encounter-based data are used to describe the grouped 
clinical activity of GPs. However, attendance patterns have an influence when 
activity is compared for individual GPs as in the investigation of variance in GPs’ 
pathology ordering (Chapter 7). For example, the finding that GPs in rural areas 
ordered more pathology than their urban counterparts is likely to reflect differences 
in attendance patterns and a need to go further down the diagnostic pathway before 
referring the patient to specialist care as access to care is more limited. 
The study predicting future growth in GPs’ pathology ordering (Chapter 8) is the 
only work in this thesis that incorporates the affect of attendance patterns. However, 
this was done using population age-sex-specific average attendance rates, as data 
about individual attendance patterns were not available. 
There are many factors for which I lacked information that may have a bearing on a 
GP’s decision to order pathology testing. These include: presence and duration of 
symptoms, presence of comorbidities not managed at the encounter, past medical 
history, family history, social circumstances, previous test results, and risk factors. 
As discussed in Chapter 5, the presence of these factors may have an influence on the 
accuracy of my assessment of appropriateness of GPs’ pathology ordering. My 
assessment was based on the pathology test linked to the problem under management 
at the encounter for only six selected problems. Even if more detailed data were 
available, it would be very difficult to design an exact measure of appropriateness 
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that reflects the complexity of GPs’ decision-making processes. The data set used in 
this thesis is one of few that links GPs’ test selection to the clinical problem for 
which it was ordered. So while there are some limitations to the method I have 
adopted to assess the appropriateness of GPs’ pathology ordering, my study is one of 
the few that incorporates the clinical problem. 
The variables available in the study also have a bearing on the study of inter-GP 
variance in rates of pathology ordering (Chapter 7). I adjusted for the available GP, 
patient and encounter variables, but there may be other factors that have a bearing on 
this variance for which I have no measure.  
As discussed in Chapter 4, the maximum of five pathology tests/batteries of tests that 
can be recorded per encounter has implications for the results presented in this thesis. 
Over time the proportion of encounters where the maximum number of pathology 
tests was recorded increased, suggesting that the proportion being missed may have 
increased over the years investigated.  
Further, the maximum of five tests/batteries may have a greater bearing on some 
types of clinical problems managed at encounters. For example, a problem for which 
many tests are usually required on an occasion of testing is more likely to have 
missing data than a problem for which only a single test is required. This selection 
bias has implications for some of my results. In the study assessing the 
appropriateness of GPs’ ordering, I could only make a judgement based on the tests 
recorded for each problem. 
The large number of comparisons made in this thesis (in particular when 
investigating changes over time) provides the potential for reporting a difference 
between groups when none exist (i.e. a Type 1 error). There may be occasions where 
a statistically significant difference has been detected by chance rather than because 
it exists in reality. However, I used non-overlapping 95% CIs as the primary measure 
of significance (which is considered a conservative approach130-132) to reduce the 
likelihood of such error. 
Appropriateness of GPs’ pathology ordering 
There is a negative narrative present throughout the literature regarding clinicians’ 
pathology testing, whereby authors link (implicitly or explicitly) the increasing rates 
of pathology testing with inappropriate ordering, leading to a prevailing opinion that 
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the quality of clinicians ordering is poor or could be improved considerably. There is 
limited evidence to support this assumption. The landmark review of appropriateness 
of pathology ordering by van Walraven and Naylor found a wide range of 
‘inappropriate’ ordering but suggested that the results were not generalisable (most 
studies having been conducted in inpatient settings) and that “allusions to extensive 
inappropriate ordering should not be made without appropriate qualifiers.”52 While 
there has been some evaluation of clinician’s pathology ordering in other health 
settings, there has been virtually none in general practice, and yet the same negative 
perceptions exist. 
In the research reported in this thesis, I evaluated the appropriateness of GPs’ 
pathology ordering for six problems: hypertension, Type 2 diabetes, lipid disorders, 
weakness/tiredness and health checks. Together these problems generated a quarter 
of pathology ordered at GP–patient encounters, and of the tests ordered 81% were 
appropriate, 13% were inappropriate and 6% could not be evaluated. GPs’ ordering 
for these problems increased over time, and this was reflected in increases in tests in 
all levels of appropriateness (i.e. appropriate, inappropriate and unevaluated tests). 
These six problems were used as indicator conditions for the quality of GPs’ 
pathology ordering, and suggest that GPs in Australia are not ordering a large 
proportion of pathology tests inappropriately, and that the increases were not driven 
by increases in inappropriate ordering, despite conjecture throughout the literature.  
When making reference to GPs’ inappropriate ordering, other authors often refer to 
studies that report interventions aiming to improve appropriateness of GPs’ 
pathology ordering. As I discussed in Chapter 2, the use of interventional studies to 
describe appropriateness is flawed because such studies demonstrate the success (or 
failure) of the interventions, rather than the appropriateness of GPs’ ordering. These 
studies are designed to improve the appropriateness of ordering in a specific area in 
which GPs’ pathology ordering is known or likely to be inappropriate. It is implied 
that preceding the intervention, an evaluation step of some kind identified the area to 
be targeted on the basis of the need for improvement. Unfortunately such evaluation 
is rarely reported.  
Further, the success of an intervention (usually measured as a reduction in testing) is 
frequently assumed to reflect an improvement in the appropriateness of GPs’ 
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ordering but this is rarely assessed. In many cases a lack of clinical data linked to 
testing data prevents assessment of appropriateness. I therefore conclude that 
interventional studies cannot act as a proxy for evaluation of appropriateness of GPs’ 
pathology ordering.  
The approach I took in this thesis to evaluate appropriateness of GPs pathology, is 
fundamentally different. The six problems for which GPs’ test ordering was 
evaluated were selected on the basis of past increases in GPs’ ordering in their 
management, and the high volume of pathology testing generated by the 
management of these problems in general practice. I made no prior assumption about 
the need for improvement in the ordering of pathology. This approach enabled me to 
conclude that (in the majority of cases) GPs’ selection of tests in the investigated 
problems reflected appropriate pathology ordering. This is a substantially different 
conclusion to that reached by other authors. To the best of my knowledge, this study 
is the first to provide an assessment not influenced by the presence of a concomitant 
intervention, of the appropriateness of GPs’ pathology test selection in the 
management of the selected problems. 
While overall the majority of ordering was appropriate, there were differences 
among the six problems investigated. For four problems alignment was very high, 
with at least 85% of tests deemed appropriate, for overweight/obesity problems (in 
adult patients) alignment was moderate (72% of tests supported), but for ‘health 
check’ problems (in patients aged 15 years and above) alignment was poor, with only 
half the tests ordered being supported.  
GPs’ ordering for ‘health checks’ was assessed against guidance for preventive care. 
As discussed in Chapter 5, some of the discord between GPs’ activity and 
recommended testing may be due to GPs’ responding to the needs of the individual 
patient. Recommendations in preventive care guidance may reflect population health 
benefit, whereas GPs’ provision of health checks will be adapted to the individual 
patient’s benefit. Further research is needed to determine whether the lower level of 
alignment in GPs’ management of ‘health check’ reflects appropriate individualised 
care or inappropriate ordering. This is particularly important if the Government 
continues to use incentives to encourage GPs’ to provide specific health assessments, 
as it has done in the past.18,232,236 These types of assessments (often labelled by GPs 
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as health checks) are one way in which the Government aimed to “encourage GPs to 
deliver quality preventative health”344 and in particular were targeted to prevent and 
detect chronic disease. Their use continues to be advocated by some peak bodies and 
researchers.405,406 My work suggests that GPs’ may need further support regarding 
the selection of appropriate pathology tests when performing health checks. 
Pathology recommendations in guidance documents 
My evaluation of the appropriateness of GPs’ pathology ordering was based on 
recommendations for pathology testing in guidance documents. In reviewing these 
documents I found that the accessibility of pathology recommendations and the 
content of recommendations need considerable improvement. 
Accessibility issues related to accessing pathology recommendations within 
documents, and included: the sheer size of documents, many of which were not 
designed for GPs; lack of a central body in Australia responsible for creating and 
structuring guidelines in a consistent format; and mixed terminology used to refer to 
testing (e.g. ‘diagnostic testing’, ‘laboratory investigations’, ‘assessment’, the 
specific test name, the disease that testing aims to identify or exclude). I believe the 
international adoption of standardised terminology to refer to pathology testing in 
guidelines could have considerable impact on accessibility. It could be achieved with 
minimal effort and is worthwhile promoting.  
Content issues identified in guidelines pertain to missing or incomplete guidance. 
Primarily these deficiencies related to recommendations for testing in long-term 
management of chronic disease, including incomplete guidance about what tests 
were needed for monitoring and the recommended interval between repeated testing, 
and lack of guidance about the interpretation of repeated test results. The latter refers 
to the critical difference between results, and describes the expected analytical and 
intra-individual variance in test results.201 Such knowledge is essential for GPs to 
correctly interpret results to determine the level at which clinical intervention is 
required to maintain ‘control’ and avoid progression of disease.328 
The majority of pathology recommendations in guidance documents refer to the 
decision to order testing and the types of tests ordered and so support GPs’ decisions 
in the pre-analytical phase of testing. In contrast, guidance regarding test results in 
the post-analytical phase of testing relates primarily to the diagnosis of differentiated 
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disease. There is considerable scope for improvements in guidance for this phase of 
testing in regard to interpretation of abnormal results in undifferentiated disease and 
interpretation of monitoring tests. As I discussed in Chapter 5, providing guidance 
about interpretation of monitoring results is complex as critical difference may vary 
between patients. This is an area in which pathologists give ongoing high quality 
support to GPs and other referring clinicians for individual patients, but it could be 
supplemented by producing guidance for interpretation of common monitoring tests.  
As discussed in Chapter 5, the poor quality of recommendations in guidance 
documents for monitoring may also be due to the lack of evidence about ideal 
monitoring protocols in health care.56,329 Despite this, the volume of monitoring 
undertaken by GPs for chronic disease, and the expected increase in prevalence and 
management of these diseases due to our ageing population, leads me to recommend 
that monitoring guidance be improved. A pragmatic approach incorporating 
consensus views may be needed where evidence is not available. 
Developing guidance about monitoring (as I have recommended) and supporting 
GPs’ in applying recommended monitoring protocols may, or may not, change GPs’ 
current monitoring practices. There are limited data about these monitoring practices. 
The study reported in Chapter 6 gives some preliminary information about GPs’ 
monitoring of lipid tests, but further research is needed to understand GPs’ current 
monitoring intervals and interpretation of repeated results. Such research should 
evaluate whether monitoring influences patients’ social, cognitive or behavioural 
responses63 (for example, whether monitoring affects medication adherence) as these 
factors will contribute to a GP’s decision to order testing. Even if no change is 
needed to current practise, supporting GPs through improved guidance is still 
valuable as it supports quality of care.  
Two recent national programs have the potential to address the accessibility and 
content issues I identified in the existing guidance. The first of these is the National 
Prescribing Service medical test program announced in the 2009–10 budget to 
promote evidence-based ordering of imaging and pathology tests. At the time this 
thesis was submitted (March 2013), programs had been initiated for only a small 
number of topic areas involving pathology testing. This program will primarily 
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involve education-based interventions, and at the time of the submission of this thesis 
there were no results available from the outcomes of the program.  
The second national program is the development of pathology guidelines for GPs to 
be implemented as decision support tools within clinical software (announced as part 
of the new funding agreement between Government and the pathology industry, July 
201125). There are potential benefits and pitfalls of this approach that bear discussion 
in regard to the results presented in this thesis.  
It appears that this approach will result in the development of ‘stand alone’ pathology 
guidelines. GPs have previously indicated that they do not want pathology guidance 
to be produced in isolation as this does not assist the integration of pathology 
ordering and interpretation of results in their clinical management of problems.407 
For example, the diagnostic process of undifferentiated disease involves more than 
the selection of appropriate pathology tests. Gialamas et al. suggested that a decision 
support tool for the management of presentations of tiredness would need to 
incorporate: patient age, sex, a psychological evaluation (to assess presence of 
depression), a physical examination (e.g. to assess presence of anaemia) as well as 
advice about appropriate tests.408 Other authors have suggested additional factors 
(such as the patient’s medical history, duration of symptoms) that may also have a 
bearing on the decision.281,283,285 Therefore, the role of pathology testing in relation to 
other factors associated with the diagnostic process needs to be considered. The way 
in which the guidelines are implemented into a decision support tool and the 
associated level of integration may address this concern. 
It is unclear how the proposed Australian decision support tools will be designed and 
integrated, but results of the few international examples of similar decision support 
tools,76,79,86 suggest these factors will have an impact on the efficacy of the tool. For 
example, existing pathology decision support tools are ‘launched’ once the GP opens 
the pathology ordering section of the electronic medical record, and provide 
guidance on test selection at this point. Such an approach is unlikely to affect the 
decision to (or not to) order because GPs’ have already decided to order before any 
advice is presented. I have demonstrated that the increase in occasions of testing was 
a feature of past growth in GPs’ pathology ordering (see discussion below). This type 
of decision support design would only support appropriate test selection in GPs’ 
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clinical management—only one aspect of GPs’ pathology testing behaviour. Further 
my results show the appropriateness of GPs’ ordering is already high. Therefore, 
there may be little or no reduction in volume or cost of pathology testing achieved 
through introduction of this type of decision support tool. 
Volume and growth of GPs’ pathology ordering 
The data presented in this thesis provides the first in-depth picture of GPs’ pathology 
ordering in Australia in more than a decade. Other national pathology data (such as 
that collected by laboratories and Medicare Australia) cannot provide the same level 
of detail about GPs’ ordering as that collected in the BEACH study. In particular, the 
complex Medicare funding structure (including the episode coning rule that restricts 
payment to the three most expensive MBS pathology items per episode of GP 
ordering, and the iso-resource grouping of some items) limits the ability of Medicare 
data to accurately reflect GPs’ pathology ordering. 
My investigation of growth in the total volume of GPs’ pathology ordering from 
2000–02 to 2006–08 demonstrated that three factors contributed to the growth, each 
of which can operate as a separate mechanism and all of which increased over the 
study period. These were: increased number of national GP encounters provided to 
the population; increased number of problems managed at GP–patient encounters; 
and increased rate of GPs’ pathology ordering in the management of problems. The 
latter was due to significant increases in the likelihood of at least one pathology test 
being ordered (i.e. more occasions of testing), and the number of pathology tests 
ordered per problem once the decision to order was made (i.e. more tests per order) 
—these increases reflect change in the GPs’ pathology ordering behaviour. 
As I discussed in Chapter 4, there are many potential drivers of change in these three 
factors and each driver can act on one or more of the factors. Examples include: 
changes in the population demographics (primarily the ageing population); 
introduction of population health policies and initiatives; publication of new 
guidelines or changes to existing recommendations in guidelines; change in disease 
prevalence; and emergence of new evidence. In addition to their potential to 
influence one or more factors, they also interact among themselves. For example, 
new evidence may have an affect on guidelines and health policy, and the ageing 
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population may influence health policy and changing disease prevalence. This 
illustrates the complexity underlying growth, as discussed by several authors.9,26-30  
Describing the growth in GPs’ ordering in terms of the three factors highlighted in 
my research takes a somewhat reductionist approach. However its strength is that it 
demonstrates that change in GPs’ ordering behaviour is only partially responsible for 
the total growth in GPs’ pathology ordering—a finding that is crucial in the context 
of much of the conjecture and discussion in the literature. There is a perception that 
the increase in pathology ordering reflects a deliberate management action by GPs to 
order more pathology testing. In reality the ‘choice’ to order as represented by 
change in ordering behaviour is just one factor. 
Similarly, in the context of an individual clinical problem, change in GPs’ pathology 
ordering behaviour is only one possible factor generating growth in the volume of 
pathology ordered for its management. Therefore, growth can still occur without 
change in GPs’ ordering behaviour. Further, where change occurs, it may be an 
increase in only one of the two measures of behaviour change—occasions of testing 
or tests per order. It is important to distinguish these as there may be different factors 
contributing to growth in each type of ordering behaviour. Also an increase in 
occasions of testing represents a higher cost burden than a decision to order 
additional tests.133,134  
While the discussion above largely focuses on factors contributing to growth over 
time, the same construct can be applied to demonstrate that GPs’ pathology ordering 
at a single time point is only partially determined by GPs’ pathology ordering 
behaviour. This holds true whether investigating the total volume of pathology 
generated by GPs’ orders or the pathology generated in GPs’ management of an 
individual clinical problem.  
Demonstrating the separate contribution of GPs’ ordering behaviour to the overall 
volume and growth of pathology testing has a bearing on the discussion of the 
appropriateness of ordering. This is because the judgement of whether a clinician’s 
ordering is ‘appropriate’ or ‘inappropriate’ can only be a reflection of the 
appropriateness of their behaviour in terms of making the ‘correct’ decisions in 
initiating testing and/or ordering certain types of tests. Therefore, when inappropriate 
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ordering is present and there is potential to ‘correct’ this ordering it will only have an 
impact on the proportion of ordering that is driven by GPs’ ordering behaviour. 
I found that the majority of the volume of GPs’ pathology testing is confined to a 
relatively small group of tests and clinical problems. Other authors have previously 
noted this concentration of ordering.79,82,89 In investigating growth in GPs’ ordering 
over time, I also demonstrated that these same tests and problems contribute to most 
of the growth that has occurred. In theory, targeting these tests and/or problems with 
interventions has the potential to have a significant impact on the volume of 
pathology tests ordered by GPs. However, my research suggests that there are not 
many situations where the quality of GPs’ ordering is measurably poor, and therefore 
not many situations that could be targeted. One of the few examples is FBC testing in 
preventive care.  
FBC tests are not recommended in preventive care guidelines (Chapter 5), but GPs’ 
indicated that 8% of those ordered were for primary prevention (Chapter 6). The 
introduction of a successful intervention aiming to reduce this testing has the 
potential to have a significant impact on the volume of testing. Even if only a minor 
reduction in the ordering rate is achieved the impact on test ordering would still be 
significant because FBC tests account for the highest volume of tests ordered by 
GPs.  
Hypothetically this type of intervention would be worthwhile, however the potential 
benefits in terms of quality of care and cost-benefit also need to be considered. For 
example, determining whether reducing FBC testing for prevention will improve 
quality of care is difficult. There is no evidence for its use in primary prevention, but 
FBC testing is unlikely to generate harm to patients and the benefit of testing to an 
individual patient’s care is not known. Therefore, GPs’ may not perceive a reduction 
of testing as of benefit to patient care, yet this perception is an important element in 
achieving change in testing behaviour.409  
Further, the current Medicare rules (in particular the coning rule) for funding GP-
ordered tests mean that a reduction in volume of testing may not translate into a 
reduction in the cost to Medicare. Due to coning, only 45–55% of GP-ordered FBCs 
performed by pathologists were funded by Medicare,19,346 so reducing the volume of 
GPs’ FBC ordering (as discussed in the example above) may not achieve any cost 
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reduction. For tests that are ‘coned out’ and therefore do not attract Medicare 
reimbursement, reducing testing will generate economic savings in terms of cost of 
reagents, labour etc., although these savings will not be reflected in public spending. 
It therefore seems that any interventions that aim to improve quality of GPs’ 
pathology ordering and at the same time to reduce cost are unlikely to be successful 
under the current funding structure. 
The growth in volume and cost of pathology testing has meant that the focus of 
governments and researchers has been on understanding the growth and managing 
the demand. As a result, the quality of GPs’ pathology ordering as a whole has not 
been evaluated, including areas of overuse and underuse of pathology testing. A 
review of pathology services in England suggested that a significant proportion of 
testing (estimated as up to 25%) was inappropriate or unnecessary but that there was 
probably a similar amount of under-requesting.410 This statement was based on the 
opinions of participants in the review about testing across the entire health sector 
rather than on quantitative evidence, yet it does highlight the possibility of significant 
amounts of under-utilisation. In my assessment of appropriateness of ordering, there 
were few recommended tests that were not ordered by GPs. However, this reflects a 
grouped measure of test appropriateness. In many cases under-utilisation may relate 
to patient-based measures such as inadequate monitoring of HbA1c over time in 
patients with diabetes. Further research to evaluate the extent of under-utilisation of 
GP pathology testing in individual patient care is needed. 
The need to contain the increasing cost of pathology testing is understandable. Health 
budgets are limited and there is pressure to ensure maximum benefit for each dollar 
spent (or as the Australian Government describes it) ensuring that “spending on 
health is sustainable, affordable and provides maximum benefit to the greatest 
number of people.”20 This reflects the need for efficient health spending and implies 
the need to consider health care spending as a whole, but there is a tendency (due to 
‘siloing’ of health budgets) to consider the pathology budget in isolation. While 
quality use of pathology services by ordering physicians has been and remains a core 
objective of the Australian Government (as reflected in the maintenance of the 
Quality Use of Pathology Program, and recently funded programs to promote 
evidence-based ordering and development of decision support tools), national 
policies have not attempted to reduce demand by ordering clinicians. Historically, the 
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Government has contained the pathology budget administratively through funding 
mechanisms, which has resulted in the current complex funding system.  
There is an inherent conflict between population health strategies introduced by the 
Government and the objective of containing pathology spending. Many public health 
initiatives represent efficient health spending, as they have a net benefit to the 
community. However they can have a cost in terms of pathology testing. For 
example, the finding of the population-based AusDiab study that one in two 
Australians with diabetes were undiagnosed,157 prompted many health initiatives to 
improve detection of diabetes, and therefore increased testing costs associated with 
its diagnosis and monitoring. It is thought that the health benefits of such initiatives 
(e.g. early detection of chronic disease, prevention of complications) more than 
outweigh the cost.405 While there are situations where logical links between 
pathology testing ‘costs’ and outcomes can be made, there are many more where 
evidence between pathology testing and outcomes is lacking. This has prompted the 
call for an outcomes-based research agenda.42,57 However, producing evidence 
linking testing to outcomes is complex and the development of methodology to do so 
is an area of current research.70 While linking testing to outcomes would be ideal, in 
reality such evidence is many years away. It will be an ongoing challenge to find the 
optimal level of testing because while not enough testing will result in more ‘flow 
on’ costs in other sectors of the health system, there is a point at which too much 
testing will have no additional benefit.  
Variance in GPs’ ordering 
The presence of considerable variance among GPs’ in their use of pathology testing 
has been noted by several authors.43-51,71-73,82,337 This variance is discussed as an 
indicator of poor quality, the rationale being that in the same clinical situation, 
clinicians should be homogeneous in their use of pathology testing, and this would 
result in low levels of variation. I similarly found variance among GPs in their 
pathology ordering at encounters. However, my investigation of this variance 
suggests that it is not a good indicator of quality of GPs’ pathology ordering.  
The amount of variance I was able to explain in the analysis (50%) was much higher 
than that explained by other researchers (10–30%). This is partially because (in most 
cases) others did not have information about the clinical problems for which GPs 
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ordered pathology tests and therefore were limited in their ability to assess the 
influence of the clinical situation on the variance. The GP’s clinical workload, in 
particular the type of clinical problem under management at GP encounters, was the 
strongest determinate of pathology testing. However, I may have underestimated the 
influence of the clinical problem on variance as I used the ICPC-2 chapter to 
represent the clinical problem in the modelling. This chapter represents the body 
system that the clinical problem is classified to; for example, diabetes and lipid 
disorders are both classified to the ‘endocrine, metabolic and nutritional’ chapter. If 
the multivariate analysis had included the individual clinical problems (not just its 
ICPC-2 chapter), more variance may have been explained. 
A number of other GP, practice and patient variables were found to be independent 
predictors of pathology ordering. These accounted for far less of the variance than 
did clinical problems. Some are not surprising such as lower testing for young 
patients aged < 5 years, and higher testing for new patients. However, others such as 
the higher ordering rates of young GPs and female GPs raise concerns (as discussed 
later) and may need to be further investigated. 
Variation in response to patient-centred care represents higher quality care.411-414 
Therefore, the finding that the clinical problem under management was the primary 
factor driving variance can be considered an indicator of good quality care. The 
variables available in my analysis (i.e. those recorded in the BEACH study) only 
‘scratch the surface’ in terms of describing the clinical situation that may generate 
‘appropriate’ variance. GPs provide holistic care to their patients and their decision 
to order pathology in the management of the patient will incorporate consideration of 
biomedical and psychosocial factors. These types of drivers of patient-centred care 
are difficult to measure.  
As discussed in Chapter 7, the inability of other researchers to incorporate the 
clinical problem in their models limits their ability to adequately assess ‘appropriate 
variance’. Without adequate data to differentiate, researchers are effectively 
assuming that GPs’ are homogeneous in the type of patients they see and care they 
provide to patients—we know this is not the case.382 However, there may be specific 
clinical circumstances in which variance among GPs’ pathology ordering reflects 
poor quality. Assessment of variance in such circumstances should reflect a specific 
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subset of pathology data; rather than variation in GPs’ total ordering—the main 
measure used to date. I believe it is reasonable to conclude that a large proportion of 
the variance in GPs’ total pathology ordering reflects patient-centred care and 
therefore quality care. It is misleading to assess variance of GPs’ ordering without 
adjusting for the clinical workload of the GP, particularly the problem under 
management. I conclude that variance in total volume of pathology ordering is too 
blunt to be considered a useful measure of the quality of GPs’ pathology ordering. 
Predicted future growth in GPs’ ordering 
My research confirms that the growth and ageing of Australia’s population will 
contribute to ongoing growth in volume of pathology tests ordered by GPs to at least 
2050. Over the 5 years from 2009–10 to 2015, I estimated that the volume of GPs’ 
pathology ordering will grow between 2.1% and 2.5% per annum purely because of 
these expected demographic changes.  
The three factors (discussed earlier) that contributed to past growth in GPs’ ordering 
behaviour were held steady in these projections. Therefore, future growth can be 
expected even if no change occurs in GPs’ ordering behaviour, the number of 
problems managed by GPs’ per encounter or the number of encounters per person. 
However, it is inevitable that there will be further changes in these three factors. In 
addition to demographic changes, governments cite technological advancements 
(including new tests) as an expected driver of increased future health spending.234,397 
Other potential contributors include the many drivers linked to past growth, such as 
changes in disease prevalence, emergence of new evidence and new technologies, 
changes in health policy etc., and there are likely to be many more that emerge over 
time.  
My research suggests that workforce factors may also influence the future growth of 
GPs’ pathology ordering. For example, the finding that young GPs and female GPs 
ordered more pathology tests after adjustment than their older and male counterparts 
(as discussed in Chapter 7), may contribute to growth as the number of trainee GPs 
and the proportion of female GPs in the workforce are increasing.383  
As I discussed in Chapter 8, under the current Medicare funding structure, the future 
increases in volume of GPs’ pathology testing will only be partially reflected in 
increases in Medicare outlays. Nevertheless, the projected increases in volume of 
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GP-ordered tests will place ongoing pressure on the pathology budget, one of many 
areas of the health budget that will be under pressure as a result of the ageing 
population.  
The ageing of the population is expected to increase the prevalence of diagnosed 
chronic disease and therefore its management in general practice. Pathology testing 
is integral to this management, and to the initiatives introduced by the Government to 
support GPs’ prevention, detection and management of chronic disease.187,235 As 
discussed earlier, some of these initiatives have encouraged GPs’ use of health 
checks to prevent (through identification of risk factors) and detect chronic disease. 
Early detection is encouraged, as the sooner chronic disease is diagnosed the greater 
the potential for preventing disease progression and complications. 
Once diagnosed, chronic disease management frequently requires long-term (often 
life-long) monitoring to determine disease progress, presence of complications, 
effectiveness of drug therapy and/or presence of side effects related to drug therapy. 
Pathology ordered for this monitoring already accounts for the majority of pathology 
testing ordered by GPs.415 If diagnosed chronic disease prevalence increases as 
expected there will be significant growth in the associated pathology testing. Early 
detection may compound this further, particularly if life expectancy in the population 
continues to increase, because if people are living longer and chronic disease is 
diagnosed earlier, there will be a longer duration of monitoring required. Therefore, 
the associated growth in pathology ordering may be exponential. The expected 
increases in this area underscore the importance of improving the poor monitoring 
guidance in guidelines, and supporting GPs in the quality use of pathology testing in 
long-term chronic disease management. 
Suggestions for future research 
Further investigation of the appropriateness of GPs’ pathology ordering for clinical 
presentations beyond the six problems investigated in this thesis, would provide a 
more comprehensive evaluation of the appropriateness of GPs’ pathology ordering. 
Such evaluation could be undertaken with BEACH data, using similar methods to 
those used in the study described in Chapter 5. This research would provide an 
assessment of the availability and quality of guidance documents for other clinical 
 318 
presentations and highlight areas for future interventions where it was found that 
GPs’ ordering and/or guidance could be improved. 
Future research will be needed to evaluate the impact of recent national programs 
that aim to introduce decision support tools for GPs, and to promote evidence-based 
testing. These programs are likely to implement educational interventions targeting 
GPs’ pathology ordering behaviour in regard to specific tests or clinical problems. 
Such interventions will need to be evaluated. The results of this thesis indicate that 
any future evaluation will need to measure the impact of the intervention on GPs’ 
ordering behaviour (including the likelihood of ordering, and the number and types 
of tests ordered), as well as changes in GP workload related to management of the 
targeted clinical problem or area. It is also important to collect sufficient variables to 
assess the appropriateness of pathology ordering in the targeted clinical area, at 
baseline and after the intervention. A simple measure of the number of tests ordered 
will not provide sufficient detail to determine success of an intervention or the 
appropriateness of any measured change. Ideally such evaluations would be 
conducted as randomised controlled trials. 
In this thesis, the need for further research has been highlighted in several other 
areas, not covered in the research proposed above. Examples include: the need to 
describe and assess the appropriateness of GPs’ pathology ordering in selected 
clinical situations (that could not assessed in this cross-sectional study); the need for 
research to establish the role of selected pathology tests in the investigation or 
monitoring of a condition/presentation; and the need for evidence about outcomes 
associated with different testing practices.  
Establishing a patient-based longitudinal study has the potential to fill these gaps. 
Experience from the research presented in this thesis suggests that the variables 
required for future pathology research include the clinical presentation, details about 
patients and their medical history (e.g. test results, presence of diagnosed 
morbidities, risk factors, use of selected medications, family history, and social 
circumstances), pathology tests ordered, and outcome measures (e.g. hospitalisations, 
measures of disease severity, and patients’ responses to testing such as psychosocial, 
cognitive and behavioural responses).  
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There are numerous ways in which data collected in this type of longitudinal patient-
based study could be utilised. For example, it would be possible to measure patient 
health outcomes associated with GPs’ adherence to pathology monitoring protocols 
in the management of specific diseases. It would also be possible to use the 
additional variables collected in this research (as listed above) to identify factors 
associated with the unexplained variance among GPs in their pathology ordering 
behaviour. Establishing a general practice patient-based longitudinal research project 
would create a data set that contains pathology test ordering and results data in the 
broader clinical context of the patient. 
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10 Conclusion 
Considerable growth in pathology services generated by GP orders has led to 
concerns about appropriateness of this ordering. In this thesis I investigated three 
aspects of GPs’ pathology: the reasons for GPs’ pathology ordering; how these 
reasons contribute to growth in pathology ordering; and the appropriateness of this 
ordering. This body of work provides the first clear picture in over a decade of GPs’ 
pathology ordering and how it has changed over time. 
Factors contributing to the increase in pathology ordering include: increasing 
likelihood of ordering pathology tests; increasing number of tests ordered per 
episode; increasing number of problems managed at GP–patient encounters; 
increasing total volume of GP services provided to the Australian population. A 
small number of tests and problems account for the majority of pathology tests 
ordered by Australian GPs, and the majority of growth. Therefore, targeting 
interventions to these tests and/or problems may have a significant impact on the 
volume of pathology ordered by GPs. 
The volume of pathology tests related to an individual problem is only partially 
determined by GPs’ pathology ordering behaviour in the management of the 
problem. This has implications for interventions that target GPs’ pathology ordering 
behaviour because if successful such interventions will only partially affect the 
associated volume of pathology tests ordered. With recent national programs being 
funded to develop interventions to support GPs’ in the area of pathology ordering, an 
evaluation strategy that measures the impact of these interventions is needed. Such 
evaluation needs to determine the impact of the intervention on the volume of 
pathology testing that can be attributed to GP ordering behaviour, and the 
appropriateness of any change in ordering behaviour. 
Variance among GPs in their volume of pathology ordering is used in the literature 
as an indicator of poor quality of GPs’ ordering. I found that the foremost factor in 
explaining variance is the clinical problem being managed by the GP, which suggests 
patient-centred care is the main driver for variance. As such variance is appropriate, I 
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conclude that variation in total rates of pathology ordering is not a reasonable 
measure of the quality of GPs’ ordering. 
The good alignment with guidance documents of GPs’ test selection in the 
management of six problems, and the fact that the increased ordering for these 
problems did not reflect a change in appropriateness of ordering, lead me to conclude 
that concerns about widespread inappropriateness of GPs pathology ordering are not 
substantiated, and that growth in testing does not equate with an increase in 
inappropriate ordering. 
The expected ageing and growth in Australia’s population will generate future 
growth in volume of pathology ordering irrespective of changes to GPs’ clinical 
workload or GPs’ pathology ordering behaviour. In particular, the ageing population 
will generate increased management of chronic diseases and along with it pathology 
testing associated with its management. The majority of this testing will be ordered 
for monitoring, however, recommendations for monitoring in guidelines were poor. 
Guidance needs to incorporate monitoring protocols detailing the pathology tests that 
have a role in ongoing monitoring, and the intervals at which these tests are required. 
Further research is needed to investigate and evaluate the monitoring protocols used 
by GPs. Ideally such research would be undertaken in a patient-based longitudinal 
research project that allows evaluation of patient health outcomes associated with 
GPs’ adherence to pathology monitoring protocols. Improving the evidence base and 
guidance for pathology testing in long-term management of chronic disease will 
support GPs’ in their quality use of pathology testing in this high growth area. 
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Appendix 5: Patient information card 
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Appendix 6: ICPC-2 and ICPC-2 PLUS code 
groups used for analysis of problems managed 
Table A6.1: Code groups from ICPC-2 and ICPC-2 PLUS 
Problem managed ICPC-2 rubric 
ICPC-2 PLUS 
code ICPC-2/ICPC-2 PLUS label 
Abdominal pain D01  Pain/cramps; abdominal general 
 D06  Pain; abdominal localised; other 
Abnormal test results A91  Abnormal result investigations NOS 
 B84  Unexplained abnormal white cells 
 U98  Abnormal urine test NOS 
 X86  Abnormal cervix smear 
Anaemia B80  Iron deficiency anaemia 
 B81  Anaemia; vitamin B12/folate deficiency 
 B82  Anaemia; other/unspecified 
  B78002 Anaemia; sickle cell 
  B78003 Anaemia; hereditary haemolytic 
  B79001 Anaemia; congenital 
  B79004 Anaemia; hereditary 
Arthritis – all L88  Rheumatoid/seropositive arthritis 
 L89   Osteoarthrosis of hip 
 L90   Osteoarthrosis of knee 
 L91   Osteoarthrosis, other 
  L70009 Arthritis; pyogenic 
  L70010 Arthritis; viral 
  L70021 Arthritis;septic 
  L81003 Arthritis; traumatic 
  L81015 Haemarthrosis 
  L83010 Arthritis; spine cervical 
  L83011 Osteoarthritis;spine;cervical 
  L84003 Arthritis; spine 
  L84004 Osteoarthritis;spine 
  L84009 Osteoarthritis;spine;thoracic 
  L84010 Osteoarthritis;spine;lumbar 
  L84011 Osteoarthritis;lumbosacral 
  L84012 Osteoarthritis;sacroiliac 
  L92006 Arthritis; shoulder 
  L92007 Osteoarthritis;shoulder 
  L92011 Humeroscapular periarthritis 
(continued) 
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Table A6.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS 
Problem managed ICPC-2 rubric 
ICPC-2 PLUS 
code ICPC-2/ICPC-2 PLUS label 
Arthritis – all (continued)  S91002 Arthritis; psoriatic 
  T99063 Arthritis; crystal (excl. gout) 
Back complaint L02  Back symptom/complaint 
 L03  Low back symptom/complaint 
 L86  Back syndrome with radiating pain 
Blood test – all(a) –34  Blood test 
Cardiovascular  
check-up 
K30  Medical examination/health evaluation, 
complete, cardiovascular system 
 K31  Medical examination/health evaluation, 
partial, cardiovascular system 
Depression P03  Feeling depressed 
 P76  Depressive disorder 
Female genital  
check-up/Pap smear 
X30  Complete medical examination/health 
evaluation, female genital 
 X31  Partial medical examination/health 
evaluation, female genital 
 X37  Histological / exfoliative cytology, 
female genital 
Health check 
(15+ years)(b) 
 A30001 Health evaluation; complete  
  A30002 Exam; complete  
  A30011 Check up; complete 
  A30010  Exam; complete; physical 
  A30017 Medical exam; complete 
  A30028 Health assessment 
  A30029 Check up; adult health; complete 
  A31001 Health evaluation; partial 
  A31003 Assessment; normal growth  
  A31004 Exam; partial; physical 
  A31005 Check up; partial  
  A31006  Exam; partial  
  A31008 Health screening  
  A31012 Check up  
  A31013 Medical exam  
  A31017 Assessment; aged care  
  A31025 Check up; adult health; partial 
  A31026  Health surveillance; partial  
  A31027  Assessment; physical fitness  
  A31030  Check up; height/weight 
(continued) 
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Table A6.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS 
Problem managed ICPC-2 rubric 
ICPC-2 PLUS 
code ICPC-2/ICPC-2 PLUS label 
K86  Hypertension; uncomplicated Hypertension  
(non-gestational) 
K87  Hypertension; complicated  
K74  Ischaemic heart disease with angina Ischaemic heart 
disease 
K75  Acute myocardial infarction 
 K76  Ischaemic heart disease without angina 
Lipid disorders T93  Lipid disorders 
Menstrual problems X02  Pain; menstrual 
 X03  Pain; intermenstrual 
 X05  Menstruation; absent/scanty 
 X06  Menstruation; excessive 
 X07  Menstruation; irregular/frequent 
 X08  Intermenstrual bleeding 
 X09  Premenstrual symptom/complaint 
 X10  Postponement of menstruation 
T82  Obesity Overweight/obesity 
(adults)(c) 
T83  Overweight 
Pregnancy W01  Question of pregnancy 
 W78  Pregnancy 
 W79  Unwanted pregnancy 
Prescription – all(d) –50  Medication prescription/request/ 
renewal/injection 
B90  HIV infection/AIDS Sexually transmitted 
infection 
X70  Syphilis; female 
 X71  Gonorrhoea; female 
 X73  Genital trichomoniasis; female 
 X74  Pelvic inflammatory disease 
 X90  Genital herpes; female 
 X91  Condylomata acuminata; female 
 X92  Chlamydia infection, genital; female 
 Y03  Urethral discharge; male 
 Y70  Syphilis; male 
 Y71  Gonorrhoea; male 
 Y72  Genital herpes; male 
 Y76  Condylomata acuminata; male 
  A78011 Disease; sexually transmitted 
  A78053 Disease; venereal 
  D72003 Hepatitis B 
(continued) 
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Table A6.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS 
Problem managed ICPC-2 rubric 
ICPC-2 PLUS 
code ICPC-2/ICPC-2 PLUS label 
 D72008 Hepatitis C Sexually transmitted 
infection (continued) 
 U72003 Urethral syndrome 
  U72005 Urethritis 
  U72006 Urethritis; non-gonococcal; female 
  U72007 Urethritis; non-gonococcal; male 
  U72008 Urethritis; non specific; female 
  U72009 Urethritis; non specific; male 
  U72010 Urethritis; chlamydial 
  Y73002 Prostatitis 
  Y99018 Chlamydia; male 
  Y99020 Donovanosis; male 
Type 2 diabetes T90  Diabetes; non-insulin-dependent 
Urinary tract infection U70  Pyelonephritis/pyelitis 
 U71  Cystitis/urinary infection other 
Weakness/tiredness A04  Weakness/tiredness, general 
(a) The ICPC-2 rubric ‘–34’ signifies that the concept ‘blood test – all’ includes all of the blood test rubrics across all 
chapters of ICPC-2 (excluding the social chapter). 
(b) Analysis of health check problems was limited to patients aged 15 years and over. 
(c) Analysis of overweight/obesity problems was limited to adult patients aged 18 years and over. 
(d) The ICPC-2 rubric ‘–50’ signifies that the concept ‘prescription – all’ includes all of the prescription rubrics across all 
chapters of ICPC-2 (excluding the social chapter). 
Note: NOS – not otherwise specified; HIV – human immunodeficiency virus; AIDS – acquired immune deficiency syndrome.  
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Appendix 7: ICPC-2 PLUS code groups used for 
analysis of pathology tests  
Table A7.1: Pathology code groups for MBS groups and individual tests/batteries 
Pathology test orders ICPC-2 PLUS code ICPC-2 PLUS label 
Chemistry   
 Amylase D34004 Test; amylase 
 C reactive protein (CRP) A34005 Test; C reactive protein 
 Calcium/phosphate A34006 Test; calcium 
 A34013 Test; phosphate 
 A34024 Test; calcium phosphate 
 Creatine kinase (CK) K34004 Test; creatine kinase 
 Drug screen A34002 Drug assay 
 A34026 Blood drug screen 
 A34027 Blood screen 
 A35003 Drug screen 
 A35005 Urine drug screen 
 K34005 Test; digoxin 
 N34003 Test; phenytoin 
 N34004 Test; valproate 
 N34005 Test; carbamazepine 
 P34002 Test; lithium 
A34007 Test; chloride  Electrolytes, urea and 
 creatinine (EUC) 
A34008 Test; electrolytes 
 A34010 Test; electrolytes, urea and creatinine (EUC) 
 A34014 Test; potassium 
 A34017 Test; sodium 
 A34029 Test; urea and electrolytes 
 A34034 Test; electrolytes and creatinine 
 U34002 Test; creatinine 
 U34003 Test; urea 
 HbA1c T34010 Test; HbA1c 
 T34017 Test; fructosamine 
 T34022 Test; HBA1 
 Ferritin B34016 Test; ferritin 
 B34019 Test; iron studies 
  (continued) 
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Table A7.1 (continued): Pathology code groups for MBS groups and individual 
tests/batteries 
Pathology test orders ICPC-2 PLUS code ICPC-2 PLUS label 
 Folic acid B34017 Test; folic acid 
 B34024 Test; folate 
 Glucose/glucose tolerance T34005 Test; glucose 
 T34009 Test; glucose tolerance 
 T34023 Test; glucose (fasting/random) 
 T34025 Test; glucose; fasting 
 T34026 Test; glucose; random 
 Hormone assay A34003 Hormone assay 
 D33015 Test; Anti gliadin antibody 
 T34007 Test; cortisol 
 T34034 Test; adrenocorticotropic hormone  
 W34005 Test; HCG 
 W34006 Test; B HCG level (titre/quant) 
 X34002 Test; luteinising hormone  
 X34003 Test; progesterone 
 X34004 Test; oestradiol 
 X34005 Test; follicle stimulating hormone  
 X34006 Test; SHBG; female 
 X34007 Test; free androgen index; female 
 Y34004 Test; SHBG; male 
 Y34005 Test; free androgen index; male 
 Lactose intolerance D38002 Test; lactose intolerance 
 Lipids T34001 Check up; cholesterol 
 T34004 Test; lipids profile 
 T34006 Test; cholesterol 
 T34011 Test; cholesterol high-density lipoprotein (HDL)
 T34013 Test; cholesterol low-density lipoprotein (LDL) 
 T34016 Test; triglycerides 
 T34020 Test; free fatty acids 
 T34024 Test; chol/trig 
 Liver function test (LFT) A34004 Test; albumin 
 D34003 Test; alkaline phosphatase 
 D34006 Test; bilirubin 
 D34007 Test; gamma-glutamyl transferase 
 D34008 Test; liver function 
 T34012 Test; lactate dehydrogenase 
(continued) 
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Table A7.1 (continued): Pathology code groups for MBS groups and individual 
tests/batteries 
Pathology test orders ICPC-2 PLUS code ICPC-2 PLUS label 
 Multi-biochemical analysis 
 (MBA) 
A34012 Test; multi-biochemical analysis (MBA) 
 A34021 Test; electrolytes & liver function test  
(E & LFT) 
 Other chemistry A33023 Test; alpha fetoprotein 
 A33026 Test; cancer antigen 125 
 A33027 Test; cancer antigen 15.3 
 A33028 Test; cancer antigen 19.9 
 A33029 Test; carcinoembryonic antigen 
 A33041 Test; cancer antigen 
 A34015 Test; protein 
 A34018 Vitamin assay 
 A34019 Test; lead 
 A34020 Test; blood gas analysis 
 A34022 Test; mineral 
 A34023 Test; zinc 
 A34025 Test; dehydroepiandrosterone sulfate  
 A34030 Test; biochemistry 
 A34031 Test; blood alcohol 
 A34032 Test; prolactin 
 A34033 Test; testosterone 
 A34037 Test; Glutathione S-transferase 
 A34038 Test; magnesium 
 A34040 Test; renin 
 A35004 Test; urine sodium 
 A35007 Test; urine; albumin 
 A35008 Test; albumin creatine ratio 
 B34023 Test; transferrin 
 D34002 Test; alanine aminotransferase 
 D35002 Test; 5-hydroxyindoleacetic acid 
 K34001 Test; blood; digitalis 
 K34006 Test; amino acids 
 K34007 Test; troponin 
 N34001 Test; blood; phenylhydantoin 
 P34003 Test; methadone 
 T34018 Test; androgens 
 T34019 Test; insulin 
 T34021 Test; C peptide 
(continued) 
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Table A7.1 (continued): Pathology code groups for MBS groups and individual 
tests/batteries 
Pathology test orders ICPC-2 PLUS code ICPC-2 PLUS label 
 Other chemistry (continued) T34029 Test; aldosterone 
 T34030 Test; parathyroid hormone 
 T34035 Test; lipase 
 T35002 Test; catecholamines 
 W34008 Test; pregnancy associated plasma  
protein A 
 W38002 Amniocentesis 
 Prostate specific antigen Y34002 Test; acid phosphatase 
 Y34003 Test; prostate specific antigen 
 Thyroid function (TFT) T34015 Test; thyroid function 
 T34027 Test; thyroxine 
 T34028 Test; thyroid stimulating hormone 
 Urate/uric acid U34004 Test; urate/uric acid 
 Vitamin B12 B34015 Test; B12 
 D34009 Test; Schillings 
Cytopathology   
 Cytology A37002 Test; cytology 
 B37003 Test; cytology; blood 
 D37002 Test; cytology; digestive 
 F37002 Test; cytology; eye 
 H37002 Test; cytology; ear 
 K37002 Test; cytology; cardiovascular 
 L37002 Test; cytology; musculoskeletal 
 N37002 Test; cytology; neurological 
 R37002 Test; cytology; respiratory 
 R37003 Test; sputum cytology 
 S37002 Test; cytology; skin 
 T37002 Test; cytology; endocrine/metabolic 
 U37002 Test; cytology; urology 
 W37002 Test; cytology; reproduction 
 Y37002 Test; cytology; genital; male 
 Pap smear X37001 Pap smear 
 X37003 Test; cytology; genital; female 
 X37004 Vault smear 
 X37005 Pap smear; thin prep 
(continued) 
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Table A7.1 (continued): Pathology code groups for MBS groups and individual 
tests/batteries 
Pathology test orders ICPC-2 PLUS code ICPC-2 PLUS label 
Haematology   
 Blood grouping & typing B33001 Test; Coombs 
 B33002 Test; blood grouping & typing 
 B33009 Test; blood group 
 B33013 Test; blood; cross match 
 Coagulation B34003 Test; coagulation time 
 B34006 Test; part thromboplastin time 
 B34009 Test; prothrombin time 
 B34014 Test; activated partial thromboplastin time 
 B34022 Test; thrombin time 
 B34025 Test; international normalised ratio (INR) 
 B34026 Test; fibrinogen 
 B34028 Test; bleeding time 
 B34029 Test; coagulation screen 
 K34008 Test; D-Dimer 
 Erythrocyte sedimentation  
 rate (ESR) 
A34009 Test; Erythrocyte sedimentation rate (ESR) 
 Full blood count (FBC) A34011 Test; full blood count  
 Haemoglobin B34018 Test; haemoglobin 
 Other blood A33042 Test; lymphocyte type & count 
 A34035 Test; blood film 
 A34036 Test; blood thick film 
 B33003 RH; antibody titer 
 B34005 Test; blood; platelets 
 B34007 Test; blood; sickle cell 
 B34021 Test; reticulocyte count 
 B34031 Test; haemoglobin epg 
 B34032 Test; packed cell volume 
 B34033 Test; blood; blood 
 B37001 Exam; bone marrow 
Histopathology (Tissue pathology)   
 Histology; skin S37001 Test; histopathology; skin 
 Other histology A37001 Test; histopathology 
 B37002 Test; histopathology; blood 
 D37001 Test; histopathology; digestive 
 F37001 Test; histopathology; eye 
(continued) 
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Table A7.1 (continued): Pathology code groups for MBS groups and individual 
tests/batteries 
Pathology test orders ICPC-2 PLUS code ICPC-2 PLUS label 
 Other histology (continued) H37001 Test; histopathology; ear 
 K37001 Test; histopathology; cardiovascular 
 L37001 Test; histopathology; musculoskeletal 
 N37001 Test; histopathology; neurological 
 R37001 Test; histopathology; respiratory 
 T37001 Test; histopathology; endocrine/metabolic 
 U37001 Test; histopathology; urology 
 W37001 Test; histopathology; reproductive 
 X37002 Test; histopathology; genital; female 
 Y37001 Test; histopathology; genital; male 
Immunology   
 Anti-nuclear antibodies L33004 Test; anti-nuclear antibodies 
 Other immunology A32001 Test; sensitivity 
 A33005 Test; immunology 
 A33011 Test; human leucocyte antigen 
 A33024 Test; bone marrow surface mark 
 A33025 Test; serum electrophoresis 
 A33051 Test; immune status 
 A33052 Test; skin patch 
 A38004 Test; deoxyribonucleic acid 
 B33005 Test; immunology; blood 
 B33007 Test; immunoglobulins 
 B33011 Test; immunoglobulin E 
 B34027 Test; FBC for surface markers 
 B34030 Test; intrinsic factor 
 D32001 Test; sensitivity; digestive 
 D33004 Test; immunology; digestive 
 D33014 Test; endomysial antibody 
 D33028 Test; mitochondrial antibodies 
 D33031 Test; anti-tissue transglutaminase 
 D34010 Test; transglutamase 
 F33002 Test; immunology; eye 
 H33002 Test; immunology; ear 
 K33002 Test; immunology; cardiovascular 
 K33003 Test; antineutrophil cytoplasmic antibodies  
 L33003 Test; immunology; musculoskeletal 
(continued) 
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Table A7.1 (continued): Pathology code groups for MBS groups and individual 
tests/batteries 
Pathology test orders ICPC-2 PLUS code ICPC-2 PLUS label 
 Other immunology (continued) L34001 Test; lupus erythematosus; cell prep 
 N33002 Test; immunology; neurological 
 R32004 Test; sensitivity; respiratory 
 R33004 Test; immunology; respiratory 
 S32001 Test; sensitivity; skin 
 S33002 Test; immunology; skin 
 T33002 Test; immunology; endocrine/metabolic 
 U33003 Test; immunology; urology 
 W33007 Test; immunology; reproductive 
 X33002 Test; immunology; genital; female 
 Y33002 Test; immunology; genital; male 
 Radioallergosorbent test (RAST) A34016 Test; RAST 
 Rheumatoid factor L33001 Test; rheumatoid factor 
Infertility and pregnancy tests W33002 Test; pregnancy 
 W34002 Test; blood; pregnancy 
 W34003 Test; antenatal 
 W34007 Test; pregnancy screen 
 Y38002 Test; sperm count 
 Y38003 Test; semen examination 
Microbiology   
 Antibody A33003 Test; antibody 
 Cervical swab X33004 Test; cervical swab M,C&S 
 Chlamydia A33006 Test; chlamydia 
 A33034 Test; chlamydia direct immunofl 
 X33006 Test; viral culture; genital; female 
 Ear swab and M,C&S H33003 Test; ear swab M,C&S 
 Faeces M,C&S D33002 Stool(s); culture 
 D33008 Test; faeces M,C&S 
 D36001 Test; faeces; cyst/ova/parasite 
 Fungal ID/sensitivity A33008 Test; fungal ID/sensitivity 
 A33030 Test; skin scraping fungal M,C&S 
 Hepatitis serology D33005 Test; hepatitis A serology 
 D33006 Test; hepatitis B serology 
 D33007 Test; hepatitis C serology 
 D33010 Test; hepatitis D serology 
 D33011 Test; hepatitis E serology 
(continued) 
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Table A7.1 (continued): Pathology code groups for MBS groups and individual 
tests/batteries 
Pathology test orders ICPC-2 PLUS code ICPC-2 PLUS label 
 Hepatitis serology (continued) D33013 Test; hepatitis serology 
 D33016 Test; hepatitis C antibody 
 D33017 Test; hepatitis B antigen 
 D33018 Test; hepatitis A antibody 
 D33019 Test; hepatitis B antibody 
 D33020 Test; hepatitis D antibody 
 D33021 Test; hepatitis E antibody 
 D33022 Test; hepatitis A antigen 
 D33023 Test; hepatitis C antigen 
 D33024 Test; hepatitis D antigen 
 D33025 Test; hepatitis E antigen 
 D33026 Test; hepatitis antibody 
 D33027 Test; hepatitis antigen 
 HIV A33021 Test; cytomegalovirus serology 
 B33006 Test; HIV 
 B33008 Test; AIDS screen 
 B33012 Test; HIV viral load 
 H pylori D33009 Test; H Pylori 
 Other microbiology A33004 Test; microbiology 
 A33007 Test; culture and sensitivity 
 A33012 Test; mycoplasma serology 
 A33013 Test; parvovirus serology 
 A33015 Test; Barmah forest virus 
 A33016 Test; Antistreptolysin O Titre 
 A33017 Test; herpes simplex culture 
 A33019 Test; herpes simplex serology 
 A33020 Test; toxoplasmosis serology 
 A33033 Test; swab M,C&S 
 A33035 Test; serology 
 A33036 Antibodies screen 
 A33038 Test; rapid plasma regain 
 A33039 Test; viral swab M,C&S 
 A33040 Test; viral serology 
 A33043 Test; human papilloma virus (HPV) 
 A33044 Test; Brucella 
 A33045 Test; fungal M,C&S 
(continued) 
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Table A7.1 (continued): Pathology code groups for MBS groups and individual 
tests/batteries 
Pathology test orders ICPC-2 PLUS code ICPC-2 PLUS label 
A33046 Test; measles virus antibodies  Other microbiology 
 (continued) 
A33047 Test; Rickettsial serology 
 A33053 Test; Bartonella 
 A33054 Test; M,C&S 
 A34028 Test; blood culture 
 A34039 Test; Q fever 
 B33004 Test; microbiology; blood 
 B33010 Test; serum immunoglobulins 
 D33003 Test; microbiology; digestive 
 D33012 Test; rotavirus 
 F33001 Test; microbiology; eye 
 F33003 Test; eye swab M,C&S 
 H33001 Test; microbiology; ear 
 K33001 Test; microbiology; cardiovascular 
 L33002 Test; microbiology; musculoskeletal 
 N33001 Test; microbiology; neurological 
 R33001 Culture; tuberculosis 
 R33002 Culture; throat 
 R33003 Test; microbiology; respiratory 
 R33009 Test; influenza serology 
 R33010 Test; Legionnaires antibodies 
 R33011 Test; respiratory syncytial virus 
 S33001 Test; microbiology; skin 
 S33005 Test; varicella zoster serology 
 S33006 Test; varicella zoster culture 
 S33007 Test; nail M,C&S 
 T33001 Test; microbiology; endocrine/metabolic 
 U33002 Test; microbiology; urology 
 W34004 Test; antenatal serology 
 W33006 Test; microbiology; reproductive 
 X33001 Test; microbiology; genital; female 
 X33003 Culture; gonococcal; female 
 Y33001 Test; microbiology; genital; male 
 Y33003 Culture; gonococcal; male 
 Y33004 Test; viral culture; genital; male 
 Y33005 Test; urethral/penile swab 
(continued) 
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Table A7.1 (continued): Pathology code groups for MBS groups and individual 
tests/batteries 
Pathology test orders ICPC-2 PLUS code ICPC-2 PLUS label 
 Monospot A33002 Test; monospot 
 A33014 Test; Paul Bunnell 
 A33031 Test; Epstein Barr virus serology 
 A33032 Test; Epstein Barr virus 
 Nose swab M,C&S R33008 Test; nose swab M,C&S 
 Pertussis R33007 Test; pertussis 
 Ross River fever A33009 Test; Ross River Fever 
 Rubella A33001 Test; rubella 
 Skin swab M,C&S S33003 Test; skin swab M,C&S 
 Sputum M,C&S R33005 Test; sputum M,C&S 
 Throat swab M,C&S R33006 Test; throat swab M,C&S 
 Urine M,C&S U33001 Test; culture; urine 
 U33004 Test; urine M,C&S 
 Vaginal swab and M,C&S X33005 Test; vaginal swab M,C&S 
A33010 Test; venereal disease  Sexually transmitted infection 
 (STI) screen 
A33022 Test; syphilis serology 
 A33057 STI screen 
Simple basic tests   
 Occult blood test D36003 Test; occult blood 
 Other simple basic tests B35001 Test; urine; blood 
 R32001 Test; Mantoux 
 R32002 Test; tuberculin 
 W33001 Test; urine; pregnancy 
 W35003 Test; urine; HCG 
Other tests NEC   
 Blood test A34001 Test; blood 
 Urine test A35001 Test; urine 
 Urinalysis A35002 Urinalysis 
 Faeces test A36001 Test; faeces 
 Other test NEC A35006 Test; urine; full ward test 
 A38001 Test; other lab 
 A38002 Pathology 
 A38003 Test; genetic 
 A38005 Test; disease screen 
 B38001 Test; other lab; blood 
 D34001 Test; blood; digestive 
 D35001 Test; urine; digestive 
(continued) 
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Table A7.1 (continued): Pathology code groups for MBS groups and individual 
tests/batteries 
Pathology test orders ICPC-2 PLUS code ICPC-2 PLUS label 
 Other test NEC (continued) D36002 Test; faeces; digestive 
 D38001 Test; other lab; digestive 
 F34001 Test; blood; eye 
 F38001 Test; other lab; eye 
 H34001 Test; blood; ear 
 H38001 Test; other lab; ear 
 K34002 Test; blood; cardiovascular 
 K38001 Test; other lab; cardiovascular 
 L34003 Test; blood; musculoskeletal 
 L38001 Test; other lab; musculoskeletal 
 N34002 Test; blood; neurological 
 N38001 Test; other lab; neurological 
 P34001 Test; blood; psychological 
 P35001 Test; urine; psychological 
 P38001 Test; other lab; psychological 
 R34001 Test; blood; respiratory 
 R38001 Test; other lab; respiratory 
 S34001 Test; blood; skin 
 S38001 Test; other lab; skin 
 T34002 Test; blood; endocrine/metabolic 
 T35001 Test; urine; endocrine/metabolic 
 T38001 Test; other lab; endocrine/metabolic 
 U34001 Test; blood; urology 
 U35002 Test; urine; urology 
 U38001 Test; other lab; urology 
  W34001 Test; blood; reproductive 
 W35001 Test; urine; reproductive 
 W38001 Test; other lab; reproductive 
 X34001 Test; blood; genital; female 
 X35001 Test; urine; genital; female 
 X38001 Test; other lab; genital; female 
 Y34001 Test; blood; genital; male 
 Y35001 Test; urine; genital; male 
 Y38001 Test; other lab; genital; male 
 Z38001 Test; other lab; social 
Note: AIDS – acquired immune deficiency syndrome; FBC – full blood count; H Pylori – Helicobacter pylori; HbA1 – 
haemoglobin alpha 1; HbA1c – haemoglobin A1c; HCG – human chorionic gonadotropin; HIV – human 
immunodeficiency virus; ID – identification; M,C&S – microscopy, culture and sensitivity; NEC – not elsewhere 
classified; SHBG – sex hormone binding globulin. 
 
